INTEDE - Interactome of Drug-Metabolizing Enzyme Database
Title - Host protein-DME interaction data (Histone & Non-coding RNA & Transcription-factor regulation / Oligomerization)
Version 1.9.1 (2020.08.15)
Provided by IDRB   Lab of Innovative Drug Reasearch and Bioinformatics
                   College of Pharmaceutical Sciences
                   Zhejiang University
                   https://idrblab.org/
Any question about data provided here, please contact with:
Dr. Yin (yinjiayi@zju.edu.cn) and Dr. Li (lifengcheng@zju.edu.cn)

--------------------------------------------------------------------------------------------------------
Abbreviations:
DME___ID	INTEDE Drug-Metabolizing Enzyme (DME) ID
DME_NAME	DME Name
SPESNAME	DME Species Name
UNIPROID	Interacting Protein UniProt ID
MIRNA_ID	Interacting ncRNA miRBase ID
PROTNAME	Interacting Protein Name
HPPI_DIS	HOSPPI Related Disease
MOFCLASS	Mode of Function (MOF) Classification
MOFDETAI	Mode of Function (MOF) Detail
SUBSTRAT	HOSPPI Realted Substrate
CELLLINE	Experimental Cell Line
PPI_SUMM	HOSPPI Summary
DESCRIPT	HOSPPI Detailed Description
--------------------------------------------------------------------------------------------------------

DME0001	DME___ID	DME0001
DME0001	DME_NAME	Cytochrome P450 3A4 (CYP3A4)
DME0001	SPESNAME	Homo sapiens
DME0001	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0001	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0001	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0001	UNIPROID	EHMT1_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-CYP3A4 interaction
DME0001	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 4 dimethylation of CYP3A4 gene is reported to activate the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between Histone methyltransferases (HMTs) and CYP3A4 can enhance the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0001	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0001	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0001	UNIPROID	HDAC1_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP3A4 interaction
DME0001	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP3A4 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between HDACs and CYP3A4 can inhibit the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	MIRNA_ID	MIMAT0000419	PROTNAME	hsa-miR-27b-3p
DME0001	MIRNA_ID	MIMAT0000419	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0001	MIRNA_ID	MIMAT0000419	MOFCLASS	Non-coding RNA regulation
DME0001	MIRNA_ID	MIMAT0000419	MOFDETAI	microRNA regulation
DME0001	MIRNA_ID	MIMAT0000419	CELLLINE	LS-180 cell line
DME0001	MIRNA_ID	MIMAT0000419	PPI_SUMM	hsa-miR-27b-3p--CYP3A4 regulation
DME0001	MIRNA_ID	MIMAT0000419	DESCRIPT	hsa-miR-27b-3p is reported to suppress CYP3A4 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP3A4 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 3A4.
DME0001	UNIPROID	NEUFC_HUMAN	PROTNAME	Neuferricin (CYB5D2)
DME0001	UNIPROID	NEUFC_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0001	UNIPROID	NEUFC_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	NEUFC_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	NEUFC_HUMAN	SUBSTRAT	Luciferin (Metabolic product: Luciferin 6' pentafluorobenzyl ether depentafluorobenzylation); Paclitaxel; Cisplatin; Doxorubicin
DME0001	UNIPROID	NEUFC_HUMAN	CELLLINE	HeLa cell line
DME0001	UNIPROID	NEUFC_HUMAN	PPI_SUMM	CYB5D2-CYP3A4 heterooligomerization
DME0001	UNIPROID	NEUFC_HUMAN	DESCRIPT	Neuferricin (CYB5D2) is reported to heterooligomerize with the CYP3A4 protein, which leads to activation of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between CYB5D2 and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	PGRC1_HUMAN	PROTNAME	Progesterone receptor 1 (PGRMC1)
DME0001	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	PGRC1_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	PGRC1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Luciferin (Metabolic product: Luciferin 6' pentafluorobenzyl ether depentafluorobenzylation); Testosterone (Metabolic product: Testosterone 6-hydroxylase); Midazolam (Metabolic product: Midazolam 1-hydroxylase)
DME0001	UNIPROID	PGRC1_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293) and Human liver cancer cell line (HepG2)
DME0001	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP3A4 heterooligomerization
DME0001	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP3A4 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between PGRMC1 and CYP3A4 can inhibit the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	NCPR_HUMAN	PROTNAME	Mutated NADPH-CYP450 reductase (mPOR)
DME0001	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	NCPR_HUMAN	CELLLINE	Escherichia coli BL21(DE3) cell line
DME0001	UNIPROID	NCPR_HUMAN	PPI_SUMM	mPOR-CYP3A4 heterooligomerization
DME0001	UNIPROID	NCPR_HUMAN	DESCRIPT	Mutated NADPH-CYP450 reductase (mPOR) is reported to heterooligomerize with the CYP3A4 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between mPOR and CYP3A4 can inhibit the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0001	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Paclitaxel; Cisplatin; Doxorubicin
DME0001	UNIPROID	PGRC1_HUMAN	CELLLINE	HeLa cell line
DME0001	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP3A4 heterodimerization
DME0001	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterodimerize with the CYP3A4 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between PGRMC1 and CYP3A4 can inhibit the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Atorvastatin (Metabolic product: Atorvastatin 2-hydroxylase)
DME0001	UNIPROID	PGRC1_HUMAN	CELLLINE	Primary human hepatocytes
DME0001	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME0001	UNIPROID	CP1A1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	CP1A1_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	CP1A1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Testosterone (Metabolic product: Testosterone 6beta-hydroxylation)
DME0001	UNIPROID	CP1A1_HUMAN	CELLLINE	Escherichia coli cell line
DME0001	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-CYP3A4 heterooligomerization
DME0001	UNIPROID	CP1A1_HUMAN	DESCRIPT	Cytochrome P450 1A1 (CYP1A1) is reported to heterooligomerize with the CYP3A4 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between CYP1A1 and CYP3A4 can facilitate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME0001	UNIPROID	CP1A2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	CP1A2_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	CP1A2_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Testosterone (Metabolic product: Testosterone 6beta-hydroxylation)
DME0001	UNIPROID	CP1A2_HUMAN	CELLLINE	Escherichia coli cell line
DME0001	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-CYP3A4 heterooligomerization
DME0001	UNIPROID	CP1A2_HUMAN	DESCRIPT	Cytochrome P450 1A2 (CYP1A2) is reported to heterooligomerize with the CYP3A4 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between CYP1A2 and CYP3A4 can facilitate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0001	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	CYB5_HUMAN	CELLLINE	Whole-BTC cell line
DME0001	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A, POR and CYP3A4 heterotrimerization
DME0001	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) and NADPH-CYP450 reductase (POR) are reported to heterooligomerize with the CYP3A4 gene, which is necessary for sustaining the enzyme activity of Cytochrome P450 3A4. As a result, the interaction among CYB5A, POR and CYP3A4 is necessary for sustaining the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0001	UNIPROID	NCPR_HUMAN	CELLLINE	Whole-BTC cell line
DME0001	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR, CYB5A and CYP3A4 heterotrimerization
DME0001	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) and Cytochrome b5 (CYB5A) are reported to heterooligomerize with the CYP3A4 gene, which is necessary for sustaining the enzyme activity of Cytochrome P450 3A4. As a result, the interaction among POR, CYB5A and CYP3A4 is necessary for sustaining the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME0001	UNIPROID	CP3A5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	CP3A5_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	CP3A5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	CP3A5_HUMAN	SUBSTRAT	7-Benzyloxyquinoline (Metabolic product: 7-BQ O-debenzylation)
DME0001	UNIPROID	CP3A5_HUMAN	CELLLINE	Insect cell microsomes
DME0001	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-CYP3A4 heterooligomerization
DME0001	UNIPROID	CP3A5_HUMAN	DESCRIPT	Cytochrome P450 3A5 (CYP3A5) is reported to heterooligomerize with the CYP3A4 protein, which leads to activation of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between CYP3A5 and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME0001	UNIPROID	CP2C9_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	CP2C9_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	CP2C9_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Testosterone
DME0001	UNIPROID	CP2C9_HUMAN	CELLLINE	pCW vector
DME0001	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-CYP3A4 heterooligomerization
DME0001	UNIPROID	CP2C9_HUMAN	DESCRIPT	Cytochrome P450 2C9 (CYP2C9) is reported to heterooligomerize with the CYP3A4 protein, which has no effect on the enzyme activity of Cytochrome P450 3A4. As a result, the interaction between CYP2C9 and CYP3A4 can have no effect on the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME0001	UNIPROID	CP2D6_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	CP2D6_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	CP2D6_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	CP2D6_HUMAN	CELLLINE	Living cells
DME0001	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-CYP3A4 heterooligomerization
DME0001	UNIPROID	CP2D6_HUMAN	DESCRIPT	Cytochrome P450 2D6 (CYP2D6) is reported to heterooligomerize with the CYP3A4 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between CYP2D6 and CYP3A4 can inhibit the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME0001	UNIPROID	CP2E1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0001	UNIPROID	CP2E1_HUMAN	MOFCLASS	Oligomerization
DME0001	UNIPROID	CP2E1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0001	UNIPROID	CP2E1_HUMAN	SUBSTRAT	7-Benzyloxyquinoline (Metabolic product: 7-BQ O-debenzylation)
DME0001	UNIPROID	CP2E1_HUMAN	CELLLINE	Insect cell microsomes
DME0001	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-CYP3A4 heterooligomerization
DME0001	UNIPROID	CP2E1_HUMAN	DESCRIPT	Cytochrome P450 2E1 (CYP2E1) is reported to heterooligomerize with the CYP3A4 protein, which leads to a slight effect on the activity of drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between CYP2E1 and CYP3A4 slightly affects the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	VDR_HUMAN	PROTNAME	Vitamin D3 receptor (VDR)
DME0001	UNIPROID	VDR_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0001	UNIPROID	VDR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0001	UNIPROID	VDR_HUMAN	MOFDETAI	Activation
DME0001	UNIPROID	VDR_HUMAN	CELLLINE	LS174T and CACO-2 cell lines
DME0001	UNIPROID	VDR_HUMAN	PPI_SUMM	VDR-CYP3A4 interaction
DME0001	UNIPROID	VDR_HUMAN	DESCRIPT	Vitamin D3 receptor (VDR) is reported to activate the transcription of CYP3A4 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between VDR and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	NR1I2_HUMAN	PROTNAME	Pregnane X receptor (PXR)
DME0001	UNIPROID	NR1I2_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0001	UNIPROID	NR1I2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0001	UNIPROID	NR1I2_HUMAN	MOFDETAI	Activation
DME0001	UNIPROID	NR1I2_HUMAN	CELLLINE	LS180, Caco-2, HT29, HCT116, DLD-1, LoVo, SW48 and SW620 cell lines
DME0001	UNIPROID	NR1I2_HUMAN	PPI_SUMM	PXR-CYP3A4 interaction
DME0001	UNIPROID	NR1I2_HUMAN	DESCRIPT	Pregnane X receptor (PXR) is reported to activate the transcription of CYP3A4 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between PXR and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	NR1I2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	NR1I2_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	VDR_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	VDR_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	DBP_HUMAN	PROTNAME	D site-binding protein (DBP)
DME0001	UNIPROID	DBP_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	DBP_HUMAN	MOFCLASS	Transcription-factor regulation
DME0001	UNIPROID	DBP_HUMAN	MOFDETAI	Activation
DME0001	UNIPROID	DBP_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	DBP_HUMAN	PPI_SUMM	DBP-CYP3A4 interaction
DME0001	UNIPROID	DBP_HUMAN	DESCRIPT	D site-binding protein (DBP) is reported to activate the transcription of CYP3A4 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between DBP and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	HNF4A_HUMAN	PROTNAME	Hepatocyte NF 4-alpha (HNF4A)
DME0001	UNIPROID	HNF4A_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	HNF4A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0001	UNIPROID	HNF4A_HUMAN	MOFDETAI	Activation
DME0001	UNIPROID	HNF4A_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	HNF4A_HUMAN	PPI_SUMM	HNF4A-CYP3A4 interaction
DME0001	UNIPROID	HNF4A_HUMAN	DESCRIPT	Hepatocyte NF 4-alpha (HNF4A) is reported to activate the transcription of CYP3A4 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between HNF4A and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	CXAR_HUMAN	PROTNAME	Constitutive androstane receptor (CAR)
DME0001	UNIPROID	CXAR_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	CXAR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0001	UNIPROID	CXAR_HUMAN	MOFDETAI	Activation
DME0001	UNIPROID	CXAR_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	CXAR_HUMAN	PPI_SUMM	CAR-CYP3A4 interaction
DME0001	UNIPROID	CXAR_HUMAN	DESCRIPT	Constitutive androstane receptor (CAR) is reported to activate the transcription of CYP3A4 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between CAR and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	NR1H4_HUMAN	PROTNAME	Farnesoid X receptor (FXR)
DME0001	UNIPROID	NR1H4_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	NR1H4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0001	UNIPROID	NR1H4_HUMAN	MOFDETAI	Activation
DME0001	UNIPROID	NR1H4_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	NR1H4_HUMAN	PPI_SUMM	FXR-CYP3A4 interaction
DME0001	UNIPROID	NR1H4_HUMAN	DESCRIPT	Farnesoid X receptor (FXR) is reported to activate the transcription of CYP3A4 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between FXR and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0001	UNIPROID	NR0B2_HUMAN	PROTNAME	Small heterodimer partner (SHP)
DME0001	UNIPROID	NR0B2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0001	UNIPROID	NR0B2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0001	UNIPROID	NR0B2_HUMAN	MOFDETAI	Activation
DME0001	UNIPROID	NR0B2_HUMAN	CELLLINE	HepG2 cell line
DME0001	UNIPROID	NR0B2_HUMAN	PPI_SUMM	SHP-CYP3A4 interaction
DME0001	UNIPROID	NR0B2_HUMAN	DESCRIPT	Small heterodimer partner (SHP) is reported to activate the transcription of CYP3A4 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 3A4. As a result, the interaction between SHP and CYP3A4 can activate the drug-metabolizing process of Cytochrome P450 3A4.
DME0002	DME___ID	DME0002
DME0002	DME_NAME	Aromatase (CYP19A1)
DME0002	SPESNAME	Homo sapiens
DME0002	MIRNA_ID	MIMAT0000732	PROTNAME	hsa-miR-378a-3p
DME0002	MIRNA_ID	MIMAT0000732	HPPI_DIS	Health [ICD-11: N.A.]
DME0002	MIRNA_ID	MIMAT0000732	MOFCLASS	Non-coding RNA regulation
DME0002	MIRNA_ID	MIMAT0000732	MOFDETAI	microRNA regulation
DME0002	MIRNA_ID	MIMAT0000732	CELLLINE	Granulosa cells
DME0002	MIRNA_ID	MIMAT0000732	PPI_SUMM	hsa-miR-378a-3p--CYP19A1 regulation
DME0002	MIRNA_ID	MIMAT0000732	DESCRIPT	hsa-miR-378a-3p is reported to suppress CYP19A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP19A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase.
DME0002	MIRNA_ID	MIMAT0000067	PROTNAME	hsa-let-7f-5p
DME0002	MIRNA_ID	MIMAT0000067	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0002	MIRNA_ID	MIMAT0000067	MOFCLASS	Non-coding RNA regulation
DME0002	MIRNA_ID	MIMAT0000067	MOFDETAI	microRNA regulation
DME0002	MIRNA_ID	MIMAT0000067	CELLLINE	MCF-7 and SK-BR-3 cell lines
DME0002	MIRNA_ID	MIMAT0000067	PPI_SUMM	hsa-let-7f-5p--CYP19A1 regulation
DME0002	MIRNA_ID	MIMAT0000067	DESCRIPT	hsa-let-7f-5p is reported to suppress CYP19A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP19A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase.
DME0002	MIRNA_ID	MIMAT0000103	PROTNAME	hsa-miR-106a-5p
DME0002	MIRNA_ID	MIMAT0000103	HPPI_DIS	Choriocarcinoma [ICD-11: 2C75]
DME0002	MIRNA_ID	MIMAT0000103	MOFCLASS	Non-coding RNA regulation
DME0002	MIRNA_ID	MIMAT0000103	MOFDETAI	microRNA regulation
DME0002	MIRNA_ID	MIMAT0000103	CELLLINE	Human choriocarcinoma JEG-3 cell line
DME0002	MIRNA_ID	MIMAT0000103	PPI_SUMM	hsa-miR-106a-5p--CYP19A1 regulation
DME0002	MIRNA_ID	MIMAT0000103	DESCRIPT	hsa-miR-106a-5p is reported to suppress CYP19A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP19A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase.
DME0002	MIRNA_ID	MIMAT0000074	PROTNAME	hsa-miR-19b-3p
DME0002	MIRNA_ID	MIMAT0000074	HPPI_DIS	Choriocarcinoma [ICD-11: 2C75]
DME0002	MIRNA_ID	MIMAT0000074	MOFCLASS	Non-coding RNA regulation
DME0002	MIRNA_ID	MIMAT0000074	MOFDETAI	microRNA regulation
DME0002	MIRNA_ID	MIMAT0000074	CELLLINE	Human choriocarcinoma JEG-3 cell line
DME0002	MIRNA_ID	MIMAT0000074	PPI_SUMM	hsa-miR-19b-3p--CYP19A1 regulation
DME0002	MIRNA_ID	MIMAT0000074	DESCRIPT	hsa-miR-19b-3p is reported to suppress CYP19A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP19A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase.
DME0002	MIRNA_ID	MIMAT0000096	PROTNAME	hsa-miR-98-5p
DME0002	MIRNA_ID	MIMAT0000096	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0002	MIRNA_ID	MIMAT0000096	MOFCLASS	Non-coding RNA regulation
DME0002	MIRNA_ID	MIMAT0000096	MOFDETAI	microRNA regulation
DME0002	MIRNA_ID	MIMAT0000096	CELLLINE	H295R cell line
DME0002	MIRNA_ID	MIMAT0000096	PPI_SUMM	hsa-miR-98-5p--CYP19A1 regulation
DME0002	MIRNA_ID	MIMAT0000096	DESCRIPT	hsa-miR-98-5p is reported to suppress CYP19A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP19A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase.
DME0002	MIRNA_ID	MIMAT0002826	PROTNAME	hsa-miR-515-5p
DME0002	MIRNA_ID	MIMAT0002826	HPPI_DIS	Preeclampsia [ICD-11: JA24]
DME0002	MIRNA_ID	MIMAT0002826	MOFCLASS	Non-coding RNA regulation
DME0002	MIRNA_ID	MIMAT0002826	MOFDETAI	microRNA regulation
DME0002	MIRNA_ID	MIMAT0002826	CELLLINE	Preeclampsia cells
DME0002	MIRNA_ID	MIMAT0002826	PPI_SUMM	hsa-miR-515-5p--CYP19A1 regulation
DME0002	MIRNA_ID	MIMAT0002826	DESCRIPT	hsa-miR-515-5p is reported to suppress CYP19A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP19A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase.
DME0002	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0002	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0002	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0002	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0002	UNIPROID	NCPR_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293)
DME0002	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR-CYP19A1 heterodimerization
DME0002	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) is reported to heterodimerize with the CYP19A1 protein, which leads to activation of the drug-metabolizing enzyme Aromatase. As a result, the interaction between POR and CYP19A1 can activate the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	NCPR_HUMAN	PROTNAME	Mutated NADPH-CYP450 reductase (mPOR)
DME0002	UNIPROID	NCPR_HUMAN	CELLLINE	Escherichia coli BL21(DE3) cell line
DME0002	UNIPROID	NCPR_HUMAN	PPI_SUMM	mPOR-CYP19A1 heterooligomerization
DME0002	UNIPROID	NCPR_HUMAN	DESCRIPT	Mutated NADPH-CYP450 reductase (mPOR) is reported to heterooligomerize with the CYP19A1 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Aromatase. As a result, the interaction between mPOR and CYP19A1 can inhibit the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	PGRC1_HUMAN	PROTNAME	Progesterone receptor 1 (PGRMC1)
DME0002	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0002	UNIPROID	PGRC1_HUMAN	MOFCLASS	Oligomerization
DME0002	UNIPROID	PGRC1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0002	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Androst-4-ene-3,17-dione (Metabolic product: Androst-4-ene-3,17-dione conversion)
DME0002	UNIPROID	PGRC1_HUMAN	CELLLINE	Breast carcinoma cell line (MCF7)
DME0002	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP19A1 heterooligomerization
DME0002	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP19A1 protein, which leads to activation of the drug-metabolizing enzyme Aromatase. As a result, the interaction between PGRMC1 and CYP19A1 can activate the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	CP21A_HUMAN	PROTNAME	Steroid 21-hydroxylase (CYP21A2)
DME0002	UNIPROID	CP21A_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0002	UNIPROID	CP21A_HUMAN	MOFCLASS	Oligomerization
DME0002	UNIPROID	CP21A_HUMAN	MOFDETAI	Hetero-oligomerization
DME0002	UNIPROID	CP21A_HUMAN	SUBSTRAT	pregnenolone
DME0002	UNIPROID	CP21A_HUMAN	CELLLINE	Escherichia coli JM109 competent cell line
DME0002	UNIPROID	CP21A_HUMAN	PPI_SUMM	CYP21A2-CYP19A1 heterooligomerization
DME0002	UNIPROID	CP21A_HUMAN	DESCRIPT	Steroid 21-hydroxylase (CYP21A2) is reported to heterooligomerize with the CYP19A1 protein, which leads to a decreased activity of the drug-metabolizing enzyme Aromatase. As a result, the interaction between CYP21A2 and CYP19A1 can decrease the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	STF1_HUMAN	PROTNAME	Steroidogenic factor 1 (NR5A1)
DME0002	UNIPROID	STF1_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0002	UNIPROID	STF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	STF1_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	STF1_HUMAN	CELLLINE	Adrenocortical carcinoma cell line
DME0002	UNIPROID	STF1_HUMAN	PPI_SUMM	NR5A1-CYP19A1 interaction
DME0002	UNIPROID	STF1_HUMAN	DESCRIPT	Steroidogenic factor 1 (NR5A1) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between NR5A1 and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	STF1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0002	UNIPROID	STF1_HUMAN	MOFDETAI	Activation
DME0002	UNIPROID	STF1_HUMAN	CELLLINE	Human endometriotic and endometrial stromal cell lines
DME0002	UNIPROID	STF1_HUMAN	DESCRIPT	Steroidogenic factor 1 (NR5A1) is reported to activate the transcription of CYP19A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between NR5A1 and CYP19A1 can activate the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	CREB1_HUMAN	PROTNAME	AMP element-binding 1 (CREB1)
DME0002	UNIPROID	CREB1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0002	UNIPROID	CREB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	CREB1_HUMAN	MOFDETAI	Activation
DME0002	UNIPROID	CREB1_HUMAN	CELLLINE	MCF-7 and MDA-MB-231 cell lines
DME0002	UNIPROID	CREB1_HUMAN	PPI_SUMM	CREB1-CYP19A1 interaction
DME0002	UNIPROID	CREB1_HUMAN	DESCRIPT	AMP element-binding 1 (CREB1) is reported to activate the transcription of CYP19A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between CREB1 and CYP19A1 can activate the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	ERR1_HUMAN	PROTNAME	Estrogen receptor-like 1 (ESRRA)
DME0002	UNIPROID	ERR1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0002	UNIPROID	ERR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	ERR1_HUMAN	MOFDETAI	Activation
DME0002	UNIPROID	ERR1_HUMAN	CELLLINE	MCF-7 and MDA-MB-231 cell lines
DME0002	UNIPROID	ERR1_HUMAN	PPI_SUMM	ESRRA-CYP19A1 interaction
DME0002	UNIPROID	ERR1_HUMAN	DESCRIPT	Estrogen receptor-like 1 (ESRRA) is reported to activate the transcription of CYP19A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between ESRRA and CYP19A1 can activate the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	GCR_HUMAN	PROTNAME	Glucocorticoid receptor (NR3C1)
DME0002	UNIPROID	GCR_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0002	UNIPROID	GCR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	GCR_HUMAN	MOFDETAI	Activation
DME0002	UNIPROID	GCR_HUMAN	CELLLINE	MCF-7 cell line
DME0002	UNIPROID	GCR_HUMAN	PPI_SUMM	NR3C1-CYP19A1 interaction
DME0002	UNIPROID	GCR_HUMAN	DESCRIPT	Glucocorticoid receptor (NR3C1) is reported to activate the transcription of CYP19A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between NR3C1 and CYP19A1 can activate the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	ESR1_HUMAN	PROTNAME	Estrogen receptor (ESR1)
DME0002	UNIPROID	ESR1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0002	UNIPROID	ESR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	ESR1_HUMAN	MOFDETAI	Activation
DME0002	UNIPROID	ESR1_HUMAN	CELLLINE	SK-BR-3 and MCF-7 cell lines
DME0002	UNIPROID	ESR1_HUMAN	PPI_SUMM	ESR1-CYP19A1 interaction
DME0002	UNIPROID	ESR1_HUMAN	DESCRIPT	Estrogen receptor (ESR1) is reported to activate the transcription of CYP19A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between ESR1 and CYP19A1 can activate the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	PRGR_HUMAN	PROTNAME	Progesterone receptor (PGR)
DME0002	UNIPROID	PRGR_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0002	UNIPROID	PRGR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	PRGR_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	PRGR_HUMAN	CELLLINE	T47D and MCF-7 cell lines
DME0002	UNIPROID	PRGR_HUMAN	PPI_SUMM	PGR-CYP19A1 interaction
DME0002	UNIPROID	PRGR_HUMAN	DESCRIPT	Progesterone receptor (PGR) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between PGR and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	BRCA1_HUMAN	PROTNAME	RING finger protein 53 (BRCA1)
DME0002	UNIPROID	BRCA1_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0002	UNIPROID	BRCA1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	BRCA1_HUMAN	MOFDETAI	Activation
DME0002	UNIPROID	BRCA1_HUMAN	CELLLINE	KGN cell line
DME0002	UNIPROID	BRCA1_HUMAN	PPI_SUMM	BRCA1-CYP19A1 interaction
DME0002	UNIPROID	BRCA1_HUMAN	DESCRIPT	RING finger protein 53 (BRCA1) is reported to activate the transcription of CYP19A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between BRCA1 and CYP19A1 can activate the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0002	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0002	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	NFKB1_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	NFKB1_HUMAN	CELLLINE	KGN cell line
DME0002	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-CYP19A1 interaction
DME0002	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between NFKB1 and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0002	UNIPROID	TF65_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0002	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	TF65_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	TF65_HUMAN	CELLLINE	KGN cell line
DME0002	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-CYP19A1 interaction
DME0002	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between RELA and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	JUN_HUMAN	PROTNAME	Transcription factor AP-1 (JUN)
DME0002	UNIPROID	JUN_HUMAN	HPPI_DIS	Virilizing Brenner Tumor [ICD-11: 2F32]
DME0002	UNIPROID	JUN_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	JUN_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	JUN_HUMAN	CELLLINE	Fibrothecoma-like and luteinized stromal cell line
DME0002	UNIPROID	JUN_HUMAN	PPI_SUMM	JUN-CYP19A1 interaction
DME0002	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between JUN and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	CEBPB_HUMAN	PROTNAME	Liver activator protein (LAP)
DME0002	UNIPROID	CEBPB_HUMAN	HPPI_DIS	Endometriosis [ICD-11: GA10]
DME0002	UNIPROID	CEBPB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	CEBPB_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	CEBPB_HUMAN	CELLLINE	Human endometriotic stromal cell line
DME0002	UNIPROID	CEBPB_HUMAN	PPI_SUMM	LAP-CYP19A1 interaction
DME0002	UNIPROID	CEBPB_HUMAN	DESCRIPT	Liver activator protein (LAP) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between LAP and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	WT1_HUMAN	PROTNAME	Wilms tumor protein (WT1)
DME0002	UNIPROID	WT1_HUMAN	HPPI_DIS	Endometriosis [ICD-11: GA10]
DME0002	UNIPROID	WT1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	WT1_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	WT1_HUMAN	CELLLINE	Human endometriotic stromal cell line
DME0002	UNIPROID	WT1_HUMAN	PPI_SUMM	WT1-CYP19A1 interaction
DME0002	UNIPROID	WT1_HUMAN	DESCRIPT	Wilms tumor protein (WT1) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between WT1 and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	CEBPD_HUMAN	PROTNAME	Nuclear factor NF-IL6-beta (CEBPD)
DME0002	UNIPROID	CEBPD_HUMAN	HPPI_DIS	Endometriosis [ICD-11: GA10]
DME0002	UNIPROID	CEBPD_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	CEBPD_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	CEBPD_HUMAN	CELLLINE	Human endometriotic stromal cell line
DME0002	UNIPROID	CEBPD_HUMAN	PPI_SUMM	CEBPD-CYP19A1 interaction
DME0002	UNIPROID	CEBPD_HUMAN	DESCRIPT	Nuclear factor NF-IL6-beta (CEBPD) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between CEBPD and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	FOXL2_HUMAN	PROTNAME	Forkhead box protein L2 (FOXL2)
DME0002	UNIPROID	FOXL2_HUMAN	HPPI_DIS	Menopausal disorder [ICD-11: GA30]
DME0002	UNIPROID	FOXL2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	FOXL2_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	FOXL2_HUMAN	CELLLINE	CHO cell line
DME0002	UNIPROID	FOXL2_HUMAN	PPI_SUMM	FOXL2-CYP19A1 interaction
DME0002	UNIPROID	FOXL2_HUMAN	DESCRIPT	Forkhead box protein L2 (FOXL2) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between FOXL2 and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	NR0B1_HUMAN	PROTNAME	Nuclear receptor family 0 B1 (NR0B1)
DME0002	UNIPROID	NR0B1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0002	UNIPROID	NR0B1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	NR0B1_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	NR0B1_HUMAN	CELLLINE	Human endometriotic and endometrial stromal cell lines
DME0002	UNIPROID	NR0B1_HUMAN	PPI_SUMM	NR0B1-CYP19A1 interaction
DME0002	UNIPROID	NR0B1_HUMAN	DESCRIPT	Nuclear receptor family 0 B1 (NR0B1) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between NR0B1 and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	USF2_HUMAN	PROTNAME	Upstream stimulatory 2 (USF2)
DME0002	UNIPROID	USF2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0002	UNIPROID	USF2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	USF2_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	USF2_HUMAN	CELLLINE	Human trophoblast cell line
DME0002	UNIPROID	USF2_HUMAN	PPI_SUMM	USF2-CYP19A1 interaction
DME0002	UNIPROID	USF2_HUMAN	DESCRIPT	Upstream stimulatory 2 (USF2) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between USF2 and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0002	UNIPROID	USF1_HUMAN	PROTNAME	Upstream stimulatory 1 (USF1)
DME0002	UNIPROID	USF1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0002	UNIPROID	USF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0002	UNIPROID	USF1_HUMAN	MOFDETAI	Repression
DME0002	UNIPROID	USF1_HUMAN	CELLLINE	Human trophoblast cell line
DME0002	UNIPROID	USF1_HUMAN	PPI_SUMM	USF1-CYP19A1 interaction
DME0002	UNIPROID	USF1_HUMAN	DESCRIPT	Upstream stimulatory 1 (USF1) is reported to repress the transcription of CYP19A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aromatase. As a result, the interaction between USF1 and CYP19A1 can repress the drug-metabolizing process of Aromatase.
DME0003	DME___ID	DME0003
DME0003	DME_NAME	Cytochrome P450 1A2 (CYP1A2)
DME0003	SPESNAME	Homo sapiens
DME0003	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0003	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0003	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0003	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0003	UNIPROID	HDAC1_HUMAN	CELLLINE	HeLa cell line
DME0003	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP1A2 interaction
DME0003	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP1A2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 1A2. As a result, the interaction between HDACs and CYP1A2 can inhibit the drug-metabolizing process of Cytochrome P450 1A2.
DME0003	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0003	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0003	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0003	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0003	UNIPROID	NCPR_HUMAN	CELLLINE	Whole-BTC cell line
DME0003	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR, CYB5A and CYP1A2 heterooligomerization
DME0003	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) and Cytochrome b5 (CYB5A) are reported to heterooligomerize with the CYP1A2 gene, which is necessary for sustaining the enzyme activity of Cytochrome P450 1A2. As a result, the interaction among POR, CYB5A and CYP1A2 is necessary for sustaining the drug-metabolizing process of Cytochrome P450 1A2.
DME0003	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0003	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0003	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0003	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0003	UNIPROID	CYB5_HUMAN	CELLLINE	Whole-BTC cell line
DME0003	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A, POR and CYP1A2 heterooligomerization
DME0003	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) and NADPH-CYP450 reductase (POR) are reported to heterooligomerize with the CYP1A2 gene, which is necessary for sustaining the enzyme activity of Cytochrome P450 1A2. As a result, the interaction among CYB5A, POR and CYP1A2 is necessary for sustaining the drug-metabolizing process of Cytochrome P450 1A2.
DME0003	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME0003	UNIPROID	CP2E1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0003	UNIPROID	CP2E1_HUMAN	MOFCLASS	Oligomerization
DME0003	UNIPROID	CP2E1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0003	UNIPROID	CP2E1_HUMAN	SUBSTRAT	7-Ethoxyresorufin (Metabolic product: Dealkylation of 7-ethoxyresorufin)
DME0003	UNIPROID	CP2E1_HUMAN	CELLLINE	Escherichia coli cell line
DME0003	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-CYP1A2 heterooligomerization
DME0003	UNIPROID	CP2E1_HUMAN	DESCRIPT	Cytochrome P450 2E1 (CYP2E1) is reported to heterooligomerize with the CYP1A2 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 1A2. As a result, the interaction between CYP2E1 and CYP1A2 can facilitate the drug-metabolizing process of Cytochrome P450 1A2.
DME0004	DME___ID	DME0004
DME0004	DME_NAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME0004	SPESNAME	Homo sapiens
DME0004	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0004	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0004	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0004	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0004	UNIPROID	EHMT1_HUMAN	CELLLINE	Fetal liver cells
DME0004	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-UGT1A1 interaction
DME0004	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 27 trimethylation of UGT1A1 gene is reported to repress the transcriptional activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between Histone methyltransferases (HMTs) and UGT1A1 can inhibit the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	EHMT1_HUMAN	CELLLINE	Adult liver cells
DME0004	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 4 dimethylation of UGT1A1 gene is reported to activate the transcriptional activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between Histone methyltransferases (HMTs) and UGT1A1 can enhance the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0004	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0004	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0004	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0004	UNIPROID	HDAC1_HUMAN	CELLLINE	Human kidney-derived HK-2 cells
DME0004	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-UGT1A1 interaction
DME0004	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the UGT1A1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between HDACs and UGT1A1 can inhibit the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	UD11_HUMAN	PROTNAME	UDPGT 1-1 (UGT1A1)
DME0004	UNIPROID	UD11_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0004	UNIPROID	UD11_HUMAN	MOFCLASS	Oligomerization
DME0004	UNIPROID	UD11_HUMAN	MOFDETAI	Homo-oligomerization
DME0004	UNIPROID	UD11_HUMAN	SUBSTRAT	Octylgallate
DME0004	UNIPROID	UD11_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell line (COS)
DME0004	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-UGT1A1 homodimerization
DME0004	UNIPROID	UD11_HUMAN	DESCRIPT	UDPGT 1-1 (UGT1A1) is reported as a homodimer, which leads to a slight effect on the enzyme activity of drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the UGT1A1 homodimerization can slightly affect the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	UD11_HUMAN	PROTNAME	Mutated UDPGT 1-1 (mUGT1A1)
DME0004	UNIPROID	UD11_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell line (COS)7
DME0004	UNIPROID	UD11_HUMAN	PPI_SUMM	mUGT1A1-UGT1A1 homodimerization
DME0004	UNIPROID	UD11_HUMAN	DESCRIPT	Mutated UDPGT 1-1 (mUGT1A1) is reported to homodimerize with the UGT1A1 protein, which leads to a markedly suppressed activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between mUGT1A1 and UGT1A1 can markedly inhibit the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	UD19_HUMAN	PROTNAME	UDPGT 1-9 (UGT1A9)
DME0004	UNIPROID	UD19_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0004	UNIPROID	UD19_HUMAN	MOFCLASS	Oligomerization
DME0004	UNIPROID	UD19_HUMAN	MOFDETAI	Hetero-oligomerization
DME0004	UNIPROID	UD19_HUMAN	SUBSTRAT	Estradiol (Metabolic product: Estradiol 3-O-glucuronide)
DME0004	UNIPROID	UD19_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293)
DME0004	UNIPROID	UD19_HUMAN	PPI_SUMM	UGT1A9-UGT1A1 heterooligomerization
DME0004	UNIPROID	UD19_HUMAN	DESCRIPT	UDPGT 1-9 (UGT1A9) is reported to heterooligomerize with the UGT1A1 protein, which leads to a suppressed activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between UGT1A9 and UGT1A1 can inhibit the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME0004	UNIPROID	CP1A1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0004	UNIPROID	CP1A1_HUMAN	MOFCLASS	Oligomerization
DME0004	UNIPROID	CP1A1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0004	UNIPROID	CP1A1_HUMAN	CELLLINE	liver microsomes
DME0004	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-UGT1A1 heterooligomerization
DME0004	UNIPROID	CP1A1_HUMAN	DESCRIPT	Cytochrome P450 1A1 (CYP1A1) is reported to heterooligomerize with the UGT1A1 protein, which leads to an increased activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between CYP1A1 and UGT1A1 can facilitate the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	AHR_HUMAN	PROTNAME	Aryl hydrocarbon receptor (AHR)
DME0004	UNIPROID	AHR_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0004	UNIPROID	AHR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0004	UNIPROID	AHR_HUMAN	MOFDETAI	Activation
DME0004	UNIPROID	AHR_HUMAN	CELLLINE	HepG2 cell line
DME0004	UNIPROID	AHR_HUMAN	PPI_SUMM	AHR-UGT1A1 interaction
DME0004	UNIPROID	AHR_HUMAN	DESCRIPT	Aryl hydrocarbon receptor (AHR) is reported to activate the transcription of UGT1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between AHR and UGT1A1 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	GCR_HUMAN	PROTNAME	Glucocorticoid receptor (NR3C1)
DME0004	UNIPROID	GCR_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0004	UNIPROID	GCR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0004	UNIPROID	GCR_HUMAN	MOFDETAI	Activation
DME0004	UNIPROID	GCR_HUMAN	CELLLINE	HepG2 cell line
DME0004	UNIPROID	GCR_HUMAN	PPI_SUMM	NR3C1-UGT1A1 interaction
DME0004	UNIPROID	GCR_HUMAN	DESCRIPT	Glucocorticoid receptor (NR3C1) is reported to activate the transcription of UGT1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between NR3C1 and UGT1A1 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	HNF1A_HUMAN	PROTNAME	Hepatocyte NF 1-alpha (HNF1A)
DME0004	UNIPROID	HNF1A_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0004	UNIPROID	HNF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0004	UNIPROID	HNF1A_HUMAN	MOFDETAI	Activation
DME0004	UNIPROID	HNF1A_HUMAN	CELLLINE	HepG2 cell line
DME0004	UNIPROID	HNF1A_HUMAN	PPI_SUMM	HNF1A-UGT1A1 interaction
DME0004	UNIPROID	HNF1A_HUMAN	DESCRIPT	Hepatocyte NF 1-alpha (HNF1A) is reported to activate the transcription of UGT1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between HNF1A and UGT1A1 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	NR1I3_HUMAN	PROTNAME	Nuclear receptor family 0 I3 (NR1I3)
DME0004	UNIPROID	NR1I3_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0004	UNIPROID	NR1I3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0004	UNIPROID	NR1I3_HUMAN	MOFDETAI	Activation
DME0004	UNIPROID	NR1I3_HUMAN	CELLLINE	HepG2 cell line
DME0004	UNIPROID	NR1I3_HUMAN	PPI_SUMM	NR1I3-UGT1A1 interaction
DME0004	UNIPROID	NR1I3_HUMAN	DESCRIPT	Nuclear receptor family 0 I3 (NR1I3) is reported to activate the transcription of UGT1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between NR1I3 and UGT1A1 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0004	UNIPROID	NR1I2_HUMAN	PROTNAME	Pregnane X receptor (PXR)
DME0004	UNIPROID	NR1I2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0004	UNIPROID	NR1I2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0004	UNIPROID	NR1I2_HUMAN	MOFDETAI	Activation
DME0004	UNIPROID	NR1I2_HUMAN	CELLLINE	HepG2 cell line
DME0004	UNIPROID	NR1I2_HUMAN	PPI_SUMM	PXR-UGT1A1 interaction
DME0004	UNIPROID	NR1I2_HUMAN	DESCRIPT	Pregnane X receptor (PXR) is reported to activate the transcription of UGT1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A1. As a result, the interaction between PXR and UGT1A1 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A1.
DME0005	DME___ID	DME0005
DME0005	DME_NAME	Cytochrome P450 2A6 (CYP2A6)
DME0005	SPESNAME	Homo sapiens
DME0005	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0005	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0005	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0005	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0005	UNIPROID	CYB5_HUMAN	CELLLINE	Whole-BTC cell line
DME0005	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A, POR and CYP2A6 heterooligomerization
DME0005	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) and NADPH-CYP450 reductase (POR) are reported to heterooligomerize with the CYP2A6 gene, which is necessary for sustaining the enzyme activity of Cytochrome P450 2A6. As a result, the interaction among CYB5A, POR and CYP2A6 is necessary for sustaining the drug-metabolizing process of Cytochrome P450 2A6.
DME0005	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0005	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0005	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0005	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0005	UNIPROID	NCPR_HUMAN	CELLLINE	Whole-BTC cell line
DME0005	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR, CYB5A and CYP2A6 heterooligomerization
DME0005	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) and Cytochrome b5 (CYB5A) are reported to heterooligomerize with the CYP2A6 gene, which is necessary for sustaining the enzyme activity of Cytochrome P450 2A6. As a result, the interaction among POR, CYB5A and CYP2A6 is necessary for sustaining the drug-metabolizing process of Cytochrome P450 2A6.
DME0005	UNIPROID	NCPR_HUMAN	SUBSTRAT	Coumarin; N-nitrosodimethylamine
DME0005	UNIPROID	NCPR_HUMAN	CELLLINE	Baculovirus expression system
DME0005	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR, CYP2E1 and CYP2A6 heterooligomerization
DME0005	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) and Cytochrome P450 2E1 (CYP2E1) are reported to heterooligomerize with the CYP2A6 protein, which leads to a decreased activity of the drug-metabolizing enzyme Cytochrome P450 2A6. As a result, the interaction among POR, CYP2E1 and CYP2A6 can decrease the drug-metabolizing process of Cytochrome P450 2A6.
DME0005	UNIPROID	NFYA_HUMAN	PROTNAME	Nuclear TF factor Y alpha (NFYA)
DME0005	UNIPROID	NFYA_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0005	UNIPROID	NFYA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0005	UNIPROID	NFYA_HUMAN	MOFDETAI	Activation
DME0005	UNIPROID	NFYA_HUMAN	CELLLINE	HepG2 cell line
DME0005	UNIPROID	NFYA_HUMAN	PPI_SUMM	NFYA-CYP2A6 interaction
DME0005	UNIPROID	NFYA_HUMAN	DESCRIPT	Nuclear TF factor Y alpha (NFYA) is reported to activate the transcription of CYP2A6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2A6. As a result, the interaction between NFYA and CYP2A6 can activate the drug-metabolizing process of Cytochrome P450 2A6.
DME0006	DME___ID	DME0006
DME0006	DME_NAME	Cytochrome P450 1A1 (CYP1A1)
DME0006	SPESNAME	Homo sapiens
DME0006	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0006	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0006	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0006	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0006	UNIPROID	HDAC1_HUMAN	CELLLINE	HeLa cell line
DME0006	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP1A1 interaction
DME0006	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP1A1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between HDACs and CYP1A1 can inhibit the drug-metabolizing process of Cytochrome P450 1A1.
DME0006	UNIPROID	HYEP_HUMAN	PROTNAME	Epoxide hydrolase 1 (EPHX1)
DME0006	UNIPROID	HYEP_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0006	UNIPROID	HYEP_HUMAN	MOFCLASS	Oligomerization
DME0006	UNIPROID	HYEP_HUMAN	MOFDETAI	Hetero-oligomerization
DME0006	UNIPROID	HYEP_HUMAN	CELLLINE	liver microsomes
DME0006	UNIPROID	HYEP_HUMAN	PPI_SUMM	EPHX1, UGT1A1 and CYP1A1 heterooligomerization
DME0006	UNIPROID	HYEP_HUMAN	DESCRIPT	Epoxide hydrolase 1 (EPHX1) and UDPGT 1-1 (UGT1A1) are reported to heterooligomerize with the CYP1A1 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction among EPHX1, UGT1A1 and CYP1A1 can facilitate the drug-metabolizing process of Cytochrome P450 1A1.
DME0006	UNIPROID	UD11_HUMAN	PROTNAME	UDPGT 1-1 (UGT1A1)
DME0006	UNIPROID	UD11_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0006	UNIPROID	UD11_HUMAN	MOFCLASS	Oligomerization
DME0006	UNIPROID	UD11_HUMAN	MOFDETAI	Hetero-oligomerization
DME0006	UNIPROID	UD11_HUMAN	CELLLINE	liver microsomes
DME0006	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1, EPHX1 and CYP1A1 heterooligomerization
DME0006	UNIPROID	UD11_HUMAN	DESCRIPT	UDPGT 1-1 (UGT1A1) and Epoxide hydrolase 1 (EPHX1) are reported to heterooligomerize with the CYP1A1 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction among UGT1A1, EPHX1and CYP1A1 can facilitate the drug-metabolizing process of Cytochrome P450 1A1.
DME0006	UNIPROID	AHR_HUMAN	PROTNAME	Aryl hydrocarbon receptor (AHR)
DME0006	UNIPROID	AHR_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0006	UNIPROID	AHR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0006	UNIPROID	AHR_HUMAN	MOFDETAI	Repression
DME0006	UNIPROID	AHR_HUMAN	CELLLINE	HepG2 and Hepa-1c1c7 cell lines
DME0006	UNIPROID	AHR_HUMAN	PPI_SUMM	AHR-CYP1A1 interaction
DME0006	UNIPROID	AHR_HUMAN	DESCRIPT	Aryl hydrocarbon receptor (AHR) is reported to repress the transcription of CYP1A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between AHR and CYP1A1 can repress the drug-metabolizing process of Cytochrome P450 1A1.
DME0006	UNIPROID	PPARA_HUMAN	PROTNAME	PPA receptor alpha (PPARA)
DME0006	UNIPROID	PPARA_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0006	UNIPROID	PPARA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0006	UNIPROID	PPARA_HUMAN	MOFDETAI	Activation
DME0006	UNIPROID	PPARA_HUMAN	CELLLINE	Caco-2 cell line
DME0006	UNIPROID	PPARA_HUMAN	PPI_SUMM	PPARA-CYP1A1 interaction
DME0006	UNIPROID	PPARA_HUMAN	DESCRIPT	PPA receptor alpha (PPARA) is reported to activate the transcription of CYP1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between PPARA and CYP1A1 can activate the drug-metabolizing process of Cytochrome P450 1A1.
DME0006	UNIPROID	ARNT_HUMAN	PROTNAME	Hypoxia-inducible factor 1-beta (ARNT)
DME0006	UNIPROID	ARNT_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0006	UNIPROID	ARNT_HUMAN	MOFCLASS	Transcription-factor regulation
DME0006	UNIPROID	ARNT_HUMAN	MOFDETAI	Activation
DME0006	UNIPROID	ARNT_HUMAN	CELLLINE	HuH7 and HepG2 cell lines
DME0006	UNIPROID	ARNT_HUMAN	PPI_SUMM	ARNT-CYP1A1 interaction
DME0006	UNIPROID	ARNT_HUMAN	DESCRIPT	Hypoxia-inducible factor 1-beta (ARNT) is reported to activate the transcription of CYP1A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between ARNT and CYP1A1 can activate the drug-metabolizing process of Cytochrome P450 1A1.
DME0006	UNIPROID	NFIC_HUMAN	PROTNAME	Nuclear factor 1 C-type (NFIC)
DME0006	UNIPROID	NFIC_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0006	UNIPROID	NFIC_HUMAN	MOFCLASS	Transcription-factor regulation
DME0006	UNIPROID	NFIC_HUMAN	MOFDETAI	Repression
DME0006	UNIPROID	NFIC_HUMAN	CELLLINE	HepG2 cell line
DME0006	UNIPROID	NFIC_HUMAN	PPI_SUMM	NFIC-CYP1A1 interaction
DME0006	UNIPROID	NFIC_HUMAN	DESCRIPT	Nuclear factor 1 C-type (NFIC) is reported to repress the transcription of CYP1A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between NFIC and CYP1A1 can repress the drug-metabolizing process of Cytochrome P450 1A1.
DME0006	UNIPROID	USF1_HUMAN	PROTNAME	Upstream stimulatory 1 (USF1)
DME0006	UNIPROID	USF1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0006	UNIPROID	USF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0006	UNIPROID	USF1_HUMAN	MOFDETAI	Repression
DME0006	UNIPROID	USF1_HUMAN	CELLLINE	Human liver cancer cell line (HepG2) and mouse hepatoma Hepa-1c1c7 cell line
DME0006	UNIPROID	USF1_HUMAN	PPI_SUMM	USF1-CYP1A1 interaction
DME0006	UNIPROID	USF1_HUMAN	DESCRIPT	Upstream stimulatory 1 (USF1) is reported to repress the transcription of CYP1A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between USF1 and CYP1A1 can repress the drug-metabolizing process of Cytochrome P450 1A1.
DME0006	UNIPROID	ESR1_HUMAN	PROTNAME	Estrogen receptor (ESR1)
DME0006	UNIPROID	ESR1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0006	UNIPROID	ESR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0006	UNIPROID	ESR1_HUMAN	MOFDETAI	Repression
DME0006	UNIPROID	ESR1_HUMAN	CELLLINE	MCF-7 cell line
DME0006	UNIPROID	ESR1_HUMAN	PPI_SUMM	ESR1-CYP1A1 interaction
DME0006	UNIPROID	ESR1_HUMAN	DESCRIPT	Estrogen receptor (ESR1) is reported to repress the transcription of CYP1A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1A1. As a result, the interaction between ESR1 and CYP1A1 can repress the drug-metabolizing process of Cytochrome P450 1A1.
DME0008	DME___ID	DME0008
DME0008	DME_NAME	Sulfotransferase 1A1 (SULT1A1)
DME0008	SPESNAME	Homo sapiens
DME0008	MIRNA_ID	MIMAT0003300	PROTNAME	hsa-miR-631
DME0008	MIRNA_ID	MIMAT0003300	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0008	MIRNA_ID	MIMAT0003300	MOFCLASS	Non-coding RNA regulation
DME0008	MIRNA_ID	MIMAT0003300	MOFDETAI	microRNA regulation
DME0008	MIRNA_ID	MIMAT0003300	CELLLINE	ZR75-1 and MCF7 cell lines
DME0008	MIRNA_ID	MIMAT0003300	PPI_SUMM	hsa-miR-631--SULT1A1 regulation
DME0008	MIRNA_ID	MIMAT0003300	DESCRIPT	hsa-miR-631 is reported to suppress SULT1A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of SULT1A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Sulfotransferase 1A1.
DME0009	DME___ID	DME0009
DME0009	DME_NAME	Cytochrome P450 2D6 (CYP2D6)
DME0009	SPESNAME	Homo sapiens
DME0009	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME0009	UNIPROID	CP2E1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0009	UNIPROID	CP2E1_HUMAN	MOFCLASS	Oligomerization
DME0009	UNIPROID	CP2E1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0009	UNIPROID	CP2E1_HUMAN	SUBSTRAT	AMMC (Metabolic product: AMMC O-demethylation)
DME0009	UNIPROID	CP2E1_HUMAN	CELLLINE	Insect cell microsomes
DME0009	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-CYP2D6 heterooligomerization
DME0009	UNIPROID	CP2E1_HUMAN	DESCRIPT	Cytochrome P450 2E1 (CYP2E1) is reported to heterooligomerize with the CYP2D6 protein, which leads to an altered activity of the drug-metabolizing enzyme Cytochrome P450 2D6. As a result, the interaction between CYP2E1 and CYP2D6 can alter the drug-metabolizing process of Cytochrome P450 2D6.
DME0009	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME0009	UNIPROID	CP2C9_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0009	UNIPROID	CP2C9_HUMAN	MOFCLASS	Oligomerization
DME0009	UNIPROID	CP2C9_HUMAN	MOFDETAI	Hetero-oligomerization
DME0009	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Dextromethorphan (Metabolic product: Dextromethorphan O-demethylation)
DME0009	UNIPROID	CP2C9_HUMAN	CELLLINE	DLPC vesicles
DME0009	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-CYP2D6 heterooligomerization
DME0009	UNIPROID	CP2C9_HUMAN	DESCRIPT	Cytochrome P450 2C9 (CYP2C9) is reported to heterooligomerize with the CYP2D6 protein, which has no effect on the enzyme activity of Cytochrome P450 2D6. As a result, the interaction between CYP2C9 and CYP2D6 can have no effect on the drug-metabolizing process of Cytochrome P450 2D6.
DME0009	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0009	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0009	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0009	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0009	UNIPROID	CYB5_HUMAN	SUBSTRAT	Dextromethorphan
DME0009	UNIPROID	CYB5_HUMAN	CELLLINE	Transformed E. coli C41 (DE3) cell line
DME0009	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP2D6 heterodimerization
DME0009	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterodimerize with the CYP2D6 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 2D6. As a result, the interaction between CYB5A and CYP2D6 can facilitate the drug-metabolizing process of Cytochrome P450 2D6.
DME0009	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME0009	UNIPROID	CP3A4_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0009	UNIPROID	CP3A4_HUMAN	MOFCLASS	Oligomerization
DME0009	UNIPROID	CP3A4_HUMAN	MOFDETAI	Hetero-oligomerization
DME0009	UNIPROID	CP3A4_HUMAN	CELLLINE	Living cells
DME0009	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-CYP2D6 heterooligomerization
DME0009	UNIPROID	CP3A4_HUMAN	DESCRIPT	Cytochrome P450 3A4 (CYP3A4) is reported to heterooligomerize with the CYP2D6 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 2D6. As a result, the interaction between CYP3A4 and CYP2D6 can inhibit the drug-metabolizing process of Cytochrome P450 2D6.
DME0009	UNIPROID	HNF4A_HUMAN	PROTNAME	Hepatocyte NF 4-alpha (HNF4A)
DME0009	UNIPROID	HNF4A_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0009	UNIPROID	HNF4A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0009	UNIPROID	HNF4A_HUMAN	MOFDETAI	Activation
DME0009	UNIPROID	HNF4A_HUMAN	CELLLINE	HepG2 cell line
DME0009	UNIPROID	HNF4A_HUMAN	PPI_SUMM	HNF4A-CYP2D6 interaction
DME0009	UNIPROID	HNF4A_HUMAN	DESCRIPT	Hepatocyte NF 4-alpha (HNF4A) is reported to activate the transcription of CYP2D6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2D6. As a result, the interaction between HNF4A and CYP2D6 can activate the drug-metabolizing process of Cytochrome P450 2D6.
DME0009	UNIPROID	HNF4G_HUMAN	PROTNAME	Hepatocyte NF 4-gamma (HNF4G)
DME0009	UNIPROID	HNF4G_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0009	UNIPROID	HNF4G_HUMAN	MOFCLASS	Transcription-factor regulation
DME0009	UNIPROID	HNF4G_HUMAN	MOFDETAI	Activation
DME0009	UNIPROID	HNF4G_HUMAN	CELLLINE	HepG2 cell line
DME0009	UNIPROID	HNF4G_HUMAN	PPI_SUMM	HNF4G-CYP2D6 interaction
DME0009	UNIPROID	HNF4G_HUMAN	DESCRIPT	Hepatocyte NF 4-gamma (HNF4G) is reported to activate the transcription of CYP2D6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2D6. As a result, the interaction between HNF4G and CYP2D6 can activate the drug-metabolizing process of Cytochrome P450 2D6.
DME0011	DME___ID	DME0011
DME0011	DME_NAME	Glutathione S-transferase alpha-1 (GSTA1)
DME0011	SPESNAME	Homo sapiens
DME0011	UNIPROID	NF2L2_HUMAN	PROTNAME	NFE2-related factor 2 (NFE2L2)
DME0011	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0011	UNIPROID	NF2L2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0011	UNIPROID	NF2L2_HUMAN	MOFDETAI	Repression
DME0011	UNIPROID	NF2L2_HUMAN	CELLLINE	HepG2 cell line
DME0011	UNIPROID	NF2L2_HUMAN	PPI_SUMM	NFE2L2-GSTA1 interaction
DME0011	UNIPROID	NF2L2_HUMAN	DESCRIPT	NFE2-related factor 2 (NFE2L2) is reported to repress the transcription of GSTA1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Glutathione S-transferase alpha-1. As a result, the interaction between NFE2L2 and GSTA1 can repress the drug-metabolizing process of Glutathione S-transferase alpha-1.
DME0011	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0011	UNIPROID	NF2L2_HUMAN	MOFDETAI	Activation
DME0011	UNIPROID	NF2L2_HUMAN	CELLLINE	HEK 293T cell line
DME0011	UNIPROID	NF2L2_HUMAN	DESCRIPT	NFE2-related factor 2 (NFE2L2) is reported to activate the transcription of GSTA1 gene, which leads to an increased expression of the drug-metabolizing enzyme Glutathione S-transferase alpha-1. As a result, the interaction between NFE2L2 and GSTA1 can activate the drug-metabolizing process of Glutathione S-transferase alpha-1.
DME0012	DME___ID	DME0012
DME0012	DME_NAME	Cytochrome P450 3A5 (CYP3A5)
DME0012	SPESNAME	Homo sapiens
DME0012	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0012	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0012	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0012	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0012	UNIPROID	CYB5_HUMAN	CELLLINE	DLPC vesicles
DME0012	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP3A5 heterooligomerization
DME0012	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterooligomerize with the CYP3A5 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction between CYB5A and CYP3A5 can facilitate the drug-metabolizing process of Cytochrome P450 3A5.
DME0012	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0012	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0012	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0012	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0012	UNIPROID	NCPR_HUMAN	SUBSTRAT	Tacrolimus
DME0012	UNIPROID	NCPR_HUMAN	CELLLINE	Reconstituted liposomes
DME0012	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR-CYP3A5 heterooligomerization
DME0012	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) is reported to heterooligomerize with the CYP3A5 protein, which leads to activation of the drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction between POR and CYP3A5 can activate the drug-metabolizing process of Cytochrome P450 3A5.
DME0012	UNIPROID	NCPR_HUMAN	PROTNAME	Mutated NADPH-CYP450 reductase (mPOR)
DME0012	UNIPROID	NCPR_HUMAN	CELLLINE	Escherichia coli BL21(DE3) cell line
DME0012	UNIPROID	NCPR_HUMAN	PPI_SUMM	mPOR-CYP3A5 heterooligomerization
DME0012	UNIPROID	NCPR_HUMAN	DESCRIPT	Mutated NADPH-CYP450 reductase (mPOR) is reported to heterooligomerize with the CYP3A5 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction mutant type between mPOR and CYP3A5 can inhibit the drug-metabolizing process of Cytochrome P450 3A5.
DME0012	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME0012	UNIPROID	CP2E1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0012	UNIPROID	CP2E1_HUMAN	MOFCLASS	Oligomerization
DME0012	UNIPROID	CP2E1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0012	UNIPROID	CP2E1_HUMAN	SUBSTRAT	7-Benzyloxyquinoline (Metabolic product: 7-BQ O-debenzylation)
DME0012	UNIPROID	CP2E1_HUMAN	CELLLINE	Insect cell microsomes
DME0012	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-CYP3A5 heterooligomerization
DME0012	UNIPROID	CP2E1_HUMAN	DESCRIPT	Cytochrome P450 2E1 (CYP2E1) is reported to heterooligomerize with the CYP3A5 protein, which leads to a slight effect on the activity of drug-metabolizing enzyme Cytochrome P450 3A5. As a result, the interaction between CYP2E1 and CYP3A5 slightly affects the drug-metabolizing process of Cytochrome P450 3A5.
DME0013	DME___ID	DME0013
DME0013	DME_NAME	Cytochrome P450 2E1 (CYP2E1)
DME0013	SPESNAME	Homo sapiens
DME0013	UNIPROID	HAT1_HUMAN	PROTNAME	Histone acetyltransferases (HATs)
DME0013	UNIPROID	HAT1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0013	UNIPROID	HAT1_HUMAN	MOFCLASS	Histone modification
DME0013	UNIPROID	HAT1_HUMAN	MOFDETAI	Histone hyperacetylation
DME0013	UNIPROID	HAT1_HUMAN	CELLLINE	HepG2 cell line
DME0013	UNIPROID	HAT1_HUMAN	PPI_SUMM	HATs-CYP2E1 interaction
DME0013	UNIPROID	HAT1_HUMAN	DESCRIPT	Histone acetyltransferases (HATs) are reported to acetylate the CYP2E1 gene and thereby activate the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between HATs and CYP2E1 can enhance the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0013	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0013	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0013	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0013	UNIPROID	CYB5_HUMAN	SUBSTRAT	Chlorzoxazone (Metabolic product: Chlorzoxazone 6-hydroxylation)
DME0013	UNIPROID	CYB5_HUMAN	CELLLINE	Escherichia coli cell line
DME0013	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP2E1 heterooligomerization
DME0013	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterooligomerize with the CYP2E1 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between CYB5A and CYP2E1 can facilitate the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0013	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0013	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0013	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0013	UNIPROID	NCPR_HUMAN	SUBSTRAT	N-nitrosodimethylamine
DME0013	UNIPROID	NCPR_HUMAN	CELLLINE	Baculovirus expression system
DME0013	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR-CYP2E1 heterodimerization
DME0013	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) is reported to heterodimerize with the CYP2E1 protein, which leads to an altered activity of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between POR and CYP2E1 can modulate the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	PGRC1_HUMAN	PROTNAME	Progesterone receptor 1 (PGRMC1)
DME0013	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0013	UNIPROID	PGRC1_HUMAN	MOFCLASS	Oligomerization
DME0013	UNIPROID	PGRC1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0013	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Chlorzoxazone (Metabolic product: Chlorzoxazone 6-hydroxylase); 7-ethoxycoumarin (Metabolic product: 7-ethoxycoumarin O-deethylase)
DME0013	UNIPROID	PGRC1_HUMAN	CELLLINE	Human liver cancer cell line (HepG2)
DME0013	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP2E1 heterooligomerization
DME0013	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP2E1 protein, which leads to a slight effect on the enzyme activity of Cytochrome P450 2E1. As a result, the interaction between PGRMC1 and CYP2E1 can slightly affect the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME0013	UNIPROID	CP3A4_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0013	UNIPROID	CP3A4_HUMAN	MOFCLASS	Oligomerization
DME0013	UNIPROID	CP3A4_HUMAN	MOFDETAI	Hetero-oligomerization
DME0013	UNIPROID	CP3A4_HUMAN	SUBSTRAT	7-Methoxy-4-(trifluoromethyl) coumarin (Metabolic product: 7-MFC O-demethylation)
DME0013	UNIPROID	CP3A4_HUMAN	CELLLINE	Insect cell microsomes
DME0013	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-CYP2E1 heterooligomerization
DME0013	UNIPROID	CP3A4_HUMAN	DESCRIPT	Cytochrome P450 3A4 (CYP3A4) is reported to heterooligomerize with the CYP2E1 protein, which leads to activation of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between CYP3A4 and CYP2E1 can activate the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME0013	UNIPROID	CP3A5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0013	UNIPROID	CP3A5_HUMAN	MOFCLASS	Oligomerization
DME0013	UNIPROID	CP3A5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0013	UNIPROID	CP3A5_HUMAN	SUBSTRAT	7-Methoxy-4-(trifluoromethyl) coumarin (Metabolic product: 7-MFC O-demethylation)
DME0013	UNIPROID	CP3A5_HUMAN	CELLLINE	Insect cell microsomes
DME0013	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-CYP2E1 heterooligomerization
DME0013	UNIPROID	CP3A5_HUMAN	DESCRIPT	Cytochrome P450 3A5 (CYP3A5) is reported to heterooligomerize with the CYP2E1 protein, which leads to activation of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between CYP3A5 and CYP2E1 can activate the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME0013	UNIPROID	CP2D6_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0013	UNIPROID	CP2D6_HUMAN	MOFCLASS	Oligomerization
DME0013	UNIPROID	CP2D6_HUMAN	MOFDETAI	Hetero-oligomerization
DME0013	UNIPROID	CP2D6_HUMAN	SUBSTRAT	7-Methoxy-4-(trifluoromethyl) coumarin (Metabolic product: 7-MFC O-demethylation)
DME0013	UNIPROID	CP2D6_HUMAN	CELLLINE	Insect cell microsomes
DME0013	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-CYP2E1 heterooligomerization
DME0013	UNIPROID	CP2D6_HUMAN	DESCRIPT	Cytochrome P450 2D6 (CYP2D6) is reported to heterooligomerize with the CYP2E1 protein, which leads to a decreased activity of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between CYP2D6 and CYP2E1 can decrease the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME0013	UNIPROID	CP2A6_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0013	UNIPROID	CP2A6_HUMAN	MOFCLASS	Oligomerization
DME0013	UNIPROID	CP2A6_HUMAN	MOFDETAI	Hetero-oligomerization
DME0013	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Coumarin; N-nitrosodimethylamine
DME0013	UNIPROID	CP2A6_HUMAN	CELLLINE	Baculovirus expression system
DME0013	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2E1, POR and CYP2A6 heterooligomerization
DME0013	UNIPROID	CP2A6_HUMAN	DESCRIPT	Cytochrome P450 2A6 (CYP2A6) and NADPH-CYP450 reductase (POR) are reported to heterooligomerize with the CYP2E1 protein, which leads to a decreased activity of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction among CYP2A6, POR and CYP2E1 can decrease the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	CP2A6_HUMAN	CELLLINE	Living cells
DME0013	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-CYP2E1 heterooligomerization
DME0013	UNIPROID	CP2A6_HUMAN	DESCRIPT	Cytochrome P450 2A6 (CYP2A6) is reported to heterooligomerize with the CYP2E1 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between CYP2A6 and CYP2E1 can inhibit the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	NFAC1_HUMAN	PROTNAME	NF of activated T-cell 1 (NFATC1)
DME0013	UNIPROID	NFAC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0013	UNIPROID	NFAC1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0013	UNIPROID	NFAC1_HUMAN	MOFDETAI	Activation
DME0013	UNIPROID	NFAC1_HUMAN	CELLLINE	B16A2 cell line
DME0013	UNIPROID	NFAC1_HUMAN	PPI_SUMM	NFATC1-CYP2E1 interaction
DME0013	UNIPROID	NFAC1_HUMAN	DESCRIPT	NF of activated T-cell 1 (NFATC1) is reported to activate the transcription of CYP2E1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between NFATC1 and CYP2E1 can activate the drug-metabolizing process of Cytochrome P450 2E1.
DME0013	UNIPROID	STAT6_HUMAN	PROTNAME	STAT 6 (STAT6)
DME0013	UNIPROID	STAT6_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0013	UNIPROID	STAT6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0013	UNIPROID	STAT6_HUMAN	MOFDETAI	Activation
DME0013	UNIPROID	STAT6_HUMAN	CELLLINE	B16A2 cell line
DME0013	UNIPROID	STAT6_HUMAN	PPI_SUMM	STAT6-CYP2E1 interaction
DME0013	UNIPROID	STAT6_HUMAN	DESCRIPT	STAT 6 (STAT6) is reported to activate the transcription of CYP2E1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2E1. As a result, the interaction between STAT6 and CYP2E1 can activate the drug-metabolizing process of Cytochrome P450 2E1.
DME0015	DME___ID	DME0015
DME0015	DME_NAME	Cytochrome P450 3A7 (CYP3A7)
DME0015	SPESNAME	Homo sapiens
DME0015	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0015	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0015	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0015	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0015	UNIPROID	EHMT1_HUMAN	CELLLINE	HepG2 cell line
DME0015	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-CYP3A7 interaction
DME0015	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 4 dimethylation of CYP3A7 gene is reported to activate the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 3A7. As a result, the interaction between Histone methyltransferases (HMTs) and CYP3A7 can enhance the drug-metabolizing process of Cytochrome P450 3A7.
DME0018	DME___ID	DME0018
DME0018	DME_NAME	Cytochrome P450 2C8 (CYP2C8)
DME0018	SPESNAME	Homo sapiens
DME0018	MIRNA_ID	MIMAT0000101	PROTNAME	hsa-miR-103a-3p
DME0018	MIRNA_ID	MIMAT0000101	HPPI_DIS	Health [ICD-11: N.A.]
DME0018	MIRNA_ID	MIMAT0000101	MOFCLASS	Non-coding RNA regulation
DME0018	MIRNA_ID	MIMAT0000101	MOFDETAI	microRNA regulation
DME0018	MIRNA_ID	MIMAT0000101	CELLLINE	Hepatocytes
DME0018	MIRNA_ID	MIMAT0000101	PPI_SUMM	hsa-miR-103a-3p--CYP2C8 regulation
DME0018	MIRNA_ID	MIMAT0000101	DESCRIPT	hsa-miR-103a-3p is reported to suppress CYP2C8 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C8 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2C8.
DME0018	MIRNA_ID	MIMAT0000104	PROTNAME	hsa-miR-107
DME0018	MIRNA_ID	MIMAT0000104	HPPI_DIS	Health [ICD-11: N.A.]
DME0018	MIRNA_ID	MIMAT0000104	MOFCLASS	Non-coding RNA regulation
DME0018	MIRNA_ID	MIMAT0000104	MOFDETAI	microRNA regulation
DME0018	MIRNA_ID	MIMAT0000104	CELLLINE	Hepatocytes
DME0018	MIRNA_ID	MIMAT0000104	PPI_SUMM	hsa-miR-107--CYP2C8 regulation
DME0018	MIRNA_ID	MIMAT0000104	DESCRIPT	hsa-miR-107 is reported to suppress CYP2C8 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C8 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2C8.
DME0018	UNIPROID	PGRC1_HUMAN	PROTNAME	Progesterone receptor 1 (PGRMC1)
DME0018	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0018	UNIPROID	PGRC1_HUMAN	MOFCLASS	Oligomerization
DME0018	UNIPROID	PGRC1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0018	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Luciferin (Metabolic product: Luciferin 6' methyl ether O-demethylation)
DME0018	UNIPROID	PGRC1_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293) and Human liver cancer cell line (HepG2)
DME0018	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP2C8 heterooligomerization
DME0018	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP2C8 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 2C8. As a result, the interaction between PGRMC1 and CYP2C8 can inhibit the drug-metabolizing process of Cytochrome P450 2C8.
DME0018	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0018	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0018	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0018	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0018	UNIPROID	CYB5_HUMAN	CELLLINE	DLPC vesicles
DME0018	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP2C8 heterooligomerization
DME0018	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterooligomerize with the CYP2C8 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 2C8. As a result, the interaction between CYB5A and CYP2C8 can facilitate the drug-metabolizing process of Cytochrome P450 2C8.
DME0018	UNIPROID	HNF4A_HUMAN	PROTNAME	Hepatocyte NF 4-alpha (HNF4A)
DME0018	UNIPROID	HNF4A_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0018	UNIPROID	HNF4A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0018	UNIPROID	HNF4A_HUMAN	MOFDETAI	Activation
DME0018	UNIPROID	HNF4A_HUMAN	CELLLINE	HepG2 cell line
DME0018	UNIPROID	HNF4A_HUMAN	PPI_SUMM	HNF4A-CYP2C8 interaction
DME0018	UNIPROID	HNF4A_HUMAN	DESCRIPT	Hepatocyte NF 4-alpha (HNF4A) is reported to activate the transcription of CYP2C8 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2C8. As a result, the interaction between HNF4A and CYP2C8 can activate the drug-metabolizing process of Cytochrome P450 2C8.
DME0019	DME___ID	DME0019
DME0019	DME_NAME	Cytochrome P450 2C9 (CYP2C9)
DME0019	SPESNAME	Homo sapiens
DME0019	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0019	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0019	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0019	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0019	UNIPROID	HDAC1_HUMAN	CELLLINE	Mouse Model
DME0019	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP2C9 interaction
DME0019	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP2C9 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between HDACs and CYP2C9 can inhibit the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	MIRNA_ID	MIMAT0000424	PROTNAME	hsa-miR-128-3p
DME0019	MIRNA_ID	MIMAT0000424	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0019	MIRNA_ID	MIMAT0000424	MOFCLASS	Non-coding RNA regulation
DME0019	MIRNA_ID	MIMAT0000424	MOFDETAI	microRNA regulation
DME0019	MIRNA_ID	MIMAT0000424	CELLLINE	HepG2 cell line
DME0019	MIRNA_ID	MIMAT0000424	PPI_SUMM	hsa-miR-128-3p--CYP2C9 regulation
DME0019	MIRNA_ID	MIMAT0000424	DESCRIPT	hsa-miR-128-3p is reported to suppress CYP2C9 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2C9.
DME0019	MIRNA_ID	MIMAT0000435	PROTNAME	hsa-miR-143-3p
DME0019	MIRNA_ID	MIMAT0000435	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0019	MIRNA_ID	MIMAT0000435	MOFCLASS	Non-coding RNA regulation
DME0019	MIRNA_ID	MIMAT0000435	MOFDETAI	microRNA regulation
DME0019	MIRNA_ID	MIMAT0000435	CELLLINE	HepG2 cell line
DME0019	MIRNA_ID	MIMAT0000435	PPI_SUMM	hsa-miR-143-3p--CYP2C9 regulation
DME0019	MIRNA_ID	MIMAT0000435	DESCRIPT	hsa-miR-143-3p is reported to suppress CYP2C9 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2C9.
DME0019	MIRNA_ID	MIMAT0000691	PROTNAME	hsa-miR-130b-3p
DME0019	MIRNA_ID	MIMAT0000691	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0019	MIRNA_ID	MIMAT0000691	MOFCLASS	Non-coding RNA regulation
DME0019	MIRNA_ID	MIMAT0000691	MOFDETAI	microRNA regulation
DME0019	MIRNA_ID	MIMAT0000691	CELLLINE	HepaRG cell line
DME0019	MIRNA_ID	MIMAT0000691	PPI_SUMM	hsa-miR-130b-3p--CYP2C9 regulation
DME0019	MIRNA_ID	MIMAT0000691	DESCRIPT	hsa-miR-130b-3p is reported to suppress CYP2C9 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2C9.
DME0019	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0019	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0019	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0019	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0019	UNIPROID	CYB5_HUMAN	SUBSTRAT	Tolbutamide (Metabolic product: Tolbutamide methyl hydroxylation)
DME0019	UNIPROID	CYB5_HUMAN	CELLLINE	Escherichia coli cell line
DME0019	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP2C9 heterooligomerization
DME0019	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterooligomerize with the CYP2C9 protein, which leads to an increased activity of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between CYB5A and CYP2C9 can facilitate the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME0019	UNIPROID	CP3A4_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0019	UNIPROID	CP3A4_HUMAN	MOFCLASS	Oligomerization
DME0019	UNIPROID	CP3A4_HUMAN	MOFDETAI	Hetero-oligomerization
DME0019	UNIPROID	CP3A4_HUMAN	SUBSTRAT	S-naproxen; S-flurbiprofen; Diclofenac
DME0019	UNIPROID	CP3A4_HUMAN	CELLLINE	pCW vector; Human hepatocyte culture model
DME0019	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-CYP2C9 heterooligomerization
DME0019	UNIPROID	CP3A4_HUMAN	DESCRIPT	Cytochrome P450 3A4 (CYP3A4) is reported to heterooligomerize with the CYP2C9 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between CYP3A4 and CYP2C9 can inhibit the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	UNIPROID	NCPR_HUMAN	PROTNAME	Mutated NADPH-CYP450 reductase (mPOR)
DME0019	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0019	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0019	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0019	UNIPROID	NCPR_HUMAN	SUBSTRAT	Warfarin; Diclofenac; Losartan
DME0019	UNIPROID	NCPR_HUMAN	CELLLINE	Reconstituted liposomes
DME0019	UNIPROID	NCPR_HUMAN	PPI_SUMM	mPOR-CYP2C9 heterooligomerization
DME0019	UNIPROID	NCPR_HUMAN	DESCRIPT	Mutated NADPH-CYP450 reductase (mPOR) is reported to heterooligomerize with the CYP2C9 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between mPOR and CYP2C9 can inhibit the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0019	UNIPROID	NCPR_HUMAN	CELLLINE	Transformed E. coli C41 (DE3) cell line
DME0019	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR-CYP2C9 heterooligomerization
DME0019	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) is reported to heterooligomerize with the CYP2C9 protein, which leads to activation of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between POR and CYP2C9 can activate the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	UNIPROID	PGRC1_HUMAN	PROTNAME	Progesterone receptor 1 (PGRMC1)
DME0019	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0019	UNIPROID	PGRC1_HUMAN	MOFCLASS	Oligomerization
DME0019	UNIPROID	PGRC1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0019	UNIPROID	PGRC1_HUMAN	SUBSTRAT	S-Warfarin (Metabolic product: S-warfarin 7-hydroxylase); Diclofenac (Metabolic product: Diclofenac 4-hydroxylase)
DME0019	UNIPROID	PGRC1_HUMAN	CELLLINE	Human liver cancer cell line (HepG2)
DME0019	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP2C9 heterooligomerization
DME0019	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP2C9 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between PGRMC1 and CYP2C9 can inhibit the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME0019	UNIPROID	CP2D6_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0019	UNIPROID	CP2D6_HUMAN	MOFCLASS	Oligomerization
DME0019	UNIPROID	CP2D6_HUMAN	MOFDETAI	Hetero-oligomerization
DME0019	UNIPROID	CP2D6_HUMAN	SUBSTRAT	(S)-flurbiprofen (Metabolic product: 4'-OH Flurbiprofen)
DME0019	UNIPROID	CP2D6_HUMAN	CELLLINE	DLPC vesicles
DME0019	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-CYP2C9 heterooligomerization
DME0019	UNIPROID	CP2D6_HUMAN	DESCRIPT	Cytochrome P450 2D6 (CYP2D6) is reported to heterooligomerize with the CYP2C9 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between CYP2D6 and CYP2C9 can inhibit the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	UNIPROID	CP2CJ_HUMAN	PROTNAME	Cytochrome P450 2C19 (CYP2C19)
DME0019	UNIPROID	CP2CJ_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0019	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Oligomerization
DME0019	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Hetero-oligomerization
DME0019	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Diclofenac (Metabolic product: Diclofenac 4-hydroxylase)
DME0019	UNIPROID	CP2CJ_HUMAN	CELLLINE	Living cells
DME0019	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-CYP2C9 heterooligomerization
DME0019	UNIPROID	CP2CJ_HUMAN	DESCRIPT	Cytochrome P450 2C19 (CYP2C19) is reported to heterooligomerize with the CYP2C9 protein, which leads to activation of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between CYP2C19 and CYP2C9 can activate the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	UNIPROID	HNF4A_HUMAN	PROTNAME	Hepatocyte NF 4-alpha (HNF4A)
DME0019	UNIPROID	HNF4A_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0019	UNIPROID	HNF4A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0019	UNIPROID	HNF4A_HUMAN	MOFDETAI	Activation
DME0019	UNIPROID	HNF4A_HUMAN	CELLLINE	HepG2 cell line
DME0019	UNIPROID	HNF4A_HUMAN	PPI_SUMM	HNF4A-CYP2C9 interaction
DME0019	UNIPROID	HNF4A_HUMAN	DESCRIPT	Hepatocyte NF 4-alpha (HNF4A) is reported to activate the transcription of CYP2C9 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between HNF4A and CYP2C9 can activate the drug-metabolizing process of Cytochrome P450 2C9.
DME0019	UNIPROID	PPARA_HUMAN	PROTNAME	PPA receptor alpha (PPARA)
DME0019	UNIPROID	PPARA_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0019	UNIPROID	PPARA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0019	UNIPROID	PPARA_HUMAN	MOFDETAI	Repression
DME0019	UNIPROID	PPARA_HUMAN	CELLLINE	Endothelial cell line
DME0019	UNIPROID	PPARA_HUMAN	PPI_SUMM	PPARA-CYP2C9 interaction
DME0019	UNIPROID	PPARA_HUMAN	DESCRIPT	PPA receptor alpha (PPARA) is reported to repress the transcription of CYP2C9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2C9. As a result, the interaction between PPARA and CYP2C9 can repress the drug-metabolizing process of Cytochrome P450 2C9.
DME0020	DME___ID	DME0020
DME0020	DME_NAME	Cytochrome P450 2B6 (CYP2B6)
DME0020	SPESNAME	Homo sapiens
DME0020	MIRNA_ID	MIMAT0000081	PROTNAME	hsa-miR-25-3p
DME0020	MIRNA_ID	MIMAT0000081	HPPI_DIS	Health [ICD-11: N.A.]
DME0020	MIRNA_ID	MIMAT0000081	MOFCLASS	Non-coding RNA regulation
DME0020	MIRNA_ID	MIMAT0000081	MOFDETAI	microRNA regulation
DME0020	MIRNA_ID	MIMAT0000081	CELLLINE	HEK293 cell line
DME0020	MIRNA_ID	MIMAT0000081	PPI_SUMM	hsa-miR-25-3p--CYP2B6 regulation
DME0020	MIRNA_ID	MIMAT0000081	DESCRIPT	hsa-miR-25-3p is reported to suppress CYP2B6 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2B6 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2B6.
DME0020	UNIPROID	ATF5_HUMAN	PROTNAME	Activating TF factor 5 (ATF5)
DME0020	UNIPROID	ATF5_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0020	UNIPROID	ATF5_HUMAN	MOFCLASS	Transcription-factor regulation
DME0020	UNIPROID	ATF5_HUMAN	MOFDETAI	Activation
DME0020	UNIPROID	ATF5_HUMAN	CELLLINE	HepG2, Hep3B and Mz cell lines
DME0020	UNIPROID	ATF5_HUMAN	PPI_SUMM	ATF5-CYP2B6 interaction
DME0020	UNIPROID	ATF5_HUMAN	DESCRIPT	Activating TF factor 5 (ATF5) is reported to activate the transcription of CYP2B6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2B6. As a result, the interaction between ATF5 and CYP2B6 can activate the drug-metabolizing process of Cytochrome P450 2B6.
DME0020	UNIPROID	EGR1_HUMAN	PROTNAME	Early growth response 1 (EGR1)
DME0020	UNIPROID	EGR1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0020	UNIPROID	EGR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0020	UNIPROID	EGR1_HUMAN	MOFDETAI	Activation
DME0020	UNIPROID	EGR1_HUMAN	CELLLINE	Ym17, Yh18 and COS-1 cell lines
DME0020	UNIPROID	EGR1_HUMAN	PPI_SUMM	EGR1-CYP2B6 interaction
DME0020	UNIPROID	EGR1_HUMAN	DESCRIPT	Early growth response 1 (EGR1) is reported to activate the transcription of CYP2B6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2B6. As a result, the interaction between EGR1 and CYP2B6 can activate the drug-metabolizing process of Cytochrome P450 2B6.
DME0020	UNIPROID	NR1I3_HUMAN	PROTNAME	Nuclear receptor family 0 I3 (NR1I3)
DME0020	UNIPROID	NR1I3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0020	UNIPROID	NR1I3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0020	UNIPROID	NR1I3_HUMAN	MOFDETAI	Activation
DME0020	UNIPROID	NR1I3_HUMAN	CELLLINE	Healthy subjects
DME0020	UNIPROID	NR1I3_HUMAN	PPI_SUMM	NR1I3-CYP2B6 interaction
DME0020	UNIPROID	NR1I3_HUMAN	DESCRIPT	Nuclear receptor family 0 I3 (NR1I3) is reported to activate the transcription of CYP2B6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2B6. As a result, the interaction between NR1I3 and CYP2B6 can activate the drug-metabolizing process of Cytochrome P450 2B6.
DME0021	DME___ID	DME0021
DME0021	DME_NAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME0021	SPESNAME	Homo sapiens
DME0021	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0021	UNIPROID	HDAC1_HUMAN	HPPI_DIS	T-cell acute lymphoblastic leukemia [ICD-11: 2A90]
DME0021	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0021	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0021	UNIPROID	HDAC1_HUMAN	CELLLINE	T-ALL cell line
DME0021	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP2C19 interaction
DME0021	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP2C19 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between HDACs and CYP2C19 can inhibit the drug-metabolizing process of Mephenytoin 4-hydroxylase.
DME0021	MIRNA_ID	MIMAT0000086	PROTNAME	hsa-miR-29a-3p
DME0021	MIRNA_ID	MIMAT0000086	HPPI_DIS	Health [ICD-11: N.A.]
DME0021	MIRNA_ID	MIMAT0000086	MOFCLASS	Non-coding RNA regulation
DME0021	MIRNA_ID	MIMAT0000086	MOFDETAI	microRNA regulation
DME0021	MIRNA_ID	MIMAT0000086	CELLLINE	HEK293 cell line
DME0021	MIRNA_ID	MIMAT0000086	PPI_SUMM	hsa-miR-29a-3p--CYP2C19 regulation
DME0021	MIRNA_ID	MIMAT0000086	DESCRIPT	hsa-miR-29a-3p is reported to suppress CYP2C19 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C19 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase.
DME0021	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0021	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0021	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0021	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0021	UNIPROID	CYB5_HUMAN	CELLLINE	DLPC vesicles
DME0021	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP2C19 heterodimerization
DME0021	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterodimerize with the CYP2C19 protein, which leads to an altered activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between CYB5A and CYP2C19 can modulate the drug-metabolizing process of Mephenytoin 4-hydroxylase.
DME0021	UNIPROID	NCPR_HUMAN	PROTNAME	Mutated NADPH-CYP450 reductase (mPOR)
DME0021	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0021	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0021	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0021	UNIPROID	NCPR_HUMAN	SUBSTRAT	S-mephenytoin; Omeprazole; Propranolol
DME0021	UNIPROID	NCPR_HUMAN	CELLLINE	Reconstituted liposomes
DME0021	UNIPROID	NCPR_HUMAN	PPI_SUMM	mPOR-CYP2C19 heterooligomerization
DME0021	UNIPROID	NCPR_HUMAN	DESCRIPT	Mutated NADPH-CYP450 reductase (mPOR) is reported to heterooligomerize with the CYP2C19 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between mPOR and CYP2C19 can inhibit the drug-metabolizing process of Mephenytoin 4-hydroxylase.
DME0021	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0021	UNIPROID	NCPR_HUMAN	CELLLINE	Transformed E. coli C41 (DE3) cell line
DME0021	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR-CYP2C19 heterooligomerization
DME0021	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) is reported to heterooligomerize with the CYP2C19 protein, which leads to activation of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between POR and CYP2C19 can activate the drug-metabolizing process of Mephenytoin 4-hydroxylase.
DME0021	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME0021	UNIPROID	CP2E1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0021	UNIPROID	CP2E1_HUMAN	MOFCLASS	Oligomerization
DME0021	UNIPROID	CP2E1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0021	UNIPROID	CP2E1_HUMAN	SUBSTRAT	7-Ethoxy-4-cyanocoumarin
DME0021	UNIPROID	CP2E1_HUMAN	CELLLINE	Escherichia coli cell line
DME0021	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-CYP2C19 heterooligomerization
DME0021	UNIPROID	CP2E1_HUMAN	DESCRIPT	Cytochrome P450 2E1 (CYP2E1) is reported to heterooligomerize with the CYP2C19 protein, which leads to an increased activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between CYP2E1 and CYP2C19 can facilitate the drug-metabolizing process of Mephenytoin 4-hydroxylase.
DME0021	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME0021	UNIPROID	CP2C9_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0021	UNIPROID	CP2C9_HUMAN	MOFCLASS	Oligomerization
DME0021	UNIPROID	CP2C9_HUMAN	MOFDETAI	Hetero-oligomerization
DME0021	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Methoxychlor and S-mephenytoin
DME0021	UNIPROID	CP2C9_HUMAN	CELLLINE	Living cells
DME0021	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-CYP2C19 heterooligomerization
DME0021	UNIPROID	CP2C9_HUMAN	DESCRIPT	Cytochrome P450 2C9 (CYP2C9) is reported to heterooligomerize with the CYP2C19 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between CYP2C9 and CYP2C19 can inhibit the drug-metabolizing process of Mephenytoin 4-hydroxylase.
DME0021	UNIPROID	ESR1_HUMAN	PROTNAME	Estrogen receptor (ESR1)
DME0021	UNIPROID	ESR1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0021	UNIPROID	ESR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0021	UNIPROID	ESR1_HUMAN	MOFDETAI	Repression
DME0021	UNIPROID	ESR1_HUMAN	CELLLINE	Embryonic kidney 293 CYP2C19 cell line
DME0021	UNIPROID	ESR1_HUMAN	PPI_SUMM	ESR1-CYP2C19 interaction
DME0021	UNIPROID	ESR1_HUMAN	DESCRIPT	Estrogen receptor (ESR1) is reported to repress the transcription of CYP2C19 gene, which leads to a decreased expression of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between ESR1 and CYP2C19 can repress the drug-metabolizing process of Mephenytoin 4-hydroxylase.
DME0023	DME___ID	DME0023
DME0023	DME_NAME	Cytochrome P450 1B1 (CYP1B1)
DME0023	SPESNAME	Homo sapiens
DME0023	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0023	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0023	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0023	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0023	UNIPROID	HDAC1_HUMAN	CELLLINE	HeLa cell line
DME0023	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP1B1 interaction
DME0023	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP1B1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 1B1. As a result, the interaction between HDACs and CYP1B1 can inhibit the drug-metabolizing process of Cytochrome P450 1B1.
DME0023	MIRNA_ID	MIMAT0000419	PROTNAME	hsa-miR-27b-3p
DME0023	MIRNA_ID	MIMAT0000419	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0023	MIRNA_ID	MIMAT0000419	MOFCLASS	Non-coding RNA regulation
DME0023	MIRNA_ID	MIMAT0000419	MOFDETAI	microRNA regulation
DME0023	MIRNA_ID	MIMAT0000419	CELLLINE	HepG2 cell line
DME0023	MIRNA_ID	MIMAT0000419	PPI_SUMM	hsa-miR-27b-3p--CYP1B1 regulation
DME0023	MIRNA_ID	MIMAT0000419	DESCRIPT	hsa-miR-27b-3p is reported to suppress CYP1B1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP1B1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1B1.
DME0023	MIRNA_ID	MIMAT0004657	PROTNAME	hsa-miR-200c-5p
DME0023	MIRNA_ID	MIMAT0004657	HPPI_DIS	Renal cell carcinoma [ICD-11: 2C90]
DME0023	MIRNA_ID	MIMAT0004657	MOFCLASS	Non-coding RNA regulation
DME0023	MIRNA_ID	MIMAT0004657	MOFDETAI	microRNA regulation
DME0023	MIRNA_ID	MIMAT0004657	CELLLINE	Renal cell carcinoma cell line
DME0023	MIRNA_ID	MIMAT0004657	PPI_SUMM	hsa-miR-200c-5p--CYP1B1 regulation
DME0023	MIRNA_ID	MIMAT0004657	DESCRIPT	hsa-miR-200c-5p is reported to suppress CYP1B1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP1B1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1B1.
DME0023	MIRNA_ID	MIMAT0004561	PROTNAME	hsa-miR-187-5p
DME0023	MIRNA_ID	MIMAT0004561	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0023	MIRNA_ID	MIMAT0004561	MOFCLASS	Non-coding RNA regulation
DME0023	MIRNA_ID	MIMAT0004561	MOFDETAI	microRNA regulation
DME0023	MIRNA_ID	MIMAT0004561	CELLLINE	A549 and SPC-A-1 cell lines
DME0023	MIRNA_ID	MIMAT0004561	PPI_SUMM	hsa-miR-187-5p--CYP1B1 regulation
DME0023	MIRNA_ID	MIMAT0004561	DESCRIPT	hsa-miR-187-5p is reported to suppress CYP1B1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP1B1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 1B1.
DME0023	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0023	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0023	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0023	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0023	UNIPROID	CYB5_HUMAN	CELLLINE	Escherichia coli cell line
DME0023	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP1B1 heterodimerization
DME0023	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterodimerize with the CYP1B1 protein, which has no effect on the enzyme activity of Cytochrome P450 1B1. As a result, the interaction between CYB5A and CYP1B1 can have no effect on the drug-metabolizing process of Cytochrome P450 1B1.
DME0023	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0023	UNIPROID	SP1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0023	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0023	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0023	UNIPROID	SP1_HUMAN	CELLLINE	LS-180 cell line
DME0023	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-CYP1B1 interaction
DME0023	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of CYP1B1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 1B1. As a result, the interaction between SP1 and CYP1B1 can activate the drug-metabolizing process of Cytochrome P450 1B1.
DME0023	UNIPROID	SP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0023	UNIPROID	SP1_HUMAN	CELLLINE	HepG2 cell line
DME0023	UNIPROID	SP1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0023	UNIPROID	SP1_HUMAN	CELLLINE	MCF-7 cell line
DME0023	UNIPROID	SP1_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0023	UNIPROID	SP1_HUMAN	CELLLINE	OMC-3 cell line
DME0023	UNIPROID	AHR_HUMAN	PROTNAME	Aryl hydrocarbon receptor (AHR)
DME0023	UNIPROID	AHR_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0023	UNIPROID	AHR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0023	UNIPROID	AHR_HUMAN	MOFDETAI	Activation
DME0023	UNIPROID	AHR_HUMAN	CELLLINE	DU145, DUPro, LNCaP, PC-3 and ND-1 cell lines
DME0023	UNIPROID	AHR_HUMAN	PPI_SUMM	AHR-CYP1B1 interaction
DME0023	UNIPROID	AHR_HUMAN	DESCRIPT	Aryl hydrocarbon receptor (AHR) is reported to activate the transcription of CYP1B1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 1B1. As a result, the interaction between AHR and CYP1B1 can activate the drug-metabolizing process of Cytochrome P450 1B1.
DME0023	UNIPROID	ARNT_HUMAN	PROTNAME	Hypoxia-inducible factor 1-beta (ARNT)
DME0023	UNIPROID	ARNT_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0023	UNIPROID	ARNT_HUMAN	MOFCLASS	Transcription-factor regulation
DME0023	UNIPROID	ARNT_HUMAN	MOFDETAI	Activation
DME0023	UNIPROID	ARNT_HUMAN	CELLLINE	DU145, DUPro, LNCaP, PC-3 and ND-1 cell lines
DME0023	UNIPROID	ARNT_HUMAN	PPI_SUMM	ARNT-CYP1B1 interaction
DME0023	UNIPROID	ARNT_HUMAN	DESCRIPT	Hypoxia-inducible factor 1-beta (ARNT) is reported to activate the transcription of CYP1B1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 1B1. As a result, the interaction between ARNT and CYP1B1 can activate the drug-metabolizing process of Cytochrome P450 1B1.
DME0024	DME___ID	DME0024
DME0024	DME_NAME	Steroid 17-alpha-monooxygenase (CYP17A1)
DME0024	SPESNAME	Homo sapiens
DME0024	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0024	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0024	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0024	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0024	UNIPROID	EHMT1_HUMAN	CELLLINE	Rat testis
DME0024	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-CYP17A1 interaction
DME0024	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 9 trimethylation of CYP17A1 gene is reported to repress the transcriptional activity of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction between Histone methyltransferases (HMTs) and CYP17A1 can inhibit the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0024	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0024	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0024	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0024	UNIPROID	HDAC1_HUMAN	CELLLINE	Mouse adrenocortical Y1 cells
DME0024	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP17A1 interaction
DME0024	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP17A1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction between HDACs and CYP17A1 can inhibit the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	PGRC1_HUMAN	PROTNAME	Progesterone receptor 1 (PGRMC1)
DME0024	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0024	UNIPROID	PGRC1_HUMAN	MOFCLASS	Oligomerization
DME0024	UNIPROID	PGRC1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0024	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Progesterone (Metabolic product: Progesterone 17-hydroxylase); 17-Hydroxyprogesterone (Metabolic product: 17-Hydroxyprogesterone 1720 lyase)
DME0024	UNIPROID	PGRC1_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell (COS)7
DME0024	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP17A1 heterooligomerization
DME0024	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP17A1 protein, which leads to a slight effect on the enzyme activity of Steroid 17-alpha-monooxygenase. As a result, the interaction between PGRMC1 and CYP17A1 can slightly affect on the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0024	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0024	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0024	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0024	UNIPROID	CYB5_HUMAN	SUBSTRAT	Pregnenolone; Progesterone (Metabolic product: 17-Hydroxy pregnenolone)
DME0024	UNIPROID	CYB5_HUMAN	CELLLINE	Yeast cell line
DME0024	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A, POR and CYP17A1 heterooligomerization
DME0024	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) and NADPH-CYP450 reductase (POR) are reported to heterooligomerize with the CYP17A1 protein, which leads to an increased activity of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction among CYB5A, POR and CYP17A1 can facilitate the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-CYP450 reductase (POR)
DME0024	UNIPROID	NCPR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0024	UNIPROID	NCPR_HUMAN	MOFCLASS	Oligomerization
DME0024	UNIPROID	NCPR_HUMAN	MOFDETAI	Hetero-oligomerization
DME0024	UNIPROID	NCPR_HUMAN	SUBSTRAT	Pregnenolone; Progesterone (Metabolic product: 17-Hydroxy pregnenolone)
DME0024	UNIPROID	NCPR_HUMAN	CELLLINE	Yeast cell line
DME0024	UNIPROID	NCPR_HUMAN	PPI_SUMM	POR, CYB5A and CYP17A1 heterooligomerization
DME0024	UNIPROID	NCPR_HUMAN	DESCRIPT	NADPH-CYP450 reductase (POR) and Cytochrome b5 (CYB5A) are reported to heterooligomerize with the CYP17A1 protein, which leads to an increased activity of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction among POR, CYB5A and CYP17A1 can facilitate the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	STF1_HUMAN	PROTNAME	Steroidogenic factor 1 (NR5A1)
DME0024	UNIPROID	STF1_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0024	UNIPROID	STF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0024	UNIPROID	STF1_HUMAN	MOFDETAI	Activation
DME0024	UNIPROID	STF1_HUMAN	CELLLINE	H295R cell line
DME0024	UNIPROID	STF1_HUMAN	PPI_SUMM	NR5A1-CYP17A1 interaction
DME0024	UNIPROID	STF1_HUMAN	DESCRIPT	Steroidogenic factor 1 (NR5A1) is reported to activate the transcription of CYP17A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction between NR5A1 and CYP17A1 can activate the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	SMAD3_HUMAN	PROTNAME	MAD homolog 3 (SMAD3)
DME0024	UNIPROID	SMAD3_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0024	UNIPROID	SMAD3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0024	UNIPROID	SMAD3_HUMAN	MOFDETAI	Repression
DME0024	UNIPROID	SMAD3_HUMAN	CELLLINE	H295R cell line
DME0024	UNIPROID	SMAD3_HUMAN	PPI_SUMM	SMAD3-CYP17A1 interaction
DME0024	UNIPROID	SMAD3_HUMAN	DESCRIPT	MAD homolog 3 (SMAD3) is reported to repress the transcription of CYP17A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction between SMAD3 and CYP17A1 can repress the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	NR0B1_HUMAN	PROTNAME	Nuclear receptor family 0 B1 (NR0B1)
DME0024	UNIPROID	NR0B1_HUMAN	HPPI_DIS	Pituitary adenoma [ICD-11: 2F37]
DME0024	UNIPROID	NR0B1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0024	UNIPROID	NR0B1_HUMAN	MOFDETAI	Repression
DME0024	UNIPROID	NR0B1_HUMAN	CELLLINE	Human adrenal gland and adrenocortical tumor cells
DME0024	UNIPROID	NR0B1_HUMAN	PPI_SUMM	NR0B1-CYP17A1 interaction
DME0024	UNIPROID	NR0B1_HUMAN	DESCRIPT	Nuclear receptor family 0 B1 (NR0B1) is reported to repress the transcription of CYP17A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction between NR0B1 and CYP17A1 can repress the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	COT1_HUMAN	PROTNAME	COUP TF factor 1 (NR2F1)
DME0024	UNIPROID	COT1_HUMAN	HPPI_DIS	Pituitary adenoma [ICD-11: 2F37]
DME0024	UNIPROID	COT1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0024	UNIPROID	COT1_HUMAN	MOFDETAI	Repression
DME0024	UNIPROID	COT1_HUMAN	CELLLINE	Human adrenal gland and adrenocortical tumor cells
DME0024	UNIPROID	COT1_HUMAN	PPI_SUMM	NR2F1-CYP17A1 interaction
DME0024	UNIPROID	COT1_HUMAN	DESCRIPT	COUP TF factor 1 (NR2F1) is reported to repress the transcription of CYP17A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction between NR2F1 and CYP17A1 can repress the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	GATA6_HUMAN	PROTNAME	TF factor GATA-6 (GATA6)
DME0024	UNIPROID	GATA6_HUMAN	HPPI_DIS	Polycystic ovary syndrome [ICD-11: 5A80]
DME0024	UNIPROID	GATA6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0024	UNIPROID	GATA6_HUMAN	MOFDETAI	Activation
DME0024	UNIPROID	GATA6_HUMAN	CELLLINE	PCOS theca cell line
DME0024	UNIPROID	GATA6_HUMAN	PPI_SUMM	GATA6-CYP17A1 interaction
DME0024	UNIPROID	GATA6_HUMAN	DESCRIPT	TF factor GATA-6 (GATA6) is reported to activate the transcription of CYP17A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction between GATA6 and CYP17A1 can activate the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0024	UNIPROID	NFIC_HUMAN	PROTNAME	Nuclear factor 1 C-type (NFIC)
DME0024	UNIPROID	NFIC_HUMAN	HPPI_DIS	Polycystic ovary syndrome [ICD-11: 5A80]
DME0024	UNIPROID	NFIC_HUMAN	MOFCLASS	Transcription-factor regulation
DME0024	UNIPROID	NFIC_HUMAN	MOFDETAI	Activation
DME0024	UNIPROID	NFIC_HUMAN	CELLLINE	PCOS theca cell line
DME0024	UNIPROID	NFIC_HUMAN	PPI_SUMM	NFIC-CYP17A1 interaction
DME0024	UNIPROID	NFIC_HUMAN	DESCRIPT	Nuclear factor 1 C-type (NFIC) is reported to activate the transcription of CYP17A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Steroid 17-alpha-monooxygenase. As a result, the interaction between NFIC and CYP17A1 can activate the drug-metabolizing process of Steroid 17-alpha-monooxygenase.
DME0026	DME___ID	DME0026
DME0026	DME_NAME	Vitamin D(3) 25-hydroxylase (CYP27A1)
DME0026	SPESNAME	Homo sapiens
DME0026	UNIPROID	SP3_HUMAN	PROTNAME	Transcription factor Sp3 (SP3)
DME0026	UNIPROID	SP3_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0026	UNIPROID	SP3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0026	UNIPROID	SP3_HUMAN	MOFDETAI	Activation
DME0026	UNIPROID	SP3_HUMAN	CELLLINE	HepG2 cell line
DME0026	UNIPROID	SP3_HUMAN	PPI_SUMM	SP3-CYP27A1 interaction
DME0026	UNIPROID	SP3_HUMAN	DESCRIPT	Transcription factor Sp3 (SP3) is reported to activate the transcription of CYP27A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between SP3 and CYP27A1 can activate the drug-metabolizing process of Vitamin D(3) 25-hydroxylase.
DME0026	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0026	UNIPROID	SP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0026	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0026	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0026	UNIPROID	SP1_HUMAN	CELLLINE	HepG2 cell line
DME0026	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-CYP27A1 interaction
DME0026	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of CYP27A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between SP1 and CYP27A1 can activate the drug-metabolizing process of Vitamin D(3) 25-hydroxylase.
DME0027	DME___ID	DME0027
DME0027	DME_NAME	Steroid 11-beta-hydroxylase (CYP11B1)
DME0027	SPESNAME	Homo sapiens
DME0027	UNIPROID	PGRC1_HUMAN	PROTNAME	Progesterone receptor 1 (PGRMC1)
DME0027	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0027	UNIPROID	PGRC1_HUMAN	MOFCLASS	Oligomerization
DME0027	UNIPROID	PGRC1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0027	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Progesterone (Metabolic product: Progesterone 11-hydroxylase)
DME0027	UNIPROID	PGRC1_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell (COS)7
DME0027	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP11B1 heterooligomerization
DME0027	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP11B1 protein, which leads to a slight effect on the enzyme activity of Steroid 11-beta-hydroxylase. As a result, the interaction between PGRMC1 and CYP11B1 can slightly affect the drug-metabolizing process of Steroid 11-beta-hydroxylase.
DME0027	UNIPROID	NR5A2_HUMAN	PROTNAME	Nuclear receptor family 5 A2 (NR5A2)
DME0027	UNIPROID	NR5A2_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0027	UNIPROID	NR5A2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0027	UNIPROID	NR5A2_HUMAN	MOFDETAI	Activation
DME0027	UNIPROID	NR5A2_HUMAN	CELLLINE	H295R cell line
DME0027	UNIPROID	NR5A2_HUMAN	PPI_SUMM	NR5A2-CYP11B1 interaction
DME0027	UNIPROID	NR5A2_HUMAN	DESCRIPT	Nuclear receptor family 5 A2 (NR5A2) is reported to activate the transcription of CYP11B1 gene, which leads to an increased expression of the drug-metabolizing enzyme Steroid 11-beta-hydroxylase. As a result, the interaction between NR5A2 and CYP11B1 can activate the drug-metabolizing process of Steroid 11-beta-hydroxylase.
DME0028	DME___ID	DME0028
DME0028	DME_NAME	Cholesterol 24-hydroxylase (CYP46A1)
DME0028	SPESNAME	Homo sapiens
DME0028	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0028	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Niemann-Pick disease type C [ICD-11: 5C56]
DME0028	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0028	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0028	UNIPROID	HDAC1_HUMAN	CELLLINE	Niemman-Pick type C patients
DME0028	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP46A1 interaction
DME0028	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP46A1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cholesterol 24-hydroxylase. As a result, the interaction between HDACs and CYP46A1 can inhibit the drug-metabolizing process of Cholesterol 24-hydroxylase.
DME0031	DME___ID	DME0031
DME0031	DME_NAME	Cytochrome P450 2J2 (CYP2J2)
DME0031	SPESNAME	Homo sapiens
DME0031	MIRNA_ID	MIMAT0000063	PROTNAME	hsa-let-7b-5p
DME0031	MIRNA_ID	MIMAT0000063	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0031	MIRNA_ID	MIMAT0000063	MOFCLASS	Non-coding RNA regulation
DME0031	MIRNA_ID	MIMAT0000063	MOFDETAI	microRNA regulation
DME0031	MIRNA_ID	MIMAT0000063	CELLLINE	Lung cancer cells
DME0031	MIRNA_ID	MIMAT0000063	PPI_SUMM	hsa-let-7b-5p--CYP2J2 regulation
DME0031	MIRNA_ID	MIMAT0000063	DESCRIPT	hsa-let-7b-5p is reported to suppress CYP2J2 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2J2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2J2.
DME0033	DME___ID	DME0033
DME0033	DME_NAME	Cytochrome P450 2S1 (CYP2S1)
DME0033	SPESNAME	Homo sapiens
DME0033	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0033	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0033	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0033	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0033	UNIPROID	HDAC1_HUMAN	CELLLINE	Human cell lines
DME0033	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP2S1 interaction
DME0033	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP2S1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 2S1. As a result, the interaction between HDACs and CYP2S1 can inhibit the drug-metabolizing process of Cytochrome P450 2S1.
DME0036	DME___ID	DME0036
DME0036	DME_NAME	Aldosterone synthase (CYP11B2)
DME0036	SPESNAME	Homo sapiens
DME0036	MIRNA_ID	MIMAT0000080	PROTNAME	hsa-miR-24-3p
DME0036	MIRNA_ID	MIMAT0000080	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0036	MIRNA_ID	MIMAT0000080	MOFCLASS	Non-coding RNA regulation
DME0036	MIRNA_ID	MIMAT0000080	MOFDETAI	microRNA regulation
DME0036	MIRNA_ID	MIMAT0000080	CELLLINE	H295R cell line
DME0036	MIRNA_ID	MIMAT0000080	PPI_SUMM	hsa-miR-24-3p--CYP11B2 regulation
DME0036	MIRNA_ID	MIMAT0000080	DESCRIPT	hsa-miR-24-3p is reported to suppress CYP11B2 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP11B2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aldosterone synthase.
DME0036	UNIPROID	STF1_HUMAN	PROTNAME	Steroidogenic factor 1 (NR5A1)
DME0036	UNIPROID	STF1_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0036	UNIPROID	STF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0036	UNIPROID	STF1_HUMAN	MOFDETAI	Repression
DME0036	UNIPROID	STF1_HUMAN	CELLLINE	H295R cell line
DME0036	UNIPROID	STF1_HUMAN	PPI_SUMM	NR5A1-CYP11B2 interaction
DME0036	UNIPROID	STF1_HUMAN	DESCRIPT	Steroidogenic factor 1 (NR5A1) is reported to repress the transcription of CYP11B2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aldosterone synthase. As a result, the interaction between NR5A1 and CYP11B2 can repress the drug-metabolizing process of Aldosterone synthase.
DME0036	UNIPROID	APEX1_HUMAN	PROTNAME	AP endonuclease 1 (APEX1)
DME0036	UNIPROID	APEX1_HUMAN	HPPI_DIS	Hypertension [ICD-11: BA00-BA04]
DME0036	UNIPROID	APEX1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0036	UNIPROID	APEX1_HUMAN	MOFDETAI	Repression
DME0036	UNIPROID	APEX1_HUMAN	CELLLINE	U3A cell line
DME0036	UNIPROID	APEX1_HUMAN	PPI_SUMM	APEX1-CYP11B2 interaction
DME0036	UNIPROID	APEX1_HUMAN	DESCRIPT	AP endonuclease 1 (APEX1) is reported to repress the transcription of CYP11B2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aldosterone synthase. As a result, the interaction between APEX1 and CYP11B2 can repress the drug-metabolizing process of Aldosterone synthase.
DME0037	DME___ID	DME0037
DME0037	DME_NAME	Steroid 21-hydroxylase (CYP21A2)
DME0037	SPESNAME	Homo sapiens
DME0037	UNIPROID	PGRC1_HUMAN	PROTNAME	Progesterone receptor 1 (PGRMC1)
DME0037	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0037	UNIPROID	PGRC1_HUMAN	MOFCLASS	Oligomerization
DME0037	UNIPROID	PGRC1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0037	UNIPROID	PGRC1_HUMAN	CELLLINE	Human embryonic kidney cells (HEK293) and Human liver cancer cell lines (HepG2)
DME0037	UNIPROID	PGRC1_HUMAN	PPI_SUMM	PGRMC1-CYP21A2 heterooligomerization
DME0037	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP21A2 protein, which leads to a slight effect on the enzyme activity of Steroid 21-hydroxylase. As a result, the interaction between PGRMC1 and CYP21A2 can slightly affect the drug-metabolizing process of Steroid 21-hydroxylase.
DME0037	UNIPROID	PGRC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0037	UNIPROID	PGRC1_HUMAN	SUBSTRAT	Progesterone (Metabolic product: Progesterone 21-hydroxylase)
DME0037	UNIPROID	PGRC1_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell (COS)7
DME0037	UNIPROID	PGRC1_HUMAN	DESCRIPT	Progesterone receptor 1 (PGRMC1) is reported to heterooligomerize with the CYP21A2 protein, which leads to activation of the drug-metabolizing enzyme Steroid 21-hydroxylase. As a result, the interaction between PGRMC1 and CYP21A2 can activate the drug-metabolizing process of Steroid 21-hydroxylase.
DME0037	UNIPROID	CP17A_HUMAN	PROTNAME	Cytochrome P450-C17 (CYP17A1)
DME0037	UNIPROID	CP17A_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0037	UNIPROID	CP17A_HUMAN	MOFCLASS	Oligomerization
DME0037	UNIPROID	CP17A_HUMAN	MOFDETAI	Hetero-oligomerization
DME0037	UNIPROID	CP17A_HUMAN	SUBSTRAT	17-Hydroxyprogesterone (Metabolic product: 11-Deoxycortisol)
DME0037	UNIPROID	CP17A_HUMAN	CELLLINE	Escherichia coli JM109 competent cell line
DME0037	UNIPROID	CP17A_HUMAN	PPI_SUMM	CYP17A1-CYP21A2 heterooligomerization
DME0037	UNIPROID	CP17A_HUMAN	DESCRIPT	Cytochrome P450-C17 (CYP17A1) is reported to heterooligomerize with the CYP21A2 protein, which leads to a decreased activity of the drug-metabolizing enzyme Steroid 21-hydroxylase. As a result, the interaction between CYP17A1 and CYP21A2 can decrease the drug-metabolizing process of Steroid 21-hydroxylase.
DME0037	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0037	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0037	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0037	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0037	UNIPROID	CYB5_HUMAN	CELLLINE	Escherichia coli cell line
DME0037	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP21A2 heterodimerization
DME0037	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterodimerize with the CYP21A2 protein, which leads to an altered activity of the drug-metabolizing enzyme Steroid 21-hydroxylase. As a result, the interaction between CYB5A and CYP21A2 can modulate the drug-metabolizing process of Steroid 21-hydroxylase.
DME0038	DME___ID	DME0038
DME0038	DME_NAME	Vitamin D(3) 24-hydroxylase (CYP24A1)
DME0038	SPESNAME	Homo sapiens
DME0038	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0038	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0038	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0038	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0038	UNIPROID	HDAC1_HUMAN	CELLLINE	Prostate cancer cells
DME0038	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP24A1 interaction
DME0038	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP24A1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Vitamin D(3 24-hydroxylase. As a result, the interaction between HDACs and CYP24A1 can inhibit the drug-metabolizing process of Vitamin D(3 24-hydroxylase.
DME0038	MIRNA_ID	MIMAT0000423	PROTNAME	hsa-miR-125b-5p
DME0038	MIRNA_ID	MIMAT0000423	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0038	MIRNA_ID	MIMAT0000423	MOFCLASS	Non-coding RNA regulation
DME0038	MIRNA_ID	MIMAT0000423	MOFDETAI	microRNA regulation
DME0038	MIRNA_ID	MIMAT0000423	CELLLINE	MCF-7 cell line
DME0038	MIRNA_ID	MIMAT0000423	PPI_SUMM	hsa-miR-125b-5p--CYP24A1 regulation
DME0038	MIRNA_ID	MIMAT0000423	DESCRIPT	hsa-miR-125b-5p is reported to suppress CYP24A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP24A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Vitamin D(3) 24-hydroxylase.
DME0038	UNIPROID	VDR_HUMAN	PROTNAME	Vitamin D3 receptor (VDR)
DME0038	UNIPROID	VDR_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0038	UNIPROID	VDR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0038	UNIPROID	VDR_HUMAN	MOFDETAI	Activation
DME0038	UNIPROID	VDR_HUMAN	CELLLINE	Colorectal adenocarcinomas cell line
DME0038	UNIPROID	VDR_HUMAN	PPI_SUMM	VDR-CYP24A1 interaction
DME0038	UNIPROID	VDR_HUMAN	DESCRIPT	Vitamin D3 receptor (VDR) is reported to activate the transcription of CYP24A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Vitamin D(3) 24-hydroxylase. As a result, the interaction between VDR and CYP24A1 can activate the drug-metabolizing process of Vitamin D(3) 24-hydroxylase.
DME0038	UNIPROID	VDR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0038	UNIPROID	VDR_HUMAN	MOFDETAI	Repression
DME0038	UNIPROID	VDR_HUMAN	CELLLINE	COS-1, CV-1 and 293-T cell lines
DME0038	UNIPROID	VDR_HUMAN	DESCRIPT	Vitamin D3 receptor (VDR) is reported to repress the transcription of CYP24A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Vitamin D(3) 24-hydroxylase. As a result, the interaction between VDR and CYP24A1 can repress the drug-metabolizing process of Vitamin D(3) 24-hydroxylase.
DME0038	UNIPROID	NR2C2_HUMAN	PROTNAME	Nuclear receptor family 2 C2 (NR2C2)
DME0038	UNIPROID	NR2C2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0038	UNIPROID	NR2C2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0038	UNIPROID	NR2C2_HUMAN	MOFDETAI	Repression
DME0038	UNIPROID	NR2C2_HUMAN	SUBSTRAT	Vitamin D3
DME0038	UNIPROID	NR2C2_HUMAN	CELLLINE	Escherichia coli BL21(DE3) cell line
DME0038	UNIPROID	NR2C2_HUMAN	PPI_SUMM	NR2C2-CYP24A1 interaction
DME0038	UNIPROID	NR2C2_HUMAN	DESCRIPT	Nuclear receptor family 2 C2 (NR2C2) is reported to repress the transcription of CYP24A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Vitamin D(3) 24-hydroxylase. As a result, the interaction between NR2C2 and CYP24A1 can repress the drug-metabolizing process of Vitamin D(3) 24-hydroxylase.
DME0040	DME___ID	DME0040
DME0040	DME_NAME	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DME0040	SPESNAME	Homo sapiens
DME0040	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0040	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0040	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0040	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0040	UNIPROID	HDAC1_HUMAN	CELLLINE	LNCaP cell line
DME0040	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-UGT2B7 interaction
DME0040	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the UGT2B7 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B7. As a result, the interaction between HDACs and UGT2B7 can inhibit the drug-metabolizing process of UDP-glucuronosyltransferase 2B7.
DME0040	MIRNA_ID	MIMAT0004959	PROTNAME	hsa-miR-216b-5p
DME0040	MIRNA_ID	MIMAT0004959	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0040	MIRNA_ID	MIMAT0004959	MOFCLASS	Non-coding RNA regulation
DME0040	MIRNA_ID	MIMAT0004959	MOFDETAI	microRNA regulation
DME0040	MIRNA_ID	MIMAT0004959	CELLLINE	HuH7 and Hep3B cell lines
DME0040	MIRNA_ID	MIMAT0004959	PPI_SUMM	hsa-miR-216b-5p--UGT2B7 regulation
DME0040	MIRNA_ID	MIMAT0004959	DESCRIPT	hsa-miR-216b-5p is reported to suppress UGT2B7 mRNA translation by binding to the 3' untranslated region (3'UTR) of UGT2B7 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B7.
DME0040	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME0040	UNIPROID	CP3A4_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0040	UNIPROID	CP3A4_HUMAN	MOFCLASS	Oligomerization
DME0040	UNIPROID	CP3A4_HUMAN	MOFDETAI	Hetero-oligomerization
DME0040	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Morphine (Metabolic product: Glucuronidation of the morphine 3-hydroxyl group); Azidothymidine
DME0040	UNIPROID	CP3A4_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell line (COS)
DME0040	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-UGT2B7 heterooligomerization
DME0040	UNIPROID	CP3A4_HUMAN	DESCRIPT	Cytochrome P450 3A4 (CYP3A4) is reported to heterooligomerize with the UGT2B7 protein, which leads to an altered activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B7. As a result, the interaction between CYP3A4 and UGT2B7 can modulate the drug-metabolizing process of UDP-glucuronosyltransferase 2B7.
DME0040	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME0040	UNIPROID	CP1A2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0040	UNIPROID	CP1A2_HUMAN	MOFCLASS	Oligomerization
DME0040	UNIPROID	CP1A2_HUMAN	MOFDETAI	Hetero-oligomerization
DME0040	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Morphine (Metabolic product: Glucuronidation of the morphine 3-hydroxyl group)
DME0040	UNIPROID	CP1A2_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell line (COS)
DME0040	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-UGT2B7 heterooligomerization
DME0040	UNIPROID	CP1A2_HUMAN	DESCRIPT	Cytochrome P450 1A2 (CYP1A2) is reported to heterooligomerize with the UGT2B7 protein, which leads to an altered activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B7. As a result, the interaction between CYP1A2 and UGT2B7 can modulate the drug-metabolizing process of UDP-glucuronosyltransferase 2B7.
DME0040	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME0040	UNIPROID	CP2C9_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0040	UNIPROID	CP2C9_HUMAN	MOFCLASS	Oligomerization
DME0040	UNIPROID	CP2C9_HUMAN	MOFDETAI	Hetero-oligomerization
DME0040	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Morphine (Metabolic product: Glucuronidation of the morphine 3-hydroxyl group)
DME0040	UNIPROID	CP2C9_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell line (COS)
DME0040	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-UGT2B7 heterooligomerization
DME0040	UNIPROID	CP2C9_HUMAN	DESCRIPT	Cytochrome P450 2C9 (CYP2C9) is reported to heterooligomerize with the UGT2B7 protein, which leads to an altered activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B7. As a result, the interaction between CYP2C9 and UGT2B7 can modulate the drug-metabolizing process of UDP-glucuronosyltransferase 2B7.
DME0040	UNIPROID	NF2L2_HUMAN	PROTNAME	NFE2-related factor 2 (NFE2L2)
DME0040	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0040	UNIPROID	NF2L2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0040	UNIPROID	NF2L2_HUMAN	MOFDETAI	Activation
DME0040	UNIPROID	NF2L2_HUMAN	CELLLINE	Caco-2 cell line
DME0040	UNIPROID	NF2L2_HUMAN	PPI_SUMM	NFE2L2-UGT2B7 interaction
DME0040	UNIPROID	NF2L2_HUMAN	DESCRIPT	NFE2-related factor 2 (NFE2L2) is reported to activate the transcription of UGT2B7 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B7. As a result, the interaction between NFE2L2 and UGT2B7 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 2B7.
DME0040	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0040	UNIPROID	NF2L2_HUMAN	CELLLINE	HepG2, HuH7 and HLE cell lines
DME0040	UNIPROID	HNF1A_HUMAN	PROTNAME	Hepatocyte NF 1-alpha (HNF1A)
DME0040	UNIPROID	HNF1A_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0040	UNIPROID	HNF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0040	UNIPROID	HNF1A_HUMAN	MOFDETAI	Activation
DME0040	UNIPROID	HNF1A_HUMAN	CELLLINE	HepG2 cell line
DME0040	UNIPROID	HNF1A_HUMAN	PPI_SUMM	HNF1A-UGT2B7 interaction
DME0040	UNIPROID	HNF1A_HUMAN	DESCRIPT	Hepatocyte NF 1-alpha (HNF1A) is reported to activate the transcription of UGT2B7 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B7. As a result, the interaction between HNF1A and UGT2B7 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 2B7.
DME0040	UNIPROID	PO2F1_HUMAN	PROTNAME	Octamer-binding protein 1 (POU2F1)
DME0040	UNIPROID	PO2F1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0040	UNIPROID	PO2F1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0040	UNIPROID	PO2F1_HUMAN	MOFDETAI	Activation
DME0040	UNIPROID	PO2F1_HUMAN	CELLLINE	HepG2 cell line
DME0040	UNIPROID	PO2F1_HUMAN	PPI_SUMM	POU2F1-UGT2B7 interaction
DME0040	UNIPROID	PO2F1_HUMAN	DESCRIPT	Octamer-binding protein 1 (POU2F1) is reported to activate the transcription of UGT2B7 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B7. As a result, the interaction between POU2F1 and UGT2B7 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 2B7.
DME0041	DME___ID	DME0041
DME0041	DME_NAME	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DME0041	SPESNAME	Homo sapiens
DME0041	UNIPROID	UD13_HUMAN	PROTNAME	UDPGT 1-3 (UGT1A3)
DME0041	UNIPROID	UD13_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0041	UNIPROID	UD13_HUMAN	MOFCLASS	Oligomerization
DME0041	UNIPROID	UD13_HUMAN	MOFDETAI	Homo-oligomerization
DME0041	UNIPROID	UD13_HUMAN	SUBSTRAT	Octylgallate
DME0041	UNIPROID	UD13_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell line (COS)
DME0041	UNIPROID	UD13_HUMAN	PPI_SUMM	UGT1A3-UGT1A3 homodimerization
DME0041	UNIPROID	UD13_HUMAN	DESCRIPT	UDP-glucuronosyltransferase 1-3 (UGT1A3) is reported as a homodimer, which leads to a slight effect on the enzyme activity of drug-metabolizing enzyme UDP-glucuronosyltransferase 1A3. As a result, the UGT1A3 homodimerization can slightly affect the drug-metabolizing process of UDP-glucuronosyltransferase 1A3.
DME0042	DME___ID	DME0042
DME0042	DME_NAME	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DME0042	SPESNAME	Homo sapiens
DME0042	UNIPROID	UD11_HUMAN	PROTNAME	UDPGT 1-1 (UGT1A1)
DME0042	UNIPROID	UD11_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0042	UNIPROID	UD11_HUMAN	MOFCLASS	Oligomerization
DME0042	UNIPROID	UD11_HUMAN	MOFDETAI	Hetero-oligomerization
DME0042	UNIPROID	UD11_HUMAN	SUBSTRAT	Propofol (Metabolic product: Propofol O-glucuronide)
DME0042	UNIPROID	UD11_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293)
DME0042	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-UGT1A9 heterooligomerization
DME0042	UNIPROID	UD11_HUMAN	DESCRIPT	UDPGT 1-1 (UGT1A1) is reported to heterooligomerize with the UGT1A9 protein, which leads to an increased activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A9. As a result, the interaction between UGT1A1 and UGT1A9 can facilitate the drug-metabolizing process of UDP-glucuronosyltransferase 1A9.
DME0042	UNIPROID	UD14_HUMAN	PROTNAME	Bilirubin-specific UDPGT 2 (UGT1A4)
DME0042	UNIPROID	UD14_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0042	UNIPROID	UD14_HUMAN	MOFCLASS	Oligomerization
DME0042	UNIPROID	UD14_HUMAN	MOFDETAI	Hetero-oligomerization
DME0042	UNIPROID	UD14_HUMAN	SUBSTRAT	Propofol (Metabolic product: Propofol O-glucuronide)
DME0042	UNIPROID	UD14_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293)
DME0042	UNIPROID	UD14_HUMAN	PPI_SUMM	UGT1A4-UGT1A9 heterooligomerization
DME0042	UNIPROID	UD14_HUMAN	DESCRIPT	Bilirubin-specific UDPGT 2 (UGT1A4) is reported to heterooligomerize with the UGT1A9 protein, which leads to an increased activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A9. As a result, the interaction between UGT1A4 and UGT1A9 can facilitate the drug-metabolizing process of UDP-glucuronosyltransferase 1A9.
DME0042	UNIPROID	UD16_HUMAN	PROTNAME	Phenol-metabolizing UDPGT (UGT1A6)
DME0042	UNIPROID	UD16_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0042	UNIPROID	UD16_HUMAN	MOFCLASS	Oligomerization
DME0042	UNIPROID	UD16_HUMAN	MOFDETAI	Hetero-oligomerization
DME0042	UNIPROID	UD16_HUMAN	SUBSTRAT	Propofol (Metabolic product: Propofol O-glucuronide)
DME0042	UNIPROID	UD16_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293)
DME0042	UNIPROID	UD16_HUMAN	PPI_SUMM	UGT1A6-UGT1A9 heterooligomerization
DME0042	UNIPROID	UD16_HUMAN	DESCRIPT	Phenol-metabolizing UDPGT (UGT1A6) is reported to heterooligomerize with the UGT1A9 protein, which leads to an increased activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A9. As a result, the interaction between UGT1A6 and UGT1A9 can facilitate the drug-metabolizing process of UDP-glucuronosyltransferase 1A9.
DME0042	UNIPROID	HNF1A_HUMAN	PROTNAME	Hepatocyte NF 1-alpha (HNF1A)
DME0042	UNIPROID	HNF1A_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0042	UNIPROID	HNF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0042	UNIPROID	HNF1A_HUMAN	MOFDETAI	Activation
DME0042	UNIPROID	HNF1A_HUMAN	CELLLINE	Caco-2 cell line
DME0042	UNIPROID	HNF1A_HUMAN	PPI_SUMM	HNF1A-UGT1A9 interaction
DME0042	UNIPROID	HNF1A_HUMAN	DESCRIPT	Hepatocyte NF 1-alpha (HNF1A) is reported to activate the transcription of UGT1A9 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A9. As a result, the interaction between HNF1A and UGT1A9 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A9.
DME0042	UNIPROID	PPARG_HUMAN	PROTNAME	PPA receptor gamma (PPARG)
DME0042	UNIPROID	PPARG_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0042	UNIPROID	PPARG_HUMAN	MOFCLASS	Transcription-factor regulation
DME0042	UNIPROID	PPARG_HUMAN	MOFDETAI	Activation
DME0042	UNIPROID	PPARG_HUMAN	CELLLINE	Peripheral blood mononuclear cell line
DME0042	UNIPROID	PPARG_HUMAN	PPI_SUMM	PPARG-UGT1A9 interaction
DME0042	UNIPROID	PPARG_HUMAN	DESCRIPT	PPA receptor gamma (PPARG) is reported to activate the transcription of UGT1A9 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A9. As a result, the interaction between PPARG and UGT1A9 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A9.
DME0042	UNIPROID	PPARA_HUMAN	PROTNAME	PPA receptor alpha (PPARA)
DME0042	UNIPROID	PPARA_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0042	UNIPROID	PPARA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0042	UNIPROID	PPARA_HUMAN	MOFDETAI	Activation
DME0042	UNIPROID	PPARA_HUMAN	CELLLINE	Peripheral blood mononuclear cell line
DME0042	UNIPROID	PPARA_HUMAN	PPI_SUMM	PPARA-UGT1A9 interaction
DME0042	UNIPROID	PPARA_HUMAN	DESCRIPT	PPA receptor alpha (PPARA) is reported to activate the transcription of UGT1A9 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A9. As a result, the interaction between PPARA and UGT1A9 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A9.
DME0044	DME___ID	DME0044
DME0044	DME_NAME	Monoamine oxidase type A (MAO-A)
DME0044	SPESNAME	Homo sapiens
DME0044	MIRNA_ID	MIMAT0000077	PROTNAME	hsa-miR-22-3p
DME0044	MIRNA_ID	MIMAT0000077	HPPI_DIS	Panic disorder [ICD-11: 6B01]
DME0044	MIRNA_ID	MIMAT0000077	MOFCLASS	Non-coding RNA regulation
DME0044	MIRNA_ID	MIMAT0000077	MOFDETAI	microRNA regulation
DME0044	MIRNA_ID	MIMAT0000077	CELLLINE	Panic Disorder cells
DME0044	MIRNA_ID	MIMAT0000077	PPI_SUMM	hsa-miR-22-3p--MAOA regulation
DME0044	MIRNA_ID	MIMAT0000077	DESCRIPT	hsa-miR-22-3p is reported to suppress MAOA mRNA translation by binding to the 3' untranslated region (3'UTR) of MAOA mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Monoamine oxidase type A.
DME0044	UNIPROID	HEN2_HUMAN	PROTNAME	Helix-loop-helix 2 (NHLH2)
DME0044	UNIPROID	HEN2_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0044	UNIPROID	HEN2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0044	UNIPROID	HEN2_HUMAN	MOFDETAI	Activation
DME0044	UNIPROID	HEN2_HUMAN	CELLLINE	N2A cell line
DME0044	UNIPROID	HEN2_HUMAN	PPI_SUMM	NHLH2-MAOA interaction
DME0044	UNIPROID	HEN2_HUMAN	DESCRIPT	Helix-loop-helix 2 (NHLH2) is reported to activate the transcription of MAOA gene, which leads to an increased expression of the drug-metabolizing enzyme Monoamine oxidase type A. As a result, the interaction between NHLH2 and MAOA can activate the drug-metabolizing process of Monoamine oxidase type A.
DME0045	DME___ID	DME0045
DME0045	DME_NAME	Monoamine oxidase type B (MAO-B)
DME0045	SPESNAME	Homo sapiens
DME0045	UNIPROID	SP4_HUMAN	PROTNAME	Transcription factor Sp4 (SP4)
DME0045	UNIPROID	SP4_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0045	UNIPROID	SP4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0045	UNIPROID	SP4_HUMAN	MOFDETAI	Activation
DME0045	UNIPROID	SP4_HUMAN	CELLLINE	1242-MG cell line
DME0045	UNIPROID	SP4_HUMAN	PPI_SUMM	SP4-MAOB interaction
DME0045	UNIPROID	SP4_HUMAN	DESCRIPT	Transcription factor Sp4 (SP4) is reported to activate the transcription of MAOB gene, which leads to an increased expression of the drug-metabolizing enzyme Monoamine oxidase type B. As a result, the interaction between SP4 and MAOB can activate the drug-metabolizing process of Monoamine oxidase type B.
DME0045	UNIPROID	SP4_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0045	UNIPROID	SP4_HUMAN	CELLLINE	HepG2 cell line
DME0045	UNIPROID	SP4_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0045	UNIPROID	SP4_HUMAN	CELLLINE	HeLa cell line
DME0045	UNIPROID	CDA7L_HUMAN	PROTNAME	Transcription factor RAM2 (CDCA7L)
DME0045	UNIPROID	CDA7L_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0045	UNIPROID	CDA7L_HUMAN	MOFCLASS	Transcription-factor regulation
DME0045	UNIPROID	CDA7L_HUMAN	MOFDETAI	Repression
DME0045	UNIPROID	CDA7L_HUMAN	CELLLINE	1242-MG cell line
DME0045	UNIPROID	CDA7L_HUMAN	PPI_SUMM	CDCA7L-MAOB interaction
DME0045	UNIPROID	CDA7L_HUMAN	DESCRIPT	Transcription factor RAM2 (CDCA7L) is reported to repress the transcription of MAOB gene, which leads to a decreased expression of the drug-metabolizing enzyme Monoamine oxidase type B. As a result, the interaction between CDCA7L and MAOB can repress the drug-metabolizing process of Monoamine oxidase type B.
DME0045	UNIPROID	EAPP_HUMAN	PROTNAME	E2F phosphoprotein (EAPP)
DME0045	UNIPROID	EAPP_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0045	UNIPROID	EAPP_HUMAN	MOFCLASS	Transcription-factor regulation
DME0045	UNIPROID	EAPP_HUMAN	MOFDETAI	Repression
DME0045	UNIPROID	EAPP_HUMAN	CELLLINE	1242-MG cell line
DME0045	UNIPROID	EAPP_HUMAN	PPI_SUMM	EAPP-MAOB interaction
DME0045	UNIPROID	EAPP_HUMAN	DESCRIPT	E2F phosphoprotein (EAPP) is reported to repress the transcription of MAOB gene, which leads to a decreased expression of the drug-metabolizing enzyme Monoamine oxidase type B. As a result, the interaction between EAPP and MAOB can repress the drug-metabolizing process of Monoamine oxidase type B.
DME0046	DME___ID	DME0046
DME0046	DME_NAME	Calcidiol 1-monooxygenase (CYP27B1)
DME0046	SPESNAME	Homo sapiens
DME0046	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0046	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0046	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0046	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0046	UNIPROID	HDAC1_HUMAN	CELLLINE	MCF-7 cell line
DME0046	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CYP27B1 interaction
DME0046	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CYP27B1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Calcidiol 1-monooxygenase. As a result, the interaction between HDACs and CYP27B1 can inhibit the drug-metabolizing process of Calcidiol 1-monooxygenase.
DME0046	UNIPROID	GFI1_HUMAN	PROTNAME	Zinc finger Gfi-1 (GFI1)
DME0046	UNIPROID	GFI1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0046	UNIPROID	GFI1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0046	UNIPROID	GFI1_HUMAN	MOFDETAI	Repression
DME0046	UNIPROID	GFI1_HUMAN	CELLLINE	DU145, PC3 and LNCaP cell lines
DME0046	UNIPROID	GFI1_HUMAN	PPI_SUMM	GFI1-CYP27B1 interaction
DME0046	UNIPROID	GFI1_HUMAN	DESCRIPT	Zinc finger Gfi-1 (GFI1) is reported to repress the transcription of CYP27B1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Calcidiol 1-monooxygenase. As a result, the interaction between GFI1 and CYP27B1 can repress the drug-metabolizing process of Calcidiol 1-monooxygenase.
DME0047	DME___ID	DME0047
DME0047	DME_NAME	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DME0047	SPESNAME	Homo sapiens
DME0047	UNIPROID	NR1H4_HUMAN	PROTNAME	Bile acid receptor (NR1H4)
DME0047	UNIPROID	NR1H4_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0047	UNIPROID	NR1H4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0047	UNIPROID	NR1H4_HUMAN	MOFDETAI	Repression
DME0047	UNIPROID	NR1H4_HUMAN	CELLLINE	HepG2 cell line
DME0047	UNIPROID	NR1H4_HUMAN	PPI_SUMM	NR1H4-UGT2B4 interaction
DME0047	UNIPROID	NR1H4_HUMAN	DESCRIPT	Bile acid receptor (NR1H4) is reported to repress the transcription of UGT2B4 gene, which leads to a decreased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B4. As a result, the interaction between NR1H4 and UGT2B4 can repress the drug-metabolizing process of UDP-glucuronosyltransferase 2B4.
DME0048	DME___ID	DME0048
DME0048	DME_NAME	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DME0048	SPESNAME	Homo sapiens
DME0048	UNIPROID	UD19_HUMAN	PROTNAME	UDPGT 1-9 (UGT1A9)
DME0048	UNIPROID	UD19_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0048	UNIPROID	UD19_HUMAN	MOFCLASS	Oligomerization
DME0048	UNIPROID	UD19_HUMAN	MOFDETAI	Hetero-oligomerization
DME0048	UNIPROID	UD19_HUMAN	SUBSTRAT	Imipramine (Metabolic product: Imipramine N-glucuronide)
DME0048	UNIPROID	UD19_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293)
DME0048	UNIPROID	UD19_HUMAN	PPI_SUMM	UGT1A9-UGT1A4 heterooligomerization
DME0048	UNIPROID	UD19_HUMAN	DESCRIPT	UDPGT 1-9 (UGT1A9) is reported to heterooligomerize with the UGT1A4 protein, which leads to an increased activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A4. As a result, the interaction between UGT1A9 and UGT1A4 can facilitate the drug-metabolizing process of UDP-glucuronosyltransferase 1A4.
DME0048	UNIPROID	ESR1_HUMAN	PROTNAME	Estrogen receptor (ESR1)
DME0048	UNIPROID	ESR1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0048	UNIPROID	ESR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0048	UNIPROID	ESR1_HUMAN	MOFDETAI	Activation
DME0048	UNIPROID	ESR1_HUMAN	CELLLINE	HepG2 cell line
DME0048	UNIPROID	ESR1_HUMAN	PPI_SUMM	ESR1-UGT1A4 interaction
DME0048	UNIPROID	ESR1_HUMAN	DESCRIPT	Estrogen receptor (ESR1) is reported to activate the transcription of UGT1A4 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A4. As a result, the interaction between ESR1 and UGT1A4 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A4.
DME0048	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0048	UNIPROID	SP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0048	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0048	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0048	UNIPROID	SP1_HUMAN	CELLLINE	HepG2 cell line
DME0048	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-UGT1A4 interaction
DME0048	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of UGT1A4 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A4. As a result, the interaction between SP1 and UGT1A4 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A4.
DME0049	DME___ID	DME0049
DME0049	DME_NAME	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DME0049	SPESNAME	Homo sapiens
DME0049	MIRNA_ID	MIMAT0000720	PROTNAME	hsa-miR-331-5p
DME0049	MIRNA_ID	MIMAT0000720	HPPI_DIS	Health [ICD-11: N.A.]
DME0049	MIRNA_ID	MIMAT0000720	MOFCLASS	Non-coding RNA regulation
DME0049	MIRNA_ID	MIMAT0000720	MOFDETAI	microRNA regulation
DME0049	MIRNA_ID	MIMAT0000720	CELLLINE	HEK293 cell line
DME0049	MIRNA_ID	MIMAT0000720	PPI_SUMM	hsa-miR-331-5p--UGT2B15 regulation
DME0049	MIRNA_ID	MIMAT0000720	DESCRIPT	hsa-miR-331-5p is reported to suppress UGT2B15 mRNA translation by binding to the 3' untranslated region (3'UTR) of UGT2B15 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B15.
DME0049	MIRNA_ID	MIMAT0000720	PROTNAME	hsa-miR-376c-3p
DME0049	MIRNA_ID	MIMAT0000720	PPI_SUMM	hsa-miR-376c-3p--UGT2B15 regulation
DME0049	MIRNA_ID	MIMAT0000720	DESCRIPT	hsa-miR-376c-3p is reported to suppress UGT2B15 mRNA translation by binding to the 3' untranslated region (3'UTR) of UGT2B15 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B15.
DME0049	UNIPROID	FOSL2_HUMAN	PROTNAME	Fos-related antigen 2 (FOSL2)
DME0049	UNIPROID	FOSL2_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0049	UNIPROID	FOSL2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0049	UNIPROID	FOSL2_HUMAN	MOFDETAI	Activation
DME0049	UNIPROID	FOSL2_HUMAN	CELLLINE	MCF-7 cell line
DME0049	UNIPROID	FOSL2_HUMAN	PPI_SUMM	FOSL2-UGT2B15 interaction
DME0049	UNIPROID	FOSL2_HUMAN	DESCRIPT	Fos-related antigen 2 (FOSL2) is reported to activate the transcription of UGT2B15 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B15. As a result, the interaction between FOSL2 and UGT2B15 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 2B15.
DME0049	UNIPROID	ESR1_HUMAN	PROTNAME	Estrogen receptor (ESR1)
DME0049	UNIPROID	ESR1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0049	UNIPROID	ESR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0049	UNIPROID	ESR1_HUMAN	MOFDETAI	Activation
DME0049	UNIPROID	ESR1_HUMAN	CELLLINE	MCF-7 cell line
DME0049	UNIPROID	ESR1_HUMAN	PPI_SUMM	ESR1-UGT2B15 interaction
DME0049	UNIPROID	ESR1_HUMAN	DESCRIPT	Estrogen receptor (ESR1) is reported to activate the transcription of UGT2B15 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B15. As a result, the interaction between ESR1 and UGT2B15 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 2B15.
DME0049	UNIPROID	JUN_HUMAN	PROTNAME	Transcription factor AP-1 (JUN)
DME0049	UNIPROID	JUN_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0049	UNIPROID	JUN_HUMAN	MOFCLASS	Transcription-factor regulation
DME0049	UNIPROID	JUN_HUMAN	MOFDETAI	Activation
DME0049	UNIPROID	JUN_HUMAN	CELLLINE	MCF-7 cell line
DME0049	UNIPROID	JUN_HUMAN	PPI_SUMM	JUN-UGT2B15 interaction
DME0049	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to activate the transcription of UGT2B15 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B15. As a result, the interaction between JUN and UGT2B15 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 2B15.
DME0050	DME___ID	DME0050
DME0050	DME_NAME	N-acetyltransferase 1 (NAT1)
DME0050	SPESNAME	Homo sapiens
DME0050	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0050	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0050	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0050	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0050	UNIPROID	HDAC1_HUMAN	CELLLINE	HepG2 cell line
DME0050	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-NAT1 interaction
DME0050	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the NAT1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme N-acetyltransferase 1. As a result, the interaction between HDACs and NAT1 can inhibit the drug-metabolizing process of N-acetyltransferase 1.
DME0050	UNIPROID	ANDR_HUMAN	PROTNAME	Androgen receptor (AR)
DME0050	UNIPROID	ANDR_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0050	UNIPROID	ANDR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0050	UNIPROID	ANDR_HUMAN	MOFDETAI	Activation
DME0050	UNIPROID	ANDR_HUMAN	CELLLINE	MCF10A and MCF7 cell lines
DME0050	UNIPROID	ANDR_HUMAN	PPI_SUMM	AR-NAT1 interaction
DME0050	UNIPROID	ANDR_HUMAN	DESCRIPT	Androgen receptor (AR) is reported to activate the transcription of NAT1 gene, which leads to an increased expression of the drug-metabolizing enzyme N-acetyltransferase 1. As a result, the interaction between AR and NAT1 can activate the drug-metabolizing process of N-acetyltransferase 1.
DME0050	UNIPROID	HSF1_HUMAN	PROTNAME	Heat shock factor 1 (HSF1)
DME0050	UNIPROID	HSF1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0050	UNIPROID	HSF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0050	UNIPROID	HSF1_HUMAN	MOFDETAI	Activation
DME0050	UNIPROID	HSF1_HUMAN	CELLLINE	22Rv1 cell line
DME0050	UNIPROID	HSF1_HUMAN	PPI_SUMM	HSF1-NAT1 interaction
DME0050	UNIPROID	HSF1_HUMAN	DESCRIPT	Heat shock factor 1 (HSF1) is reported to activate the transcription of NAT1 gene, which leads to an increased expression of the drug-metabolizing enzyme N-acetyltransferase 1. As a result, the interaction between HSF1 and NAT1 can activate the drug-metabolizing process of N-acetyltransferase 1.
DME0053	DME___ID	DME0053
DME0053	DME_NAME	Dihydrothymine dehydrogenase (DPYD)
DME0053	SPESNAME	Homo sapiens
DME0053	MIRNA_ID	MIMAT0000084	PROTNAME	hsa-miR-27a-3p
DME0053	MIRNA_ID	MIMAT0000084	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0053	MIRNA_ID	MIMAT0000084	MOFCLASS	Non-coding RNA regulation
DME0053	MIRNA_ID	MIMAT0000084	MOFDETAI	microRNA regulation
DME0053	MIRNA_ID	MIMAT0000084	CELLLINE	HCT116 cell line
DME0053	MIRNA_ID	MIMAT0000084	PPI_SUMM	hsa-miR-27a-3p--DPYD regulation
DME0053	MIRNA_ID	MIMAT0000084	DESCRIPT	hsa-miR-27a-3p is reported to suppress DPYD mRNA translation by binding to the 3' untranslated region (3'UTR) of DPYD mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dihydrothymine dehydrogenase.
DME0053	MIRNA_ID	MIMAT0000419	PROTNAME	hsa-miR-27b-3p
DME0053	MIRNA_ID	MIMAT0000419	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0053	MIRNA_ID	MIMAT0000419	MOFCLASS	Non-coding RNA regulation
DME0053	MIRNA_ID	MIMAT0000419	MOFDETAI	microRNA regulation
DME0053	MIRNA_ID	MIMAT0000419	CELLLINE	HCT116 cell line
DME0053	MIRNA_ID	MIMAT0000419	PPI_SUMM	hsa-miR-27b-3p--DPYD regulation
DME0053	MIRNA_ID	MIMAT0000419	DESCRIPT	hsa-miR-27b-3p is reported to suppress DPYD mRNA translation by binding to the 3' untranslated region (3'UTR) of DPYD mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dihydrothymine dehydrogenase.
DME0053	MIRNA_ID	MIMAT0026607	PROTNAME	hsa-miR-494-5p
DME0053	MIRNA_ID	MIMAT0026607	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0053	MIRNA_ID	MIMAT0026607	MOFCLASS	Non-coding RNA regulation
DME0053	MIRNA_ID	MIMAT0026607	MOFDETAI	microRNA regulation
DME0053	MIRNA_ID	MIMAT0026607	CELLLINE	SW480 cell line
DME0053	MIRNA_ID	MIMAT0026607	PPI_SUMM	hsa-miR-494-5p--DPYD regulation
DME0053	MIRNA_ID	MIMAT0026607	DESCRIPT	hsa-miR-494-5p is reported to suppress DPYD mRNA translation by binding to the 3' untranslated region (3'UTR) of DPYD mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dihydrothymine dehydrogenase.
DME0053	MIRNA_ID	MIMAT0000715	PROTNAME	hsa-miR-302b-3p
DME0053	MIRNA_ID	MIMAT0000715	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0053	MIRNA_ID	MIMAT0000715	MOFCLASS	Non-coding RNA regulation
DME0053	MIRNA_ID	MIMAT0000715	MOFDETAI	microRNA regulation
DME0053	MIRNA_ID	MIMAT0000715	CELLLINE	HepG2 cell line
DME0053	MIRNA_ID	MIMAT0000715	PPI_SUMM	hsa-miR-302b-3p--DPYD regulation
DME0053	MIRNA_ID	MIMAT0000715	DESCRIPT	hsa-miR-302b-3p is reported to suppress DPYD mRNA translation by binding to the 3' untranslated region (3'UTR) of DPYD mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dihydrothymine dehydrogenase.
DME0058	DME___ID	DME0058
DME0058	DME_NAME	Acetylcholinesterase (ACHE)
DME0058	SPESNAME	Homo sapiens
DME0058	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0058	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0058	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0058	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0058	UNIPROID	EHMT1_HUMAN	CELLLINE	Human neuroblastoma cells SH-SY5Y
DME0058	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-ACHE interaction
DME0058	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 27 trimethylation of ACHE gene is reported to repress the transcriptional activity of the drug-metabolizing enzyme Acetylcholinesterase. As a result, the interaction between Histone methyltransferases (HMTs) and ACHE can inhibit the drug-metabolizing process of Acetylcholinesterase.
DME0058	MIRNA_ID	MIMAT0000269	PROTNAME	hsa-miR-212-3p
DME0058	MIRNA_ID	MIMAT0000269	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0058	MIRNA_ID	MIMAT0000269	MOFCLASS	Non-coding RNA regulation
DME0058	MIRNA_ID	MIMAT0000269	MOFDETAI	microRNA regulation
DME0058	MIRNA_ID	MIMAT0000269	CELLLINE	NCI-H460 and NCI-H520 cell lines
DME0058	MIRNA_ID	MIMAT0000269	PPI_SUMM	hsa-miR-212-3p--ACHE regulation
DME0058	MIRNA_ID	MIMAT0000269	DESCRIPT	hsa-miR-212-3p is reported to suppress ACHE mRNA translation by binding to the 3' untranslated region (3'UTR) of ACHE mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Acetylcholinesterase.
DME0058	MIRNA_ID	MIMAT0004591	PROTNAME	hsa-miR-124-5p
DME0058	MIRNA_ID	MIMAT0004591	HPPI_DIS	Pediatric intestinal failure [ICD-11: DA96]
DME0058	MIRNA_ID	MIMAT0004591	MOFCLASS	Non-coding RNA regulation
DME0058	MIRNA_ID	MIMAT0004591	MOFDETAI	microRNA regulation
DME0058	MIRNA_ID	MIMAT0004591	CELLLINE	Pediatric intestinal failure cells
DME0058	MIRNA_ID	MIMAT0004591	PPI_SUMM	hsa-miR-124-5p--ACHE regulation
DME0058	MIRNA_ID	MIMAT0004591	DESCRIPT	hsa-miR-124-5p is reported to suppress ACHE mRNA translation by binding to the 3' untranslated region (3'UTR) of ACHE mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Acetylcholinesterase.
DME0058	UNIPROID	AP2A_HUMAN	PROTNAME	TF factor AP-2-alpha (TFAP2A)
DME0058	UNIPROID	AP2A_HUMAN	HPPI_DIS	Teratocarcinoma [ICD-11: 2C80]
DME0058	UNIPROID	AP2A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0058	UNIPROID	AP2A_HUMAN	MOFDETAI	Repression
DME0058	UNIPROID	AP2A_HUMAN	CELLLINE	Human NT2/D1 teratocarcinoma cell line
DME0058	UNIPROID	AP2A_HUMAN	PPI_SUMM	TFAP2A-ACHE interaction
DME0058	UNIPROID	AP2A_HUMAN	DESCRIPT	TF factor AP-2-alpha (TFAP2A) is reported to repress the transcription of ACHE gene, which leads to a decreased expression of the drug-metabolizing enzyme Acetylcholinesterase. As a result, the interaction between TFAP2A and ACHE can repress the drug-metabolizing process of Acetylcholinesterase.
DME0060	DME___ID	DME0060
DME0060	DME_NAME	Adenosine aminohydrolase (ADA)
DME0060	SPESNAME	Homo sapiens
DME0060	MIRNA_ID	MIMAT0000431	PROTNAME	hsa-miR-140-5p
DME0060	MIRNA_ID	MIMAT0000431	HPPI_DIS	Tongue squamous cell carcinoma [ICD-11: 2B62]
DME0060	MIRNA_ID	MIMAT0000431	MOFCLASS	Non-coding RNA regulation
DME0060	MIRNA_ID	MIMAT0000431	MOFDETAI	microRNA regulation
DME0060	MIRNA_ID	MIMAT0000431	CELLLINE	Tongue squamous cell carcinoma cells
DME0060	MIRNA_ID	MIMAT0000431	PPI_SUMM	hsa-miR-140-5p--ADA regulation
DME0060	MIRNA_ID	MIMAT0000431	DESCRIPT	hsa-miR-140-5p is reported to suppress ADA mRNA translation by binding to the 3' untranslated region (3'UTR) of ADA mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Adenosine aminohydrolase.
DME0061	DME___ID	DME0061
DME0061	DME_NAME	Sulfotransferase 1E1 (SULT1E1)
DME0061	SPESNAME	Homo sapiens
DME0061	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0061	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Hypertrophy of breast [ICD-11: GB22]
DME0061	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0061	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0061	UNIPROID	HDAC1_HUMAN	CELLLINE	MCF10A lineage cell line
DME0061	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-SULT1E1 interaction
DME0061	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the SULT1E1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Sulfotransferase 1E1. As a result, the interaction between HDACs and SULT1E1 can inhibit the drug-metabolizing process of Sulfotransferase 1E1.
DME0061	MIRNA_ID	MIMAT0000231	PROTNAME	hsa-miR-199a-5p
DME0061	MIRNA_ID	MIMAT0000231	HPPI_DIS	Health [ICD-11: N.A.]
DME0061	MIRNA_ID	MIMAT0000231	MOFCLASS	Non-coding RNA regulation
DME0061	MIRNA_ID	MIMAT0000231	MOFDETAI	microRNA regulation
DME0061	MIRNA_ID	MIMAT0000231	CELLLINE	Human dermal microvascular endothelial cells
DME0061	MIRNA_ID	MIMAT0000231	PPI_SUMM	hsa-miR-199a-5p--SULT1E1 regulation
DME0061	MIRNA_ID	MIMAT0000231	DESCRIPT	hsa-miR-199a-5p is reported to suppress SULT1E1 mRNA translation by binding to the 3' untranslated region (3'UTR) of SULT1E1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Sulfotransferase 1E1.
DME0061	UNIPROID	AP2C_HUMAN	PROTNAME	TF factor AP-2 gamma (TFAP2C)
DME0061	UNIPROID	AP2C_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0061	UNIPROID	AP2C_HUMAN	MOFCLASS	Transcription-factor regulation
DME0061	UNIPROID	AP2C_HUMAN	MOFDETAI	Activation
DME0061	UNIPROID	AP2C_HUMAN	CELLLINE	MCF10A and MCF7 cell lines
DME0061	UNIPROID	AP2C_HUMAN	PPI_SUMM	TFAP2C-SULT1E1 interaction
DME0061	UNIPROID	AP2C_HUMAN	DESCRIPT	TF factor AP-2 gamma (TFAP2C) is reported to activate the transcription of SULT1E1 gene, which leads to an increased expression of the drug-metabolizing enzyme Sulfotransferase 1E1. As a result, the interaction between TFAP2C and SULT1E1 can activate the drug-metabolizing process of Sulfotransferase 1E1.
DME0061	UNIPROID	AP2A_HUMAN	PROTNAME	TF factor AP-2-alpha (TFAP2A)
DME0061	UNIPROID	AP2A_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0061	UNIPROID	AP2A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0061	UNIPROID	AP2A_HUMAN	MOFDETAI	Activation
DME0061	UNIPROID	AP2A_HUMAN	CELLLINE	MCF10A and MCF7 cell lines
DME0061	UNIPROID	AP2A_HUMAN	PPI_SUMM	TFAP2A-SULT1E1 interaction
DME0061	UNIPROID	AP2A_HUMAN	DESCRIPT	TF factor AP-2-alpha (TFAP2A) is reported to activate the transcription of SULT1E1 gene, which leads to an increased expression of the drug-metabolizing enzyme Sulfotransferase 1E1. As a result, the interaction between TFAP2A and SULT1E1 can activate the drug-metabolizing process of Sulfotransferase 1E1.
DME0064	DME___ID	DME0064
DME0064	DME_NAME	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DME0064	SPESNAME	Homo sapiens
DME0064	UNIPROID	HNF1A_HUMAN	PROTNAME	Hepatocyte NF 1-alpha (HNF1A)
DME0064	UNIPROID	HNF1A_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0064	UNIPROID	HNF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0064	UNIPROID	HNF1A_HUMAN	MOFDETAI	Activation
DME0064	UNIPROID	HNF1A_HUMAN	CELLLINE	Caco-2 cell line
DME0064	UNIPROID	HNF1A_HUMAN	PPI_SUMM	HNF1A-UGT1A8 interaction
DME0064	UNIPROID	HNF1A_HUMAN	DESCRIPT	Hepatocyte NF 1-alpha (HNF1A) is reported to activate the transcription of UGT1A8 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A8. As a result, the interaction between HNF1A and UGT1A8 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A8.
DME0064	UNIPROID	CDX2_HUMAN	PROTNAME	Homeobox protein CDX-2 (CDX2)
DME0064	UNIPROID	CDX2_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0064	UNIPROID	CDX2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0064	UNIPROID	CDX2_HUMAN	MOFDETAI	Activation
DME0064	UNIPROID	CDX2_HUMAN	CELLLINE	Caco-2 cell line
DME0064	UNIPROID	CDX2_HUMAN	PPI_SUMM	CDX2-UGT1A8 interaction
DME0064	UNIPROID	CDX2_HUMAN	DESCRIPT	Homeobox protein CDX-2 (CDX2) is reported to activate the transcription of UGT1A8 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A8. As a result, the interaction between CDX2 and UGT1A8 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A8.
DME0065	DME___ID	DME0065
DME0065	DME_NAME	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DME0065	SPESNAME	Homo sapiens
DME0065	UNIPROID	UD11_HUMAN	PROTNAME	UDPGT 1-1 (UGT1A1)
DME0065	UNIPROID	UD11_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0065	UNIPROID	UD11_HUMAN	MOFCLASS	Oligomerization
DME0065	UNIPROID	UD11_HUMAN	MOFDETAI	Hetero-oligomerization
DME0065	UNIPROID	UD11_HUMAN	SUBSTRAT	2-Napthol
DME0065	UNIPROID	UD11_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell line (COS)
DME0065	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-UGT1A7 heterodimerization
DME0065	UNIPROID	UD11_HUMAN	DESCRIPT	UDPGT 1-1 (UGT1A1) is reported to heterodimerize with the UGT1A7 protein, which leads to a slight effect on the enzyme activity of UDP-glucuronosyltransferase 1A7. As a result, the interaction between UGT1A1 and UGT1A7 can slightly affect the drug-metabolizing process of UDP-glucuronosyltransferase 1A7.
DME0065	UNIPROID	UD17_HUMAN	PROTNAME	UDPGT 1-7 (UGT1A7)
DME0065	UNIPROID	UD17_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0065	UNIPROID	UD17_HUMAN	MOFCLASS	Oligomerization
DME0065	UNIPROID	UD17_HUMAN	MOFDETAI	Homo-oligomerization
DME0065	UNIPROID	UD17_HUMAN	SUBSTRAT	2-Napthol
DME0065	UNIPROID	UD17_HUMAN	CELLLINE	Monkey kidney fibroblast-like cell line (COS)
DME0065	UNIPROID	UD17_HUMAN	PPI_SUMM	UGT1A7-UGT1A7 homodimerization
DME0065	UNIPROID	UD17_HUMAN	DESCRIPT	UDP-glucuronosyltransferase 1-7 (UGT1A7) is reported as a homodimer, which leads to a slight effect on the enzyme activity of drug-metabolizing enzyme UDP-glucuronosyltransferase 1A7. As a result, the UGT1A7 homodimerization can slightly affect the drug-metabolizing process of UDP-glucuronosyltransferase 1A7.
DME0066	DME___ID	DME0066
DME0066	DME_NAME	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DME0066	SPESNAME	Homo sapiens
DME0066	MIRNA_ID	MIMAT0000720	PROTNAME	hsa-miR-376c-3p
DME0066	MIRNA_ID	MIMAT0000720	HPPI_DIS	Health [ICD-11: N.A.]
DME0066	MIRNA_ID	MIMAT0000720	MOFCLASS	Non-coding RNA regulation
DME0066	MIRNA_ID	MIMAT0000720	MOFDETAI	microRNA regulation
DME0066	MIRNA_ID	MIMAT0000720	CELLLINE	HEK293 cell line
DME0066	MIRNA_ID	MIMAT0000720	PPI_SUMM	hsa-miR-376c-3p--UGT2B17 regulation
DME0066	MIRNA_ID	MIMAT0000720	DESCRIPT	hsa-miR-376c-3p is reported to suppress UGT2B17 mRNA translation by binding to the 3' untranslated region (3'UTR) of UGT2B17 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B17.
DME0066	MIRNA_ID	MIMAT0001639	PROTNAME	hsa-miR-409-3p
DME0066	MIRNA_ID	MIMAT0001639	HPPI_DIS	Health [ICD-11: N.A.]
DME0066	MIRNA_ID	MIMAT0001639	MOFCLASS	Non-coding RNA regulation
DME0066	MIRNA_ID	MIMAT0001639	MOFDETAI	microRNA regulation
DME0066	MIRNA_ID	MIMAT0001639	CELLLINE	HEK293 cell line
DME0066	MIRNA_ID	MIMAT0001639	PPI_SUMM	hsa-miR-409-3p--UGT2B17 regulation
DME0066	MIRNA_ID	MIMAT0001639	DESCRIPT	hsa-miR-409-3p is reported to suppress UGT2B17 mRNA translation by binding to the 3' untranslated region (3'UTR) of UGT2B17 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B17.
DME0066	MIRNA_ID	MIMAT0002816	PROTNAME	hsa-miR-494-3p
DME0066	MIRNA_ID	MIMAT0002816	HPPI_DIS	Health [ICD-11: N.A.]
DME0066	MIRNA_ID	MIMAT0002816	MOFCLASS	Non-coding RNA regulation
DME0066	MIRNA_ID	MIMAT0002816	MOFDETAI	microRNA regulation
DME0066	MIRNA_ID	MIMAT0002816	CELLLINE	HEK293 cell line
DME0066	MIRNA_ID	MIMAT0002816	PPI_SUMM	hsa-miR-494-3p--UGT2B17 regulation
DME0066	MIRNA_ID	MIMAT0002816	DESCRIPT	hsa-miR-494-3p is reported to suppress UGT2B17 mRNA translation by binding to the 3' untranslated region (3'UTR) of UGT2B17 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B17.
DME0066	UNIPROID	ADH1B_HUMAN	PROTNAME	Alcohol dehydrogenase 1B (ADH1B)
DME0066	UNIPROID	ADH1B_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0066	UNIPROID	ADH1B_HUMAN	MOFCLASS	Oligomerization
DME0066	UNIPROID	ADH1B_HUMAN	MOFDETAI	Hetero-oligomerization
DME0066	UNIPROID	ADH1B_HUMAN	CELLLINE	Colorectal adenocarcinomas cell line
DME0066	UNIPROID	ADH1B_HUMAN	PPI_SUMM	ADH1B-UGT2B17 heterooligomerization
DME0066	UNIPROID	ADH1B_HUMAN	DESCRIPT	Alcohol dehydrogenase 1B (ADH1B) is reported to heterooligomerize with the UGT2B17 protein, which leads to an increased activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B17. As a result, the interaction between ADH1B and UGT2B17 can facilitate the drug-metabolizing process of UDP-glucuronosyltransferase 2B17.
DME0066	UNIPROID	HNF1A_HUMAN	PROTNAME	Hepatocyte NF 1-alpha (HNF1A)
DME0066	UNIPROID	HNF1A_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0066	UNIPROID	HNF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0066	UNIPROID	HNF1A_HUMAN	MOFDETAI	Activation
DME0066	UNIPROID	HNF1A_HUMAN	CELLLINE	HepG2 cell line
DME0066	UNIPROID	HNF1A_HUMAN	PPI_SUMM	HNF1A-UGT2B17 interaction
DME0066	UNIPROID	HNF1A_HUMAN	DESCRIPT	Hepatocyte NF 1-alpha (HNF1A) is reported to activate the transcription of UGT2B17 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B17. As a result, the interaction between HNF1A and UGT2B17 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 2B17.
DME0066	UNIPROID	HNF1A_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0066	UNIPROID	HNF1A_HUMAN	CELLLINE	LNCaP cell line
DME0066	UNIPROID	FOXA1_HUMAN	PROTNAME	Hepatocyte NF 3-alpha (FOXA1)
DME0066	UNIPROID	FOXA1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0066	UNIPROID	FOXA1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0066	UNIPROID	FOXA1_HUMAN	MOFDETAI	Activation
DME0066	UNIPROID	FOXA1_HUMAN	CELLLINE	LNCaP cell line
DME0066	UNIPROID	FOXA1_HUMAN	PPI_SUMM	FOXA1-UGT2B17 interaction
DME0066	UNIPROID	FOXA1_HUMAN	DESCRIPT	Hepatocyte NF 3-alpha (FOXA1) is reported to activate the transcription of UGT2B17 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B17. As a result, the interaction between FOXA1 and UGT2B17 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 2B17.
DME0069	DME___ID	DME0069
DME0069	DME_NAME	Butyrylcholine esterase (BCHE)
DME0069	SPESNAME	Homo sapiens
DME0069	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0069	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0069	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0069	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0069	UNIPROID	EHMT1_HUMAN	CELLLINE	Human neuroblastoma cells SH-SY5Y
DME0069	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-BCHE interaction
DME0069	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 27 trimethylation of BCHE gene is reported to repress the transcriptional activity of the drug-metabolizing enzyme Butyrylcholine esterase. As a result, the interaction between Histone methyltransferases (HMTs) and BCHE can inhibit the drug-metabolizing process of Butyrylcholine esterase.
DME0069	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0069	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0069	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0069	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0069	UNIPROID	HDAC1_HUMAN	CELLLINE	SH-SY5Y cell line
DME0069	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-BCHE interaction
DME0069	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the BCHE gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Butyrylcholine esterase. As a result, the interaction between HDACs and BCHE can inhibit the drug-metabolizing process of Butyrylcholine esterase.
DME0072	DME___ID	DME0072
DME0072	DME_NAME	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DME0072	SPESNAME	Homo sapiens
DME0072	UNIPROID	UD19_HUMAN	PROTNAME	UDPGT 1-9 (UGT1A9)
DME0072	UNIPROID	UD19_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0072	UNIPROID	UD19_HUMAN	MOFCLASS	Oligomerization
DME0072	UNIPROID	UD19_HUMAN	MOFDETAI	Hetero-oligomerization
DME0072	UNIPROID	UD19_HUMAN	SUBSTRAT	Serotonin (Metabolic product: Serotonin O-glucuronide)
DME0072	UNIPROID	UD19_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293)
DME0072	UNIPROID	UD19_HUMAN	PPI_SUMM	UGT1A9-UGT1A6 heterooligomerization
DME0072	UNIPROID	UD19_HUMAN	DESCRIPT	UDPGT 1-9 (UGT1A9) is reported to heterooligomerize with the UGT1A6 protein, which leads to a suppressed activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A6. As a result, the interaction between UGT1A9 and UGT1A6 can inhibit the drug-metabolizing process of UDP-glucuronosyltransferase 1A6.
DME0074	DME___ID	DME0074
DME0074	DME_NAME	Sulfotransferase 2A1 (SULT2A1)
DME0074	SPESNAME	Homo sapiens
DME0074	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0074	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0074	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0074	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0074	UNIPROID	HDAC1_HUMAN	CELLLINE	MCF-7 cell line
DME0074	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-SULT2A1 interaction
DME0074	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the SULT2A1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Sulfotransferase 2A1. As a result, the interaction between HDACs and SULT2A1 can inhibit the drug-metabolizing process of Sulfotransferase 2A1.
DME0074	UNIPROID	MED1_HUMAN	PROTNAME	PPAR-binding protein (MED1)
DME0074	UNIPROID	MED1_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0074	UNIPROID	MED1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0074	UNIPROID	MED1_HUMAN	MOFDETAI	Activation
DME0074	UNIPROID	MED1_HUMAN	CELLLINE	H295R cell line
DME0074	UNIPROID	MED1_HUMAN	PPI_SUMM	MED1-SULT2A1 interaction
DME0074	UNIPROID	MED1_HUMAN	DESCRIPT	PPAR-binding protein (MED1) is reported to activate the transcription of SULT2A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Sulfotransferase 2A1. As a result, the interaction between MED1 and SULT2A1 can activate the drug-metabolizing process of Sulfotransferase 2A1.
DME0074	UNIPROID	SF01_HUMAN	PROTNAME	Splicing factor 1 (SF1)
DME0074	UNIPROID	SF01_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0074	UNIPROID	SF01_HUMAN	MOFCLASS	Transcription-factor regulation
DME0074	UNIPROID	SF01_HUMAN	MOFDETAI	Activation
DME0074	UNIPROID	SF01_HUMAN	CELLLINE	HEK 293T cell line
DME0074	UNIPROID	SF01_HUMAN	PPI_SUMM	SF1-SULT2A1 interaction
DME0074	UNIPROID	SF01_HUMAN	DESCRIPT	Splicing factor 1 (SF1) is reported to activate the transcription of SULT2A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Sulfotransferase 2A1. As a result, the interaction between SF1 and SULT2A1 can activate the drug-metabolizing process of Sulfotransferase 2A1.
DME0074	UNIPROID	GATA6_HUMAN	PROTNAME	TF factor GATA-6 (GATA6)
DME0074	UNIPROID	GATA6_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0074	UNIPROID	GATA6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0074	UNIPROID	GATA6_HUMAN	MOFDETAI	Activation
DME0074	UNIPROID	GATA6_HUMAN	CELLLINE	HEK293 and H295R cell lines
DME0074	UNIPROID	GATA6_HUMAN	PPI_SUMM	GATA6-SULT2A1 interaction
DME0074	UNIPROID	GATA6_HUMAN	DESCRIPT	TF factor GATA-6 (GATA6) is reported to activate the transcription of SULT2A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Sulfotransferase 2A1. As a result, the interaction between GATA6 and SULT2A1 can activate the drug-metabolizing process of Sulfotransferase 2A1.
DME0075	DME___ID	DME0075
DME0075	DME_NAME	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DME0075	SPESNAME	Homo sapiens
DME0075	UNIPROID	HNF1A_HUMAN	PROTNAME	Hepatocyte NF 1-alpha (HNF1A)
DME0075	UNIPROID	HNF1A_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0075	UNIPROID	HNF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0075	UNIPROID	HNF1A_HUMAN	MOFDETAI	Activation
DME0075	UNIPROID	HNF1A_HUMAN	CELLLINE	Caco-2 cell line
DME0075	UNIPROID	HNF1A_HUMAN	PPI_SUMM	HNF1A-UGT1A10 interaction
DME0075	UNIPROID	HNF1A_HUMAN	DESCRIPT	Hepatocyte NF 1-alpha (HNF1A) is reported to activate the transcription of UGT1A10 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A10. As a result, the interaction between HNF1A and UGT1A10 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A10.
DME0075	UNIPROID	CDX2_HUMAN	PROTNAME	Homeobox protein CDX-2 (CDX2)
DME0075	UNIPROID	CDX2_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0075	UNIPROID	CDX2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0075	UNIPROID	CDX2_HUMAN	MOFDETAI	Activation
DME0075	UNIPROID	CDX2_HUMAN	CELLLINE	Caco-2 cell line
DME0075	UNIPROID	CDX2_HUMAN	PPI_SUMM	CDX2-UGT1A10 interaction
DME0075	UNIPROID	CDX2_HUMAN	DESCRIPT	Homeobox protein CDX-2 (CDX2) is reported to activate the transcription of UGT1A10 gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucuronosyltransferase 1A10. As a result, the interaction between CDX2 and UGT1A10 can activate the drug-metabolizing process of UDP-glucuronosyltransferase 1A10.
DME0076	DME___ID	DME0076
DME0076	DME_NAME	NADPH-cytochrome P450 reductase (CPR)
DME0076	SPESNAME	Homo sapiens
DME0076	MIRNA_ID	MIMAT0000271	PROTNAME	hsa-miR-214-3p
DME0076	MIRNA_ID	MIMAT0000271	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0076	MIRNA_ID	MIMAT0000271	MOFCLASS	Non-coding RNA regulation
DME0076	MIRNA_ID	MIMAT0000271	MOFDETAI	microRNA regulation
DME0076	MIRNA_ID	MIMAT0000271	CELLLINE	Bel7402 cell line
DME0076	MIRNA_ID	MIMAT0000271	PPI_SUMM	hsa-miR-214-3p--POR regulation
DME0076	MIRNA_ID	MIMAT0000271	DESCRIPT	hsa-miR-214-3p is reported to suppress POR mRNA translation by binding to the 3' untranslated region (3'UTR) of POR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme NADPH-cytochrome P450 reductase.
DME0076	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0076	UNIPROID	SP1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0076	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0076	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0076	UNIPROID	SP1_HUMAN	CELLLINE	Rat liver
DME0076	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-POR interaction
DME0076	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of CPR gene, which leads to an increased expression of the drug-metabolizing enzyme NADPH-cytochrome P450 reductase. As a result, the interaction between SP1 and CPR can activate the drug-metabolizing process of NADPH-cytochrome P450 reductase.
DME0077	DME___ID	DME0077
DME0077	DME_NAME	Aldehyde dehydrogenase 2 (ALDH2)
DME0077	SPESNAME	Homo sapiens
DME0077	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0077	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0077	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0077	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0077	UNIPROID	HDAC1_HUMAN	CELLLINE	HepG2 cell line
DME0077	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-ALDH2 interaction
DME0077	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the ALDH2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Aldehyde dehydrogenase 2. As a result, the interaction between HDACs and ALDH2 can inhibit the drug-metabolizing process of Aldehyde dehydrogenase 2.
DME0077	UNIPROID	ALDH2_HUMAN	PROTNAME	Mutated ALDH-E2 (mALDH2)
DME0077	UNIPROID	ALDH2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0077	UNIPROID	ALDH2_HUMAN	MOFCLASS	Oligomerization
DME0077	UNIPROID	ALDH2_HUMAN	MOFDETAI	Hetero-oligomerization
DME0077	UNIPROID	ALDH2_HUMAN	SUBSTRAT	Acetaldehyde
DME0077	UNIPROID	ALDH2_HUMAN	CELLLINE	Escherichia coli cell line
DME0077	UNIPROID	ALDH2_HUMAN	PPI_SUMM	mALDH2-ALDH2 heterooligomerization
DME0077	UNIPROID	ALDH2_HUMAN	DESCRIPT	Mutated ALDH-E2 (mALDH2) is reported to heterooligomerize with the ALDH2 protein, which leads to an increased activity of the drug-metabolizing enzyme Aldehyde dehydrogenase 2. As a result, the interaction between mALDH2 and ALDH2 can facilitate the drug-metabolizing process of Aldehyde dehydrogenase 2.
DME0079	DME___ID	DME0079
DME0079	DME_NAME	Alkaline phosphatase (ALPL)
DME0079	SPESNAME	Homo sapiens
DME0079	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0079	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0079	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0079	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0079	UNIPROID	EHMT1_HUMAN	CELLLINE	Human mesenchymal stem cells (hMSCs)
DME0079	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-ALPL interaction
DME0079	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 9 trimethylation of ALPL gene is reported to repress the transcriptional activity of the drug-metabolizing enzyme Alkaline phosphatase. As a result, the interaction between Histone methyltransferases (HMTs) and ALPL can inhibit the drug-metabolizing process of Alkaline phosphatase.
DME0079	MIRNA_ID	MIMAT0000265	PROTNAME	hsa-miR-204-5p
DME0079	MIRNA_ID	MIMAT0000265	HPPI_DIS	Health [ICD-11: N.A.]
DME0079	MIRNA_ID	MIMAT0000265	MOFCLASS	Non-coding RNA regulation
DME0079	MIRNA_ID	MIMAT0000265	MOFDETAI	microRNA regulation
DME0079	MIRNA_ID	MIMAT0000265	CELLLINE	M-Osx cell line
DME0079	MIRNA_ID	MIMAT0000265	PPI_SUMM	hsa-miR-204-5p--ALPL regulation
DME0079	MIRNA_ID	MIMAT0000265	DESCRIPT	hsa-miR-204-5p is reported to suppress ALPL mRNA translation by binding to the 3' untranslated region (3'UTR) of ALPL mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Alkaline phosphatase.
DME0079	UNIPROID	SP3_HUMAN	PROTNAME	Transcription factor Sp3 (SP3)
DME0079	UNIPROID	SP3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0079	UNIPROID	SP3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0079	UNIPROID	SP3_HUMAN	MOFDETAI	Activation
DME0079	UNIPROID	SP3_HUMAN	CELLLINE	Drosophila Schneider cell line
DME0079	UNIPROID	SP3_HUMAN	PPI_SUMM	SP3-ALPL interaction
DME0079	UNIPROID	SP3_HUMAN	DESCRIPT	Transcription factor Sp3 (SP3) is reported to activate the transcription of ALPL gene, which leads to an increased expression of the drug-metabolizing enzyme Alkaline phosphatase. As a result, the interaction between SP3 and ALPL can activate the drug-metabolizing process of Alkaline phosphatase.
DME0080	DME___ID	DME0080
DME0080	DME_NAME	Cytidine aminohydrolase (CDA)
DME0080	SPESNAME	Homo sapiens
DME0080	UNIPROID	GATA1_HUMAN	PROTNAME	Erythroid TF factor (GATA1)
DME0080	UNIPROID	GATA1_HUMAN	HPPI_DIS	Acute myeloid leukemia [ICD-11: 2A60]
DME0080	UNIPROID	GATA1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0080	UNIPROID	GATA1_HUMAN	MOFDETAI	Activation
DME0080	UNIPROID	GATA1_HUMAN	CELLLINE	CMK cell line
DME0080	UNIPROID	GATA1_HUMAN	PPI_SUMM	GATA1-CDA interaction
DME0080	UNIPROID	GATA1_HUMAN	DESCRIPT	Erythroid TF factor (GATA1) is reported to activate the transcription of CDA gene, which leads to an increased expression of the drug-metabolizing enzyme Cytidine aminohydrolase. As a result, the interaction between GATA1 and CDA can activate the drug-metabolizing process of Cytidine aminohydrolase.
DME0083	DME___ID	DME0083
DME0083	DME_NAME	Methylenetetrahydrofolate reductase (MTHFR)
DME0083	SPESNAME	Homo sapiens
DME0083	MIRNA_ID	MIMAT0000450	PROTNAME	hsa-miR-149-5p
DME0083	MIRNA_ID	MIMAT0000450	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0083	MIRNA_ID	MIMAT0000450	MOFCLASS	Non-coding RNA regulation
DME0083	MIRNA_ID	MIMAT0000450	MOFDETAI	microRNA regulation
DME0083	MIRNA_ID	MIMAT0000450	CELLLINE	QGY-7703 cell line
DME0083	MIRNA_ID	MIMAT0000450	PPI_SUMM	hsa-miR-149-5p--MTHFR regulation
DME0083	MIRNA_ID	MIMAT0000450	DESCRIPT	hsa-miR-149-5p is reported to suppress MTHFR mRNA translation by binding to the 3' untranslated region (3'UTR) of MTHFR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Methylenetetrahydrofolate reductase.
DME0083	MIRNA_ID	MIMAT0000077	PROTNAME	hsa-miR-22-3p
DME0083	MIRNA_ID	MIMAT0000077	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0083	MIRNA_ID	MIMAT0000077	MOFCLASS	Non-coding RNA regulation
DME0083	MIRNA_ID	MIMAT0000077	MOFDETAI	microRNA regulation
DME0083	MIRNA_ID	MIMAT0000077	CELLLINE	QGY-7703 cell line
DME0083	MIRNA_ID	MIMAT0000077	PPI_SUMM	hsa-miR-22-3p--MTHFR regulation
DME0083	MIRNA_ID	MIMAT0000077	DESCRIPT	hsa-miR-22-3p is reported to suppress MTHFR mRNA translation by binding to the 3' untranslated region (3'UTR) of MTHFR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Methylenetetrahydrofolate reductase.
DME0083	UNIPROID	NF2L2_HUMAN	PROTNAME	NFE2-related factor 2 (NFE2L2)
DME0083	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0083	UNIPROID	NF2L2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0083	UNIPROID	NF2L2_HUMAN	MOFDETAI	Activation
DME0083	UNIPROID	NF2L2_HUMAN	CELLLINE	HEK 293T cell line
DME0083	UNIPROID	NF2L2_HUMAN	PPI_SUMM	NFE2L2-MTHFR interaction
DME0083	UNIPROID	NF2L2_HUMAN	DESCRIPT	NFE2-related factor 2 (NFE2L2) is reported to activate the transcription of MTHFR gene, which leads to an increased expression of the drug-metabolizing enzyme Methylenetetrahydrofolate reductase. As a result, the interaction between NFE2L2 and MTHFR can activate the drug-metabolizing process of Methylenetetrahydrofolate reductase.
DME0086	DME___ID	DME0086
DME0086	DME_NAME	Bleomycin hydrolase (BLMH)
DME0086	SPESNAME	Homo sapiens
DME0086	UNIPROID	MZF1_HUMAN	PROTNAME	Myeloid zinc finger 1 (MZF1)
DME0086	UNIPROID	MZF1_HUMAN	HPPI_DIS	Atopic dermatitis [ICD-11: EA80]
DME0086	UNIPROID	MZF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0086	UNIPROID	MZF1_HUMAN	MOFDETAI	Activation
DME0086	UNIPROID	MZF1_HUMAN	CELLLINE	Epidermal keratinocytes
DME0086	UNIPROID	MZF1_HUMAN	PPI_SUMM	MZF1-BLMH interaction
DME0086	UNIPROID	MZF1_HUMAN	DESCRIPT	Myeloid zinc finger 1 (MZF1) is reported to activate the transcription of BLMH gene, which leads to an increased expression of the drug-metabolizing enzyme Bleomycin hydrolase. As a result, the interaction between MZF1 and BLMH can activate the drug-metabolizing process of Bleomycin hydrolase.
DME0086	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0086	UNIPROID	SP1_HUMAN	HPPI_DIS	Atopic dermatitis [ICD-11: EA80]
DME0086	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0086	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0086	UNIPROID	SP1_HUMAN	CELLLINE	Epidermal keratinocytes
DME0086	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-BLMH interaction
DME0086	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of BLMH gene, which leads to an increased expression of the drug-metabolizing enzyme Bleomycin hydrolase. As a result, the interaction between SP1 and BLMH can activate the drug-metabolizing process of Bleomycin hydrolase.
DME0088	DME___ID	DME0088
DME0088	DME_NAME	Glutathione S-transferase pi (GSTP1)
DME0088	SPESNAME	Homo sapiens
DME0088	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0088	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0088	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0088	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0088	UNIPROID	HDAC1_HUMAN	CELLLINE	hepatocellular LCL-PI 11 cell line
DME0088	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-GSTP1 interaction
DME0088	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the GSTP1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Glutathione S-transferase pi. As a result, the interaction between HDACs and GSTP1 can inhibit the drug-metabolizing process of Glutathione S-transferase pi.
DME0088	MIRNA_ID	MIMAT0000427	PROTNAME	hsa-miR-133a-3p
DME0088	MIRNA_ID	MIMAT0000427	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0088	MIRNA_ID	MIMAT0000427	MOFCLASS	Non-coding RNA regulation
DME0088	MIRNA_ID	MIMAT0000427	MOFDETAI	microRNA regulation
DME0088	MIRNA_ID	MIMAT0000427	CELLLINE	Bladder cancer cells
DME0088	MIRNA_ID	MIMAT0000427	PPI_SUMM	hsa-miR-133a-3p--GSTP1 regulation
DME0088	MIRNA_ID	MIMAT0000427	DESCRIPT	hsa-miR-133a-3p is reported to suppress GSTP1 mRNA translation by binding to the 3' untranslated region (3'UTR) of GSTP1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glutathione S-transferase pi.
DME0088	MIRNA_ID	MIMAT0004777	PROTNAME	hsa-miR-513a-3p
DME0088	MIRNA_ID	MIMAT0004777	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0088	MIRNA_ID	MIMAT0004777	MOFCLASS	Non-coding RNA regulation
DME0088	MIRNA_ID	MIMAT0004777	MOFDETAI	microRNA regulation
DME0088	MIRNA_ID	MIMAT0004777	CELLLINE	A549 cell line
DME0088	MIRNA_ID	MIMAT0004777	PPI_SUMM	hsa-miR-513a-3p--GSTP1 regulation
DME0088	MIRNA_ID	MIMAT0004777	DESCRIPT	hsa-miR-513a-3p is reported to suppress GSTP1 mRNA translation by binding to the 3' untranslated region (3'UTR) of GSTP1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glutathione S-transferase pi.
DME0088	MIRNA_ID	MIMAT0000770	PROTNAME	hsa-miR-133b
DME0088	MIRNA_ID	MIMAT0000770	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0088	MIRNA_ID	MIMAT0000770	MOFCLASS	Non-coding RNA regulation
DME0088	MIRNA_ID	MIMAT0000770	MOFDETAI	microRNA regulation
DME0088	MIRNA_ID	MIMAT0000770	CELLLINE	A2780 cell line
DME0088	MIRNA_ID	MIMAT0000770	PPI_SUMM	hsa-miR-133b--GSTP1 regulation
DME0088	MIRNA_ID	MIMAT0000770	DESCRIPT	hsa-miR-133b is reported to suppress GSTP1 mRNA translation by binding to the 3' untranslated region (3'UTR) of GSTP1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glutathione S-transferase pi.
DME0088	UNIPROID	GSTP1_HUMAN	PROTNAME	GS-transferase P (GSTP1)
DME0088	UNIPROID	GSTP1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0088	UNIPROID	GSTP1_HUMAN	MOFCLASS	Oligomerization
DME0088	UNIPROID	GSTP1_HUMAN	MOFDETAI	Homo-oligomerization
DME0088	UNIPROID	GSTP1_HUMAN	CELLLINE	Jurkat cells
DME0088	UNIPROID	GSTP1_HUMAN	PPI_SUMM	GSTP1-GSTP1 homodimerization
DME0088	UNIPROID	GSTP1_HUMAN	DESCRIPT	Glutathione S-transferase Pi (GSTP1) is reported as a homodimer, which leads to an altered activity of the drug-metabolizing enzyme Glutathione S-transferase pi. As a result, the GSTP1 homodimerization can modulate the drug-metabolizing process of Glutathione S-transferase pi.
DME0088	UNIPROID	P53_HUMAN	PROTNAME	Tumor suppressor p53 (TP53)
DME0088	UNIPROID	P53_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0088	UNIPROID	P53_HUMAN	MOFCLASS	Transcription-factor regulation
DME0088	UNIPROID	P53_HUMAN	MOFDETAI	Activation
DME0088	UNIPROID	P53_HUMAN	CELLLINE	MGR2, MGR3, UW28, UW281, UW78 cell lines
DME0088	UNIPROID	P53_HUMAN	PPI_SUMM	TP53-GSTP1 interaction
DME0088	UNIPROID	P53_HUMAN	DESCRIPT	Tumor suppressor p53 (TP53) is reported to activate the transcription of GSTP1 gene, which leads to an increased expression of the drug-metabolizing enzyme Glutathione S-transferase pi. As a result, the interaction between TP53 and GSTP1 can activate the drug-metabolizing process of Glutathione S-transferase pi.
DME0088	UNIPROID	P53_HUMAN	HPPI_DIS	Medulloblastoma [ICD-11: 2A00.10]
DME0088	UNIPROID	P53_HUMAN	CELLLINE	UW228 cell line
DME0088	UNIPROID	P53_HUMAN	HPPI_DIS	Leiomyosarcoma [ICD-11: 2B58]
DME0088	UNIPROID	P53_HUMAN	CELLLINE	SKLMS-1 cell line
DME0088	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0088	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0088	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0088	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0088	UNIPROID	NFKB1_HUMAN	CELLLINE	K562 cell line
DME0088	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-GSTP1 interaction
DME0088	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of GSTP1 gene, which leads to an increased expression of the drug-metabolizing enzyme Glutathione S-transferase pi. As a result, the interaction between NFKB1 and GSTP1 can activate the drug-metabolizing process of Glutathione S-transferase pi.
DME0088	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0088	UNIPROID	TF65_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0088	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0088	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0088	UNIPROID	TF65_HUMAN	CELLLINE	K562 cell line
DME0088	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-GSTP1 interaction
DME0088	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of GSTP1 gene, which leads to an increased expression of the drug-metabolizing enzyme Glutathione S-transferase pi. As a result, the interaction between RELA and GSTP1 can activate the drug-metabolizing process of Glutathione S-transferase pi.
DME0088	UNIPROID	MBD2_HUMAN	PROTNAME	Demethylase (MBD2)
DME0088	UNIPROID	MBD2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0088	UNIPROID	MBD2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0088	UNIPROID	MBD2_HUMAN	MOFDETAI	Repression
DME0088	UNIPROID	MBD2_HUMAN	CELLLINE	Hep3B cell line
DME0088	UNIPROID	MBD2_HUMAN	PPI_SUMM	MBD2-GSTP1 interaction
DME0088	UNIPROID	MBD2_HUMAN	DESCRIPT	Demethylase (MBD2) is reported to repress the transcription of GSTP1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Glutathione S-transferase pi. As a result, the interaction between MBD2 and GSTP1 can repress the drug-metabolizing process of Glutathione S-transferase pi.
DME0088	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0088	UNIPROID	SP1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0088	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0088	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0088	UNIPROID	SP1_HUMAN	CELLLINE	Human mammary carcinoma cell line (MCF7)
DME0088	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-GSTP1 interaction
DME0088	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of GSTP1 gene, which leads to an increased expression of the drug-metabolizing enzyme Glutathione S-transferase pi. As a result, the interaction between SP1 and GSTP1 can activate the drug-metabolizing process of Glutathione S-transferase pi.
DME0089	DME___ID	DME0089
DME0089	DME_NAME	Microsomal glutathione S-transferase 2 (MGST2)
DME0089	SPESNAME	Homo sapiens
DME0089	MIRNA_ID	MIMAT0000103	PROTNAME	hsa-miR-106a-5p
DME0089	MIRNA_ID	MIMAT0000103	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0089	MIRNA_ID	MIMAT0000103	MOFCLASS	Non-coding RNA regulation
DME0089	MIRNA_ID	MIMAT0000103	MOFDETAI	microRNA regulation
DME0089	MIRNA_ID	MIMAT0000103	CELLLINE	U87/DDP cell line
DME0089	MIRNA_ID	MIMAT0000103	PPI_SUMM	hsa-miR-106a-5p--MGST2 regulation
DME0089	MIRNA_ID	MIMAT0000103	DESCRIPT	hsa-miR-106a-5p is reported to suppress MGST2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MGST2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Microsomal glutathione S-transferase 2.
DME0089	UNIPROID	GSTA1_HUMAN	PROTNAME	GS-transferase A1 (GSTA1)
DME0089	UNIPROID	GSTA1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0089	UNIPROID	GSTA1_HUMAN	MOFCLASS	Oligomerization
DME0089	UNIPROID	GSTA1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0089	UNIPROID	GSTA1_HUMAN	SUBSTRAT	1-Chloro-2,4-dinitrobenzene
DME0089	UNIPROID	GSTA1_HUMAN	CELLLINE	Monkey kidney cell line (CV-1)
DME0089	UNIPROID	GSTA1_HUMAN	PPI_SUMM	GSTA1-MGST2 heterooligomerization
DME0089	UNIPROID	GSTA1_HUMAN	DESCRIPT	GS-transferase A1 (GSTA1) is reported to heterooligomerize with the MGST2 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Microsomal glutathione S-transferase 2. As a result, the interaction between GSTA1 and MGST2 can inhibit the drug-metabolizing process of Microsomal glutathione S-transferase 2.
DME0089	UNIPROID	MGST2_HUMAN	PROTNAME	Microsomal GST-II (MGST2)
DME0089	UNIPROID	MGST2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0089	UNIPROID	MGST2_HUMAN	MOFCLASS	Oligomerization
DME0089	UNIPROID	MGST2_HUMAN	MOFDETAI	Homo-oligomerization
DME0089	UNIPROID	MGST2_HUMAN	SUBSTRAT	Glutathione (Metabolic product: Activates glutathione to form a thiolate)
DME0089	UNIPROID	MGST2_HUMAN	CELLLINE	Yeast pichia pastoris cell line
DME0089	UNIPROID	MGST2_HUMAN	PPI_SUMM	MGST2-MGST2 homotrimerization
DME0089	UNIPROID	MGST2_HUMAN	DESCRIPT	Microsomal glutathione S-transferase 2 (MGST2) is reported as a homotrimer, which is necessary for sustaining the enzyme activity of Microsomal glutathione S-transferase 2. As a result, MGST2 homotrimerization is necessary for sustaining the drug-metabolizing process of Microsomal glutathione S-transferase 2.
DME0090	DME___ID	DME0090
DME0090	DME_NAME	Catalase (CAT)
DME0090	SPESNAME	Homo sapiens
DME0090	MIRNA_ID	MIMAT0000420	PROTNAME	hsa-miR-30b-5p
DME0090	MIRNA_ID	MIMAT0000420	HPPI_DIS	Health [ICD-11: N.A.]
DME0090	MIRNA_ID	MIMAT0000420	MOFCLASS	Non-coding RNA regulation
DME0090	MIRNA_ID	MIMAT0000420	MOFDETAI	microRNA regulation
DME0090	MIRNA_ID	MIMAT0000420	CELLLINE	ARPE-19 cell line
DME0090	MIRNA_ID	MIMAT0000420	PPI_SUMM	hsa-miR-30b-5p--CAT regulation
DME0090	MIRNA_ID	MIMAT0000420	DESCRIPT	hsa-miR-30b-5p is reported to suppress CAT mRNA translation by binding to the 3' untranslated region (3'UTR) of CAT mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Catalase.
DME0090	UNIPROID	NF2L2_HUMAN	PROTNAME	NFE2-related factor 2 (NFE2L2)
DME0090	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0090	UNIPROID	NF2L2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0090	UNIPROID	NF2L2_HUMAN	MOFDETAI	Activation
DME0090	UNIPROID	NF2L2_HUMAN	CELLLINE	MCF-7, T47D and HCC1937 cell lines
DME0090	UNIPROID	NF2L2_HUMAN	PPI_SUMM	NFE2L2-CAT interaction
DME0090	UNIPROID	NF2L2_HUMAN	DESCRIPT	NFE2-related factor 2 (NFE2L2) is reported to activate the transcription of CAT gene, which leads to an increased expression of the drug-metabolizing enzyme Catalase. As a result, the interaction between NFE2L2 and CAT can activate the drug-metabolizing process of Catalase.
DME0090	UNIPROID	PPARD_HUMAN	PROTNAME	PPA receptor delta (PPARD)
DME0090	UNIPROID	PPARD_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0090	UNIPROID	PPARD_HUMAN	MOFCLASS	Transcription-factor regulation
DME0090	UNIPROID	PPARD_HUMAN	MOFDETAI	Activation
DME0090	UNIPROID	PPARD_HUMAN	CELLLINE	Human umbilical vein endothelial cell line
DME0090	UNIPROID	PPARD_HUMAN	PPI_SUMM	PPARD-CAT interaction
DME0090	UNIPROID	PPARD_HUMAN	DESCRIPT	PPA receptor delta (PPARD) is reported to activate the transcription of CAT gene, which leads to an increased expression of the drug-metabolizing enzyme Catalase. As a result, the interaction between PPARD and CAT can activate the drug-metabolizing process of Catalase.
DME0090	UNIPROID	EGR3_HUMAN	PROTNAME	Early growth response 3 (EGR3)
DME0090	UNIPROID	EGR3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0090	UNIPROID	EGR3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0090	UNIPROID	EGR3_HUMAN	MOFDETAI	Activation
DME0090	UNIPROID	EGR3_HUMAN	CELLLINE	Rodent and human fibroblasts and a monkey kidney epithelial cell line
DME0090	UNIPROID	EGR3_HUMAN	PPI_SUMM	EGR3-CAT interaction
DME0090	UNIPROID	EGR3_HUMAN	DESCRIPT	Early growth response 3 (EGR3) is reported to activate the transcription of CAT gene, which leads to an increased expression of the drug-metabolizing enzyme Catalase. As a result, the interaction between EGR3 and CAT can activate the drug-metabolizing process of Catalase.
DME0091	DME___ID	DME0091
DME0091	DME_NAME	Prostaglandin G/H synthase 1 (COX-1)
DME0091	SPESNAME	Homo sapiens
DME0091	UNIPROID	KLF10_HUMAN	PROTNAME	Krueppel-like factor 10 (KLF10)
DME0091	UNIPROID	KLF10_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0091	UNIPROID	KLF10_HUMAN	MOFCLASS	Transcription-factor regulation
DME0091	UNIPROID	KLF10_HUMAN	MOFDETAI	Activation
DME0091	UNIPROID	KLF10_HUMAN	CELLLINE	Human A549, HeLa and mouse bEnd.3 cell lines
DME0091	UNIPROID	KLF10_HUMAN	PPI_SUMM	KLF10-PTGS1 interaction
DME0091	UNIPROID	KLF10_HUMAN	DESCRIPT	Krueppel-like factor 10 (KLF10) is reported to activate the transcription of COX1 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 1. As a result, the interaction between KLF10 and COX1 can activate the drug-metabolizing process of Prostaglandin G/H synthase 1.
DME0095	DME___ID	DME0095
DME0095	DME_NAME	Metallothionein-2A (MT2A)
DME0095	SPESNAME	Homo sapiens
DME0095	MIRNA_ID	MIMAT0000078	PROTNAME	hsa-miR-23a-3p
DME0095	MIRNA_ID	MIMAT0000078	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0095	MIRNA_ID	MIMAT0000078	MOFCLASS	Non-coding RNA regulation
DME0095	MIRNA_ID	MIMAT0000078	MOFDETAI	microRNA regulation
DME0095	MIRNA_ID	MIMAT0000078	CELLLINE	BGC823, MGC803 and AGS cell lines
DME0095	MIRNA_ID	MIMAT0000078	PPI_SUMM	hsa-miR-23a-3p--MT2A regulation
DME0095	MIRNA_ID	MIMAT0000078	DESCRIPT	hsa-miR-23a-3p is reported to suppress MT2A mRNA translation by binding to the 3' untranslated region (3'UTR) of MT2A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Metallothionein-2A.
DME0095	UNIPROID	AHR_HUMAN	PROTNAME	Aryl hydrocarbon receptor (AHR)
DME0095	UNIPROID	AHR_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0095	UNIPROID	AHR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0095	UNIPROID	AHR_HUMAN	MOFDETAI	Activation
DME0095	UNIPROID	AHR_HUMAN	CELLLINE	Human liver cancer cell line (HepG2) and mouse hepatoma Hepa-1c1c7 cell line
DME0095	UNIPROID	AHR_HUMAN	PPI_SUMM	AHR-MT2A interaction
DME0095	UNIPROID	AHR_HUMAN	DESCRIPT	Aryl hydrocarbon receptor (AHR) is reported to activate the transcription of MT2A gene, which leads to an increased expression of the drug-metabolizing enzyme Metallothionein-2A. As a result, the interaction between AHR and MT2A can activate the drug-metabolizing process of Metallothionein-2A.
DME0096	DME___ID	DME0096
DME0096	DME_NAME	Myeloperoxidase (MPO)
DME0096	SPESNAME	Homo sapiens
DME0096	UNIPROID	CERU_HUMAN	PROTNAME	Ceruloplasmin (CP)
DME0096	UNIPROID	CERU_HUMAN	HPPI_DIS	Systemic vasculitides [ICD-11: 8E40]
DME0096	UNIPROID	CERU_HUMAN	MOFCLASS	Oligomerization
DME0096	UNIPROID	CERU_HUMAN	MOFDETAI	Hetero-oligomerization
DME0096	UNIPROID	CERU_HUMAN	CELLLINE	Healthy subjects
DME0096	UNIPROID	CERU_HUMAN	PPI_SUMM	CP, LTF and MPO heterotrimerization
DME0096	UNIPROID	CERU_HUMAN	DESCRIPT	Ceruloplasmin (CP) and Lactotransferrin (LTF) is reported to heterotrimerize with the MPO protein, which leads to a suppressed activity of the drug-metabolizing enzyme Myeloperoxidase. As a result, the interaction among CP, LTF and MPO can inhibit the drug-metabolizing process of Myeloperoxidase.
DME0096	UNIPROID	TRFL_HUMAN	PROTNAME	Lactotransferrin (LTF)
DME0096	UNIPROID	TRFL_HUMAN	HPPI_DIS	Systemic vasculitides [ICD-11: 8E40]
DME0096	UNIPROID	TRFL_HUMAN	MOFCLASS	Oligomerization
DME0096	UNIPROID	TRFL_HUMAN	MOFDETAI	Hetero-oligomerization
DME0096	UNIPROID	TRFL_HUMAN	CELLLINE	Healthy subjects
DME0096	UNIPROID	TRFL_HUMAN	PPI_SUMM	LTF, CP and MPO heterotrimerization
DME0096	UNIPROID	TRFL_HUMAN	DESCRIPT	Lactotransferrin (LTF) and Ceruloplasmin (CP) is reported to heterotrimerize with the MPO protein, which leads to a suppressed activity of the drug-metabolizing enzyme Myeloperoxidase. As a result, the interaction among LTF, CP and MPO can inhibit the drug-metabolizing process of Myeloperoxidase.
DME0096	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0096	UNIPROID	SP1_HUMAN	HPPI_DIS	Vasculitis [ICD-11: 4A44]
DME0096	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0096	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0096	UNIPROID	SP1_HUMAN	CELLLINE	ANCA-associated vasculitis cell line
DME0096	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-MPO interaction
DME0096	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of MPO gene, which leads to an increased expression of the drug-metabolizing enzyme Myeloperoxidase. As a result, the interaction between SP1 and MPO can activate the drug-metabolizing process of Myeloperoxidase.
DME0097	DME___ID	DME0097
DME0097	DME_NAME	Quinone reductase 1 (NQO1)
DME0097	SPESNAME	Homo sapiens
DME0097	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0097	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0097	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0097	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0097	UNIPROID	HDAC1_HUMAN	CELLLINE	Retinal tissues
DME0097	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-NQO1 interaction
DME0097	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the NQO1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Quinone reductase 1. As a result, the interaction between HDACs and NQO1 can inhibit the drug-metabolizing process of Quinone reductase 1.
DME0097	UNIPROID	NF2L2_HUMAN	PROTNAME	NFE2-related factor 2 (NFE2L2)
DME0097	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0097	UNIPROID	NF2L2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0097	UNIPROID	NF2L2_HUMAN	MOFDETAI	Activation
DME0097	UNIPROID	NF2L2_HUMAN	CELLLINE	HepG2 cell line
DME0097	UNIPROID	NF2L2_HUMAN	PPI_SUMM	NFE2L2-NQO1 interaction
DME0097	UNIPROID	NF2L2_HUMAN	DESCRIPT	NFE2-related factor 2 (NFE2L2) is reported to activate the transcription of NQO1 gene, which leads to an increased expression of the drug-metabolizing enzyme Quinone reductase 1. As a result, the interaction between NFE2L2 and NQO1 can activate the drug-metabolizing process of Quinone reductase 1.
DME0097	UNIPROID	NF2L1_HUMAN	PROTNAME	NFE2-related factor 1 (NFE2L1)
DME0097	UNIPROID	NF2L1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0097	UNIPROID	NF2L1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0097	UNIPROID	NF2L1_HUMAN	MOFDETAI	Activation
DME0097	UNIPROID	NF2L1_HUMAN	CELLLINE	HepG2 cell line
DME0097	UNIPROID	NF2L1_HUMAN	PPI_SUMM	NFE2L1-NQO1 interaction
DME0097	UNIPROID	NF2L1_HUMAN	DESCRIPT	NFE2-related factor 1 (NFE2L1) is reported to activate the transcription of NQO1 gene, which leads to an increased expression of the drug-metabolizing enzyme Quinone reductase 1. As a result, the interaction between NFE2L1 and NQO1 can activate the drug-metabolizing process of Quinone reductase 1.
DME0097	UNIPROID	ESR1_HUMAN	PROTNAME	Estrogen receptor (ESR1)
DME0097	UNIPROID	ESR1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0097	UNIPROID	ESR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0097	UNIPROID	ESR1_HUMAN	MOFDETAI	Repression
DME0097	UNIPROID	ESR1_HUMAN	CELLLINE	MCF-7, T47D and MDA-MB-231 cell lines
DME0097	UNIPROID	ESR1_HUMAN	PPI_SUMM	ESR1-NQO1 interaction
DME0097	UNIPROID	ESR1_HUMAN	DESCRIPT	Estrogen receptor (ESR1) is reported to repress the transcription of NQO1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Quinone reductase 1. As a result, the interaction between ESR1 and NQO1 can repress the drug-metabolizing process of Quinone reductase 1.
DME0097	UNIPROID	SIR1_HUMAN	PROTNAME	SIR2-like protein 1 (SIRT1)
DME0097	UNIPROID	SIR1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0097	UNIPROID	SIR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0097	UNIPROID	SIR1_HUMAN	MOFDETAI	Repression
DME0097	UNIPROID	SIR1_HUMAN	CELLLINE	MCF-7, T47D and MDA-MB-231 cell lines
DME0097	UNIPROID	SIR1_HUMAN	PPI_SUMM	SIRT1-NQO1 interaction
DME0097	UNIPROID	SIR1_HUMAN	DESCRIPT	SIR2-like protein 1 (SIRT1) is reported to repress the transcription of NQO1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Quinone reductase 1. As a result, the interaction between SIRT1 and NQO1 can repress the drug-metabolizing process of Quinone reductase 1.
DME0099	DME___ID	DME0099
DME0099	DME_NAME	Cholesterol desmolase (CYP11A1)
DME0099	SPESNAME	Homo sapiens
DME0099	UNIPROID	CYB5_HUMAN	PROTNAME	Cytochrome b5 (CYB5A)
DME0099	UNIPROID	CYB5_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0099	UNIPROID	CYB5_HUMAN	MOFCLASS	Oligomerization
DME0099	UNIPROID	CYB5_HUMAN	MOFDETAI	Hetero-oligomerization
DME0099	UNIPROID	CYB5_HUMAN	CELLLINE	Escherichia coli cell line
DME0099	UNIPROID	CYB5_HUMAN	PPI_SUMM	CYB5A-CYP11A1 heterodimerization
DME0099	UNIPROID	CYB5_HUMAN	DESCRIPT	Cytochrome b5 (CYB5A) is reported to heterodimerize with the CYP11A1 protein, which has no effect on the enzyme activity of Cholesterol desmolase. As a result, the interaction between CYB5A and CYP11A1 can have no effect on the drug-metabolizing process of Cholesterol desmolase.
DME0099	UNIPROID	SF01_HUMAN	PROTNAME	Splicing factor 1 (SF1)
DME0099	UNIPROID	SF01_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0099	UNIPROID	SF01_HUMAN	MOFCLASS	Transcription-factor regulation
DME0099	UNIPROID	SF01_HUMAN	MOFDETAI	Activation
DME0099	UNIPROID	SF01_HUMAN	CELLLINE	Y1 adrenocortical cell line
DME0099	UNIPROID	SF01_HUMAN	PPI_SUMM	SF1-CYP11A1 interaction
DME0099	UNIPROID	SF01_HUMAN	DESCRIPT	Splicing factor 1 (SF1) is reported to activate the transcription of CYP11A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cholesterol desmolase. As a result, the interaction between SF1 and CYP11A1 can activate the drug-metabolizing process of Cholesterol desmolase.
DME0099	UNIPROID	GATA6_HUMAN	PROTNAME	TF factor GATA-6 (GATA6)
DME0099	UNIPROID	GATA6_HUMAN	HPPI_DIS	Polycystic ovary syndrome [ICD-11: 5A80]
DME0099	UNIPROID	GATA6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0099	UNIPROID	GATA6_HUMAN	MOFDETAI	Activation
DME0099	UNIPROID	GATA6_HUMAN	CELLLINE	PCOS theca cell line
DME0099	UNIPROID	GATA6_HUMAN	PPI_SUMM	GATA6-CYP11A1 interaction
DME0099	UNIPROID	GATA6_HUMAN	DESCRIPT	TF factor GATA-6 (GATA6) is reported to activate the transcription of CYP11A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cholesterol desmolase. As a result, the interaction between GATA6 and CYP11A1 can activate the drug-metabolizing process of Cholesterol desmolase.
DME0099	UNIPROID	FOXL2_HUMAN	PROTNAME	Forkhead box protein L2 (FOXL2)
DME0099	UNIPROID	FOXL2_HUMAN	HPPI_DIS	Menopausal disorder [ICD-11: GA30]
DME0099	UNIPROID	FOXL2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0099	UNIPROID	FOXL2_HUMAN	MOFDETAI	Repression
DME0099	UNIPROID	FOXL2_HUMAN	CELLLINE	CHO cell line
DME0099	UNIPROID	FOXL2_HUMAN	PPI_SUMM	FOXL2-CYP11A1 interaction
DME0099	UNIPROID	FOXL2_HUMAN	DESCRIPT	Forkhead box protein L2 (FOXL2) is reported to repress the transcription of CYP11A1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Cholesterol desmolase. As a result, the interaction between FOXL2 and CYP11A1 can repress the drug-metabolizing process of Cholesterol desmolase.
DME0099	UNIPROID	GATA1_HUMAN	PROTNAME	Erythroid TF factor (GATA1)
DME0099	UNIPROID	GATA1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0099	UNIPROID	GATA1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0099	UNIPROID	GATA1_HUMAN	MOFDETAI	Activation
DME0099	UNIPROID	GATA1_HUMAN	CELLLINE	Adrenal cortex and testicular Leydig cell line
DME0099	UNIPROID	GATA1_HUMAN	PPI_SUMM	GATA1-CYP11A1 interaction
DME0099	UNIPROID	GATA1_HUMAN	DESCRIPT	Erythroid TF factor (GATA1) is reported to activate the transcription of CYP11A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cholesterol desmolase. As a result, the interaction between GATA1 and CYP11A1 can activate the drug-metabolizing process of Cholesterol desmolase.
DME0099	UNIPROID	LBP_HUMAN	PROTNAME	Lipopolysaccharide-binding (LBP)
DME0099	UNIPROID	LBP_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0099	UNIPROID	LBP_HUMAN	MOFCLASS	Transcription-factor regulation
DME0099	UNIPROID	LBP_HUMAN	MOFDETAI	Activation
DME0099	UNIPROID	LBP_HUMAN	CELLLINE	Adrenal cortex and testicular Leydig cell line
DME0099	UNIPROID	LBP_HUMAN	PPI_SUMM	LBP-CYP11A1 interaction
DME0099	UNIPROID	LBP_HUMAN	DESCRIPT	Lipopolysaccharide-binding (LBP) is reported to activate the transcription of CYP11A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cholesterol desmolase. As a result, the interaction between LBP and CYP11A1 can activate the drug-metabolizing process of Cholesterol desmolase.
DME0099	UNIPROID	NR0B1_HUMAN	PROTNAME	Nuclear receptor family 0 B1 (NR0B1)
DME0099	UNIPROID	NR0B1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0099	UNIPROID	NR0B1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0099	UNIPROID	NR0B1_HUMAN	MOFDETAI	Activation
DME0099	UNIPROID	NR0B1_HUMAN	CELLLINE	Adrenal cortex and testicular Leydig cell line
DME0099	UNIPROID	NR0B1_HUMAN	PPI_SUMM	NR0B1-CYP11A1 interaction
DME0099	UNIPROID	NR0B1_HUMAN	DESCRIPT	Nuclear receptor family 0 B1 (NR0B1) is reported to activate the transcription of CYP11A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cholesterol desmolase. As a result, the interaction between NR0B1 and CYP11A1 can activate the drug-metabolizing process of Cholesterol desmolase.
DME0099	UNIPROID	STF1_HUMAN	PROTNAME	Steroidogenic factor 1 (NR5A1)
DME0099	UNIPROID	STF1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0099	UNIPROID	STF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0099	UNIPROID	STF1_HUMAN	MOFDETAI	Activation
DME0099	UNIPROID	STF1_HUMAN	CELLLINE	Adrenal cortex and testicular Leydig cell line
DME0099	UNIPROID	STF1_HUMAN	PPI_SUMM	NR5A1-CYP11A1 interaction
DME0099	UNIPROID	STF1_HUMAN	DESCRIPT	Steroidogenic factor 1 (NR5A1) is reported to activate the transcription of CYP11A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cholesterol desmolase. As a result, the interaction between NR5A1 and CYP11A1 can activate the drug-metabolizing process of Cholesterol desmolase.
DME0099	UNIPROID	TREF1_HUMAN	PROTNAME	Zinc finger protein rapa (TRERF1)
DME0099	UNIPROID	TREF1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0099	UNIPROID	TREF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0099	UNIPROID	TREF1_HUMAN	MOFDETAI	Activation
DME0099	UNIPROID	TREF1_HUMAN	CELLLINE	Adrenal cortex and testicular Leydig cell line
DME0099	UNIPROID	TREF1_HUMAN	PPI_SUMM	TRERF1-CYP11A1 interaction
DME0099	UNIPROID	TREF1_HUMAN	DESCRIPT	Zinc finger protein rapa (TRERF1) is reported to activate the transcription of CYP11A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cholesterol desmolase. As a result, the interaction between TRERF1 and CYP11A1 can activate the drug-metabolizing process of Cholesterol desmolase.
DME0109	DME___ID	DME0109
DME0109	DME_NAME	Superoxide dismutase 1 (SOD1)
DME0109	SPESNAME	Homo sapiens
DME0109	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0109	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0109	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0109	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0109	UNIPROID	HDAC1_HUMAN	CELLLINE	Human lens epithelial cells (HLECs)
DME0109	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-SOD1 interaction
DME0109	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the SOD1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between HDACs and SOD1 can inhibit the drug-metabolizing process of Superoxide dismutase 1.
DME0109	MIRNA_ID	MIMAT0000730	PROTNAME	hsa-miR-377-3p
DME0109	MIRNA_ID	MIMAT0000730	HPPI_DIS	Diabetic nephropathy [ICD-11: GB61]
DME0109	MIRNA_ID	MIMAT0000730	MOFCLASS	Non-coding RNA regulation
DME0109	MIRNA_ID	MIMAT0000730	MOFDETAI	microRNA regulation
DME0109	MIRNA_ID	MIMAT0000730	CELLLINE	Human mesangial cells
DME0109	MIRNA_ID	MIMAT0000730	PPI_SUMM	hsa-miR-377-3p--SOD1 regulation
DME0109	MIRNA_ID	MIMAT0000730	DESCRIPT	hsa-miR-377-3p is reported to suppress SOD1 mRNA translation by binding to the 3' untranslated region (3'UTR) of SOD1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Superoxide dismutase 1.
DME0109	MIRNA_ID	MIMAT0000462	PROTNAME	hsa-miR-206
DME0109	MIRNA_ID	MIMAT0000462	HPPI_DIS	Health [ICD-11: N.A.]
DME0109	MIRNA_ID	MIMAT0000462	MOFCLASS	Non-coding RNA regulation
DME0109	MIRNA_ID	MIMAT0000462	MOFDETAI	microRNA regulation
DME0109	MIRNA_ID	MIMAT0000462	CELLLINE	Primary canine myocardial cells
DME0109	MIRNA_ID	MIMAT0000462	PPI_SUMM	hsa-miR-206--SOD1 regulation
DME0109	MIRNA_ID	MIMAT0000462	DESCRIPT	hsa-miR-206 is reported to suppress SOD1 mRNA translation by binding to the 3' untranslated region (3'UTR) of SOD1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Superoxide dismutase 1.
DME0109	UNIPROID	MTF1_HUMAN	PROTNAME	Transcription factor MTF-1 (MTF1)
DME0109	UNIPROID	MTF1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0109	UNIPROID	MTF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0109	UNIPROID	MTF1_HUMAN	MOFDETAI	Activation
DME0109	UNIPROID	MTF1_HUMAN	CELLLINE	HepG2 cell line
DME0109	UNIPROID	MTF1_HUMAN	PPI_SUMM	MTF1-SOD1 interaction
DME0109	UNIPROID	MTF1_HUMAN	DESCRIPT	Transcription factor MTF-1 (MTF1) is reported to activate the transcription of SOD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between MTF1 and SOD1 can activate the drug-metabolizing process of Superoxide dismutase 1.
DME0109	UNIPROID	NF2L2_HUMAN	PROTNAME	NFE2-related factor 2 (NFE2L2)
DME0109	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0109	UNIPROID	NF2L2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0109	UNIPROID	NF2L2_HUMAN	MOFDETAI	Activation
DME0109	UNIPROID	NF2L2_HUMAN	CELLLINE	MCF-7, T47D and HCC1937 cell lines
DME0109	UNIPROID	NF2L2_HUMAN	PPI_SUMM	NFE2L2-SOD1 interaction
DME0109	UNIPROID	NF2L2_HUMAN	DESCRIPT	NFE2-related factor 2 (NFE2L2) is reported to activate the transcription of SOD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between NFE2L2 and SOD1 can activate the drug-metabolizing process of Superoxide dismutase 1.
DME0109	UNIPROID	EGR1_HUMAN	PROTNAME	Early growth response 1 (EGR1)
DME0109	UNIPROID	EGR1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0109	UNIPROID	EGR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0109	UNIPROID	EGR1_HUMAN	MOFDETAI	Activation
DME0109	UNIPROID	EGR1_HUMAN	CELLLINE	HeLa cell line
DME0109	UNIPROID	EGR1_HUMAN	PPI_SUMM	EGR1-SOD1 interaction
DME0109	UNIPROID	EGR1_HUMAN	DESCRIPT	Early growth response 1 (EGR1) is reported to activate the transcription of SOD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between EGR1 and SOD1 can activate the drug-metabolizing process of Superoxide dismutase 1.
DME0109	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0109	UNIPROID	SP1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0109	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0109	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0109	UNIPROID	SP1_HUMAN	CELLLINE	HeLa cell line
DME0109	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-SOD1 interaction
DME0109	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of SOD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between SP1 and SOD1 can activate the drug-metabolizing process of Superoxide dismutase 1.
DME0109	UNIPROID	CEBPD_HUMAN	PROTNAME	Nuclear factor NF-IL6-beta (CEBPD)
DME0109	UNIPROID	CEBPD_HUMAN	HPPI_DIS	Urothelial carcinoma [ICD-11: 2C91-2C95]
DME0109	UNIPROID	CEBPD_HUMAN	MOFCLASS	Transcription-factor regulation
DME0109	UNIPROID	CEBPD_HUMAN	MOFDETAI	Activation
DME0109	UNIPROID	CEBPD_HUMAN	CELLLINE	NTUB1 cell line
DME0109	UNIPROID	CEBPD_HUMAN	PPI_SUMM	CEBPD-SOD1 interaction
DME0109	UNIPROID	CEBPD_HUMAN	DESCRIPT	Nuclear factor NF-IL6-beta (CEBPD) is reported to activate the transcription of SOD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between CEBPD and SOD1 can activate the drug-metabolizing process of Superoxide dismutase 1.
DME0109	UNIPROID	KLF4_HUMAN	PROTNAME	Krueppel-like factor 4 (KLF4)
DME0109	UNIPROID	KLF4_HUMAN	HPPI_DIS	Parkinson disease [ICD-11: 8A00]
DME0109	UNIPROID	KLF4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0109	UNIPROID	KLF4_HUMAN	MOFDETAI	Repression
DME0109	UNIPROID	KLF4_HUMAN	CELLLINE	M17 neuroblastoma cell line
DME0109	UNIPROID	KLF4_HUMAN	PPI_SUMM	KLF4-SOD1 interaction
DME0109	UNIPROID	KLF4_HUMAN	DESCRIPT	Krueppel-like factor 4 (KLF4) is reported to repress the transcription of SOD1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between KLF4 and SOD1 can repress the drug-metabolizing process of Superoxide dismutase 1.
DME0109	UNIPROID	MSX2_HUMAN	PROTNAME	Homeobox protein MSX-2 (MSX2)
DME0109	UNIPROID	MSX2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0109	UNIPROID	MSX2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0109	UNIPROID	MSX2_HUMAN	MOFDETAI	Activation
DME0109	UNIPROID	MSX2_HUMAN	CELLLINE	Healthy subjects
DME0109	UNIPROID	MSX2_HUMAN	PPI_SUMM	MSX2-SOD1 interaction
DME0109	UNIPROID	MSX2_HUMAN	DESCRIPT	Homeobox protein MSX-2 (MSX2) is reported to activate the transcription of SOD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between MSX2 and SOD1 can activate the drug-metabolizing process of Superoxide dismutase 1.
DME0109	UNIPROID	PPARD_HUMAN	PROTNAME	PPA receptor delta (PPARD)
DME0109	UNIPROID	PPARD_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0109	UNIPROID	PPARD_HUMAN	MOFCLASS	Transcription-factor regulation
DME0109	UNIPROID	PPARD_HUMAN	MOFDETAI	Activation
DME0109	UNIPROID	PPARD_HUMAN	CELLLINE	Human umbilical vein endothelial cell line
DME0109	UNIPROID	PPARD_HUMAN	PPI_SUMM	PPARD-SOD1 interaction
DME0109	UNIPROID	PPARD_HUMAN	DESCRIPT	PPA receptor delta (PPARD) is reported to activate the transcription of SOD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Superoxide dismutase 1. As a result, the interaction between PPARD and SOD1 can activate the drug-metabolizing process of Superoxide dismutase 1.
DME0110	DME___ID	DME0110
DME0110	DME_NAME	Glutathione reductase (GSR)
DME0110	SPESNAME	Homo sapiens
DME0110	MIRNA_ID	MIMAT0000271	PROTNAME	hsa-miR-214-3p
DME0110	MIRNA_ID	MIMAT0000271	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0110	MIRNA_ID	MIMAT0000271	MOFCLASS	Non-coding RNA regulation
DME0110	MIRNA_ID	MIMAT0000271	MOFDETAI	microRNA regulation
DME0110	MIRNA_ID	MIMAT0000271	CELLLINE	Bel7402 cell line
DME0110	MIRNA_ID	MIMAT0000271	PPI_SUMM	hsa-miR-214-3p--GSR regulation
DME0110	MIRNA_ID	MIMAT0000271	DESCRIPT	hsa-miR-214-3p is reported to suppress GSR mRNA translation by binding to the 3' untranslated region (3'UTR) of GSR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glutathione reductase.
DME0111	DME___ID	DME0111
DME0111	DME_NAME	Ecto-5'-nucleotidase (NT5E)
DME0111	SPESNAME	Homo sapiens
DME0111	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0111	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0111	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0111	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0111	UNIPROID	HDAC1_HUMAN	CELLLINE	Human breast cancer cell lines
DME0111	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-NT5E interaction
DME0111	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the NT5E gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Ecto-5'-nucleotidase. As a result, the interaction between HDACs and NT5E can inhibit the drug-metabolizing process of Ecto-5'-nucleotidase.
DME0111	MIRNA_ID	MIMAT0000087	PROTNAME	hsa-miR-30a-5p
DME0111	MIRNA_ID	MIMAT0000087	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0111	MIRNA_ID	MIMAT0000087	MOFCLASS	Non-coding RNA regulation
DME0111	MIRNA_ID	MIMAT0000087	MOFDETAI	microRNA regulation
DME0111	MIRNA_ID	MIMAT0000087	CELLLINE	A549 and H226 cell lines
DME0111	MIRNA_ID	MIMAT0000087	PPI_SUMM	hsa-miR-30a-5p--NT5E regulation
DME0111	MIRNA_ID	MIMAT0000087	DESCRIPT	hsa-miR-30a-5p is reported to suppress NT5E mRNA translation by binding to the 3' untranslated region (3'UTR) of NT5E mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Ecto-5'-nucleotidase.
DME0111	UNIPROID	HIF1A_HUMAN	PROTNAME	ARNT-interacting protein (HIF1A)
DME0111	UNIPROID	HIF1A_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0111	UNIPROID	HIF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0111	UNIPROID	HIF1A_HUMAN	MOFDETAI	Activation
DME0111	UNIPROID	HIF1A_HUMAN	CELLLINE	T84 cell line
DME0111	UNIPROID	HIF1A_HUMAN	PPI_SUMM	HIF1A-NT5E interaction
DME0111	UNIPROID	HIF1A_HUMAN	DESCRIPT	ARNT-interacting protein (HIF1A) is reported to activate the transcription of NT5E gene, which leads to an increased expression of the drug-metabolizing enzyme Ecto-5'-nucleotidase. As a result, the interaction between HIF1A and NT5E can activate the drug-metabolizing process of Ecto-5'-nucleotidase.
DME0113	DME___ID	DME0113
DME0113	DME_NAME	Heparanase (HPSE)
DME0113	SPESNAME	Homo sapiens
DME0113	MIRNA_ID	MIMAT0005909	PROTNAME	hsa-miR-1258
DME0113	MIRNA_ID	MIMAT0005909	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0113	MIRNA_ID	MIMAT0005909	MOFCLASS	Non-coding RNA regulation
DME0113	MIRNA_ID	MIMAT0005909	MOFDETAI	microRNA regulation
DME0113	MIRNA_ID	MIMAT0005909	CELLLINE	MDA-MB-231 cell line
DME0113	MIRNA_ID	MIMAT0005909	PPI_SUMM	hsa-miR-1258--HPSE regulation
DME0113	MIRNA_ID	MIMAT0005909	DESCRIPT	hsa-miR-1258 is reported to suppress HPSE mRNA translation by binding to the 3' untranslated region (3'UTR) of HPSE mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Heparanase.
DME0113	MIRNA_ID	MIMAT0003222	PROTNAME	hsa-miR-558
DME0113	MIRNA_ID	MIMAT0003222	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0113	MIRNA_ID	MIMAT0003222	MOFCLASS	Non-coding RNA regulation
DME0113	MIRNA_ID	MIMAT0003222	MOFDETAI	microRNA regulation
DME0113	MIRNA_ID	MIMAT0003222	CELLLINE	AGS, SGC-7901, MKN-28 and MKN-45 cell lines
DME0113	MIRNA_ID	MIMAT0003222	PPI_SUMM	hsa-miR-558--HPSE regulation
DME0113	MIRNA_ID	MIMAT0003222	DESCRIPT	hsa-miR-558 is reported to suppress HPSE mRNA translation by binding to the 3' untranslated region (3'UTR) of HPSE mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Heparanase.
DME0113	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0113	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0113	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0113	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0113	UNIPROID	NFKB1_HUMAN	CELLLINE	LS-174T cell line
DME0113	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-HPSE interaction
DME0113	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of HPSE gene, which leads to an increased expression of the drug-metabolizing enzyme Heparanase. As a result, the interaction between NFKB1 and HPSE can activate the drug-metabolizing process of Heparanase.
DME0113	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0113	UNIPROID	TF65_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0113	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0113	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0113	UNIPROID	TF65_HUMAN	CELLLINE	LS-174T cell line
DME0113	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-HPSE interaction
DME0113	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of HPSE gene, which leads to an increased expression of the drug-metabolizing enzyme Heparanase. As a result, the interaction between RELA and HPSE can activate the drug-metabolizing process of Heparanase.
DME0113	UNIPROID	EGR1_HUMAN	PROTNAME	Early growth response 1 (EGR1)
DME0113	UNIPROID	EGR1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0113	UNIPROID	EGR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0113	UNIPROID	EGR1_HUMAN	MOFDETAI	Activation
DME0113	UNIPROID	EGR1_HUMAN	CELLLINE	Du145, DuPro, LNCaP and PC-3 cell lines
DME0113	UNIPROID	EGR1_HUMAN	PPI_SUMM	EGR1-HPSE interaction
DME0113	UNIPROID	EGR1_HUMAN	DESCRIPT	Early growth response 1 (EGR1) is reported to activate the transcription of HPSE gene, which leads to an increased expression of the drug-metabolizing enzyme Heparanase. As a result, the interaction between EGR1 and HPSE can activate the drug-metabolizing process of Heparanase.
DME0114	DME___ID	DME0114
DME0114	DME_NAME	Prostaglandin G/H synthase 2 (COX-2)
DME0114	SPESNAME	Homo sapiens
DME0114	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0114	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0114	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0114	UNIPROID	EHMT1_HUMAN	CELLLINE	Mouse embryonic fibroblast cells
DME0114	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-COX2 interaction
DME0114	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 9 trimethylation of COX2 gene is reported to repress the transcriptional activity of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between Histone methyltransferases (HMTs) and COX2 can inhibit the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000232	PROTNAME	hsa-miR-199a-3p
DME0114	MIRNA_ID	MIMAT0000232	HPPI_DIS	Osteoarthritis [ICD-11: FA00]
DME0114	MIRNA_ID	MIMAT0000232	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000232	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000232	CELLLINE	Osteoarthritis chondrocytes
DME0114	MIRNA_ID	MIMAT0000232	PPI_SUMM	hsa-miR-199a-3p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000232	DESCRIPT	hsa-miR-199a-3p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MI0000454	PROTNAME	hsa-miR-137
DME0114	MIRNA_ID	MI0000454	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0114	MIRNA_ID	MI0000454	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MI0000454	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MI0000454	CELLLINE	LN229 cell line
DME0114	MIRNA_ID	MI0000454	PPI_SUMM	hsa-miR-137--PTGS2 regulation
DME0114	MIRNA_ID	MI0000454	DESCRIPT	hsa-miR-137 is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000449	PROTNAME	hsa-miR-146a-5p
DME0114	MIRNA_ID	MIMAT0000449	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	MIRNA_ID	MIMAT0000449	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000449	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000449	CELLLINE	GES-1 and HEK293 cell lines
DME0114	MIRNA_ID	MIMAT0000449	PPI_SUMM	hsa-miR-146a-5p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000449	DESCRIPT	hsa-miR-146a-5p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000069	PROTNAME	hsa-miR-16-5p
DME0114	MIRNA_ID	MIMAT0000069	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0114	MIRNA_ID	MIMAT0000069	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000069	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000069	CELLLINE	WRL68, HepG2 and Hep3B cell lines
DME0114	MIRNA_ID	MIMAT0000069	PPI_SUMM	hsa-miR-16-5p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000069	DESCRIPT	hsa-miR-16-5p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0003222	PROTNAME	hsa-miR-558
DME0114	MIRNA_ID	MIMAT0003222	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	MIRNA_ID	MIMAT0003222	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0003222	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0003222	CELLLINE	SW1353 cell line
DME0114	MIRNA_ID	MIMAT0003222	PPI_SUMM	hsa-miR-558--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0003222	DESCRIPT	hsa-miR-558 is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000435	PROTNAME	hsa-miR-143-3p
DME0114	MIRNA_ID	MIMAT0000435	HPPI_DIS	Pancreatic adenocarcinoma [ICD-11: 2C10]
DME0114	MIRNA_ID	MIMAT0000435	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000435	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000435	CELLLINE	BxPC-3 cell line
DME0114	MIRNA_ID	MIMAT0000435	PPI_SUMM	hsa-miR-143-3p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000435	DESCRIPT	hsa-miR-143-3p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0004799	PROTNAME	hsa-miR-589-5p
DME0114	MIRNA_ID	MIMAT0004799	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0114	MIRNA_ID	MIMAT0004799	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0004799	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0004799	CELLLINE	A549 cell line
DME0114	MIRNA_ID	MIMAT0004799	PPI_SUMM	hsa-miR-589-5p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0004799	DESCRIPT	hsa-miR-589-5p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000231	PROTNAME	hsa-miR-199a-5p
DME0114	MIRNA_ID	MIMAT0000231	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	MIRNA_ID	MIMAT0000231	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000231	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000231	CELLLINE	BEAS-2B cell line
DME0114	MIRNA_ID	MIMAT0000231	PPI_SUMM	hsa-miR-199a-5p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000231	DESCRIPT	hsa-miR-199a-5p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000099	PROTNAME	hsa-miR-101-3p
DME0114	MIRNA_ID	MIMAT0000099	HPPI_DIS	Esophageal squamous cell carcinoma [ICD-11: 2E60]
DME0114	MIRNA_ID	MIMAT0000099	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000099	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000099	CELLLINE	EC9706 cell line
DME0114	MIRNA_ID	MIMAT0000099	PPI_SUMM	hsa-miR-101-3p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000099	DESCRIPT	hsa-miR-101-3p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000436	PROTNAME	hsa-miR-144-3p
DME0114	MIRNA_ID	MIMAT0000436	HPPI_DIS	Esophageal squamous cell carcinoma [ICD-11: 2E60]
DME0114	MIRNA_ID	MIMAT0000436	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000436	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000436	CELLLINE	EC9706 cell line
DME0114	MIRNA_ID	MIMAT0000436	PPI_SUMM	hsa-miR-144-3p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000436	DESCRIPT	hsa-miR-144-3p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000082	PROTNAME	hsa-miR-26a-5p
DME0114	MIRNA_ID	MIMAT0000082	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0114	MIRNA_ID	MIMAT0000082	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000082	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000082	CELLLINE	LNCaP cell line
DME0114	MIRNA_ID	MIMAT0000082	PPI_SUMM	hsa-miR-26a-5p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000082	DESCRIPT	hsa-miR-26a-5p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	MIRNA_ID	MIMAT0000083	PROTNAME	hsa-miR-26b-5p
DME0114	MIRNA_ID	MIMAT0000083	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0114	MIRNA_ID	MIMAT0000083	MOFCLASS	Non-coding RNA regulation
DME0114	MIRNA_ID	MIMAT0000083	MOFDETAI	microRNA regulation
DME0114	MIRNA_ID	MIMAT0000083	CELLLINE	U373 cell line
DME0114	MIRNA_ID	MIMAT0000083	PPI_SUMM	hsa-miR-26b-5p--PTGS2 regulation
DME0114	MIRNA_ID	MIMAT0000083	DESCRIPT	hsa-miR-26b-5p is reported to suppress PTGS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2.
DME0114	UNIPROID	PGH2_HUMAN	PROTNAME	Cyclooxygenase-2 (COX2)
DME0114	UNIPROID	PGH2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	PGH2_HUMAN	MOFCLASS	Oligomerization
DME0114	UNIPROID	PGH2_HUMAN	MOFDETAI	Hetero-oligomerization
DME0114	UNIPROID	PGH2_HUMAN	SUBSTRAT	Arachidonic acid (Metabolic product: Prostaglandin endoperoxide H(2))
DME0114	UNIPROID	PGH2_HUMAN	CELLLINE	Insect cell microsomes
DME0114	UNIPROID	PGH2_HUMAN	PPI_SUMM	COX2-PTGS2 heterodimerization
DME0114	UNIPROID	PGH2_HUMAN	DESCRIPT	Cyclooxygenase-2 (COX2) is reported to heterodimerize with the COX2 protein, which leads to an increased activity of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between COX2 and COX2 can facilitate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0114	UNIPROID	SP1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0114	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	SP1_HUMAN	CELLLINE	Colon cancer cell line
DME0114	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-PTGS2 interaction
DME0114	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between SP1 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	CEBPB_HUMAN	PROTNAME	Liver activator protein (LAP)
DME0114	UNIPROID	CEBPB_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0114	UNIPROID	CEBPB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	CEBPB_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	CEBPB_HUMAN	CELLLINE	NCI-H520, NCI-H460, and NCI-H1299 cell lines
DME0114	UNIPROID	CEBPB_HUMAN	PPI_SUMM	LAP-PTGS2 interaction
DME0114	UNIPROID	CEBPB_HUMAN	DESCRIPT	Liver activator protein (LAP) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between LAP and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	CEBPB_HUMAN	HPPI_DIS	Epidermoid carcinoma [ICD-11: 2E64]
DME0114	UNIPROID	CEBPB_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	CEBPB_HUMAN	CELLLINE	A431 cell line
DME0114	UNIPROID	CEBPB_HUMAN	DESCRIPT	Liver activator protein (LAP) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between LAP and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0114	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Asthma [ICD-11: CA23]
DME0114	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	NFKB1_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	NFKB1_HUMAN	CELLLINE	Nasal polyps from aspirin-intolerant asthma/rhinitis patients
DME0114	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-PTGS2 interaction
DME0114	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between NFKB1 and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	NFKB1_HUMAN	CELLLINE	Human bronchial epithelial primary cell line
DME0114	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between NFKB1 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	PPARG_HUMAN	PROTNAME	PPA receptor gamma (PPARG)
DME0114	UNIPROID	PPARG_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0114	UNIPROID	PPARG_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	PPARG_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	PPARG_HUMAN	CELLLINE	HT-29 cell line
DME0114	UNIPROID	PPARG_HUMAN	PPI_SUMM	PPARG-PTGS2 interaction
DME0114	UNIPROID	PPARG_HUMAN	DESCRIPT	PPA receptor gamma (PPARG) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between PPARG and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	PPARG_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0114	UNIPROID	PPARG_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	PPARG_HUMAN	CELLLINE	CaSki cell line
DME0114	UNIPROID	PPARG_HUMAN	DESCRIPT	PPA receptor gamma (PPARG) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between PPARG and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0114	UNIPROID	TF65_HUMAN	HPPI_DIS	Asthma [ICD-11: CA23]
DME0114	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	TF65_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	TF65_HUMAN	CELLLINE	Nasal polyps from aspirin-intolerant asthma/rhinitis patients
DME0114	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-PTGS2 interaction
DME0114	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between RELA and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	TF65_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	TF65_HUMAN	CELLLINE	Human bronchial epithelial primary cell line
DME0114	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between RELA and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	CDX2_HUMAN	PROTNAME	Homeobox protein CDX-2 (CDX2)
DME0114	UNIPROID	CDX2_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0114	UNIPROID	CDX2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	CDX2_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	CDX2_HUMAN	CELLLINE	U87 cell line
DME0114	UNIPROID	CDX2_HUMAN	PPI_SUMM	CDX2-PTGS2 interaction
DME0114	UNIPROID	CDX2_HUMAN	DESCRIPT	Homeobox protein CDX-2 (CDX2) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between CDX2 and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	CDX2_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0114	UNIPROID	CDX2_HUMAN	CELLLINE	HCT-116 and SNU-C4 cell lines
DME0114	UNIPROID	STAT3_HUMAN	PROTNAME	STAT 3 (STAT3)
DME0114	UNIPROID	STAT3_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0114	UNIPROID	STAT3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	STAT3_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	STAT3_HUMAN	CELLLINE	U87MG and T98G cell lines
DME0114	UNIPROID	STAT3_HUMAN	PPI_SUMM	STAT3-PTGS2 interaction
DME0114	UNIPROID	STAT3_HUMAN	DESCRIPT	STAT 3 (STAT3) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between STAT3 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	USF1_HUMAN	PROTNAME	Upstream stimulatory 1 (USF1)
DME0114	UNIPROID	USF1_HUMAN	HPPI_DIS	Medulloblastoma [ICD-11: 2A00.10]
DME0114	UNIPROID	USF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	USF1_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	USF1_HUMAN	CELLLINE	TE671 cell line
DME0114	UNIPROID	USF1_HUMAN	PPI_SUMM	USF1-PTGS2 interaction
DME0114	UNIPROID	USF1_HUMAN	DESCRIPT	Upstream stimulatory 1 (USF1) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between USF1 and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	PPARA_HUMAN	PROTNAME	PPA receptor alpha (PPARA)
DME0114	UNIPROID	PPARA_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0114	UNIPROID	PPARA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	PPARA_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	PPARA_HUMAN	CELLLINE	HT-29 cell line
DME0114	UNIPROID	PPARA_HUMAN	PPI_SUMM	PPARA-PTGS2 interaction
DME0114	UNIPROID	PPARA_HUMAN	DESCRIPT	PPA receptor alpha (PPARA) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between PPARA and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	APC_HUMAN	PROTNAME	Adenomatous polyposis coli (APC)
DME0114	UNIPROID	APC_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0114	UNIPROID	APC_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	APC_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	APC_HUMAN	CELLLINE	HT-29 cell line
DME0114	UNIPROID	APC_HUMAN	PPI_SUMM	APC-PTGS2 interaction
DME0114	UNIPROID	APC_HUMAN	DESCRIPT	Adenomatous polyposis coli (APC) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between APC and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	HMGA1_HUMAN	PROTNAME	High mobility group A1 (HMGA1)
DME0114	UNIPROID	HMGA1_HUMAN	HPPI_DIS	Pancreatic adenocarcinoma [ICD-11: 2C10]
DME0114	UNIPROID	HMGA1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	HMGA1_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	HMGA1_HUMAN	CELLLINE	BxPC-3, HPAF-II, MiaPaCa Panc1, PL45 and XPA-3 cell lines
DME0114	UNIPROID	HMGA1_HUMAN	PPI_SUMM	HMGA1-PTGS2 interaction
DME0114	UNIPROID	HMGA1_HUMAN	DESCRIPT	High mobility group A1 (HMGA1) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between HMGA1 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	STAT6_HUMAN	PROTNAME	STAT 6 (STAT6)
DME0114	UNIPROID	STAT6_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0114	UNIPROID	STAT6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	STAT6_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	STAT6_HUMAN	CELLLINE	A427 and H2122 cell lines
DME0114	UNIPROID	STAT6_HUMAN	PPI_SUMM	STAT6-PTGS2 interaction
DME0114	UNIPROID	STAT6_HUMAN	DESCRIPT	STAT 6 (STAT6) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between STAT6 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	ING4_HUMAN	PROTNAME	Inhibitor of growth 4 (ING4)
DME0114	UNIPROID	ING4_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0114	UNIPROID	ING4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	ING4_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	ING4_HUMAN	CELLLINE	A549 cell line
DME0114	UNIPROID	ING4_HUMAN	PPI_SUMM	ING4-PTGS2 interaction
DME0114	UNIPROID	ING4_HUMAN	DESCRIPT	Inhibitor of growth 4 (ING4) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between ING4 and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	PRGR_HUMAN	PROTNAME	Progesterone receptor (PGR)
DME0114	UNIPROID	PRGR_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0114	UNIPROID	PRGR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	PRGR_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	PRGR_HUMAN	CELLLINE	T47D and MCF-7 cell lines
DME0114	UNIPROID	PRGR_HUMAN	PPI_SUMM	PGR-PTGS2 interaction
DME0114	UNIPROID	PRGR_HUMAN	DESCRIPT	Progesterone receptor (PGR) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between PGR and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	CDX1_HUMAN	PROTNAME	Homeobox protein CDX-1 (CDX1)
DME0114	UNIPROID	CDX1_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0114	UNIPROID	CDX1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	CDX1_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	CDX1_HUMAN	CELLLINE	SKOV3 and A2780 cell lines
DME0114	UNIPROID	CDX1_HUMAN	PPI_SUMM	CDX1-PTGS2 interaction
DME0114	UNIPROID	CDX1_HUMAN	DESCRIPT	Homeobox protein CDX-1 (CDX1) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between CDX1 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	NR0B2_HUMAN	PROTNAME	Nuclear receptor family 0 B2 (NR0B2)
DME0114	UNIPROID	NR0B2_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0114	UNIPROID	NR0B2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	NR0B2_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	NR0B2_HUMAN	CELLLINE	SKOV3 and A2780 cell lines
DME0114	UNIPROID	NR0B2_HUMAN	PPI_SUMM	NR0B2-PTGS2 interaction
DME0114	UNIPROID	NR0B2_HUMAN	DESCRIPT	Nuclear receptor family 0 B2 (NR0B2) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between NR0B2 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	ANDR_HUMAN	PROTNAME	Androgen receptor (AR)
DME0114	UNIPROID	ANDR_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0114	UNIPROID	ANDR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	ANDR_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	ANDR_HUMAN	CELLLINE	LNCaP and PC-3 cell lines
DME0114	UNIPROID	ANDR_HUMAN	PPI_SUMM	AR-PTGS2 interaction
DME0114	UNIPROID	ANDR_HUMAN	DESCRIPT	Androgen receptor (AR) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between AR and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	JUN_HUMAN	PROTNAME	Transcription factor AP-1 (JUN)
DME0114	UNIPROID	JUN_HUMAN	HPPI_DIS	Epidermoid carcinoma [ICD-11: 2E64]
DME0114	UNIPROID	JUN_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	JUN_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	JUN_HUMAN	CELLLINE	A431 cell line
DME0114	UNIPROID	JUN_HUMAN	PPI_SUMM	JUN-PTGS2 interaction
DME0114	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between JUN and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	HDAC4_HUMAN	PROTNAME	Histone deacetylase 4 (HDAC4)
DME0114	UNIPROID	HDAC4_HUMAN	HPPI_DIS	Epidermoid carcinoma [ICD-11: 2E64]
DME0114	UNIPROID	HDAC4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	HDAC4_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	HDAC4_HUMAN	CELLLINE	A431 cell line
DME0114	UNIPROID	HDAC4_HUMAN	PPI_SUMM	HDAC4-PTGS2 interaction
DME0114	UNIPROID	HDAC4_HUMAN	DESCRIPT	Histone deacetylase 4 (HDAC4) is reported to deacetylate the COX2 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between HDAC4 and COX2 can inhibit the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	STAT1_HUMAN	PROTNAME	STAT 1-alpha/beta (STAT1)
DME0114	UNIPROID	STAT1_HUMAN	HPPI_DIS	Myocardial ischemia/reperfusion injury [ICD-11: BA6Z]
DME0114	UNIPROID	STAT1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	STAT1_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	STAT1_HUMAN	CELLLINE	Myocardial ischemia/reperfusion injury cell line
DME0114	UNIPROID	STAT1_HUMAN	PPI_SUMM	STAT1-PTGS2 interaction
DME0114	UNIPROID	STAT1_HUMAN	DESCRIPT	STAT 1-alpha/beta (STAT1) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between STAT1 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	STAT2_HUMAN	PROTNAME	STAT 2 (STAT2)
DME0114	UNIPROID	STAT2_HUMAN	HPPI_DIS	Myocardial ischemia/reperfusion injury [ICD-11: BA6Z]
DME0114	UNIPROID	STAT2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	STAT2_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	STAT2_HUMAN	CELLLINE	Myocardial ischemia/reperfusion injury cell line
DME0114	UNIPROID	STAT2_HUMAN	PPI_SUMM	STAT2-PTGS2 interaction
DME0114	UNIPROID	STAT2_HUMAN	DESCRIPT	STAT 2 (STAT2) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between STAT2 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	NC2B_HUMAN	PROTNAME	Protein Dr1 (DR1)
DME0114	UNIPROID	NC2B_HUMAN	HPPI_DIS	Osteoarthritis [ICD-11: FA00]
DME0114	UNIPROID	NC2B_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	NC2B_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	NC2B_HUMAN	CELLLINE	Synovial lining cell linr
DME0114	UNIPROID	NC2B_HUMAN	PPI_SUMM	DR1-PTGS2 interaction
DME0114	UNIPROID	NC2B_HUMAN	DESCRIPT	Protein Dr1 (DR1) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between DR1 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylase 1 (HDAC1)
DME0114	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	HDAC1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	HDAC1_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	HDAC1_HUMAN	CELLLINE	BEAS-2B cell line
DME0114	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDAC1-PTGS2 interaction
DME0114	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylase 1 (HDAC1) is reported to deacetylate the COX2 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between HDAC1 and COX2 can inhibit the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	CREB1_HUMAN	PROTNAME	AMP element-binding 1 (CREB1)
DME0114	UNIPROID	CREB1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	CREB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	CREB1_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	CREB1_HUMAN	CELLLINE	Human amnion fibroblast cell line
DME0114	UNIPROID	CREB1_HUMAN	PPI_SUMM	CREB1-PTGS2 interaction
DME0114	UNIPROID	CREB1_HUMAN	DESCRIPT	AMP element-binding 1 (CREB1) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between CREB1 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	JUND_HUMAN	PROTNAME	TF factor jun-D (JUND)
DME0114	UNIPROID	JUND_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	JUND_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	JUND_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	JUND_HUMAN	CELLLINE	Human chondrocytes
DME0114	UNIPROID	JUND_HUMAN	PPI_SUMM	JUND-PTGS2 interaction
DME0114	UNIPROID	JUND_HUMAN	DESCRIPT	TF factor jun-D (JUND) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between JUND and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	FOS_HUMAN	PROTNAME	Proto-oncogene c-Fos (FOS)
DME0114	UNIPROID	FOS_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	FOS_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	FOS_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	FOS_HUMAN	CELLLINE	Human chondrocytes
DME0114	UNIPROID	FOS_HUMAN	PPI_SUMM	FOS-PTGS2 interaction
DME0114	UNIPROID	FOS_HUMAN	DESCRIPT	Proto-oncogene c-Fos (FOS) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between FOS and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	JUNB_HUMAN	PROTNAME	TF factor jun-B (JUNB)
DME0114	UNIPROID	JUNB_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	JUNB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	JUNB_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	JUNB_HUMAN	CELLLINE	Human chondrocytes
DME0114	UNIPROID	JUNB_HUMAN	PPI_SUMM	JUNB-PTGS2 interaction
DME0114	UNIPROID	JUNB_HUMAN	DESCRIPT	TF factor jun-B (JUNB) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between JUNB and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	EP300_HUMAN	PROTNAME	His-acetyltransferase p300 (EP300)
DME0114	UNIPROID	EP300_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	EP300_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	EP300_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	EP300_HUMAN	CELLLINE	Human foreskin fibroblasts
DME0114	UNIPROID	EP300_HUMAN	PPI_SUMM	EP300-PTGS2 interaction
DME0114	UNIPROID	EP300_HUMAN	DESCRIPT	His-acetyltransferase p300 (EP300) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between EP300 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	ETV4_HUMAN	PROTNAME	ETS translocation 4 (ETV4)
DME0114	UNIPROID	ETV4_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	ETV4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	ETV4_HUMAN	MOFDETAI	Activation
DME0114	UNIPROID	ETV4_HUMAN	CELLLINE	Mouse mammary epithelial cell line
DME0114	UNIPROID	ETV4_HUMAN	PPI_SUMM	ETV4-PTGS2 interaction
DME0114	UNIPROID	ETV4_HUMAN	DESCRIPT	ETS translocation 4 (ETV4) is reported to activate the transcription of COX2 gene, which leads to an increased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between ETV4 and COX2 can activate the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	SETBP_HUMAN	PROTNAME	SET-binding protein (SETBP1)
DME0114	UNIPROID	SETBP_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	SETBP_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	SETBP_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	SETBP_HUMAN	CELLLINE	Airway structural cell line
DME0114	UNIPROID	SETBP_HUMAN	PPI_SUMM	SETBP1-PTGS2 interaction
DME0114	UNIPROID	SETBP_HUMAN	DESCRIPT	SET-binding protein (SETBP1) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between SETBP1 and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0114	UNIPROID	EGR1_HUMAN	PROTNAME	Early growth response 1 (EGR1)
DME0114	UNIPROID	EGR1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0114	UNIPROID	EGR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0114	UNIPROID	EGR1_HUMAN	MOFDETAI	Repression
DME0114	UNIPROID	EGR1_HUMAN	CELLLINE	Human mammary and oral epithelial cell line
DME0114	UNIPROID	EGR1_HUMAN	PPI_SUMM	EGR1-PTGS2 interaction
DME0114	UNIPROID	EGR1_HUMAN	DESCRIPT	Early growth response 1 (EGR1) is reported to repress the transcription of COX2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin G/H synthase 2. As a result, the interaction between EGR1 and COX2 can repress the drug-metabolizing process of Prostaglandin G/H synthase 2.
DME0116	DME___ID	DME0116
DME0116	DME_NAME	Alpha-methylacyl-CoA racemase (AMACR)
DME0116	SPESNAME	Homo sapiens
DME0116	MIRNA_ID	MIMAT0000082	PROTNAME	hsa-miR-26a-5p
DME0116	MIRNA_ID	MIMAT0000082	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0116	MIRNA_ID	MIMAT0000082	MOFCLASS	Non-coding RNA regulation
DME0116	MIRNA_ID	MIMAT0000082	MOFDETAI	microRNA regulation
DME0116	MIRNA_ID	MIMAT0000082	CELLLINE	DU145, PC3 and LNCaP cell lines
DME0116	MIRNA_ID	MIMAT0000082	PPI_SUMM	hsa-miR-26a-5p--AMACR regulation
DME0116	MIRNA_ID	MIMAT0000082	DESCRIPT	hsa-miR-26a-5p is reported to suppress AMACR mRNA translation by binding to the 3' untranslated region (3'UTR) of AMACR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Alpha-methylacyl-CoA racemase.
DME0118	DME___ID	DME0118
DME0118	DME_NAME	Aldo-keto reductase 1C3 (AKR1C3)
DME0118	SPESNAME	Homo sapiens
DME0118	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0118	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0118	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0118	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0118	UNIPROID	HDAC1_HUMAN	CELLLINE	HGC-27 cell line
DME0118	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-AKR1C3 interaction
DME0118	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the AKR1C3 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Aldo-keto reductase 1C3. As a result, the interaction between HDACs and AKR1C3 can inhibit the drug-metabolizing process of Aldo-keto reductase 1C3.
DME0118	UNIPROID	ANDR_HUMAN	PROTNAME	Androgen receptor (AR)
DME0118	UNIPROID	ANDR_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0118	UNIPROID	ANDR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0118	UNIPROID	ANDR_HUMAN	MOFDETAI	Repression
DME0118	UNIPROID	ANDR_HUMAN	CELLLINE	LNCaP cell line
DME0118	UNIPROID	ANDR_HUMAN	PPI_SUMM	AR-AKR1C3 interaction
DME0118	UNIPROID	ANDR_HUMAN	DESCRIPT	Androgen receptor (AR) is reported to repress the transcription of AKR1C3 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aldo-keto reductase 1C3. As a result, the interaction between AR and AKR1C3 can repress the drug-metabolizing process of Aldo-keto reductase 1C3.
DME0122	DME___ID	DME0122
DME0122	DME_NAME	Nitric oxide synthase brain (NOS1)
DME0122	SPESNAME	Homo sapiens
DME0122	MIRNA_ID	MIMAT0000449	PROTNAME	hsa-miR-146a-5p
DME0122	MIRNA_ID	MIMAT0000449	HPPI_DIS	Health [ICD-11: N.A.]
DME0122	MIRNA_ID	MIMAT0000449	MOFCLASS	Non-coding RNA regulation
DME0122	MIRNA_ID	MIMAT0000449	MOFDETAI	microRNA regulation
DME0122	MIRNA_ID	MIMAT0000449	CELLLINE	HTR-8/SVneo cell line
DME0122	MIRNA_ID	MIMAT0000449	PPI_SUMM	hsa-miR-146a-5p--NOS1 regulation
DME0122	MIRNA_ID	MIMAT0000449	DESCRIPT	hsa-miR-146a-5p is reported to suppress NOS1 mRNA translation by binding to the 3' untranslated region (3'UTR) of NOS1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase brain.
DME0122	UNIPROID	NR0B1_HUMAN	PROTNAME	Nuclear receptor family 0 B1 (NR0B1)
DME0122	UNIPROID	NR0B1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0122	UNIPROID	NR0B1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0122	UNIPROID	NR0B1_HUMAN	MOFDETAI	Activation
DME0122	UNIPROID	NR0B1_HUMAN	CELLLINE	TGW-nu-I cell line
DME0122	UNIPROID	NR0B1_HUMAN	PPI_SUMM	NR0B1-NOS1 interaction
DME0122	UNIPROID	NR0B1_HUMAN	DESCRIPT	Nuclear receptor family 0 B1 (NR0B1) is reported to activate the transcription of NOS1 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase brain. As a result, the interaction between NR0B1 and NOS1 can activate the drug-metabolizing process of Nitric oxide synthase brain.
DME0122	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0122	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0122	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0122	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0122	UNIPROID	NFKB1_HUMAN	CELLLINE	Human umbilical endothelial cell line
DME0122	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-NOS1 interaction
DME0122	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of NOS1 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase brain. As a result, the interaction between NFKB1 and NOS1 can activate the drug-metabolizing process of Nitric oxide synthase brain.
DME0122	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0122	UNIPROID	TF65_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0122	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0122	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0122	UNIPROID	TF65_HUMAN	CELLLINE	Human umbilical endothelial cell line
DME0122	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-NOS1 interaction
DME0122	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of NOS1 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase brain. As a result, the interaction between RELA and NOS1 can activate the drug-metabolizing process of Nitric oxide synthase brain.
DME0123	DME___ID	DME0123
DME0123	DME_NAME	Nitric oxide synthase endothelial (NOS3)
DME0123	SPESNAME	Homo sapiens
DME0123	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0123	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0123	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0123	UNIPROID	HDAC1_HUMAN	CELLLINE	Cultured bovine aortic endothelial cells (BAECs)
DME0123	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-NOS3 interaction
DME0123	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the NOS3 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between HDACs and NOS3 can inhibit the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	MIRNA_ID	MIMAT0000646	PROTNAME	hsa-miR-155-5p
DME0123	MIRNA_ID	MIMAT0000646	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	MIRNA_ID	MIMAT0000646	MOFCLASS	Non-coding RNA regulation
DME0123	MIRNA_ID	MIMAT0000646	MOFDETAI	microRNA regulation
DME0123	MIRNA_ID	MIMAT0000646	CELLLINE	Human umbilical vein endothelial cell line
DME0123	MIRNA_ID	MIMAT0000646	PPI_SUMM	hsa-miR-155-5p--NOS3 regulation
DME0123	MIRNA_ID	MIMAT0000646	DESCRIPT	hsa-miR-155-5p is reported to suppress NOS3 mRNA translation by binding to the 3' untranslated region (3'UTR) of NOS3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial.
DME0123	MIRNA_ID	MIMAT0000080	PROTNAME	hsa-miR-24-3p
DME0123	MIRNA_ID	MIMAT0000080	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	MIRNA_ID	MIMAT0000080	MOFCLASS	Non-coding RNA regulation
DME0123	MIRNA_ID	MIMAT0000080	MOFDETAI	microRNA regulation
DME0123	MIRNA_ID	MIMAT0000080	CELLLINE	Human umbilical vein endothelial cell line
DME0123	MIRNA_ID	MIMAT0000080	PPI_SUMM	hsa-miR-24-3p--NOS3 regulation
DME0123	MIRNA_ID	MIMAT0000080	DESCRIPT	hsa-miR-24-3p is reported to suppress NOS3 mRNA translation by binding to the 3' untranslated region (3'UTR) of NOS3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial.
DME0123	MIRNA_ID	MIMAT0004703	PROTNAME	hsa-miR-335-3p
DME0123	MIRNA_ID	MIMAT0004703	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0123	MIRNA_ID	MIMAT0004703	MOFCLASS	Non-coding RNA regulation
DME0123	MIRNA_ID	MIMAT0004703	MOFDETAI	microRNA regulation
DME0123	MIRNA_ID	MIMAT0004703	CELLLINE	PC3 cell line
DME0123	MIRNA_ID	MIMAT0004703	PPI_SUMM	hsa-miR-335-3p--NOS3 regulation
DME0123	MIRNA_ID	MIMAT0004703	DESCRIPT	hsa-miR-335-3p is reported to suppress NOS3 mRNA translation by binding to the 3' untranslated region (3'UTR) of NOS3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial.
DME0123	MIRNA_ID	MIMAT0004954	PROTNAME	hsa-miR-543
DME0123	MIRNA_ID	MIMAT0004954	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0123	MIRNA_ID	MIMAT0004954	MOFCLASS	Non-coding RNA regulation
DME0123	MIRNA_ID	MIMAT0004954	MOFDETAI	microRNA regulation
DME0123	MIRNA_ID	MIMAT0004954	CELLLINE	PC3 cell line
DME0123	MIRNA_ID	MIMAT0004954	PPI_SUMM	hsa-miR-543--NOS3 regulation
DME0123	MIRNA_ID	MIMAT0004954	DESCRIPT	hsa-miR-543 is reported to suppress NOS3 mRNA translation by binding to the 3' untranslated region (3'UTR) of NOS3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial.
DME0123	MIRNA_ID	MIMAT0000617	PROTNAME	hsa-miR-200c-3p
DME0123	MIRNA_ID	MIMAT0000617	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	MIRNA_ID	MIMAT0000617	MOFCLASS	Non-coding RNA regulation
DME0123	MIRNA_ID	MIMAT0000617	MOFDETAI	microRNA regulation
DME0123	MIRNA_ID	MIMAT0000617	CELLLINE	Human umbilical vein endothelial cell line
DME0123	MIRNA_ID	MIMAT0000617	PPI_SUMM	hsa-miR-200c-3p--NOS3 regulation
DME0123	MIRNA_ID	MIMAT0000617	DESCRIPT	hsa-miR-200c-3p is reported to suppress NOS3 mRNA translation by binding to the 3' untranslated region (3'UTR) of NOS3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial.
DME0123	UNIPROID	NOS3_HUMAN	PROTNAME	Endothelial NOS (NOS3)
DME0123	UNIPROID	NOS3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	NOS3_HUMAN	MOFCLASS	Oligomerization
DME0123	UNIPROID	NOS3_HUMAN	MOFDETAI	Homo-oligomerization
DME0123	UNIPROID	NOS3_HUMAN	CELLLINE	Recombinant BL21(DE3)-pNTF cells
DME0123	UNIPROID	NOS3_HUMAN	PPI_SUMM	NOS3-NOS3 homodimerization
DME0123	UNIPROID	NOS3_HUMAN	DESCRIPT	Endothelial NOS (NOS3) is reported to homodimerize with the NOS3 protein, which leads to an increased activity of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between NOS3 and NOS3 can facilitate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	ACTB_HUMAN	PROTNAME	Cytoplasmic actin 1 (ACTB)
DME0123	UNIPROID	ACTB_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	ACTB_HUMAN	MOFCLASS	Oligomerization
DME0123	UNIPROID	ACTB_HUMAN	MOFDETAI	Hetero-oligomerization
DME0123	UNIPROID	ACTB_HUMAN	CELLLINE	Endothelial cells
DME0123	UNIPROID	ACTB_HUMAN	PPI_SUMM	ACTB, HSP90AA1 and NOS3 heterotrimerization
DME0123	UNIPROID	ACTB_HUMAN	DESCRIPT	Cytoplasmic actin 1 (ACTB) and Heat shock 90-alpha (HSP90AA1) are reported to heterotrimerize with the NOS3 protein, which leads to an altered activity of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction among ACTB, HSP90AA1 and NOS3 can modulate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	HS90A_HUMAN	PROTNAME	Heat shock 90-alpha (HSP90AA1)
DME0123	UNIPROID	HS90A_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	HS90A_HUMAN	MOFCLASS	Oligomerization
DME0123	UNIPROID	HS90A_HUMAN	MOFDETAI	Hetero-oligomerization
DME0123	UNIPROID	HS90A_HUMAN	CELLLINE	Endothelial cells
DME0123	UNIPROID	HS90A_HUMAN	PPI_SUMM	HSP90AA1, ACTB and NOS3 heterotrimerization
DME0123	UNIPROID	HS90A_HUMAN	DESCRIPT	Heat shock 90-alpha (HSP90AA1) and Cytoplasmic actin 1 (ACTB) are reported to heterotrimerize with the NOS3 protein, which leads to an altered activity of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction among HSP90AA1, ACTB and NOS3 can modulate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	KLF2_HUMAN	PROTNAME	Krueppel-like factor 2 (KLF2)
DME0123	UNIPROID	KLF2_HUMAN	HPPI_DIS	Hypertension [ICD-11: BA00-BA04]
DME0123	UNIPROID	KLF2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	KLF2_HUMAN	MOFDETAI	Activation
DME0123	UNIPROID	KLF2_HUMAN	CELLLINE	Human umbilical vessel cell line
DME0123	UNIPROID	KLF2_HUMAN	PPI_SUMM	KLF2-NOS3 interaction
DME0123	UNIPROID	KLF2_HUMAN	DESCRIPT	Krueppel-like factor 2 (KLF2) is reported to activate the transcription of NOS3 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between KLF2 and NOS3 can activate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	GATA4_HUMAN	PROTNAME	TF factor GATA-4 (GATA4)
DME0123	UNIPROID	GATA4_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	GATA4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	GATA4_HUMAN	MOFDETAI	Activation
DME0123	UNIPROID	GATA4_HUMAN	CELLLINE	Bovine lung microvessel endothelial cell line
DME0123	UNIPROID	GATA4_HUMAN	PPI_SUMM	GATA4-NOS3 interaction
DME0123	UNIPROID	GATA4_HUMAN	DESCRIPT	TF factor GATA-4 (GATA4) is reported to activate the transcription of NOS3 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between GATA4 and NOS3 can activate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	SP3_HUMAN	PROTNAME	Transcription factor Sp3 (SP3)
DME0123	UNIPROID	SP3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	SP3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	SP3_HUMAN	MOFDETAI	Activation
DME0123	UNIPROID	SP3_HUMAN	CELLLINE	Bovine lung microvessel endothelial cell line
DME0123	UNIPROID	SP3_HUMAN	PPI_SUMM	SP3-NOS3 interaction
DME0123	UNIPROID	SP3_HUMAN	DESCRIPT	Transcription factor Sp3 (SP3) is reported to activate the transcription of NOS3 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between SP3 and NOS3 can activate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0123	UNIPROID	SP1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0123	UNIPROID	SP1_HUMAN	CELLLINE	H441 cell line
DME0123	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-NOS3 interaction
DME0123	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of NOS3 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between SP1 and NOS3 can activate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0123	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0123	UNIPROID	NFKB1_HUMAN	CELLLINE	Human umbilical endothelial cell line
DME0123	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-NOS3 interaction
DME0123	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of NOS3 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between NFKB1 and NOS3 can activate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0123	UNIPROID	TF65_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0123	UNIPROID	TF65_HUMAN	CELLLINE	Human umbilical endothelial cell line
DME0123	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-NOS3 interaction
DME0123	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of NOS3 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between RELA and NOS3 can activate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	GATA2_HUMAN	PROTNAME	GATA-binding factor 2 (GATA2)
DME0123	UNIPROID	GATA2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	GATA2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	GATA2_HUMAN	MOFDETAI	Activation
DME0123	UNIPROID	GATA2_HUMAN	CELLLINE	NCI-H441 cell line
DME0123	UNIPROID	GATA2_HUMAN	PPI_SUMM	GATA2-NOS3 interaction
DME0123	UNIPROID	GATA2_HUMAN	DESCRIPT	GATA-binding factor 2 (GATA2) is reported to activate the transcription of NOS3 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between GATA2 and NOS3 can activate the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	ATF2_HUMAN	PROTNAME	Activating TF factor 2 (ATF2)
DME0123	UNIPROID	ATF2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	ATF2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	ATF2_HUMAN	MOFDETAI	Repression
DME0123	UNIPROID	ATF2_HUMAN	CELLLINE	Endothelial cell line
DME0123	UNIPROID	ATF2_HUMAN	PPI_SUMM	ATF2-NOS3 interaction
DME0123	UNIPROID	ATF2_HUMAN	DESCRIPT	Activating TF factor 2 (ATF2) is reported to repress the transcription of NOS3 gene, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between ATF2 and NOS3 can repress the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0123	UNIPROID	DDIT3_HUMAN	PROTNAME	C/EBP-homologous protein (DDIT3)
DME0123	UNIPROID	DDIT3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0123	UNIPROID	DDIT3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0123	UNIPROID	DDIT3_HUMAN	MOFDETAI	Repression
DME0123	UNIPROID	DDIT3_HUMAN	CELLLINE	Human umbilical vein endothelial cell line
DME0123	UNIPROID	DDIT3_HUMAN	PPI_SUMM	DDIT3-NOS3 interaction
DME0123	UNIPROID	DDIT3_HUMAN	DESCRIPT	C/EBP-homologous protein (DDIT3) is reported to repress the transcription of NOS3 gene, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase endothelial. As a result, the interaction between DDIT3 and NOS3 can repress the drug-metabolizing process of Nitric oxide synthase endothelial.
DME0124	DME___ID	DME0124
DME0124	DME_NAME	Nitric oxide synthase inducible (NOS2)
DME0124	SPESNAME	Homo sapiens
DME0124	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0124	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0124	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0124	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0124	UNIPROID	HDAC1_HUMAN	CELLLINE	Microglial cell line
DME0124	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-NOS2 interaction
DME0124	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the NOS2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between HDACs and NOS2 can inhibit the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	MIRNA_ID	MIMAT0000082	PROTNAME	hsa-miR-26a-5p
DME0124	MIRNA_ID	MIMAT0000082	HPPI_DIS	Osteoarthritis [ICD-11: FA00]
DME0124	MIRNA_ID	MIMAT0000082	MOFCLASS	Non-coding RNA regulation
DME0124	MIRNA_ID	MIMAT0000082	MOFDETAI	microRNA regulation
DME0124	MIRNA_ID	MIMAT0000082	CELLLINE	Osteoarthritis chondrocytes
DME0124	MIRNA_ID	MIMAT0000082	PPI_SUMM	hsa-miR-26a-5p--NOS2 regulation
DME0124	MIRNA_ID	MIMAT0000082	DESCRIPT	hsa-miR-26a-5p is reported to suppress NOS2 mRNA translation by binding to the 3' untranslated region (3'UTR) of NOS2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible.
DME0124	UNIPROID	FOS_HUMAN	PROTNAME	Proto-oncogene c-Fos (FOS)
DME0124	UNIPROID	FOS_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0124	UNIPROID	FOS_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	FOS_HUMAN	MOFDETAI	Repression
DME0124	UNIPROID	FOS_HUMAN	CELLLINE	Human epithelial-like DLD-I cell line
DME0124	UNIPROID	FOS_HUMAN	PPI_SUMM	FOS-NOS2 interaction
DME0124	UNIPROID	FOS_HUMAN	DESCRIPT	Proto-oncogene c-Fos (FOS) is reported to repress the transcription of NOS2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between FOS and NOS2 can repress the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	FOS_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0124	UNIPROID	FOS_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	FOS_HUMAN	CELLLINE	Human airway epithelial cell line, 293T and A549 cell lines
DME0124	UNIPROID	FOS_HUMAN	DESCRIPT	Proto-oncogene c-Fos (FOS) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between FOS and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	JUN_HUMAN	PROTNAME	Transcription factor AP-1 (JUN)
DME0124	UNIPROID	JUN_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0124	UNIPROID	JUN_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	JUN_HUMAN	MOFDETAI	Repression
DME0124	UNIPROID	JUN_HUMAN	CELLLINE	Human epithelial-like DLD-I cell line
DME0124	UNIPROID	JUN_HUMAN	PPI_SUMM	JUN-NOS2 interaction
DME0124	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to repress the transcription of NOS2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between JUN and NOS2 can repress the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	JUN_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0124	UNIPROID	JUN_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	JUN_HUMAN	CELLLINE	Human airway epithelial cell line, 293T and A549 cell lines
DME0124	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between JUN and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	APC_HUMAN	PROTNAME	Adenomatous polyposis coli (APC)
DME0124	UNIPROID	APC_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0124	UNIPROID	APC_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	APC_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	APC_HUMAN	CELLLINE	Colorectal adenocarcinomas cell line
DME0124	UNIPROID	APC_HUMAN	PPI_SUMM	APC-NOS2 interaction
DME0124	UNIPROID	APC_HUMAN	DESCRIPT	Adenomatous polyposis coli (APC) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between APC and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	MTA1_HUMAN	PROTNAME	Metastasis-associated MTA1 (MTA1)
DME0124	UNIPROID	MTA1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0124	UNIPROID	MTA1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	MTA1_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	MTA1_HUMAN	CELLLINE	HepG2 cell line
DME0124	UNIPROID	MTA1_HUMAN	PPI_SUMM	MTA1-NOS2 interaction
DME0124	UNIPROID	MTA1_HUMAN	DESCRIPT	Metastasis-associated MTA1 (MTA1) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between MTA1 and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	FOSL2_HUMAN	PROTNAME	Fos-related antigen 2 (FOSL2)
DME0124	UNIPROID	FOSL2_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0124	UNIPROID	FOSL2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	FOSL2_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	FOSL2_HUMAN	CELLLINE	Human airway epithelial cell line, 293T and A549 cell lines
DME0124	UNIPROID	FOSL2_HUMAN	PPI_SUMM	FOSL2-NOS2 interaction
DME0124	UNIPROID	FOSL2_HUMAN	DESCRIPT	Fos-related antigen 2 (FOSL2) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between FOSL2 and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	JUND_HUMAN	PROTNAME	TF factor jun-D (JUND)
DME0124	UNIPROID	JUND_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0124	UNIPROID	JUND_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	JUND_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	JUND_HUMAN	CELLLINE	Human airway epithelial cell line, 293T and A549 cell lines
DME0124	UNIPROID	JUND_HUMAN	PPI_SUMM	JUND-NOS2 interaction
DME0124	UNIPROID	JUND_HUMAN	DESCRIPT	TF factor jun-D (JUND) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between JUND and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	STAT1_HUMAN	PROTNAME	STAT 1-alpha/beta (STAT1)
DME0124	UNIPROID	STAT1_HUMAN	HPPI_DIS	Myocardial ischemia/reperfusion injury [ICD-11: BA6Z]
DME0124	UNIPROID	STAT1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	STAT1_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	STAT1_HUMAN	CELLLINE	Myocardial ischemia/reperfusion injury cell line
DME0124	UNIPROID	STAT1_HUMAN	PPI_SUMM	STAT1-NOS2 interaction
DME0124	UNIPROID	STAT1_HUMAN	DESCRIPT	STAT 1-alpha/beta (STAT1) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between STAT1 and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	STAT2_HUMAN	PROTNAME	STAT 2 (STAT2)
DME0124	UNIPROID	STAT2_HUMAN	HPPI_DIS	Myocardial ischemia/reperfusion injury [ICD-11: BA6Z]
DME0124	UNIPROID	STAT2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	STAT2_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	STAT2_HUMAN	CELLLINE	Myocardial ischemia/reperfusion injury cell line
DME0124	UNIPROID	STAT2_HUMAN	PPI_SUMM	STAT2-NOS2 interaction
DME0124	UNIPROID	STAT2_HUMAN	DESCRIPT	STAT 2 (STAT2) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between STAT2 and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	KLF6_HUMAN	PROTNAME	Krueppel-like factor 6 (KLF6)
DME0124	UNIPROID	KLF6_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0124	UNIPROID	KLF6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	KLF6_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	KLF6_HUMAN	CELLLINE	COS-7 and Jurkat cell lines
DME0124	UNIPROID	KLF6_HUMAN	PPI_SUMM	KLF6-NOS2 interaction
DME0124	UNIPROID	KLF6_HUMAN	DESCRIPT	Krueppel-like factor 6 (KLF6) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between KLF6 and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0124	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0124	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	NFKB1_HUMAN	CELLLINE	Human umbilical endothelial cell line
DME0124	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-NOS2 interaction
DME0124	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between NFKB1 and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0124	UNIPROID	TF65_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0124	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0124	UNIPROID	TF65_HUMAN	CELLLINE	Human umbilical endothelial cell line
DME0124	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-NOS2 interaction
DME0124	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of NOS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between RELA and NOS2 can activate the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	IKKB_HUMAN	PROTNAME	I-kappa-B-kinase beta (IKBKB)
DME0124	UNIPROID	IKKB_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0124	UNIPROID	IKKB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	IKKB_HUMAN	MOFDETAI	Repression
DME0124	UNIPROID	IKKB_HUMAN	CELLLINE	Human intimal smooth muscle cell line
DME0124	UNIPROID	IKKB_HUMAN	PPI_SUMM	IKBKB-NOS2 interaction
DME0124	UNIPROID	IKKB_HUMAN	DESCRIPT	I-kappa-B-kinase beta (IKBKB) is reported to repress the transcription of NOS2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between IKBKB and NOS2 can repress the drug-metabolizing process of Nitric oxide synthase inducible.
DME0124	UNIPROID	IKBA_HUMAN	PROTNAME	I-kappa-B-alpha (NFKBIA)
DME0124	UNIPROID	IKBA_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0124	UNIPROID	IKBA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0124	UNIPROID	IKBA_HUMAN	MOFDETAI	Repression
DME0124	UNIPROID	IKBA_HUMAN	CELLLINE	Human intimal smooth muscle cell line
DME0124	UNIPROID	IKBA_HUMAN	PPI_SUMM	NFKBIA-NOS2 interaction
DME0124	UNIPROID	IKBA_HUMAN	DESCRIPT	I-kappa-B-alpha (NFKBIA) is reported to repress the transcription of NOS2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Nitric oxide synthase inducible. As a result, the interaction between NFKBIA and NOS2 can repress the drug-metabolizing process of Nitric oxide synthase inducible.
DME0125	DME___ID	DME0125
DME0125	DME_NAME	DOPA decarboxylase (DDC)
DME0125	SPESNAME	Homo sapiens
DME0125	MIRNA_ID	MIMAT0000437	PROTNAME	hsa-miR-145-5p
DME0125	MIRNA_ID	MIMAT0000437	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0125	MIRNA_ID	MIMAT0000437	MOFCLASS	Non-coding RNA regulation
DME0125	MIRNA_ID	MIMAT0000437	MOFDETAI	microRNA regulation
DME0125	MIRNA_ID	MIMAT0000437	CELLLINE	LNCaP cell line
DME0125	MIRNA_ID	MIMAT0000437	PPI_SUMM	hsa-miR-145-5p--DDC regulation
DME0125	MIRNA_ID	MIMAT0000437	DESCRIPT	hsa-miR-145-5p is reported to suppress DDC mRNA translation by binding to the 3' untranslated region (3'UTR) of DDC mRNA, which leads to a decreased expression of the drug-metabolizing enzyme DOPA decarboxylase.
DME0126	DME___ID	DME0126
DME0126	DME_NAME	L-glutamine amidohydrolase (GLS)
DME0126	SPESNAME	Homo sapiens
DME0126	MIRNA_ID	MIMAT0000078	PROTNAME	hsa-miR-23a-3p
DME0126	MIRNA_ID	MIMAT0000078	HPPI_DIS	Health [ICD-11: N.A.]
DME0126	MIRNA_ID	MIMAT0000078	MOFCLASS	Non-coding RNA regulation
DME0126	MIRNA_ID	MIMAT0000078	MOFDETAI	microRNA regulation
DME0126	MIRNA_ID	MIMAT0000078	CELLLINE	ARPE-19 cell line
DME0126	MIRNA_ID	MIMAT0000078	PPI_SUMM	hsa-miR-23a-3p--GLS regulation
DME0126	MIRNA_ID	MIMAT0000078	DESCRIPT	hsa-miR-23a-3p is reported to suppress GLS mRNA translation by binding to the 3' untranslated region (3'UTR) of GLS mRNA, which leads to a decreased expression of the drug-metabolizing enzyme L-glutamine amidohydrolase.
DME0127	DME___ID	DME0127
DME0127	DME_NAME	Alcohol dehydrogenase class-I alpha (ADH1A)
DME0127	SPESNAME	Homo sapiens
DME0127	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylase 1 (HDAC1)
DME0127	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0127	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0127	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0127	UNIPROID	HDAC1_HUMAN	CELLLINE	HepG2 cell line
DME0127	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDAC1-ADH1A interaction
DME0127	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylase 1 (HDAC1) is reported to deacetylate the ADH1A gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Alcohol dehydrogenase class-I alpha. As a result, the interaction between HDAC1 and ADH1A can inhibit the drug-metabolizing process of Alcohol dehydrogenase class-I alpha.
DME0127	UNIPROID	GATA2_HUMAN	PROTNAME	GATA-binding factor 2 (GATA2)
DME0127	UNIPROID	GATA2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0127	UNIPROID	GATA2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0127	UNIPROID	GATA2_HUMAN	MOFDETAI	Activation
DME0127	UNIPROID	GATA2_HUMAN	CELLLINE	H4IIE-C3 and CV-1 cell lines
DME0127	UNIPROID	GATA2_HUMAN	PPI_SUMM	GATA2-ADH1A interaction
DME0127	UNIPROID	GATA2_HUMAN	DESCRIPT	GATA-binding factor 2 (GATA2) is reported to activate the transcription of ADH1A gene, which leads to an increased expression of the drug-metabolizing enzyme Alcohol dehydrogenase class-I alpha. As a result, the interaction between GATA2 and ADH1A can activate the drug-metabolizing process of Alcohol dehydrogenase class-I alpha.
DME0129	DME___ID	DME0129
DME0129	DME_NAME	Alcohol dehydrogenase class-I gamma (ADH1C)
DME0129	SPESNAME	Homo sapiens
DME0129	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0129	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0129	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0129	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0129	UNIPROID	HDAC1_HUMAN	CELLLINE	HepG2 cell line
DME0129	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-ADH1C interaction
DME0129	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the ADH1C gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Alcohol dehydrogenase class-I gamma. As a result, the interaction between HDACs and ADH1C can inhibit the drug-metabolizing process of Alcohol dehydrogenase class-I gamma.
DME0137	DME___ID	DME0137
DME0137	DME_NAME	Thymidylate synthase (TYMS)
DME0137	SPESNAME	Homo sapiens
DME0137	UNIPROID	HDAC6_HUMAN	PROTNAME	Histone deacetylase 6 (HDAC6)
DME0137	UNIPROID	HDAC6_HUMAN	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0137	UNIPROID	HDAC6_HUMAN	MOFCLASS	Histone modification
DME0137	UNIPROID	HDAC6_HUMAN	MOFDETAI	Histone hypoacetylation
DME0137	UNIPROID	HDAC6_HUMAN	CELLLINE	Gastric cancer cells
DME0137	UNIPROID	HDAC6_HUMAN	PPI_SUMM	HDAC6-TYMS interaction
DME0137	UNIPROID	HDAC6_HUMAN	DESCRIPT	Histone deacetylase 6 (HDAC6) is reported to deacetylate the TYMS gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Thymidylate synthase. As a result, the interaction between HDAC6 and TYMS can inhibit the drug-metabolizing process of Thymidylate synthase.
DME0137	MIRNA_ID	MIMAT0001627	PROTNAME	hsa-miR-433-3p
DME0137	MIRNA_ID	MIMAT0001627	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0137	MIRNA_ID	MIMAT0001627	MOFCLASS	Non-coding RNA regulation
DME0137	MIRNA_ID	MIMAT0001627	MOFDETAI	microRNA regulation
DME0137	MIRNA_ID	MIMAT0001627	CELLLINE	HeLa cell line
DME0137	MIRNA_ID	MIMAT0001627	PPI_SUMM	hsa-miR-433-3p--TYMS regulation
DME0137	MIRNA_ID	MIMAT0001627	DESCRIPT	hsa-miR-433-3p is reported to suppress TYMS mRNA translation by binding to the 3' untranslated region (3'UTR) of TYMS mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Thymidylate synthase.
DME0137	MIRNA_ID	MIMAT0000226	PROTNAME	hsa-miR-196a-5p
DME0137	MIRNA_ID	MIMAT0000226	HPPI_DIS	Renal cell carcinoma [ICD-11: 2C90]
DME0137	MIRNA_ID	MIMAT0000226	MOFCLASS	Non-coding RNA regulation
DME0137	MIRNA_ID	MIMAT0000226	MOFDETAI	microRNA regulation
DME0137	MIRNA_ID	MIMAT0000226	CELLLINE	Renal cell carcinoma cell line
DME0137	MIRNA_ID	MIMAT0000226	PPI_SUMM	hsa-miR-196a-5p--TYMS regulation
DME0137	MIRNA_ID	MIMAT0000226	DESCRIPT	hsa-miR-196a-5p is reported to suppress TYMS mRNA translation by binding to the 3' untranslated region (3'UTR) of TYMS mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Thymidylate synthase.
DME0137	MIRNA_ID	MIMAT0000264	PROTNAME	hsa-miR-203a-3p
DME0137	MIRNA_ID	MIMAT0000264	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0137	MIRNA_ID	MIMAT0000264	MOFCLASS	Non-coding RNA regulation
DME0137	MIRNA_ID	MIMAT0000264	MOFDETAI	microRNA regulation
DME0137	MIRNA_ID	MIMAT0000264	CELLLINE	HCT116, Caco2 and SW480 cell lines
DME0137	MIRNA_ID	MIMAT0000264	PPI_SUMM	hsa-miR-203a-3p--TYMS regulation
DME0137	MIRNA_ID	MIMAT0000264	DESCRIPT	hsa-miR-203a-3p is reported to suppress TYMS mRNA translation by binding to the 3' untranslated region (3'UTR) of TYMS mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Thymidylate synthase.
DME0137	MIRNA_ID	MIMAT0000459	PROTNAME	hsa-miR-193a-3p
DME0137	MIRNA_ID	MIMAT0000459	HPPI_DIS	Malignant pleural mesothelioma [ICD-11: 2C26]
DME0137	MIRNA_ID	MIMAT0000459	MOFCLASS	Non-coding RNA regulation
DME0137	MIRNA_ID	MIMAT0000459	MOFDETAI	microRNA regulation
DME0137	MIRNA_ID	MIMAT0000459	CELLLINE	H28, H2052 and H2452 cell lines
DME0137	MIRNA_ID	MIMAT0000459	PPI_SUMM	hsa-miR-193a-3p--TYMS regulation
DME0137	MIRNA_ID	MIMAT0000459	DESCRIPT	hsa-miR-193a-3p is reported to suppress TYMS mRNA translation by binding to the 3' untranslated region (3'UTR) of TYMS mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Thymidylate synthase.
DME0137	UNIPROID	DYR_HUMAN	PROTNAME	Dihydrofolate reductase (DHFR)
DME0137	UNIPROID	DYR_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0137	UNIPROID	DYR_HUMAN	MOFCLASS	Oligomerization
DME0137	UNIPROID	DYR_HUMAN	MOFDETAI	Homo-oligomerization
DME0137	UNIPROID	DYR_HUMAN	CELLLINE	Escherichia coli cells
DME0137	UNIPROID	DYR_HUMAN	PPI_SUMM	DHFR-TYMS homodimerization
DME0137	UNIPROID	DYR_HUMAN	DESCRIPT	Dihydrofolate reductase (DHFR) is reported to homodimerize with the TYMS gene, which is necessary for sustaining the enzyme activity of Thymidylate synthase. As a result, the interaction between DHFR and TYMS is necessary for sustaining the drug-metabolizing process of Thymidylate synthase.
DME0137	UNIPROID	E2F1_HUMAN	PROTNAME	TF factor E2F1 (E2F1)
DME0137	UNIPROID	E2F1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0137	UNIPROID	E2F1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0137	UNIPROID	E2F1_HUMAN	MOFDETAI	Activation
DME0137	UNIPROID	E2F1_HUMAN	CELLLINE	Hep3B cell line
DME0137	UNIPROID	E2F1_HUMAN	PPI_SUMM	E2F1-TYMS interaction
DME0137	UNIPROID	E2F1_HUMAN	DESCRIPT	TF factor E2F1 (E2F1) is reported to activate the transcription of TYMS gene, which leads to an increased expression of the drug-metabolizing enzyme Thymidylate synthase. As a result, the interaction between E2F1 and TYMS can activate the drug-metabolizing process of Thymidylate synthase.
DME0137	UNIPROID	TFDP1_HUMAN	PROTNAME	TF factor Dp-1 (TFDP1)
DME0137	UNIPROID	TFDP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0137	UNIPROID	TFDP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0137	UNIPROID	TFDP1_HUMAN	MOFDETAI	Activation
DME0137	UNIPROID	TFDP1_HUMAN	CELLLINE	Hep3B cell line
DME0137	UNIPROID	TFDP1_HUMAN	PPI_SUMM	TFDP1-TYMS interaction
DME0137	UNIPROID	TFDP1_HUMAN	DESCRIPT	TF factor Dp-1 (TFDP1) is reported to activate the transcription of TYMS gene, which leads to an increased expression of the drug-metabolizing enzyme Thymidylate synthase. As a result, the interaction between TFDP1 and TYMS can activate the drug-metabolizing process of Thymidylate synthase.
DME0137	UNIPROID	YBOX1_HUMAN	PROTNAME	Y-box-binding protein 1 (YBX1)
DME0137	UNIPROID	YBOX1_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0137	UNIPROID	YBOX1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0137	UNIPROID	YBOX1_HUMAN	MOFDETAI	Repression
DME0137	UNIPROID	YBOX1_HUMAN	CELLLINE	OVCAR-3 and SKOV-3 cell lines
DME0137	UNIPROID	YBOX1_HUMAN	PPI_SUMM	YBX1-TYMS interaction
DME0137	UNIPROID	YBOX1_HUMAN	DESCRIPT	Y-box-binding protein 1 (YBX1) is reported to repress the transcription of TYMS gene, which leads to a decreased expression of the drug-metabolizing enzyme Thymidylate synthase. As a result, the interaction between YBX1 and TYMS can repress the drug-metabolizing process of Thymidylate synthase.
DME0137	UNIPROID	P53_HUMAN	PROTNAME	Tumor suppressor p53 (TP53)
DME0137	UNIPROID	P53_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0137	UNIPROID	P53_HUMAN	MOFCLASS	Transcription-factor regulation
DME0137	UNIPROID	P53_HUMAN	MOFDETAI	Repression
DME0137	UNIPROID	P53_HUMAN	CELLLINE	LNCaP, C4-2 and PC3 cell lines
DME0137	UNIPROID	P53_HUMAN	PPI_SUMM	TP53-TYMS interaction
DME0137	UNIPROID	P53_HUMAN	DESCRIPT	Tumor suppressor p53 (TP53) is reported to repress the transcription of TYMS gene, which leads to a decreased expression of the drug-metabolizing enzyme Thymidylate synthase. As a result, the interaction between TP53 and TYMS can repress the drug-metabolizing process of Thymidylate synthase.
DME0139	DME___ID	DME0139
DME0139	DME_NAME	Uridine phosphorylase 1 (UPP1)
DME0139	SPESNAME	Homo sapiens
DME0139	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0139	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0139	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0139	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0139	UNIPROID	NFKB1_HUMAN	CELLLINE	EMT6 cell line
DME0139	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-UPP1 interaction
DME0139	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of UPP1 gene, which leads to an increased expression of the drug-metabolizing enzyme Uridine phosphorylase 1. As a result, the interaction between NFKB1 and UPP1 can activate the drug-metabolizing process of Uridine phosphorylase 1.
DME0139	UNIPROID	STAT1_HUMAN	PROTNAME	STAT 1-alpha/beta (STAT1)
DME0139	UNIPROID	STAT1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0139	UNIPROID	STAT1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0139	UNIPROID	STAT1_HUMAN	MOFDETAI	Activation
DME0139	UNIPROID	STAT1_HUMAN	CELLLINE	EMT6 cell line
DME0139	UNIPROID	STAT1_HUMAN	PPI_SUMM	STAT1-UPP1 interaction
DME0139	UNIPROID	STAT1_HUMAN	DESCRIPT	STAT 1-alpha/beta (STAT1) is reported to activate the transcription of UPP1 gene, which leads to an increased expression of the drug-metabolizing enzyme Uridine phosphorylase 1. As a result, the interaction between STAT1 and UPP1 can activate the drug-metabolizing process of Uridine phosphorylase 1.
DME0139	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0139	UNIPROID	TF65_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0139	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0139	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0139	UNIPROID	TF65_HUMAN	CELLLINE	EMT6 cell line
DME0139	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-UPP1 interaction
DME0139	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of UPP1 gene, which leads to an increased expression of the drug-metabolizing enzyme Uridine phosphorylase 1. As a result, the interaction between RELA and UPP1 can activate the drug-metabolizing process of Uridine phosphorylase 1.
DME0141	DME___ID	DME0141
DME0141	DME_NAME	Dihydrofolate reductase (DHFR)
DME0141	SPESNAME	Homo sapiens
DME0141	MIRNA_ID	MIMAT0000080	PROTNAME	hsa-miR-24-3p
DME0141	MIRNA_ID	MIMAT0000080	HPPI_DIS	Health [ICD-11: N.A.]
DME0141	MIRNA_ID	MIMAT0000080	MOFCLASS	Non-coding RNA regulation
DME0141	MIRNA_ID	MIMAT0000080	MOFDETAI	microRNA regulation
DME0141	MIRNA_ID	MIMAT0000080	CELLLINE	CHO DG44 cell line
DME0141	MIRNA_ID	MIMAT0000080	PPI_SUMM	hsa-miR-24-3p--DHFR regulation
DME0141	MIRNA_ID	MIMAT0000080	DESCRIPT	hsa-miR-24-3p is reported to suppress DHFR mRNA translation by binding to the 3' untranslated region (3'UTR) of DHFR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dihydrofolate reductase.
DME0141	MIRNA_ID	MIMAT0000222	PROTNAME	hsa-miR-192-5p
DME0141	MIRNA_ID	MIMAT0000222	HPPI_DIS	Medulloblastoma [ICD-11: 2A00.10]
DME0141	MIRNA_ID	MIMAT0000222	MOFCLASS	Non-coding RNA regulation
DME0141	MIRNA_ID	MIMAT0000222	MOFDETAI	microRNA regulation
DME0141	MIRNA_ID	MIMAT0000222	CELLLINE	D283 cell line
DME0141	MIRNA_ID	MIMAT0000222	PPI_SUMM	hsa-miR-192-5p--DHFR regulation
DME0141	MIRNA_ID	MIMAT0000222	DESCRIPT	hsa-miR-192-5p is reported to suppress DHFR mRNA translation by binding to the 3' untranslated region (3'UTR) of DHFR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dihydrofolate reductase.
DME0141	MIRNA_ID	MIMAT0000081	PROTNAME	hsa-miR-25-3p
DME0141	MIRNA_ID	MIMAT0000081	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0141	MIRNA_ID	MIMAT0000081	MOFCLASS	Non-coding RNA regulation
DME0141	MIRNA_ID	MIMAT0000081	MOFDETAI	microRNA regulation
DME0141	MIRNA_ID	MIMAT0000081	CELLLINE	MCF-7 cell line
DME0141	MIRNA_ID	MIMAT0000081	PPI_SUMM	hsa-miR-25-3p--DHFR regulation
DME0141	MIRNA_ID	MIMAT0000081	DESCRIPT	hsa-miR-25-3p is reported to suppress DHFR mRNA translation by binding to the 3' untranslated region (3'UTR) of DHFR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dihydrofolate reductase.
DME0141	UNIPROID	TYSY_HUMAN	PROTNAME	Thymidylate synthase (TYMS)
DME0141	UNIPROID	TYSY_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0141	UNIPROID	TYSY_HUMAN	MOFCLASS	Oligomerization
DME0141	UNIPROID	TYSY_HUMAN	MOFDETAI	Homo-oligomerization
DME0141	UNIPROID	TYSY_HUMAN	CELLLINE	Escherichia coli cells
DME0141	UNIPROID	TYSY_HUMAN	PPI_SUMM	TYMS-DHFR homodimerization
DME0141	UNIPROID	TYSY_HUMAN	DESCRIPT	Thymidylate synthase (TYMS) is reported to homodimerize with the DHFR gene, which is necessary for sustaining the enzyme activity of Dihydrofolate reductase. As a result, the interaction between TYMS and DHFR is necessary for sustaining the drug-metabolizing process of Dihydrofolate reductase.
DME0141	UNIPROID	RB_HUMAN	PROTNAME	Retinoblastoma-associated (RB1)
DME0141	UNIPROID	RB_HUMAN	HPPI_DIS	Osteosarcoma [ICD-11: 2B51]
DME0141	UNIPROID	RB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0141	UNIPROID	RB_HUMAN	MOFDETAI	Repression
DME0141	UNIPROID	RB_HUMAN	CELLLINE	SAOS and MCF-10A cell lines
DME0141	UNIPROID	RB_HUMAN	PPI_SUMM	RB1-DHFR interaction
DME0141	UNIPROID	RB_HUMAN	DESCRIPT	Retinoblastoma-associated (RB1) is reported to repress the transcription of DHFR gene, which leads to a decreased expression of the drug-metabolizing enzyme Dihydrofolate reductase. As a result, the interaction between RB1 and DHFR can repress the drug-metabolizing process of Dihydrofolate reductase.
DME0141	UNIPROID	E2F1_HUMAN	PROTNAME	TF factor E2F1 (E2F1)
DME0141	UNIPROID	E2F1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0141	UNIPROID	E2F1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0141	UNIPROID	E2F1_HUMAN	MOFDETAI	Activation
DME0141	UNIPROID	E2F1_HUMAN	CELLLINE	Hep3B cell line
DME0141	UNIPROID	E2F1_HUMAN	PPI_SUMM	E2F1-DHFR interaction
DME0141	UNIPROID	E2F1_HUMAN	DESCRIPT	TF factor E2F1 (E2F1) is reported to activate the transcription of DHFR gene, which leads to an increased expression of the drug-metabolizing enzyme Dihydrofolate reductase. As a result, the interaction between E2F1 and DHFR can activate the drug-metabolizing process of Dihydrofolate reductase.
DME0141	UNIPROID	TFDP1_HUMAN	PROTNAME	TF factor Dp-1 (TFDP1)
DME0141	UNIPROID	TFDP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0141	UNIPROID	TFDP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0141	UNIPROID	TFDP1_HUMAN	MOFDETAI	Activation
DME0141	UNIPROID	TFDP1_HUMAN	CELLLINE	Hep3B cell line
DME0141	UNIPROID	TFDP1_HUMAN	PPI_SUMM	TFDP1-DHFR interaction
DME0141	UNIPROID	TFDP1_HUMAN	DESCRIPT	TF factor Dp-1 (TFDP1) is reported to activate the transcription of DHFR gene, which leads to an increased expression of the drug-metabolizing enzyme Dihydrofolate reductase. As a result, the interaction between TFDP1 and DHFR can activate the drug-metabolizing process of Dihydrofolate reductase.
DME0145	DME___ID	DME0145
DME0145	DME_NAME	Alanyl aminopeptidase (ANPEP)
DME0145	SPESNAME	Homo sapiens
DME0145	UNIPROID	ETS1_HUMAN	PROTNAME	Protein C-ets-1 (ETS1)
DME0145	UNIPROID	ETS1_HUMAN	HPPI_DIS	Kaposi sarcoma [ICD-11: 2B57]
DME0145	UNIPROID	ETS1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0145	UNIPROID	ETS1_HUMAN	MOFDETAI	Activation
DME0145	UNIPROID	ETS1_HUMAN	CELLLINE	KS1767 cell line
DME0145	UNIPROID	ETS1_HUMAN	PPI_SUMM	ETS1-ANPEP interaction
DME0145	UNIPROID	ETS1_HUMAN	DESCRIPT	Protein C-ets-1 (ETS1) is reported to activate the transcription of ANPEP gene, which leads to an increased expression of the drug-metabolizing enzyme Alanyl aminopeptidase. As a result, the interaction between ETS1 and ANPEP can activate the drug-metabolizing process of Alanyl aminopeptidase.
DME0145	UNIPROID	ETS1_HUMAN	HPPI_DIS	Benign vascular neoplasms [ICD-11: 2E81]
DME0145	UNIPROID	ETS1_HUMAN	CELLLINE	EOMA cell line
DME0145	UNIPROID	ETS2_HUMAN	PROTNAME	Protein C-ets-2 (ETS2)
DME0145	UNIPROID	ETS2_HUMAN	HPPI_DIS	Kaposi sarcoma [ICD-11: 2B57]
DME0145	UNIPROID	ETS2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0145	UNIPROID	ETS2_HUMAN	MOFDETAI	Activation
DME0145	UNIPROID	ETS2_HUMAN	CELLLINE	KS1767 cell line
DME0145	UNIPROID	ETS2_HUMAN	PPI_SUMM	ETS2-ANPEP interaction
DME0145	UNIPROID	ETS2_HUMAN	DESCRIPT	Protein C-ets-2 (ETS2) is reported to activate the transcription of ANPEP gene, which leads to an increased expression of the drug-metabolizing enzyme Alanyl aminopeptidase. As a result, the interaction between ETS2 and ANPEP can activate the drug-metabolizing process of Alanyl aminopeptidase.
DME0145	UNIPROID	ETS2_HUMAN	HPPI_DIS	Benign vascular neoplasms [ICD-11: 2E81]
DME0145	UNIPROID	ETS2_HUMAN	CELLLINE	EOMA cell line
DME0146	DME___ID	DME0146
DME0146	DME_NAME	Phosphoglucomutase 1 (PGM1)
DME0146	SPESNAME	Homo sapiens
DME0146	UNIPROID	HDAC8_HUMAN	PROTNAME	Histone deacetylase 8 (HDAC8)
DME0146	UNIPROID	HDAC8_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0146	UNIPROID	HDAC8_HUMAN	MOFCLASS	Histone modification
DME0146	UNIPROID	HDAC8_HUMAN	MOFDETAI	Histone hyperacetylation
DME0146	UNIPROID	HDAC8_HUMAN	CELLLINE	Lung cancer cells
DME0146	UNIPROID	HDAC8_HUMAN	PPI_SUMM	HDAC8-PGM1 interaction
DME0146	UNIPROID	HDAC8_HUMAN	DESCRIPT	Histone deacetylase 8 (HDAC8) phosphorylation is reported to acetylate the PGM1 gene and thereby activates the transcriptional activity of the drug-metabolizing enzyme Phosphoglucomutase 1. As a result, the interaction between HDAC8 and PGM1 can enhance the drug-metabolizing process of Phosphoglucomutase 1.
DME0147	DME___ID	DME0147
DME0147	DME_NAME	Cellular glutathione peroxidase (GPX1)
DME0147	SPESNAME	Homo sapiens
DME0147	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0147	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0147	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0147	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0147	UNIPROID	HDAC1_HUMAN	CELLLINE	Rat bone marrow cells
DME0147	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-GPX1 interaction
DME0147	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the GPX1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cellular glutathione peroxidase. As a result, the interaction between HDACs and GPX1 can inhibit the drug-metabolizing process of Cellular glutathione peroxidase.
DME0147	UNIPROID	AP2C_HUMAN	PROTNAME	TF factor AP-2 gamma (TFAP2C)
DME0147	UNIPROID	AP2C_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0147	UNIPROID	AP2C_HUMAN	MOFCLASS	Transcription-factor regulation
DME0147	UNIPROID	AP2C_HUMAN	MOFDETAI	Activation
DME0147	UNIPROID	AP2C_HUMAN	CELLLINE	MCF-7, BT-474, MDA-MB-453 and SKBR-3 cell lines
DME0147	UNIPROID	AP2C_HUMAN	PPI_SUMM	TFAP2C-GPX1 interaction
DME0147	UNIPROID	AP2C_HUMAN	DESCRIPT	TF factor AP-2 gamma (TFAP2C) is reported to activate the transcription of GPX1 gene, which leads to an increased expression of the drug-metabolizing enzyme Cellular glutathione peroxidase. As a result, the interaction between TFAP2C and GPX1 can activate the drug-metabolizing process of Cellular glutathione peroxidase.
DME0149	DME___ID	DME0149
DME0149	DME_NAME	Vitamin K1 2,3-epoxide reductase 1 (VKOR)
DME0149	SPESNAME	Homo sapiens
DME0149	MIRNA_ID	MIMAT0000427	PROTNAME	hsa-miR-133a-3p
DME0149	MIRNA_ID	MIMAT0000427	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0149	MIRNA_ID	MIMAT0000427	MOFCLASS	Non-coding RNA regulation
DME0149	MIRNA_ID	MIMAT0000427	MOFDETAI	microRNA regulation
DME0149	MIRNA_ID	MIMAT0000427	CELLLINE	HepG2 cell line
DME0149	MIRNA_ID	MIMAT0000427	PPI_SUMM	hsa-miR-133a-3p--VKORC1 regulation
DME0149	MIRNA_ID	MIMAT0000427	DESCRIPT	hsa-miR-133a-3p is reported to suppress VKORC1 mRNA translation by binding to the 3' untranslated region (3'UTR) of VKORC1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Vitamin K1 2,3-epoxide reductase 1.
DME0151	DME___ID	DME0151
DME0151	DME_NAME	Phosphorylcholine transferase A (PCYT1A)
DME0151	SPESNAME	Homo sapiens
DME0151	UNIPROID	ZNF76_HUMAN	PROTNAME	Zinc finger protein 76 (ZNF76)
DME0151	UNIPROID	ZNF76_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0151	UNIPROID	ZNF76_HUMAN	MOFCLASS	Transcription-factor regulation
DME0151	UNIPROID	ZNF76_HUMAN	MOFDETAI	Activation
DME0151	UNIPROID	ZNF76_HUMAN	CELLLINE	HepG2 cell line
DME0151	UNIPROID	ZNF76_HUMAN	PPI_SUMM	ZNF76-PCYT1A interaction
DME0151	UNIPROID	ZNF76_HUMAN	DESCRIPT	Zinc finger protein 76 (ZNF76) is reported to activate the transcription of PCYT1A gene, which leads to an increased expression of the drug-metabolizing enzyme Phosphorylcholine transferase A. As a result, the interaction between ZNF76 and PCYT1A can activate the drug-metabolizing process of Phosphorylcholine transferase A.
DME0151	UNIPROID	ZNF76_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0151	UNIPROID	ZNF76_HUMAN	CELLLINE	HeLa cell line
DME0151	UNIPROID	ZN143_HUMAN	PROTNAME	Zinc finger 143 (ZNF143)
DME0151	UNIPROID	ZN143_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0151	UNIPROID	ZN143_HUMAN	MOFCLASS	Transcription-factor regulation
DME0151	UNIPROID	ZN143_HUMAN	MOFDETAI	Activation
DME0151	UNIPROID	ZN143_HUMAN	CELLLINE	HepG2 cell line
DME0151	UNIPROID	ZN143_HUMAN	PPI_SUMM	ZNF143-PCYT1A interaction
DME0151	UNIPROID	ZN143_HUMAN	DESCRIPT	Zinc finger 143 (ZNF143) is reported to activate the transcription of PCYT1A gene, which leads to an increased expression of the drug-metabolizing enzyme Phosphorylcholine transferase A. As a result, the interaction between ZNF143 and PCYT1A can activate the drug-metabolizing process of Phosphorylcholine transferase A.
DME0151	UNIPROID	ZN143_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0151	UNIPROID	ZN143_HUMAN	CELLLINE	HeLa cell line
DME0152	DME___ID	DME0152
DME0152	DME_NAME	Phosphorylethanolamine transferase (PCYT2)
DME0152	SPESNAME	Homo sapiens
DME0152	UNIPROID	HAT1_HUMAN	PROTNAME	Histone acetyltransferases (HATs)
DME0152	UNIPROID	HAT1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0152	UNIPROID	HAT1_HUMAN	MOFCLASS	Histone modification
DME0152	UNIPROID	HAT1_HUMAN	MOFDETAI	Histone hyperacetylation
DME0152	UNIPROID	HAT1_HUMAN	CELLLINE	Transferred cell line
DME0152	UNIPROID	HAT1_HUMAN	PPI_SUMM	HATs-PCYT2 interaction
DME0152	UNIPROID	HAT1_HUMAN	DESCRIPT	Histone acetyltransferases (HATs) are reported to acetylate the PCYT2 gene and thereby activate the transcriptional activity of the drug-metabolizing enzyme Phosphorylethanolamine transferase. As a result, the interaction between HATs and PCYT2 can enhance the drug-metabolizing process of Phosphorylethanolamine transferase.
DME0154	DME___ID	DME0154
DME0154	DME_NAME	Asparagine synthetase (ASNS)
DME0154	SPESNAME	Homo sapiens
DME0154	UNIPROID	WWTR1_HUMAN	PROTNAME	WW-containing regulator 1 (WWTR1)
DME0154	UNIPROID	WWTR1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0154	UNIPROID	WWTR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0154	UNIPROID	WWTR1_HUMAN	MOFDETAI	Repression
DME0154	UNIPROID	WWTR1_HUMAN	CELLLINE	RKO and HCT116 cell lines
DME0154	UNIPROID	WWTR1_HUMAN	PPI_SUMM	WWTR1-ASNS interaction
DME0154	UNIPROID	WWTR1_HUMAN	DESCRIPT	WW-containing regulator 1 (WWTR1) is reported to repress the transcription of ASNS gene, which leads to a decreased expression of the drug-metabolizing enzyme Asparagine synthetase. As a result, the interaction between WWTR1 and ASNS can repress the drug-metabolizing process of Asparagine synthetase.
DME0154	UNIPROID	ATF4_HUMAN	PROTNAME	Activating TF factor 4 (ATF4)
DME0154	UNIPROID	ATF4_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0154	UNIPROID	ATF4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0154	UNIPROID	ATF4_HUMAN	MOFDETAI	Activation
DME0154	UNIPROID	ATF4_HUMAN	CELLLINE	HepG2 cell line
DME0154	UNIPROID	ATF4_HUMAN	PPI_SUMM	ATF4-ASNS interaction
DME0154	UNIPROID	ATF4_HUMAN	DESCRIPT	Activating TF factor 4 (ATF4) is reported to activate the transcription of ASNS gene, which leads to an increased expression of the drug-metabolizing enzyme Asparagine synthetase. As a result, the interaction between ATF4 and ASNS can activate the drug-metabolizing process of Asparagine synthetase.
DME0154	UNIPROID	ATF3_HUMAN	PROTNAME	Activating TF factor 3 (ATF3)
DME0154	UNIPROID	ATF3_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0154	UNIPROID	ATF3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0154	UNIPROID	ATF3_HUMAN	MOFDETAI	Activation
DME0154	UNIPROID	ATF3_HUMAN	CELLLINE	HepG2 cell line
DME0154	UNIPROID	ATF3_HUMAN	PPI_SUMM	ATF3-ASNS interaction
DME0154	UNIPROID	ATF3_HUMAN	DESCRIPT	Activating TF factor 3 (ATF3) is reported to activate the transcription of ASNS gene, which leads to an increased expression of the drug-metabolizing enzyme Asparagine synthetase. As a result, the interaction between ATF3 and ASNS can activate the drug-metabolizing process of Asparagine synthetase.
DME0154	UNIPROID	DDIT3_HUMAN	PROTNAME	C/EBP-homologous protein (DDIT3)
DME0154	UNIPROID	DDIT3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0154	UNIPROID	DDIT3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0154	UNIPROID	DDIT3_HUMAN	MOFDETAI	Repression
DME0154	UNIPROID	DDIT3_HUMAN	CELLLINE	HEK 293T cell line
DME0154	UNIPROID	DDIT3_HUMAN	PPI_SUMM	DDIT3-ASNS interaction
DME0154	UNIPROID	DDIT3_HUMAN	DESCRIPT	C/EBP-homologous protein (DDIT3) is reported to repress the transcription of ASNS gene, which leads to a decreased expression of the drug-metabolizing enzyme Asparagine synthetase. As a result, the interaction between DDIT3 and ASNS can repress the drug-metabolizing process of Asparagine synthetase.
DME0159	DME___ID	DME0159
DME0159	DME_NAME	Glutamine amidotransferase (GMPS)
DME0159	SPESNAME	Homo sapiens
DME0159	UNIPROID	APBB1_HUMAN	PROTNAME	Amyloid-beta A4 binding B1 (APBB1)
DME0159	UNIPROID	APBB1_HUMAN	HPPI_DIS	Alzheimer disease [ICD-11: 8A20]
DME0159	UNIPROID	APBB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0159	UNIPROID	APBB1_HUMAN	MOFDETAI	Repression
DME0159	UNIPROID	APBB1_HUMAN	CELLLINE	Alzheimer frontal cortex brain samples
DME0159	UNIPROID	APBB1_HUMAN	PPI_SUMM	APBB1-GMPS interaction
DME0159	UNIPROID	APBB1_HUMAN	DESCRIPT	Amyloid-beta A4 binding B1 (APBB1) is reported to repress the transcription of GMPS gene, which leads to a decreased expression of the drug-metabolizing enzyme Glutamine amidotransferase. As a result, the interaction between APBB1 and GMPS can repress the drug-metabolizing process of Glutamine amidotransferase.
DME0159	UNIPROID	KAT5_HUMAN	PROTNAME	Lysine acetyltransferase 5 (KAT5)
DME0159	UNIPROID	KAT5_HUMAN	HPPI_DIS	Alzheimer disease [ICD-11: 8A20]
DME0159	UNIPROID	KAT5_HUMAN	MOFCLASS	Transcription-factor regulation
DME0159	UNIPROID	KAT5_HUMAN	MOFDETAI	Repression
DME0159	UNIPROID	KAT5_HUMAN	CELLLINE	Frontal cortex brain cell line
DME0159	UNIPROID	KAT5_HUMAN	PPI_SUMM	KAT5-GMPS interaction
DME0159	UNIPROID	KAT5_HUMAN	DESCRIPT	Lysine acetyltransferase 5 (KAT5) is reported to repress the transcription of GMPS gene, which leads to a decreased expression of the drug-metabolizing enzyme Glutamine amidotransferase. As a result, the interaction between KAT5 and GMPS can repress the drug-metabolizing process of Glutamine amidotransferase.
DME0162	DME___ID	DME0162
DME0162	DME_NAME	Transglutaminase H (TGM2)
DME0162	SPESNAME	Homo sapiens
DME0162	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0162	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0162	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0162	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0162	UNIPROID	HDAC1_HUMAN	CELLLINE	Glioma cells
DME0162	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-TGM2 interaction
DME0162	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the TGM2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Transglutaminase H. As a result, the interaction between HDACs and TGM2 can inhibit the drug-metabolizing process of Transglutaminase H.
DME0162	MIRNA_ID	MIMAT0005876	PROTNAME	hsa-miR-1285-3p
DME0162	MIRNA_ID	MIMAT0005876	HPPI_DIS	Renal cell carcinoma [ICD-11: 2C90]
DME0162	MIRNA_ID	MIMAT0005876	MOFCLASS	Non-coding RNA regulation
DME0162	MIRNA_ID	MIMAT0005876	MOFDETAI	microRNA regulation
DME0162	MIRNA_ID	MIMAT0005876	CELLLINE	A498, 786-O, ACHN and caki-2 cell lines
DME0162	MIRNA_ID	MIMAT0005876	PPI_SUMM	hsa-miR-1285-3p--TGM2 regulation
DME0162	MIRNA_ID	MIMAT0005876	DESCRIPT	hsa-miR-1285-3p is reported to suppress TGM2 mRNA translation by binding to the 3' untranslated region (3'UTR) of TGM2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Transglutaminase H.
DME0166	DME___ID	DME0166
DME0166	DME_NAME	Transglutaminase K (TGM1)
DME0166	SPESNAME	Homo sapiens
DME0166	UNIPROID	HDAC3_HUMAN	PROTNAME	Histone deacetylase 3 (HDAC3)
DME0166	UNIPROID	HDAC3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0166	UNIPROID	HDAC3_HUMAN	MOFCLASS	Histone modification
DME0166	UNIPROID	HDAC3_HUMAN	MOFDETAI	Histone hypoacetylation
DME0166	UNIPROID	HDAC3_HUMAN	CELLLINE	Basal cells
DME0166	UNIPROID	HDAC3_HUMAN	PPI_SUMM	HDAC3-TGM1 interaction
DME0166	UNIPROID	HDAC3_HUMAN	DESCRIPT	Histone deacetylase 3 (HDAC3) is reported to deacetylate the TGM1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Transglutaminase K. As a result, the interaction between HDAC3 and TGM1 can inhibit the drug-metabolizing process of Transglutaminase K.
DME0168	DME___ID	DME0168
DME0168	DME_NAME	Neprilysin (MME)
DME0168	SPESNAME	Homo sapiens
DME0168	UNIPROID	HXC6_HUMAN	PROTNAME	Homeobox protein Hox-C6 (HOXC6)
DME0168	UNIPROID	HXC6_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0168	UNIPROID	HXC6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0168	UNIPROID	HXC6_HUMAN	MOFDETAI	Repression
DME0168	UNIPROID	HXC6_HUMAN	CELLLINE	LnCaP, C4-2, DU145, and PC3 PCa cell lines
DME0168	UNIPROID	HXC6_HUMAN	PPI_SUMM	HOXC6-MME interaction
DME0168	UNIPROID	HXC6_HUMAN	DESCRIPT	Homeobox protein Hox-C6 (HOXC6) is reported to repress the transcription of MME gene, which leads to a decreased expression of the drug-metabolizing enzyme Neprilysin. As a result, the interaction between HOXC6 and MME can repress the drug-metabolizing process of Neprilysin.
DME0168	UNIPROID	MYC_HUMAN	PROTNAME	Proto-oncogene c-Myc (MYC)
DME0168	UNIPROID	MYC_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0168	UNIPROID	MYC_HUMAN	MOFCLASS	Transcription-factor regulation
DME0168	UNIPROID	MYC_HUMAN	MOFDETAI	Activation
DME0168	UNIPROID	MYC_HUMAN	CELLLINE	EREB2-5 cell line
DME0168	UNIPROID	MYC_HUMAN	PPI_SUMM	MYC-MME interaction
DME0168	UNIPROID	MYC_HUMAN	DESCRIPT	Proto-oncogene c-Myc (MYC) is reported to activate the transcription of MME gene, which leads to an increased expression of the drug-metabolizing enzyme Neprilysin. As a result, the interaction between MYC and MME can activate the drug-metabolizing process of Neprilysin.
DME0169	DME___ID	DME0169
DME0169	DME_NAME	Serum paraoxonase/arylesterase 1 (PON1)
DME0169	SPESNAME	Homo sapiens
DME0169	MIRNA_ID	MIMAT0004805	PROTNAME	hsa-miR-616-3p
DME0169	MIRNA_ID	MIMAT0004805	HPPI_DIS	Ischemic stroke [ICD-11: 8B11]
DME0169	MIRNA_ID	MIMAT0004805	MOFCLASS	Non-coding RNA regulation
DME0169	MIRNA_ID	MIMAT0004805	MOFDETAI	microRNA regulation
DME0169	MIRNA_ID	MIMAT0004805	CELLLINE	Ischemic stroke cells
DME0169	MIRNA_ID	MIMAT0004805	PPI_SUMM	hsa-miR-616-3p--PON1 regulation
DME0169	MIRNA_ID	MIMAT0004805	DESCRIPT	hsa-miR-616-3p is reported to suppress PON1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PON1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1.
DME0169	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0169	UNIPROID	SP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0169	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0169	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0169	UNIPROID	SP1_HUMAN	CELLLINE	HepG2 cell line
DME0169	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-PON1 interaction
DME0169	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of PON1 gene, which leads to an increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between SP1 and PON1 can activate the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME0169	UNIPROID	SRBP2_HUMAN	PROTNAME	Sterol element-binding 2 (SREBF2)
DME0169	UNIPROID	SRBP2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0169	UNIPROID	SRBP2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0169	UNIPROID	SRBP2_HUMAN	MOFDETAI	Activation
DME0169	UNIPROID	SRBP2_HUMAN	CELLLINE	HuH7 cell line
DME0169	UNIPROID	SRBP2_HUMAN	PPI_SUMM	SREBF2-PON1 interaction
DME0169	UNIPROID	SRBP2_HUMAN	DESCRIPT	Sterol element-binding 2 (SREBF2) is reported to activate the transcription of PON1 gene, which leads to an increased expression of the drug-metabolizing enzyme Serum paraoxonase/arylesterase 1. As a result, the interaction between SREBF2 and PON1 can activate the drug-metabolizing process of Serum paraoxonase/arylesterase 1.
DME0171	DME___ID	DME0171
DME0171	DME_NAME	Indoleamine 2,3-dioxygenase 1 (IDO1)
DME0171	SPESNAME	Homo sapiens
DME0171	MIRNA_ID	MIMAT0000439	PROTNAME	hsa-miR-153-3p
DME0171	MIRNA_ID	MIMAT0000439	HPPI_DIS	Graft-versus-host disease [ICD-11: 4B24]
DME0171	MIRNA_ID	MIMAT0000439	MOFCLASS	Non-coding RNA regulation
DME0171	MIRNA_ID	MIMAT0000439	MOFDETAI	microRNA regulation
DME0171	MIRNA_ID	MIMAT0000439	CELLLINE	Graft-versus-host disease cells
DME0171	MIRNA_ID	MIMAT0000439	PPI_SUMM	hsa-miR-153-3p--IDO1 regulation
DME0171	MIRNA_ID	MIMAT0000439	DESCRIPT	hsa-miR-153-3p is reported to suppress IDO1 mRNA translation by binding to the 3' untranslated region (3'UTR) of IDO1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Indoleamine 2,3-dioxygenase 1.
DME0171	UNIPROID	PTMA_HUMAN	PROTNAME	Prothymosin alpha (PTMA)
DME0171	UNIPROID	PTMA_HUMAN	HPPI_DIS	Aplastic anemia [ICD-11: 3A70]
DME0171	UNIPROID	PTMA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0171	UNIPROID	PTMA_HUMAN	MOFDETAI	Activation
DME0171	UNIPROID	PTMA_HUMAN	CELLLINE	Mesenchymal stem cell line
DME0171	UNIPROID	PTMA_HUMAN	PPI_SUMM	PTMA-IDO1 interaction
DME0171	UNIPROID	PTMA_HUMAN	DESCRIPT	Prothymosin alpha (PTMA) is reported to activate the transcription of IDO1 gene, which leads to an increased expression of the drug-metabolizing enzyme Indoleamine 2,3-dioxygenase 1. As a result, the interaction between PTMA and IDO1 can activate the drug-metabolizing process of Indoleamine 2,3-dioxygenase 1.
DME0173	DME___ID	DME0173
DME0173	DME_NAME	Tryptophan 5-hydroxylase 1 (TPH1)
DME0173	SPESNAME	Homo sapiens
DME0173	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0173	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0173	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0173	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0173	UNIPROID	HDAC1_HUMAN	CELLLINE	Rat islets cell
DME0173	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-TPH1 interaction
DME0173	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the TPH1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Tryptophan 5-hydroxylase 1. As a result, the interaction between HDACs and TPH1 can inhibit the drug-metabolizing process of Tryptophan 5-hydroxylase 1.
DME0173	UNIPROID	NFYB_HUMAN	PROTNAME	Nuclear TF factor Y beta (NFYB)
DME0173	UNIPROID	NFYB_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0173	UNIPROID	NFYB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0173	UNIPROID	NFYB_HUMAN	MOFDETAI	Activation
DME0173	UNIPROID	NFYB_HUMAN	CELLLINE	HeLa cell line
DME0173	UNIPROID	NFYB_HUMAN	PPI_SUMM	NFYB-TPH1 interaction
DME0173	UNIPROID	NFYB_HUMAN	DESCRIPT	Nuclear TF factor Y beta (NFYB) is reported to activate the transcription of TPH1 gene, which leads to an increased expression of the drug-metabolizing enzyme Tryptophan 5-hydroxylase 1. As a result, the interaction between NFYB and TPH1 can activate the drug-metabolizing process of Tryptophan 5-hydroxylase 1.
DME0173	UNIPROID	ASCL1_HUMAN	PROTNAME	Achaete-scute homolog 1 (ASCL1)
DME0173	UNIPROID	ASCL1_HUMAN	HPPI_DIS	Pancreatic endocrine tumour [ICD-11: 2E92]
DME0173	UNIPROID	ASCL1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0173	UNIPROID	ASCL1_HUMAN	MOFDETAI	Repression
DME0173	UNIPROID	ASCL1_HUMAN	CELLLINE	BON1 cell line
DME0173	UNIPROID	ASCL1_HUMAN	PPI_SUMM	ASCL1-TPH1 interaction
DME0173	UNIPROID	ASCL1_HUMAN	DESCRIPT	Achaete-scute homolog 1 (ASCL1) is reported to repress the transcription of TPH1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Tryptophan 5-hydroxylase 1. As a result, the interaction between ASCL1 and TPH1 can repress the drug-metabolizing process of Tryptophan 5-hydroxylase 1.
DME0174	DME___ID	DME0174
DME0174	DME_NAME	Tryptophan 5-hydroxylase 2 (TPH2)
DME0174	SPESNAME	Homo sapiens
DME0174	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0174	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0174	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0174	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0174	UNIPROID	HDAC1_HUMAN	CELLLINE	RN46A cells
DME0174	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-TPH2 interaction
DME0174	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the TPH2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Tryptophan 5-hydroxylase 2. As a result, the interaction between HDACs and TPH2 can inhibit the drug-metabolizing process of Tryptophan 5-hydroxylase 2.
DME0174	UNIPROID	REST_HUMAN	PROTNAME	X2 box repressor (REST)
DME0174	UNIPROID	REST_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0174	UNIPROID	REST_HUMAN	MOFCLASS	Transcription-factor regulation
DME0174	UNIPROID	REST_HUMAN	MOFDETAI	Activation
DME0174	UNIPROID	REST_HUMAN	CELLLINE	C6-glioma cell line
DME0174	UNIPROID	REST_HUMAN	PPI_SUMM	REST-TPH2 interaction
DME0174	UNIPROID	REST_HUMAN	DESCRIPT	X2 box repressor (REST) is reported to activate the transcription of TPH2 gene, which leads to an increased expression of the drug-metabolizing enzyme Tryptophan 5-hydroxylase 2. As a result, the interaction between REST and TPH2 can activate the drug-metabolizing process of Tryptophan 5-hydroxylase 2.
DME0183	DME___ID	DME0183
DME0183	DME_NAME	Methionine adenosyltransferase II beta (MAT2B)
DME0183	SPESNAME	Homo sapiens
DME0183	MIRNA_ID	MIMAT0004494	PROTNAME	hsa-miR-21-3p
DME0183	MIRNA_ID	MIMAT0004494	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0183	MIRNA_ID	MIMAT0004494	MOFCLASS	Non-coding RNA regulation
DME0183	MIRNA_ID	MIMAT0004494	MOFDETAI	microRNA regulation
DME0183	MIRNA_ID	MIMAT0004494	CELLLINE	HepG2 cell line
DME0183	MIRNA_ID	MIMAT0004494	PPI_SUMM	hsa-miR-21-3p--MAT2B regulation
DME0183	MIRNA_ID	MIMAT0004494	DESCRIPT	hsa-miR-21-3p is reported to suppress MAT2B mRNA translation by binding to the 3' untranslated region (3'UTR) of MAT2B mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Methionine adenosyltransferase II beta.
DME0183	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0183	UNIPROID	SP1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0183	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0183	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0183	UNIPROID	SP1_HUMAN	CELLLINE	Cos-1 and Jurkat human leukemic T cell lines
DME0183	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-MAT2B interaction
DME0183	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of MAT2B gene, which leads to an increased expression of the drug-metabolizing enzyme Methionine adenosyltransferase II beta. As a result, the interaction between SP1 and MAT2B can activate the drug-metabolizing process of Methionine adenosyltransferase II beta.
DME0189	DME___ID	DME0189
DME0189	DME_NAME	S-adenosylmethionine synthase 1 (MAT1A)
DME0189	SPESNAME	Homo sapiens
DME0189	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0189	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0189	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0189	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0189	UNIPROID	HDAC1_HUMAN	CELLLINE	HepG2 cell line
DME0189	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-MAT1A interaction
DME0189	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the MAT1A gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme S-adenosylmethionine synthase 1. As a result, the interaction between HDACs and MAT1A can inhibit the drug-metabolizing process of S-adenosylmethionine synthase 1.
DME0189	MIRNA_ID	MIMAT0002176	PROTNAME	hsa-miR-485-3p
DME0189	MIRNA_ID	MIMAT0002176	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0189	MIRNA_ID	MIMAT0002176	MOFCLASS	Non-coding RNA regulation
DME0189	MIRNA_ID	MIMAT0002176	MOFDETAI	microRNA regulation
DME0189	MIRNA_ID	MIMAT0002176	CELLLINE	Hep3B and HepG2 cell lines
DME0189	MIRNA_ID	MIMAT0002176	PPI_SUMM	hsa-miR-485-3p--MAT1A regulation
DME0189	MIRNA_ID	MIMAT0002176	DESCRIPT	hsa-miR-485-3p is reported to suppress MAT1A mRNA translation by binding to the 3' untranslated region (3'UTR) of MAT1A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 1.
DME0189	MIRNA_ID	MIMAT0002817	PROTNAME	hsa-miR-495-3p
DME0189	MIRNA_ID	MIMAT0002817	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0189	MIRNA_ID	MIMAT0002817	MOFCLASS	Non-coding RNA regulation
DME0189	MIRNA_ID	MIMAT0002817	MOFDETAI	microRNA regulation
DME0189	MIRNA_ID	MIMAT0002817	CELLLINE	Hep3B and HepG2 cell lines
DME0189	MIRNA_ID	MIMAT0002817	PPI_SUMM	hsa-miR-495-3p--MAT1A regulation
DME0189	MIRNA_ID	MIMAT0002817	DESCRIPT	hsa-miR-495-3p is reported to suppress MAT1A mRNA translation by binding to the 3' untranslated region (3'UTR) of MAT1A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 1.
DME0189	MIRNA_ID	MIMAT0005949	PROTNAME	hsa-miR-664a-3p
DME0189	MIRNA_ID	MIMAT0005949	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0189	MIRNA_ID	MIMAT0005949	MOFCLASS	Non-coding RNA regulation
DME0189	MIRNA_ID	MIMAT0005949	MOFDETAI	microRNA regulation
DME0189	MIRNA_ID	MIMAT0005949	CELLLINE	Hep3B and HepG2 cell lines
DME0189	MIRNA_ID	MIMAT0005949	PPI_SUMM	hsa-miR-664a-3p--MAT1A regulation
DME0189	MIRNA_ID	MIMAT0005949	DESCRIPT	hsa-miR-664a-3p is reported to suppress MAT1A mRNA translation by binding to the 3' untranslated region (3'UTR) of MAT1A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 1.
DME0190	DME___ID	DME0190
DME0190	DME_NAME	S-adenosylmethionine synthase 2 (MAT2A)
DME0190	SPESNAME	Homo sapiens
DME0190	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0190	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0190	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0190	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0190	UNIPROID	HDAC1_HUMAN	CELLLINE	Human hepatocytes
DME0190	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-MAT2A interaction
DME0190	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the MAT2A gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme S-adenosylmethionine synthase 2. As a result, the interaction between HDACs and MAT2A can inhibit the drug-metabolizing process of S-adenosylmethionine synthase 2.
DME0190	MIRNA_ID	MIMAT0004494	PROTNAME	hsa-miR-21-3p
DME0190	MIRNA_ID	MIMAT0004494	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0190	MIRNA_ID	MIMAT0004494	MOFCLASS	Non-coding RNA regulation
DME0190	MIRNA_ID	MIMAT0004494	MOFDETAI	microRNA regulation
DME0190	MIRNA_ID	MIMAT0004494	CELLLINE	HepG2 cell line
DME0190	MIRNA_ID	MIMAT0004494	PPI_SUMM	hsa-miR-21-3p--MAT2A regulation
DME0190	MIRNA_ID	MIMAT0004494	DESCRIPT	hsa-miR-21-3p is reported to suppress MAT2A mRNA translation by binding to the 3' untranslated region (3'UTR) of MAT2A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 2.
DME0190	MIRNA_ID	MIMAT0004766	PROTNAME	hsa-miR-146b-3p
DME0190	MIRNA_ID	MIMAT0004766	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0190	MIRNA_ID	MIMAT0004766	MOFCLASS	Non-coding RNA regulation
DME0190	MIRNA_ID	MIMAT0004766	MOFDETAI	microRNA regulation
DME0190	MIRNA_ID	MIMAT0004766	CELLLINE	MCF-7 and MDA-MB-231 cell lines
DME0190	MIRNA_ID	MIMAT0004766	PPI_SUMM	hsa-miR-146b-3p--MAT2A regulation
DME0190	MIRNA_ID	MIMAT0004766	DESCRIPT	hsa-miR-146b-3p is reported to suppress MAT2A mRNA translation by binding to the 3' untranslated region (3'UTR) of MAT2A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 2.
DME0190	UNIPROID	MYB_HUMAN	PROTNAME	Proto-oncogene c-Myb (MYB)
DME0190	UNIPROID	MYB_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0190	UNIPROID	MYB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0190	UNIPROID	MYB_HUMAN	MOFDETAI	Activation
DME0190	UNIPROID	MYB_HUMAN	CELLLINE	HCC and HepG2 cell lines
DME0190	UNIPROID	MYB_HUMAN	PPI_SUMM	MYB-MAT2A interaction
DME0190	UNIPROID	MYB_HUMAN	DESCRIPT	Proto-oncogene c-Myb (MYB) is reported to activate the transcription of MAT2A gene, which leads to an increased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 2. As a result, the interaction between MYB and MAT2A can activate the drug-metabolizing process of S-adenosylmethionine synthase 2.
DME0190	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0190	UNIPROID	SP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0190	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0190	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0190	UNIPROID	SP1_HUMAN	CELLLINE	HCC and HepG2 cell lines
DME0190	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-MAT2A interaction
DME0190	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of MAT2A gene, which leads to an increased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 2. As a result, the interaction between SP1 and MAT2A can activate the drug-metabolizing process of S-adenosylmethionine synthase 2.
DME0190	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0190	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0190	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0190	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0190	UNIPROID	NFKB1_HUMAN	CELLLINE	HepG2 cell line
DME0190	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-MAT2A interaction
DME0190	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of MAT2A gene, which leads to an increased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 2. As a result, the interaction between NFKB1 and MAT2A can activate the drug-metabolizing process of S-adenosylmethionine synthase 2.
DME0190	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0190	UNIPROID	TF65_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0190	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0190	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0190	UNIPROID	TF65_HUMAN	CELLLINE	HepG2 cell line
DME0190	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-MAT2A interaction
DME0190	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of MAT2A gene, which leads to an increased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 2. As a result, the interaction between RELA and MAT2A can activate the drug-metabolizing process of S-adenosylmethionine synthase 2.
DME0190	UNIPROID	JUN_HUMAN	PROTNAME	Transcription factor AP-1 (JUN)
DME0190	UNIPROID	JUN_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0190	UNIPROID	JUN_HUMAN	MOFCLASS	Transcription-factor regulation
DME0190	UNIPROID	JUN_HUMAN	MOFDETAI	Activation
DME0190	UNIPROID	JUN_HUMAN	CELLLINE	HepG2 cell line
DME0190	UNIPROID	JUN_HUMAN	PPI_SUMM	JUN-MAT2A interaction
DME0190	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to activate the transcription of MAT2A gene, which leads to an increased expression of the drug-metabolizing enzyme S-adenosylmethionine synthase 2. As a result, the interaction between JUN and MAT2A can activate the drug-metabolizing process of S-adenosylmethionine synthase 2.
DME0191	DME___ID	DME0191
DME0191	DME_NAME	Folylpolyglutamate synthase (FPGS)
DME0191	SPESNAME	Homo sapiens
DME0191	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0191	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0191	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0191	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0191	UNIPROID	HDAC1_HUMAN	CELLLINE	T-ALL cell line
DME0191	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-FPGS interaction
DME0191	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the FPGS gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Folylpolyglutamate synthase. As a result, the interaction between HDACs and FPGS can inhibit the drug-metabolizing process of Folylpolyglutamate synthase.
DME0194	DME___ID	DME0194
DME0194	DME_NAME	Choline phosphatase 1 (PLD1)
DME0194	SPESNAME	Homo sapiens
DME0194	MIRNA_ID	MIMAT0003308	PROTNAME	hsa-miR-638
DME0194	MIRNA_ID	MIMAT0003308	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0194	MIRNA_ID	MIMAT0003308	MOFCLASS	Non-coding RNA regulation
DME0194	MIRNA_ID	MIMAT0003308	MOFDETAI	microRNA regulation
DME0194	MIRNA_ID	MIMAT0003308	CELLLINE	MKN-45 and SGC-7901 cell lines
DME0194	MIRNA_ID	MIMAT0003308	PPI_SUMM	hsa-miR-638--PLD1 regulation
DME0194	MIRNA_ID	MIMAT0003308	DESCRIPT	hsa-miR-638 is reported to suppress PLD1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PLD1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Choline phosphatase 1.
DME0194	MIRNA_ID	MIMAT0000259	PROTNAME	hsa-miR-182-5p
DME0194	MIRNA_ID	MIMAT0000259	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0194	MIRNA_ID	MIMAT0000259	MOFCLASS	Non-coding RNA regulation
DME0194	MIRNA_ID	MIMAT0000259	MOFDETAI	microRNA regulation
DME0194	MIRNA_ID	MIMAT0000259	CELLLINE	MCF-7 and BT-474 cell lines
DME0194	MIRNA_ID	MIMAT0000259	PPI_SUMM	hsa-miR-182-5p--PLD1 regulation
DME0194	MIRNA_ID	MIMAT0000259	DESCRIPT	hsa-miR-182-5p is reported to suppress PLD1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PLD1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Choline phosphatase 1.
DME0194	UNIPROID	RALA_HUMAN	PROTNAME	Ras-related Ral-A (RALA)
DME0194	UNIPROID	RALA_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0194	UNIPROID	RALA_HUMAN	MOFCLASS	Oligomerization
DME0194	UNIPROID	RALA_HUMAN	MOFDETAI	Hetero-oligomerization
DME0194	UNIPROID	RALA_HUMAN	CELLLINE	Pansorbin cell line
DME0194	UNIPROID	RALA_HUMAN	PPI_SUMM	RALA-PLD1 heterooligomerization
DME0194	UNIPROID	RALA_HUMAN	DESCRIPT	Ras-related Ral-A (RALA) is reported to heterooligomerize with the PLD1 protein, which leads to activation of the drug-metabolizing enzyme Choline phosphatase 1. As a result, the interaction between RALA and PLD1 can activate the drug-metabolizing process of Choline phosphatase 1.
DME0194	UNIPROID	C42S1_HUMAN	PROTNAME	CDC42 small effector 1 (CDC42SE1)
DME0194	UNIPROID	C42S1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0194	UNIPROID	C42S1_HUMAN	MOFCLASS	Oligomerization
DME0194	UNIPROID	C42S1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0194	UNIPROID	C42S1_HUMAN	CELLLINE	Sf9 insect cell line
DME0194	UNIPROID	C42S1_HUMAN	PPI_SUMM	CDC42SE1-PLD1 heterooligomerization
DME0194	UNIPROID	C42S1_HUMAN	DESCRIPT	CDC42 small effector 1 (CDC42SE1) is reported to heterooligomerize with the PLD1 gene, which leads to activation of the drug-metabolizing enzyme Choline phosphatase 1. As a result, the interaction between CDC42SE1 and PLD1 can activate the drug-metabolizing process of Choline phosphatase 1.
DME0194	UNIPROID	ITF2_HUMAN	PROTNAME	Transcription factor 4 (TCF4)
DME0194	UNIPROID	ITF2_HUMAN	HPPI_DIS	Osteosarcoma [ICD-11: 2B51]
DME0194	UNIPROID	ITF2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0194	UNIPROID	ITF2_HUMAN	MOFDETAI	Activation
DME0194	UNIPROID	ITF2_HUMAN	CELLLINE	HOS cell line
DME0194	UNIPROID	ITF2_HUMAN	PPI_SUMM	TCF4-PLD1 interaction
DME0194	UNIPROID	ITF2_HUMAN	DESCRIPT	Transcription factor 4 (TCF4) is reported to activate the transcription of PLD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Choline phosphatase 1. As a result, the interaction between TCF4 and PLD1 can activate the drug-metabolizing process of Choline phosphatase 1.
DME0194	UNIPROID	ITF2_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0194	UNIPROID	ITF2_HUMAN	CELLLINE	HCT116 and SW480 cell lines
DME0194	UNIPROID	ITF2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0194	UNIPROID	ITF2_HUMAN	CELLLINE	SNU475 and SNU-C5 cell lines
DME0194	UNIPROID	ITF2_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0194	UNIPROID	ITF2_HUMAN	CELLLINE	MDA-MB 231; MDA-MB 361; SK-BR3 cell lines
DME0194	UNIPROID	CTNB1_HUMAN	PROTNAME	Catenin beta-1 (CTNNB1)
DME0194	UNIPROID	CTNB1_HUMAN	HPPI_DIS	Osteosarcoma [ICD-11: 2B51]
DME0194	UNIPROID	CTNB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0194	UNIPROID	CTNB1_HUMAN	MOFDETAI	Activation
DME0194	UNIPROID	CTNB1_HUMAN	CELLLINE	HOS cell line
DME0194	UNIPROID	CTNB1_HUMAN	PPI_SUMM	CTNNB1-PLD1 interaction
DME0194	UNIPROID	CTNB1_HUMAN	DESCRIPT	Catenin beta-1 (CTNNB1) is reported to activate the transcription of PLD1 gene, which leads to an increased expression of the drug-metabolizing enzyme Choline phosphatase 1. As a result, the interaction between CTNNB1 and PLD1 can activate the drug-metabolizing process of Choline phosphatase 1.
DME0194	UNIPROID	CTNB1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0194	UNIPROID	CTNB1_HUMAN	CELLLINE	HCT116 and SW480 cell lines
DME0194	UNIPROID	CTNB1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0194	UNIPROID	CTNB1_HUMAN	CELLLINE	SNU475 and SNU-C5 cell lines
DME0194	UNIPROID	CTNB1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0194	UNIPROID	CTNB1_HUMAN	CELLLINE	MDA-MB 231; MDA-MB 361; SK-BR3 cell lines
DME0195	DME___ID	DME0195
DME0195	DME_NAME	Phosphodiesterase 5A (PDE5A)
DME0195	SPESNAME	Homo sapiens
DME0195	UNIPROID	PO3F2_HUMAN	PROTNAME	Octamer-binding protein 7 (POU3F2)
DME0195	UNIPROID	PO3F2_HUMAN	HPPI_DIS	Melanoma [ICD-11: 2C30]
DME0195	UNIPROID	PO3F2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0195	UNIPROID	PO3F2_HUMAN	MOFDETAI	Repression
DME0195	UNIPROID	PO3F2_HUMAN	CELLLINE	WM266.4, A375P, A375M2, Skeml28, Skmel24, Colo829, Skeml5, Skmel13, MEL-HO, 501mel and 4599 cell lines
DME0195	UNIPROID	PO3F2_HUMAN	PPI_SUMM	POU3F2-PDE5A interaction
DME0195	UNIPROID	PO3F2_HUMAN	DESCRIPT	Octamer-binding protein 7 (POU3F2) is reported to repress the transcription of PDE5A gene, which leads to a decreased expression of the drug-metabolizing enzyme Phosphodiesterase 5A. As a result, the interaction between POU3F2 and PDE5A can repress the drug-metabolizing process of Phosphodiesterase 5A.
DME0201	DME___ID	DME0201
DME0201	DME_NAME	Arachidonate 5-lipoxygenase (ALOX5)
DME0201	SPESNAME	Homo sapiens
DME0201	UNIPROID	HDAC2_HUMAN	PROTNAME	Histone deacetylase 2 (HDAC2)
DME0201	UNIPROID	HDAC2_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0201	UNIPROID	HDAC2_HUMAN	MOFCLASS	Histone modification
DME0201	UNIPROID	HDAC2_HUMAN	MOFDETAI	Histone hypoacetylation
DME0201	UNIPROID	HDAC2_HUMAN	CELLLINE	HL-60, U937 and Mono Mac6 cell lines
DME0201	UNIPROID	HDAC2_HUMAN	PPI_SUMM	HDAC2-ALOX5 interaction
DME0201	UNIPROID	HDAC2_HUMAN	DESCRIPT	Histone deacetylase 2 (HDAC2) is reported to deacetylate the ALOX5 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Arachidonate 5-lipoxygenase. As a result, the interaction between HDAC2 and ALOX5 can inhibit the drug-metabolizing process of Arachidonate 5-lipoxygenase.
DME0201	UNIPROID	HDAC3_HUMAN	PROTNAME	Histone deacetylase 3 (HDAC3)
DME0201	UNIPROID	HDAC3_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0201	UNIPROID	HDAC3_HUMAN	MOFCLASS	Histone modification
DME0201	UNIPROID	HDAC3_HUMAN	MOFDETAI	Histone hypoacetylation
DME0201	UNIPROID	HDAC3_HUMAN	CELLLINE	HL-60, U937 and Mono Mac6 cell lines
DME0201	UNIPROID	HDAC3_HUMAN	PPI_SUMM	HDAC3-ALOX5 interaction
DME0201	UNIPROID	HDAC3_HUMAN	DESCRIPT	Histone deacetylase 3 (HDAC3) is reported to deacetylate the ALOX5 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Arachidonate 5-lipoxygenase. As a result, the interaction between HDAC3 and ALOX5 can inhibit the drug-metabolizing process of Arachidonate 5-lipoxygenase.
DME0201	MIRNA_ID	MIMAT0000423	PROTNAME	hsa-miR-125b-5p
DME0201	MIRNA_ID	MIMAT0000423	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0201	MIRNA_ID	MIMAT0000423	MOFCLASS	Non-coding RNA regulation
DME0201	MIRNA_ID	MIMAT0000423	MOFDETAI	microRNA regulation
DME0201	MIRNA_ID	MIMAT0000423	CELLLINE	Mono Mac 6 cell line
DME0201	MIRNA_ID	MIMAT0000423	PPI_SUMM	hsa-miR-125b-5p--ALOX5 regulation
DME0201	MIRNA_ID	MIMAT0000423	DESCRIPT	hsa-miR-125b-5p is reported to suppress ALOX5 mRNA translation by binding to the 3' untranslated region (3'UTR) of ALOX5 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Arachidonate 5-lipoxygenase.
DME0201	MIRNA_ID	MIMAT0000073	PROTNAME	hsa-miR-19a-3p
DME0201	MIRNA_ID	MIMAT0000073	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0201	MIRNA_ID	MIMAT0000073	MOFCLASS	Non-coding RNA regulation
DME0201	MIRNA_ID	MIMAT0000073	MOFDETAI	microRNA regulation
DME0201	MIRNA_ID	MIMAT0000073	CELLLINE	Mono Mac 6 cell line
DME0201	MIRNA_ID	MIMAT0000073	PPI_SUMM	hsa-miR-19a-3p--ALOX5 regulation
DME0201	MIRNA_ID	MIMAT0000073	DESCRIPT	hsa-miR-19a-3p is reported to suppress ALOX5 mRNA translation by binding to the 3' untranslated region (3'UTR) of ALOX5 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Arachidonate 5-lipoxygenase.
DME0201	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0201	UNIPROID	SP1_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0201	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0201	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0201	UNIPROID	SP1_HUMAN	CELLLINE	MM6, HL-60 and U937 cell lines
DME0201	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-ALOX5 interaction
DME0201	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of ALOX5 gene, which leads to an increased expression of the drug-metabolizing enzyme Arachidonate 5-lipoxygenase. As a result, the interaction between SP1 and ALOX5 can activate the drug-metabolizing process of Arachidonate 5-lipoxygenase.
DME0201	UNIPROID	MBD1_HUMAN	PROTNAME	Methyl-CpG-binding MBD1 (MBD1)
DME0201	UNIPROID	MBD1_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0201	UNIPROID	MBD1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0201	UNIPROID	MBD1_HUMAN	MOFDETAI	Repression
DME0201	UNIPROID	MBD1_HUMAN	CELLLINE	HL-60, U937 and Mono Mac6 cell lines
DME0201	UNIPROID	MBD1_HUMAN	PPI_SUMM	MBD1-ALOX5 interaction
DME0201	UNIPROID	MBD1_HUMAN	DESCRIPT	Methyl-CpG-binding MBD1 (MBD1) is reported to repress the transcription of ALOX5 gene, which leads to a decreased expression of the drug-metabolizing enzyme Arachidonate 5-lipoxygenase. As a result, the interaction between MBD1 and ALOX5 can repress the drug-metabolizing process of Arachidonate 5-lipoxygenase.
DME0201	UNIPROID	EGR1_HUMAN	PROTNAME	Early growth response 1 (EGR1)
DME0201	UNIPROID	EGR1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0201	UNIPROID	EGR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0201	UNIPROID	EGR1_HUMAN	MOFDETAI	Activation
DME0201	UNIPROID	EGR1_HUMAN	CELLLINE	HeLa cell line
DME0201	UNIPROID	EGR1_HUMAN	PPI_SUMM	EGR1-ALOX5 interaction
DME0201	UNIPROID	EGR1_HUMAN	DESCRIPT	Early growth response 1 (EGR1) is reported to activate the transcription of ALOX5 gene, which leads to an increased expression of the drug-metabolizing enzyme Arachidonate 5-lipoxygenase. As a result, the interaction between EGR1 and ALOX5 can activate the drug-metabolizing process of Arachidonate 5-lipoxygenase.
DME0203	DME___ID	DME0203
DME0203	DME_NAME	Fatty acid desaturase 2 (FADS2)
DME0203	SPESNAME	Homo sapiens
DME0203	UNIPROID	HAT1_HUMAN	PROTNAME	Histone acetyltransferases (HATs)
DME0203	UNIPROID	HAT1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0203	UNIPROID	HAT1_HUMAN	MOFCLASS	Histone modification
DME0203	UNIPROID	HAT1_HUMAN	MOFDETAI	Histone hyperacetylation
DME0203	UNIPROID	HAT1_HUMAN	CELLLINE	HCC cell line
DME0203	UNIPROID	HAT1_HUMAN	PPI_SUMM	HATs-FADS2 interaction
DME0203	UNIPROID	HAT1_HUMAN	DESCRIPT	Histone acetyltransferases (HATs) are reported to acetylate the FADS2 gene and thereby activate the transcriptional activity of the drug-metabolizing enzyme Fatty acid desaturase 2. As a result, the interaction between HATs and FADS2 can enhance the drug-metabolizing process of Fatty acid desaturase 2.
DME0206	DME___ID	DME0206
DME0206	DME_NAME	Sodium/potassium-transporting ATPase gamma (FXYD2)
DME0206	SPESNAME	Homo sapiens
DME0206	UNIPROID	PHS_HUMAN	PROTNAME	Dimerization cofactor of HNF1 (PCBD1)
DME0206	UNIPROID	PHS_HUMAN	HPPI_DIS	Hyperphenylalaninemia [ICD-11: 5C50]
DME0206	UNIPROID	PHS_HUMAN	MOFCLASS	Transcription-factor regulation
DME0206	UNIPROID	PHS_HUMAN	MOFDETAI	Repression
DME0206	UNIPROID	PHS_HUMAN	CELLLINE	HEK293 cell line
DME0206	UNIPROID	PHS_HUMAN	PPI_SUMM	PCBD1-FXYD2 interaction
DME0206	UNIPROID	PHS_HUMAN	DESCRIPT	Dimerization cofactor of HNF1 (PCBD1) is reported to repress the transcription of FXYD2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Sodium/potassium-transporting ATPase gamma. As a result, the interaction between PCBD1 and FXYD2 can repress the drug-metabolizing process of Sodium/potassium-transporting ATPase gamma.
DME0206	UNIPROID	PHS_HUMAN	HPPI_DIS	Primapterinuria [ICD-11: 5C59]
DME0207	DME___ID	DME0207
DME0207	DME_NAME	Proline dehydrogenase 1 (PRODH)
DME0207	SPESNAME	Homo sapiens
DME0207	MIRNA_ID	MIMAT0004587	PROTNAME	hsa-miR-23b-5p
DME0207	MIRNA_ID	MIMAT0004587	HPPI_DIS	Renal cell carcinoma [ICD-11: 2C90]
DME0207	MIRNA_ID	MIMAT0004587	MOFCLASS	Non-coding RNA regulation
DME0207	MIRNA_ID	MIMAT0004587	MOFDETAI	microRNA regulation
DME0207	MIRNA_ID	MIMAT0004587	CELLLINE	786-0, TK10 and UO31 cell lines
DME0207	MIRNA_ID	MIMAT0004587	PPI_SUMM	hsa-miR-23b-5p--PRODH regulation
DME0207	MIRNA_ID	MIMAT0004587	DESCRIPT	hsa-miR-23b-5p is reported to suppress PRODH mRNA translation by binding to the 3' untranslated region (3'UTR) of PRODH mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Proline dehydrogenase 1.
DME0207	UNIPROID	MYC_HUMAN	PROTNAME	Proto-oncogene c-Myc (MYC)
DME0207	UNIPROID	MYC_HUMAN	HPPI_DIS	Burkitt lymphoma [ICD-11: 1C62]
DME0207	UNIPROID	MYC_HUMAN	MOFCLASS	Transcription-factor regulation
DME0207	UNIPROID	MYC_HUMAN	MOFDETAI	Repression
DME0207	UNIPROID	MYC_HUMAN	CELLLINE	P493 cell line
DME0207	UNIPROID	MYC_HUMAN	PPI_SUMM	MYC-PRODH interaction
DME0207	UNIPROID	MYC_HUMAN	DESCRIPT	Proto-oncogene c-Myc (MYC) is reported to repress the transcription of PRODH gene, which leads to a decreased expression of the drug-metabolizing enzyme Proline dehydrogenase 1. As a result, the interaction between MYC and PRODH can repress the drug-metabolizing process of Proline dehydrogenase 1.
DME0207	UNIPROID	MYC_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0207	UNIPROID	MYC_HUMAN	CELLLINE	PC3 cell line
DME0208	DME___ID	DME0208
DME0208	DME_NAME	Oleamide hydrolase 1 (FAAH)
DME0208	SPESNAME	Homo sapiens
DME0208	UNIPROID	STAT3_HUMAN	PROTNAME	STAT 3 (STAT3)
DME0208	UNIPROID	STAT3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0208	UNIPROID	STAT3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0208	UNIPROID	STAT3_HUMAN	MOFDETAI	Activation
DME0208	UNIPROID	STAT3_HUMAN	CELLLINE	Human T lymphocytes
DME0208	UNIPROID	STAT3_HUMAN	PPI_SUMM	STAT3-FAAH interaction
DME0208	UNIPROID	STAT3_HUMAN	DESCRIPT	STAT 3 (STAT3) is reported to activate the transcription of FAAH gene, which leads to an increased expression of the drug-metabolizing enzyme Oleamide hydrolase 1. As a result, the interaction between STAT3 and FAAH can activate the drug-metabolizing process of Oleamide hydrolase 1.
DME0212	DME___ID	DME0212
DME0212	DME_NAME	Acetyl-CoA synthetase (ACSS2)
DME0212	SPESNAME	Homo sapiens
DME0212	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0212	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Human immunodeficiency virus infection [ICD-11: 1C60]
DME0212	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0212	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0212	UNIPROID	EHMT1_HUMAN	CELLLINE	Human CD4+ T cells
DME0212	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-ACSS2 interaction
DME0212	UNIPROID	EHMT1_HUMAN	DESCRIPT	Histone methyltransferases (HMTs) are reported to hyper-methylate the ACSS2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Acetyl-CoA synthetase. As a result, the interaction between HMTs and ACSS2 can inhibit the drug-metabolizing process of Acetyl-CoA synthetase.
DME0212	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0212	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Human immunodeficiency virus infection [ICD-11: 1C60]
DME0212	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0212	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0212	UNIPROID	HDAC1_HUMAN	CELLLINE	Human CD4+ T cells
DME0212	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-ACSS2 interaction
DME0212	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the ACSS2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Acetyl-CoA synthetase. As a result, the interaction between HDACs and ACSS2 can inhibit the drug-metabolizing process of Acetyl-CoA synthetase.
DME0214	DME___ID	DME0214
DME0214	DME_NAME	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DME0214	SPESNAME	Homo sapiens
DME0214	MIRNA_ID	MI0005544	PROTNAME	hsa-miR-147b
DME0214	MIRNA_ID	MI0005544	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0214	MIRNA_ID	MI0005544	MOFCLASS	Non-coding RNA regulation
DME0214	MIRNA_ID	MI0005544	MOFDETAI	microRNA regulation
DME0214	MIRNA_ID	MI0005544	CELLLINE	A549 cell line
DME0214	MIRNA_ID	MI0005544	PPI_SUMM	hsa-miR-147b--ALDH5A1 regulation
DME0214	MIRNA_ID	MI0005544	DESCRIPT	hsa-miR-147b is reported to suppress ALDH5A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of ALDH5A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Succinate-semialdehyde dehydrogenase.
DME0214	MIRNA_ID	MIMAT0000267	PROTNAME	hsa-miR-210-3p
DME0214	MIRNA_ID	MIMAT0000267	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0214	MIRNA_ID	MIMAT0000267	MOFCLASS	Non-coding RNA regulation
DME0214	MIRNA_ID	MIMAT0000267	MOFDETAI	microRNA regulation
DME0214	MIRNA_ID	MIMAT0000267	CELLLINE	A549 cell line
DME0214	MIRNA_ID	MIMAT0000267	PPI_SUMM	hsa-miR-210-3p--ALDH5A1 regulation
DME0214	MIRNA_ID	MIMAT0000267	DESCRIPT	hsa-miR-210-3p is reported to suppress ALDH5A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of ALDH5A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Succinate-semialdehyde dehydrogenase.
DME0214	MIRNA_ID	MIMAT0000086	PROTNAME	hsa-miR-29a-3p
DME0214	MIRNA_ID	MIMAT0000086	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0214	MIRNA_ID	MIMAT0000086	MOFCLASS	Non-coding RNA regulation
DME0214	MIRNA_ID	MIMAT0000086	MOFDETAI	microRNA regulation
DME0214	MIRNA_ID	MIMAT0000086	CELLLINE	HepaRG cell line
DME0214	MIRNA_ID	MIMAT0000086	PPI_SUMM	hsa-miR-29a-3p--ALDH5A1 regulation
DME0214	MIRNA_ID	MIMAT0000086	DESCRIPT	hsa-miR-29a-3p is reported to suppress ALDH5A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of ALDH5A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Succinate-semialdehyde dehydrogenase.
DME0216	DME___ID	DME0216
DME0216	DME_NAME	Putrescine acetyltransferase (SSAT1)
DME0216	SPESNAME	Homo sapiens
DME0216	UNIPROID	PPARD_HUMAN	PROTNAME	PPA receptor delta (PPARD)
DME0216	UNIPROID	PPARD_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0216	UNIPROID	PPARD_HUMAN	MOFCLASS	Transcription-factor regulation
DME0216	UNIPROID	PPARD_HUMAN	MOFDETAI	Activation
DME0216	UNIPROID	PPARD_HUMAN	CELLLINE	Caco-2 cell line
DME0216	UNIPROID	PPARD_HUMAN	PPI_SUMM	PPARD-SAT1 interaction
DME0216	UNIPROID	PPARD_HUMAN	DESCRIPT	PPA receptor delta (PPARD) is reported to activate the transcription of SSAT1 gene, which leads to an increased expression of the drug-metabolizing enzyme Putrescine acetyltransferase. As a result, the interaction between PPARD and SSAT1 can activate the drug-metabolizing process of Putrescine acetyltransferase.
DME0216	UNIPROID	PPARG_HUMAN	PROTNAME	PPA receptor gamma (PPARG)
DME0216	UNIPROID	PPARG_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0216	UNIPROID	PPARG_HUMAN	MOFCLASS	Transcription-factor regulation
DME0216	UNIPROID	PPARG_HUMAN	MOFDETAI	Activation
DME0216	UNIPROID	PPARG_HUMAN	CELLLINE	Caco-2 cell line
DME0216	UNIPROID	PPARG_HUMAN	PPI_SUMM	PPARG-SAT1 interaction
DME0216	UNIPROID	PPARG_HUMAN	DESCRIPT	PPA receptor gamma (PPARG) is reported to activate the transcription of SSAT1 gene, which leads to an increased expression of the drug-metabolizing enzyme Putrescine acetyltransferase. As a result, the interaction between PPARG and SSAT1 can activate the drug-metabolizing process of Putrescine acetyltransferase.
DME0221	DME___ID	DME0221
DME0221	DME_NAME	Dihydrotestosterone oxidoreductase (HSD3B1)
DME0221	SPESNAME	Homo sapiens
DME0221	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0221	UNIPROID	SP1_HUMAN	HPPI_DIS	Choriocarcinoma [ICD-11: 2C75]
DME0221	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0221	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0221	UNIPROID	SP1_HUMAN	CELLLINE	Human choriocarcinoma JEG-3 cell line
DME0221	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-HSD3B1 interaction
DME0221	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of HSD3B1 gene, which leads to an increased expression of the drug-metabolizing enzyme Dihydrotestosterone oxidoreductase. As a result, the interaction between SP1 and HSD3B1 can activate the drug-metabolizing process of Dihydrotestosterone oxidoreductase.
DME0221	UNIPROID	SP1_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0221	UNIPROID	SP1_HUMAN	CELLLINE	Adrenal cortex adenocarcinoma SW13 cell line
DME0222	DME___ID	DME0222
DME0222	DME_NAME	Beta-HSD adrenal and gonadal type (HSD3B2)
DME0222	SPESNAME	Homo sapiens
DME0222	UNIPROID	NR5A2_HUMAN	PROTNAME	Nuclear receptor family 5 A2 (NR5A2)
DME0222	UNIPROID	NR5A2_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0222	UNIPROID	NR5A2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0222	UNIPROID	NR5A2_HUMAN	MOFDETAI	Activation
DME0222	UNIPROID	NR5A2_HUMAN	CELLLINE	HEC-1A cell line
DME0222	UNIPROID	NR5A2_HUMAN	PPI_SUMM	NR5A2-HSD3B2 interaction
DME0222	UNIPROID	NR5A2_HUMAN	DESCRIPT	Nuclear receptor family 5 A2 (NR5A2) is reported to activate the transcription of HSD3B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Beta-HSD adrenal and gonadal type. As a result, the interaction between NR5A2 and HSD3B2 can activate the drug-metabolizing process of Beta-HSD adrenal and gonadal type.
DME0222	UNIPROID	NR5A2_HUMAN	HPPI_DIS	Endometrial cancer [ICD-11: 2C76]
DME0222	UNIPROID	NR5A2_HUMAN	CELLLINE	Ishikawa cell line
DME0222	UNIPROID	TYY1_HUMAN	PROTNAME	Transcriptional repressor YY1 (YY1)
DME0222	UNIPROID	TYY1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0222	UNIPROID	TYY1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0222	UNIPROID	TYY1_HUMAN	MOFDETAI	Activation
DME0222	UNIPROID	TYY1_HUMAN	CELLLINE	LNCap cell line
DME0222	UNIPROID	TYY1_HUMAN	PPI_SUMM	YY1-HSD3B2 interaction
DME0222	UNIPROID	TYY1_HUMAN	DESCRIPT	Transcriptional repressor YY1 (YY1) is reported to activate the transcription of HSD3B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Beta-HSD adrenal and gonadal type. As a result, the interaction between YY1 and HSD3B2 can activate the drug-metabolizing process of Beta-HSD adrenal and gonadal type.
DME0222	UNIPROID	TYY1_HUMAN	HPPI_DIS	Adrenocortical carcinoma [ICD-11: 2D11]
DME0222	UNIPROID	TYY1_HUMAN	CELLLINE	SW-13 cell line
DME0222	UNIPROID	STF1_HUMAN	PROTNAME	Steroidogenic factor 1 (NR5A1)
DME0222	UNIPROID	STF1_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0222	UNIPROID	STF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0222	UNIPROID	STF1_HUMAN	MOFDETAI	Activation
DME0222	UNIPROID	STF1_HUMAN	CELLLINE	HEC-1A cell line
DME0222	UNIPROID	STF1_HUMAN	PPI_SUMM	NR5A1-HSD3B2 interaction
DME0222	UNIPROID	STF1_HUMAN	DESCRIPT	Steroidogenic factor 1 (NR5A1) is reported to activate the transcription of HSD3B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Beta-HSD adrenal and gonadal type. As a result, the interaction between NR5A1 and HSD3B2 can activate the drug-metabolizing process of Beta-HSD adrenal and gonadal type.
DME0222	UNIPROID	STF1_HUMAN	HPPI_DIS	Endometrial cancer [ICD-11: 2C76]
DME0222	UNIPROID	STF1_HUMAN	CELLLINE	Ishikawa cell line
DME0222	UNIPROID	NR4A1_HUMAN	PROTNAME	Nuclear receptor family 4 A1 (NR4A1)
DME0222	UNIPROID	NR4A1_HUMAN	HPPI_DIS	Pituitary adenoma [ICD-11: 2F37]
DME0222	UNIPROID	NR4A1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0222	UNIPROID	NR4A1_HUMAN	MOFDETAI	Activation
DME0222	UNIPROID	NR4A1_HUMAN	CELLLINE	H295R adrenocortical cell line
DME0222	UNIPROID	NR4A1_HUMAN	PPI_SUMM	NR4A1-HSD3B2 interaction
DME0222	UNIPROID	NR4A1_HUMAN	DESCRIPT	Nuclear receptor family 4 A1 (NR4A1) is reported to activate the transcription of HSD3B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Beta-HSD adrenal and gonadal type. As a result, the interaction between NR4A1 and HSD3B2 can activate the drug-metabolizing process of Beta-HSD adrenal and gonadal type.
DME0223	DME___ID	DME0223
DME0223	DME_NAME	Hypoxanthine phosphoribosyltransferase (HPRT1)
DME0223	SPESNAME	Homo sapiens
DME0223	UNIPROID	A16A1_HUMAN	PROTNAME	Aldehyde dehydrogenase 16A1 (ALDH16A1)
DME0223	UNIPROID	A16A1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0223	UNIPROID	A16A1_HUMAN	MOFCLASS	Oligomerization
DME0223	UNIPROID	A16A1_HUMAN	MOFDETAI	Hetero-oligomerization
DME0223	UNIPROID	A16A1_HUMAN	CELLLINE	SH-SY5Y cell line
DME0223	UNIPROID	A16A1_HUMAN	PPI_SUMM	ALDH16A1-HPRT1 heterooligomerization
DME0223	UNIPROID	A16A1_HUMAN	DESCRIPT	Aldehyde dehydrogenase 16A1 (ALDH16A1) is reported to heterooligomerize with the HPRT1 protein, which leads to an increased activity of the drug-metabolizing enzyme Hypoxanthine phosphoribosyltransferase. As a result, the interaction between ALDH16A1 and HPRT1 can facilitate the drug-metabolizing process of Hypoxanthine phosphoribosyltransferase.
DME0223	UNIPROID	A16A1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0223	UNIPROID	A16A1_HUMAN	CELLLINE	HepG2 cell line
DME0223	UNIPROID	A16A1_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0223	UNIPROID	A16A1_HUMAN	CELLLINE	A549 cell line
DME0224	DME___ID	DME0224
DME0224	DME_NAME	HMG-CoA reductase (HMGCR)
DME0224	SPESNAME	Homo sapiens
DME0224	MIRNA_ID	MIMAT0000084	PROTNAME	hsa-miR-27a-3p
DME0224	MIRNA_ID	MIMAT0000084	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0224	MIRNA_ID	MIMAT0000084	MOFCLASS	Non-coding RNA regulation
DME0224	MIRNA_ID	MIMAT0000084	MOFDETAI	microRNA regulation
DME0224	MIRNA_ID	MIMAT0000084	CELLLINE	Huh7 cell line
DME0224	MIRNA_ID	MIMAT0000084	PPI_SUMM	hsa-miR-27a-3p--HMGCR regulation
DME0224	MIRNA_ID	MIMAT0000084	DESCRIPT	hsa-miR-27a-3p is reported to suppress HMGCR mRNA translation by binding to the 3' untranslated region (3'UTR) of HMGCR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme HMG-CoA reductase.
DME0224	MIRNA_ID	MIMAT0000086	PROTNAME	hsa-miR-29a-3p
DME0224	MIRNA_ID	MIMAT0000086	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0224	MIRNA_ID	MIMAT0000086	MOFCLASS	Non-coding RNA regulation
DME0224	MIRNA_ID	MIMAT0000086	MOFDETAI	microRNA regulation
DME0224	MIRNA_ID	MIMAT0000086	CELLLINE	HepG2 cell line
DME0224	MIRNA_ID	MIMAT0000086	PPI_SUMM	hsa-miR-29a-3p--HMGCR regulation
DME0224	MIRNA_ID	MIMAT0000086	DESCRIPT	hsa-miR-29a-3p is reported to suppress HMGCR mRNA translation by binding to the 3' untranslated region (3'UTR) of HMGCR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme HMG-CoA reductase.
DME0224	MIRNA_ID	MIMAT0000100	PROTNAME	hsa-miR-29b-3p
DME0224	MIRNA_ID	MIMAT0000100	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0224	MIRNA_ID	MIMAT0000100	MOFCLASS	Non-coding RNA regulation
DME0224	MIRNA_ID	MIMAT0000100	MOFDETAI	microRNA regulation
DME0224	MIRNA_ID	MIMAT0000100	CELLLINE	HepG2 cell line
DME0224	MIRNA_ID	MIMAT0000100	PPI_SUMM	hsa-miR-29b-3p--HMGCR regulation
DME0224	MIRNA_ID	MIMAT0000100	DESCRIPT	hsa-miR-29b-3p is reported to suppress HMGCR mRNA translation by binding to the 3' untranslated region (3'UTR) of HMGCR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme HMG-CoA reductase.
DME0224	MIRNA_ID	MIMAT0000681	PROTNAME	hsa-miR-29c-3p
DME0224	MIRNA_ID	MIMAT0000681	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0224	MIRNA_ID	MIMAT0000681	MOFCLASS	Non-coding RNA regulation
DME0224	MIRNA_ID	MIMAT0000681	MOFDETAI	microRNA regulation
DME0224	MIRNA_ID	MIMAT0000681	CELLLINE	HepG2 cell line
DME0224	MIRNA_ID	MIMAT0000681	PPI_SUMM	hsa-miR-29c-3p--HMGCR regulation
DME0224	MIRNA_ID	MIMAT0000681	DESCRIPT	hsa-miR-29c-3p is reported to suppress HMGCR mRNA translation by binding to the 3' untranslated region (3'UTR) of HMGCR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme HMG-CoA reductase.
DME0224	UNIPROID	SRBP2_HUMAN	PROTNAME	Sterol element-binding 2 (SREBF2)
DME0224	UNIPROID	SRBP2_HUMAN	HPPI_DIS	Gallstone disease [ICD-11: DC11]
DME0224	UNIPROID	SRBP2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0224	UNIPROID	SRBP2_HUMAN	MOFDETAI	Activation
DME0224	UNIPROID	SRBP2_HUMAN	CELLLINE	Gallstone disease liver tissue
DME0224	UNIPROID	SRBP2_HUMAN	PPI_SUMM	SREBF2-HMGCR interaction
DME0224	UNIPROID	SRBP2_HUMAN	DESCRIPT	Sterol element-binding 2 (SREBF2) is reported to activate the transcription of HMGCR gene, which leads to an increased expression of the drug-metabolizing enzyme HMG-CoA reductase. As a result, the interaction between SREBF2 and HMGCR can activate the drug-metabolizing process of HMG-CoA reductase.
DME0225	DME___ID	DME0225
DME0225	DME_NAME	Cytosolic phospholipase A2 (PLA2G4A)
DME0225	SPESNAME	Homo sapiens
DME0225	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0225	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0225	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0225	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0225	UNIPROID	HDAC1_HUMAN	CELLLINE	Human neuroblastoma cells SH-SY5Y
DME0225	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-PLA2G4A interaction
DME0225	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the PLA2G4A gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cytosolic phospholipase A2. As a result, the interaction between HDACs and PLA2G4A can inhibit the drug-metabolizing process of Cytosolic phospholipase A2.
DME0227	DME___ID	DME0227
DME0227	DME_NAME	Retinoic acid 4-hydroxylase 26A1 (CYP26A1)
DME0227	SPESNAME	Homo sapiens
DME0227	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylase 1 (HDAC1)
DME0227	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0227	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0227	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0227	UNIPROID	HDAC1_HUMAN	CELLLINE	Embryonic stem cell
DME0227	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDAC1-CYP26A1 interaction
DME0227	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylase 1 (HDAC1) is reported to deacetylate the CYP26A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between HDAC1 and CYP26A1 can inhibit the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1.
DME0227	UNIPROID	HDAC2_HUMAN	PROTNAME	Histone deacetylase 2 (HDAC2)
DME0227	UNIPROID	HDAC2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0227	UNIPROID	HDAC2_HUMAN	MOFCLASS	Histone modification
DME0227	UNIPROID	HDAC2_HUMAN	MOFDETAI	Histone hypoacetylation
DME0227	UNIPROID	HDAC2_HUMAN	CELLLINE	Embryonic stem cell
DME0227	UNIPROID	HDAC2_HUMAN	PPI_SUMM	HDAC2-CYP26A1 interaction
DME0227	UNIPROID	HDAC2_HUMAN	DESCRIPT	Histone deacetylase 2 (HDAC2) is reported to deacetylate the CYP26A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between HDAC2 and CYP26A1 can inhibit the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1.
DME0227	UNIPROID	HDAC3_HUMAN	PROTNAME	Histone deacetylase 3 (HDAC3)
DME0227	UNIPROID	HDAC3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0227	UNIPROID	HDAC3_HUMAN	MOFCLASS	Histone modification
DME0227	UNIPROID	HDAC3_HUMAN	MOFDETAI	Histone hypoacetylation
DME0227	UNIPROID	HDAC3_HUMAN	CELLLINE	Embryonic stem cell
DME0227	UNIPROID	HDAC3_HUMAN	PPI_SUMM	HDAC3-CYP26A1 interaction
DME0227	UNIPROID	HDAC3_HUMAN	DESCRIPT	Histone deacetylase 3 (HDAC3) is reported to deacetylate the CYP26A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between HDAC3 and CYP26A1 can inhibit the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1.
DME0230	DME___ID	DME0230
DME0230	DME_NAME	Tartrate-resistant acid ATPase (ACP5)
DME0230	SPESNAME	Homo sapiens
DME0230	UNIPROID	MITF_HUMAN	PROTNAME	Microphthalmia-associated TF (MITF)
DME0230	UNIPROID	MITF_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0230	UNIPROID	MITF_HUMAN	MOFCLASS	Transcription-factor regulation
DME0230	UNIPROID	MITF_HUMAN	MOFDETAI	Activation
DME0230	UNIPROID	MITF_HUMAN	CELLLINE	NIH 3T3 and COS-7 cell lines
DME0230	UNIPROID	MITF_HUMAN	PPI_SUMM	MITF-ACP5 interaction
DME0230	UNIPROID	MITF_HUMAN	DESCRIPT	Microphthalmia-associated TF (MITF) is reported to activate the transcription of ACP5 gene, which leads to an increased expression of the drug-metabolizing enzyme Tartrate-resistant acid ATPase. As a result, the interaction between MITF and ACP5 can activate the drug-metabolizing process of Tartrate-resistant acid ATPase.
DME0230	UNIPROID	SPI1_HUMAN	PROTNAME	TF factor PU.1 (SPI1)
DME0230	UNIPROID	SPI1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0230	UNIPROID	SPI1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0230	UNIPROID	SPI1_HUMAN	MOFDETAI	Activation
DME0230	UNIPROID	SPI1_HUMAN	CELLLINE	NIH 3T3 cell line
DME0230	UNIPROID	SPI1_HUMAN	PPI_SUMM	SPI1-ACP5 interaction
DME0230	UNIPROID	SPI1_HUMAN	DESCRIPT	TF factor PU.1 (SPI1) is reported to activate the transcription of ACP5 gene, which leads to an increased expression of the drug-metabolizing enzyme Tartrate-resistant acid ATPase. As a result, the interaction between SPI1 and ACP5 can activate the drug-metabolizing process of Tartrate-resistant acid ATPase.
DME0233	DME___ID	DME0233
DME0233	DME_NAME	Aldo-keto reductase 1C2 (AKR1C2)
DME0233	SPESNAME	Homo sapiens
DME0233	MIRNA_ID	MIMAT0002819	PROTNAME	hsa-miR-193b-3p
DME0233	MIRNA_ID	MIMAT0002819	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0233	MIRNA_ID	MIMAT0002819	MOFCLASS	Non-coding RNA regulation
DME0233	MIRNA_ID	MIMAT0002819	MOFDETAI	microRNA regulation
DME0233	MIRNA_ID	MIMAT0002819	CELLLINE	MCF-7 cell line
DME0233	MIRNA_ID	MIMAT0002819	PPI_SUMM	hsa-miR-193b-3p--AKR1C2 regulation
DME0233	MIRNA_ID	MIMAT0002819	DESCRIPT	hsa-miR-193b-3p is reported to suppress AKR1C2 mRNA translation by binding to the 3' untranslated region (3'UTR) of AKR1C2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aldo-keto reductase 1C2.
DME0233	UNIPROID	TWST1_HUMAN	PROTNAME	Twist-related 1 (TWIST1)
DME0233	UNIPROID	TWST1_HUMAN	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0233	UNIPROID	TWST1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0233	UNIPROID	TWST1_HUMAN	MOFDETAI	Activation
DME0233	UNIPROID	TWST1_HUMAN	CELLLINE	SGC-7901, HGC-27, MGC-803 and BGC-823 cell lines
DME0233	UNIPROID	TWST1_HUMAN	PPI_SUMM	TWIST1-AKR1C2 interaction
DME0233	UNIPROID	TWST1_HUMAN	DESCRIPT	Twist-related 1 (TWIST1) is reported to activate the transcription of AKR1C2 gene, which leads to an increased expression of the drug-metabolizing enzyme Aldo-keto reductase 1C2. As a result, the interaction between TWIST1 and AKR1C2 can activate the drug-metabolizing process of Aldo-keto reductase 1C2.
DME0233	UNIPROID	TWST2_HUMAN	PROTNAME	Twist-related 2 (TWIST2)
DME0233	UNIPROID	TWST2_HUMAN	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0233	UNIPROID	TWST2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0233	UNIPROID	TWST2_HUMAN	MOFDETAI	Activation
DME0233	UNIPROID	TWST2_HUMAN	CELLLINE	SGC-7901, HGC-27, MGC-803 and BGC-823 cell lines
DME0233	UNIPROID	TWST2_HUMAN	PPI_SUMM	TWIST2-AKR1C2 interaction
DME0233	UNIPROID	TWST2_HUMAN	DESCRIPT	Twist-related 2 (TWIST2) is reported to activate the transcription of AKR1C2 gene, which leads to an increased expression of the drug-metabolizing enzyme Aldo-keto reductase 1C2. As a result, the interaction between TWIST2 and AKR1C2 can activate the drug-metabolizing process of Aldo-keto reductase 1C2.
DME0246	DME___ID	DME0246
DME0246	DME_NAME	Lactoperoxidase (LPO)
DME0246	SPESNAME	Homo sapiens
DME0246	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0246	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0246	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0246	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0246	UNIPROID	HDAC1_HUMAN	CELLLINE	MCF-7 cell line
DME0246	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-LPO interaction
DME0246	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the LPO gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Lactoperoxidase. As a result, the interaction between HDACs and LPO can inhibit the drug-metabolizing process of Lactoperoxidase.
DME0286	DME___ID	DME0286
DME0286	DME_NAME	Aldehyde dehydrogenase 1 (ALDH1)
DME0286	SPESNAME	Homo sapiens
DME0286	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0286	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0286	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0286	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0286	UNIPROID	HDAC1_HUMAN	CELLLINE	HEK293 cell line
DME0286	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-ALDH1 interaction
DME0286	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the ALDH1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Aldehyde dehydrogenase 1. As a result, the interaction between HDACs and ALDH1 can inhibit the drug-metabolizing process of Aldehyde dehydrogenase 1.
DME0286	MIRNA_ID	MIMAT0000431	PROTNAME	hsa-miR-140-5p
DME0286	MIRNA_ID	MIMAT0000431	HPPI_DIS	Ductal carcinoma in situ [ICD-11: 2E65]
DME0286	MIRNA_ID	MIMAT0000431	MOFCLASS	Non-coding RNA regulation
DME0286	MIRNA_ID	MIMAT0000431	MOFDETAI	microRNA regulation
DME0286	MIRNA_ID	MIMAT0000431	CELLLINE	SUM225CWN and SUM102PT cell lines
DME0286	MIRNA_ID	MIMAT0000431	PPI_SUMM	hsa-miR-140-5p--ALDH1A1 regulation
DME0286	MIRNA_ID	MIMAT0000431	DESCRIPT	hsa-miR-140-5p is reported to suppress ALDH1A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of ALDH1A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Aldehyde dehydrogenase 1.
DME0286	UNIPROID	AL1A1_HUMAN	PROTNAME	Retinal dehydrogenase 1 (ALDH1A1)
DME0286	UNIPROID	AL1A1_HUMAN	HPPI_DIS	Pancreatic adenocarcinoma [ICD-11: 2C10]
DME0286	UNIPROID	AL1A1_HUMAN	MOFCLASS	Oligomerization
DME0286	UNIPROID	AL1A1_HUMAN	MOFDETAI	Homo-oligomerization
DME0286	UNIPROID	AL1A1_HUMAN	CELLLINE	BxPC3, Panc1, and HEK293 cell lines
DME0286	UNIPROID	AL1A1_HUMAN	PPI_SUMM	ALDH1A1-ALDH1A1 homotetramerization
DME0286	UNIPROID	AL1A1_HUMAN	DESCRIPT	Retinal dehydrogenase 1 (ALDH1A1) is reported to homotetramerize with the ALDH1 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Aldehyde dehydrogenase 1. As a result, the interaction between ALDH1A1 and ALDH1 can inhibit the drug-metabolizing process of Aldehyde dehydrogenase 1.
DME0286	UNIPROID	EZH2_HUMAN	PROTNAME	Enhancer of zeste homolog 2 (EZH2)
DME0286	UNIPROID	EZH2_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0286	UNIPROID	EZH2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0286	UNIPROID	EZH2_HUMAN	MOFDETAI	Repression
DME0286	UNIPROID	EZH2_HUMAN	CELLLINE	SKOV3 cell line
DME0286	UNIPROID	EZH2_HUMAN	PPI_SUMM	EZH2-ALDH1A1 interaction
DME0286	UNIPROID	EZH2_HUMAN	DESCRIPT	Enhancer of zeste homolog 2 (EZH2) is reported to repress the transcription of ALDH1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Aldehyde dehydrogenase 1. As a result, the interaction between EZH2 and ALDH1 can repress the drug-metabolizing process of Aldehyde dehydrogenase 1.
DME0287	DME___ID	DME0287
DME0287	DME_NAME	Retinal dehydrogenase 2 (ALDH1A2)
DME0287	SPESNAME	Homo sapiens
DME0287	UNIPROID	TAL1_HUMAN	PROTNAME	Stem cell protein (TAL1)
DME0287	UNIPROID	TAL1_HUMAN	HPPI_DIS	T-cell acute lymphoblastic leukemia [ICD-11: 2A90]
DME0287	UNIPROID	TAL1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0287	UNIPROID	TAL1_HUMAN	MOFDETAI	Activation
DME0287	UNIPROID	TAL1_HUMAN	CELLLINE	T-ALL cell line
DME0287	UNIPROID	TAL1_HUMAN	PPI_SUMM	TAL1-ALDH1A2 interaction
DME0287	UNIPROID	TAL1_HUMAN	DESCRIPT	Stem cell protein (TAL1) is reported to activate the transcription of ALDH1A2 gene, which leads to an increased expression of the drug-metabolizing enzyme Retinal dehydrogenase 2. As a result, the interaction between TAL1 and ALDH1A2 can activate the drug-metabolizing process of Retinal dehydrogenase 2.
DME0308	DME___ID	DME0308
DME0308	DME_NAME	Glutathione S-transferase mu-1 (GSTM1)
DME0308	SPESNAME	Homo sapiens
DME0308	UNIPROID	HAT1_HUMAN	PROTNAME	Histone acetyltransferases (HATs)
DME0308	UNIPROID	HAT1_HUMAN	HPPI_DIS	Cutaneous T Cell Lymphoma [ICD-11: 2B01]
DME0308	UNIPROID	HAT1_HUMAN	MOFCLASS	Histone modification
DME0308	UNIPROID	HAT1_HUMAN	MOFDETAI	Histone hyperacetylation
DME0308	UNIPROID	HAT1_HUMAN	CELLLINE	T cells from 39 pre/post-treatment peripheral blood samples
DME0308	UNIPROID	HAT1_HUMAN	PPI_SUMM	HATs-GSTM1 interaction
DME0308	UNIPROID	HAT1_HUMAN	DESCRIPT	Histone acetyltransferases (HATs) are reported to acetylate the GSTM1 gene and thereby activate the transcriptional activity of the drug-metabolizing enzyme Glutathione S-transferase mu-1. As a result, the interaction between HATs and GSTM1 can enhance the drug-metabolizing process of Glutathione S-transferase mu-1.
DME0308	UNIPROID	MYB_HUMAN	PROTNAME	Proto-oncogene c-Myb (MYB)
DME0308	UNIPROID	MYB_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0308	UNIPROID	MYB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0308	UNIPROID	MYB_HUMAN	MOFDETAI	Activation
DME0308	UNIPROID	MYB_HUMAN	CELLLINE	Estrogen-regulated Myb-transformed cell line
DME0308	UNIPROID	MYB_HUMAN	PPI_SUMM	MYB-GSTM1 interaction
DME0308	UNIPROID	MYB_HUMAN	DESCRIPT	Proto-oncogene c-Myb (MYB) is reported to activate the transcription of GSTM1 gene, which leads to an increased expression of the drug-metabolizing enzyme Glutathione S-transferase mu-1. As a result, the interaction between MYB and GSTM1 can activate the drug-metabolizing process of Glutathione S-transferase mu-1.
DME0384	DME___ID	DME0384
DME0384	DME_NAME	Sulfotransferase 2B1 (SULT2B1)
DME0384	SPESNAME	Homo sapiens
DME0384	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0384	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0384	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0384	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0384	UNIPROID	HDAC1_HUMAN	CELLLINE	Immortalized human keratinocytes
DME0384	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-SULT2B1 interaction
DME0384	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the SULT2B1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Sulfotransferase 2B1. As a result, the interaction between HDACs and SULT2B1 can inhibit the drug-metabolizing process of Sulfotransferase 2B1.
DME0403	DME___ID	DME0403
DME0403	DME_NAME	Arachidonate 15-lipoxygenase (ALOX15)
DME0403	SPESNAME	Homo sapiens
DME0403	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0403	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0403	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0403	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0403	UNIPROID	HDAC1_HUMAN	CELLLINE	SH-SY5Y cell line
DME0403	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-ALOX15 interaction
DME0403	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the ALOX15 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Arachidonate 15-lipoxygenase. As a result, the interaction between HDACs and ALOX15 can inhibit the drug-metabolizing process of Arachidonate 15-lipoxygenase.
DME0403	UNIPROID	SPI1_HUMAN	PROTNAME	TF factor PU.1 (SPI1)
DME0403	UNIPROID	SPI1_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0403	UNIPROID	SPI1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0403	UNIPROID	SPI1_HUMAN	MOFDETAI	Activation
DME0403	UNIPROID	SPI1_HUMAN	CELLLINE	A549 cell line
DME0403	UNIPROID	SPI1_HUMAN	PPI_SUMM	SPI1-ALOX15 interaction
DME0403	UNIPROID	SPI1_HUMAN	DESCRIPT	TF factor PU.1 (SPI1) is reported to activate the transcription of ALOX15 gene, which leads to an increased expression of the drug-metabolizing enzyme Arachidonate 15-lipoxygenase. As a result, the interaction between SPI1 and ALOX15 can activate the drug-metabolizing process of Arachidonate 15-lipoxygenase.
DME0403	UNIPROID	STAT6_HUMAN	PROTNAME	STAT 6 (STAT6)
DME0403	UNIPROID	STAT6_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0403	UNIPROID	STAT6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0403	UNIPROID	STAT6_HUMAN	MOFDETAI	Activation
DME0403	UNIPROID	STAT6_HUMAN	CELLLINE	A549 cell line
DME0403	UNIPROID	STAT6_HUMAN	PPI_SUMM	STAT6-ALOX15 interaction
DME0403	UNIPROID	STAT6_HUMAN	DESCRIPT	STAT 6 (STAT6) is reported to activate the transcription of ALOX15 gene, which leads to an increased expression of the drug-metabolizing enzyme Arachidonate 15-lipoxygenase. As a result, the interaction between STAT6 and ALOX15 can activate the drug-metabolizing process of Arachidonate 15-lipoxygenase.
DME0403	UNIPROID	CBP_HUMAN	PROTNAME	CREB-binding protein (CREBBP)
DME0403	UNIPROID	CBP_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0403	UNIPROID	CBP_HUMAN	MOFCLASS	Transcription-factor regulation
DME0403	UNIPROID	CBP_HUMAN	MOFDETAI	Activation
DME0403	UNIPROID	CBP_HUMAN	CELLLINE	A549 cell line
DME0403	UNIPROID	CBP_HUMAN	PPI_SUMM	CREBBP-ALOX15 interaction
DME0403	UNIPROID	CBP_HUMAN	DESCRIPT	CREB-binding protein (CREBBP) is reported to activate the transcription of ALOX15 gene, which leads to an increased expression of the drug-metabolizing enzyme Arachidonate 15-lipoxygenase. As a result, the interaction between CREBBP and ALOX15 can activate the drug-metabolizing process of Arachidonate 15-lipoxygenase.
DME0403	UNIPROID	EP300_HUMAN	PROTNAME	His-acetyltransferase p300 (EP300)
DME0403	UNIPROID	EP300_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0403	UNIPROID	EP300_HUMAN	MOFCLASS	Transcription-factor regulation
DME0403	UNIPROID	EP300_HUMAN	MOFDETAI	Activation
DME0403	UNIPROID	EP300_HUMAN	CELLLINE	A549 cell line
DME0403	UNIPROID	EP300_HUMAN	PPI_SUMM	EP300-ALOX15 interaction
DME0403	UNIPROID	EP300_HUMAN	DESCRIPT	His-acetyltransferase p300 (EP300) is reported to activate the transcription of ALOX15 gene, which leads to an increased expression of the drug-metabolizing enzyme Arachidonate 15-lipoxygenase. As a result, the interaction between EP300 and ALOX15 can activate the drug-metabolizing process of Arachidonate 15-lipoxygenase.
DME0408	DME___ID	DME0408
DME0408	DME_NAME	Arsenite methyltransferase (AS3MT)
DME0408	SPESNAME	Homo sapiens
DME0408	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0408	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0408	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0408	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0408	UNIPROID	EHMT1_HUMAN	CELLLINE	Human peripheral blood mononuclear cells
DME0408	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-AS3MT interaction
DME0408	UNIPROID	EHMT1_HUMAN	DESCRIPT	Histone methyltransferases (HMTs) are reported to hyper-methylate the AS3MT gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Arsenite methyltransferase. As a result, the interaction between HMTs and AS3MT can inhibit the drug-metabolizing process of Arsenite methyltransferase.
DME0409	DME___ID	DME0409
DME0409	DME_NAME	Carbonic anhydrase II (CA2)
DME0409	SPESNAME	Homo sapiens
DME0409	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0409	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Acute myeloid leukemia [ICD-11: 2A60]
DME0409	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0409	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0409	UNIPROID	HDAC1_HUMAN	CELLLINE	Erythroleukemia cell line HD3
DME0409	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CA2 interaction
DME0409	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CA2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Carbonic anhydrase II. As a result, the interaction between HDACs and CA2 can inhibit the drug-metabolizing process of Carbonic anhydrase II.
DME0409	MIRNA_ID	MIMAT0000418	PROTNAME	hsa-miR-23b-3p
DME0409	MIRNA_ID	MIMAT0000418	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0409	MIRNA_ID	MIMAT0000418	MOFCLASS	Non-coding RNA regulation
DME0409	MIRNA_ID	MIMAT0000418	MOFDETAI	microRNA regulation
DME0409	MIRNA_ID	MIMAT0000418	CELLLINE	Hepatocellular carcinoma cells
DME0409	MIRNA_ID	MIMAT0000418	PPI_SUMM	hsa-miR-23b-3p--CA2 regulation
DME0409	MIRNA_ID	MIMAT0000418	DESCRIPT	hsa-miR-23b-3p is reported to suppress CA2 mRNA translation by binding to the 3' untranslated region (3'UTR) of CA2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Carbonic anhydrase II.
DME0410	DME___ID	DME0410
DME0410	DME_NAME	Serine sulfhydrase (CBS)
DME0410	SPESNAME	Homo sapiens
DME0410	UNIPROID	NFYA_HUMAN	PROTNAME	Nuclear TF factor Y alpha (NFYA)
DME0410	UNIPROID	NFYA_HUMAN	HPPI_DIS	Fibrosarcoma [ICD-11: 2B5J]
DME0410	UNIPROID	NFYA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0410	UNIPROID	NFYA_HUMAN	MOFDETAI	Activation
DME0410	UNIPROID	NFYA_HUMAN	CELLLINE	HT1080 cell line
DME0410	UNIPROID	NFYA_HUMAN	PPI_SUMM	NFYA-CBS interaction
DME0410	UNIPROID	NFYA_HUMAN	DESCRIPT	Nuclear TF factor Y alpha (NFYA) is reported to activate the transcription of CBS gene, which leads to an increased expression of the drug-metabolizing enzyme Serine sulfhydrase. As a result, the interaction between NFYA and CBS can activate the drug-metabolizing process of Serine sulfhydrase.
DME0410	UNIPROID	NFYA_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0410	UNIPROID	NFYA_HUMAN	CELLLINE	HepG2 cell line
DME0411	DME___ID	DME0411
DME0411	DME_NAME	Microsomal cytochrome MCB5 (CYB5A)
DME0411	SPESNAME	Homo sapiens
DME0411	MIRNA_ID	MIMAT0000280	PROTNAME	hsa-miR-223-3p
DME0411	MIRNA_ID	MIMAT0000280	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0411	MIRNA_ID	MIMAT0000280	MOFCLASS	Non-coding RNA regulation
DME0411	MIRNA_ID	MIMAT0000280	MOFDETAI	microRNA regulation
DME0411	MIRNA_ID	MIMAT0000280	CELLLINE	HepG2 cell line
DME0411	MIRNA_ID	MIMAT0000280	PPI_SUMM	hsa-miR-223-3p--CYB5A regulation
DME0411	MIRNA_ID	MIMAT0000280	DESCRIPT	hsa-miR-223-3p is reported to suppress CYB5A mRNA translation by binding to the 3' untranslated region (3'UTR) of CYB5A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Microsomal cytochrome MCB5.
DME0413	DME___ID	DME0413
DME0413	DME_NAME	Delta(24)-sterol reductase (DHCR24)
DME0413	SPESNAME	Homo sapiens
DME0413	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0413	UNIPROID	SP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0413	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0413	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0413	UNIPROID	SP1_HUMAN	CELLLINE	HepG2 and RzM6 cell lines
DME0413	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-DHCR24 interaction
DME0413	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of DHCR24 gene, which leads to an increased expression of the drug-metabolizing enzyme Delta(24)-sterol reductase. As a result, the interaction between SP1 and DHCR24 can activate the drug-metabolizing process of Delta(24)-sterol reductase.
DME0414	DME___ID	DME0414
DME0414	DME_NAME	Short-chain dehydrogenase/reductase retSDR1 (DHRS3)
DME0414	SPESNAME	Homo sapiens
DME0414	UNIPROID	RDH10_HUMAN	PROTNAME	Retinol dehydrogenase 10 (RDH10)
DME0414	UNIPROID	RDH10_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0414	UNIPROID	RDH10_HUMAN	MOFCLASS	Oligomerization
DME0414	UNIPROID	RDH10_HUMAN	MOFDETAI	Homo-oligomerization
DME0414	UNIPROID	RDH10_HUMAN	SUBSTRAT	Reduction of retinaldehyde (Metabolic product: Retinol)
DME0414	UNIPROID	RDH10_HUMAN	CELLLINE	Human embryonic kidney cell line (HEK293)
DME0414	UNIPROID	RDH10_HUMAN	PPI_SUMM	RDH10-DHRS3 homooligomerization
DME0414	UNIPROID	RDH10_HUMAN	DESCRIPT	Retinol dehydrogenase 10 (RDH10) is reported to homooligomerize with the DHRS3 protein, which leads to activation of the drug-metabolizing enzyme Short-chain dehydrogenase/reductase retSDR1. As a result, the interaction between RDH10 and DHRS3 can activate the drug-metabolizing process of Short-chain dehydrogenase/reductase retSDR1.
DME0416	DME___ID	DME0416
DME0416	DME_NAME	Friedreich ataxia protein (FXN)
DME0416	SPESNAME	Homo sapiens
DME0416	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0416	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0416	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0416	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0416	UNIPROID	HDAC1_HUMAN	CELLLINE	Mouse Model
DME0416	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-FXN interaction
DME0416	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the FXN gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Friedreich ataxia protein. As a result, the interaction between HDACs and FXN can inhibit the drug-metabolizing process of Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0000422	PROTNAME	hsa-miR-124-3p
DME0416	MIRNA_ID	MIMAT0000422	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0000422	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0000422	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0000422	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0000422	PPI_SUMM	hsa-miR-124-3p--FXN regulation
DME0416	MIRNA_ID	MIMAT0000422	DESCRIPT	hsa-miR-124-3p is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0005924	PROTNAME	hsa-miR-1270
DME0416	MIRNA_ID	MIMAT0005924	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0005924	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0005924	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0005924	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0005924	PPI_SUMM	hsa-miR-1270--FXN regulation
DME0416	MIRNA_ID	MIMAT0005924	DESCRIPT	hsa-miR-1270 is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0000687	PROTNAME	hsa-miR-299-3p
DME0416	MIRNA_ID	MIMAT0000687	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0000687	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0000687	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0000687	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0000687	PPI_SUMM	hsa-miR-299-3p--FXN regulation
DME0416	MIRNA_ID	MIMAT0000687	DESCRIPT	hsa-miR-299-3p is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0002878	PROTNAME	hsa-miR-506-3p
DME0416	MIRNA_ID	MIMAT0002878	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0002878	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0002878	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0002878	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0002878	PPI_SUMM	hsa-miR-506-3p--FXN regulation
DME0416	MIRNA_ID	MIMAT0002878	DESCRIPT	hsa-miR-506-3p is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0002868	PROTNAME	hsa-miR-522-3p
DME0416	MIRNA_ID	MIMAT0002868	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0002868	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0002868	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0002868	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0002868	PPI_SUMM	hsa-miR-522-3p--FXN regulation
DME0416	MIRNA_ID	MIMAT0002868	DESCRIPT	hsa-miR-522-3p is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0003223	PROTNAME	hsa-miR-559
DME0416	MIRNA_ID	MIMAT0003223	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0003223	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0003223	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0003223	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0003223	PPI_SUMM	hsa-miR-559--FXN regulation
DME0416	MIRNA_ID	MIMAT0003223	DESCRIPT	hsa-miR-559 is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0004799	PROTNAME	hsa-miR-589-5p
DME0416	MIRNA_ID	MIMAT0004799	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0004799	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0004799	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0004799	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0004799	PPI_SUMM	hsa-miR-589-5p--FXN regulation
DME0416	MIRNA_ID	MIMAT0004799	DESCRIPT	hsa-miR-589-5p is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0003289	PROTNAME	hsa-miR-620
DME0416	MIRNA_ID	MIMAT0003289	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0003289	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0003289	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0003289	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0003289	PPI_SUMM	hsa-miR-620--FXN regulation
DME0416	MIRNA_ID	MIMAT0003289	DESCRIPT	hsa-miR-620 is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0004807	PROTNAME	hsa-miR-624-3p
DME0416	MIRNA_ID	MIMAT0004807	HPPI_DIS	Friedreich's ataxia [ICD-11: 8A03]
DME0416	MIRNA_ID	MIMAT0004807	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0004807	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0004807	CELLLINE	Friedreich's ataxia cells
DME0416	MIRNA_ID	MIMAT0004807	PPI_SUMM	hsa-miR-624-3p--FXN regulation
DME0416	MIRNA_ID	MIMAT0004807	DESCRIPT	hsa-miR-624-3p is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0416	MIRNA_ID	MIMAT0000437	PROTNAME	hsa-miR-145-5p
DME0416	MIRNA_ID	MIMAT0000437	HPPI_DIS	Congenital heart disease [ICD-11: LA8Z]
DME0416	MIRNA_ID	MIMAT0000437	MOFCLASS	Non-coding RNA regulation
DME0416	MIRNA_ID	MIMAT0000437	MOFDETAI	microRNA regulation
DME0416	MIRNA_ID	MIMAT0000437	CELLLINE	Congenital heart disease cells
DME0416	MIRNA_ID	MIMAT0000437	PPI_SUMM	hsa-miR-145-5p--FXN regulation
DME0416	MIRNA_ID	MIMAT0000437	DESCRIPT	hsa-miR-145-5p is reported to suppress FXN mRNA translation by binding to the 3' untranslated region (3'UTR) of FXN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Friedreich ataxia protein.
DME0418	DME___ID	DME0418
DME0418	DME_NAME	Glutamine synthetase (GLUL)
DME0418	SPESNAME	Homo sapiens
DME0418	MIRNA_ID	MIMAT0000086	PROTNAME	hsa-miR-29a-3p
DME0418	MIRNA_ID	MIMAT0000086	HPPI_DIS	Irritable bowel syndrome [ICD-11: DD91]
DME0418	MIRNA_ID	MIMAT0000086	MOFCLASS	Non-coding RNA regulation
DME0418	MIRNA_ID	MIMAT0000086	MOFDETAI	microRNA regulation
DME0418	MIRNA_ID	MIMAT0000086	CELLLINE	Irritable Bowel Syndrome cell line
DME0418	MIRNA_ID	MIMAT0000086	PPI_SUMM	hsa-miR-29a-3p--GLUL regulation
DME0418	MIRNA_ID	MIMAT0000086	DESCRIPT	hsa-miR-29a-3p is reported to suppress GLUL mRNA translation by binding to the 3' untranslated region (3'UTR) of GLUL mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glutamine synthetase.
DME0419	DME___ID	DME0419
DME0419	DME_NAME	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DME0419	SPESNAME	Homo sapiens
DME0419	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0419	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0419	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0419	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0419	UNIPROID	EHMT1_HUMAN	CELLLINE	Rodent model
DME0419	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-HSD11B2 interaction
DME0419	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 36 trimethylation of HSD11B2 gene is reported to activate the transcriptional activity of the drug-metabolizing enzyme Corticosteroid 11-beta-dehydrogenase 2. As a result, the interaction between Histone methyltransferases (HMTs) and HSD11B2 can enhance the drug-metabolizing process of Corticosteroid 11-beta-dehydrogenase 2.
DME0419	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0419	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0419	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0419	UNIPROID	NFKB1_HUMAN	MOFDETAI	Repression
DME0419	UNIPROID	NFKB1_HUMAN	CELLLINE	SW620 cell line
DME0419	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-HSD11B2 interaction
DME0419	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to repress the transcription of HSD11B2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Corticosteroid 11-beta-dehydrogenase 2. As a result, the interaction between NFKB1 and HSD11B2 can repress the drug-metabolizing process of Corticosteroid 11-beta-dehydrogenase 2.
DME0419	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0419	UNIPROID	TF65_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0419	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0419	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0419	UNIPROID	TF65_HUMAN	CELLLINE	SW620 cell line
DME0419	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-HSD11B2 interaction
DME0419	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of HSD11B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Corticosteroid 11-beta-dehydrogenase 2. As a result, the interaction between RELA and HSD11B2 can activate the drug-metabolizing process of Corticosteroid 11-beta-dehydrogenase 2.
DME0419	UNIPROID	EGR1_HUMAN	PROTNAME	Early growth response 1 (EGR1)
DME0419	UNIPROID	EGR1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0419	UNIPROID	EGR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0419	UNIPROID	EGR1_HUMAN	MOFDETAI	Repression
DME0419	UNIPROID	EGR1_HUMAN	CELLLINE	SW620 cell line
DME0419	UNIPROID	EGR1_HUMAN	PPI_SUMM	EGR1-HSD11B2 interaction
DME0419	UNIPROID	EGR1_HUMAN	DESCRIPT	Early growth response 1 (EGR1) is reported to repress the transcription of HSD11B2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Corticosteroid 11-beta-dehydrogenase 2. As a result, the interaction between EGR1 and HSD11B2 can repress the drug-metabolizing process of Corticosteroid 11-beta-dehydrogenase 2.
DME0419	UNIPROID	PPARD_HUMAN	PROTNAME	PPA receptor delta (PPARD)
DME0419	UNIPROID	PPARD_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0419	UNIPROID	PPARD_HUMAN	MOFCLASS	Transcription-factor regulation
DME0419	UNIPROID	PPARD_HUMAN	MOFDETAI	Repression
DME0419	UNIPROID	PPARD_HUMAN	CELLLINE	Placental trophoblast cell line
DME0419	UNIPROID	PPARD_HUMAN	PPI_SUMM	PPARD-HSD11B2 interaction
DME0419	UNIPROID	PPARD_HUMAN	DESCRIPT	PPA receptor delta (PPARD) is reported to repress the transcription of HSD11B2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Corticosteroid 11-beta-dehydrogenase 2. As a result, the interaction between PPARD and HSD11B2 can repress the drug-metabolizing process of Corticosteroid 11-beta-dehydrogenase 2.
DME0420	DME___ID	DME0420
DME0420	DME_NAME	Estradiol 17-beta-dehydrogenase 1 (HSD17B1)
DME0420	SPESNAME	Homo sapiens
DME0420	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0420	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Polycystic ovary syndrome [ICD-11: 5A80]
DME0420	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0420	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0420	UNIPROID	HDAC1_HUMAN	CELLLINE	Primary bovine theca (TC) and granulosa (GC) cells
DME0420	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-HSD17B1 interaction
DME0420	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the HSD17B1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 1. As a result, the interaction between HDACs and HSD17B1 can inhibit the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 1.
DME0420	MIRNA_ID	MIMAT0000267	PROTNAME	hsa-miR-210-3p
DME0420	MIRNA_ID	MIMAT0000267	HPPI_DIS	Preeclampsia [ICD-11: JA24]
DME0420	MIRNA_ID	MIMAT0000267	MOFCLASS	Non-coding RNA regulation
DME0420	MIRNA_ID	MIMAT0000267	MOFDETAI	microRNA regulation
DME0420	MIRNA_ID	MIMAT0000267	CELLLINE	Preeclampsia cells
DME0420	MIRNA_ID	MIMAT0000267	PPI_SUMM	hsa-miR-210-3p--HSD17B1 regulation
DME0420	MIRNA_ID	MIMAT0000267	DESCRIPT	hsa-miR-210-3p is reported to suppress HSD17B1 mRNA translation by binding to the 3' untranslated region (3'UTR) of HSD17B1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 1.
DME0420	MIRNA_ID	MIMAT0002848	PROTNAME	hsa-miR-518c-3p
DME0420	MIRNA_ID	MIMAT0002848	HPPI_DIS	Preeclampsia [ICD-11: JA24]
DME0420	MIRNA_ID	MIMAT0002848	MOFCLASS	Non-coding RNA regulation
DME0420	MIRNA_ID	MIMAT0002848	MOFDETAI	microRNA regulation
DME0420	MIRNA_ID	MIMAT0002848	CELLLINE	Preeclampsia cells
DME0420	MIRNA_ID	MIMAT0002848	PPI_SUMM	hsa-miR-518c-3p--HSD17B1 regulation
DME0420	MIRNA_ID	MIMAT0002848	DESCRIPT	hsa-miR-518c-3p is reported to suppress HSD17B1 mRNA translation by binding to the 3' untranslated region (3'UTR) of HSD17B1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 1.
DME0420	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0420	UNIPROID	SP1_HUMAN	HPPI_DIS	Choriocarcinoma [ICD-11: 2C75]
DME0420	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0420	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0420	UNIPROID	SP1_HUMAN	CELLLINE	Choriocarcinoma cell line
DME0420	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-HSD17B1 interaction
DME0420	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of HSD17B1 gene, which leads to an increased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 1. As a result, the interaction between SP1 and HSD17B1 can activate the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 1.
DME0420	UNIPROID	GATA3_HUMAN	PROTNAME	GATA-binding factor 3 (GATA3)
DME0420	UNIPROID	GATA3_HUMAN	HPPI_DIS	Choriocarcinoma [ICD-11: 2C75]
DME0420	UNIPROID	GATA3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0420	UNIPROID	GATA3_HUMAN	MOFDETAI	Repression
DME0420	UNIPROID	GATA3_HUMAN	CELLLINE	Choriocarcinoma cell line
DME0420	UNIPROID	GATA3_HUMAN	PPI_SUMM	GATA3-HSD17B1 interaction
DME0420	UNIPROID	GATA3_HUMAN	DESCRIPT	GATA-binding factor 3 (GATA3) is reported to repress the transcription of HSD17B1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 1. As a result, the interaction between GATA3 and HSD17B1 can repress the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 1.
DME0420	UNIPROID	AP2A_HUMAN	PROTNAME	TF factor AP-2-alpha (TFAP2A)
DME0420	UNIPROID	AP2A_HUMAN	HPPI_DIS	Choriocarcinoma [ICD-11: 2C75]
DME0420	UNIPROID	AP2A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0420	UNIPROID	AP2A_HUMAN	MOFDETAI	Repression
DME0420	UNIPROID	AP2A_HUMAN	CELLLINE	Choriocarcinoma cell line
DME0420	UNIPROID	AP2A_HUMAN	PPI_SUMM	TFAP2A-HSD17B1 interaction
DME0420	UNIPROID	AP2A_HUMAN	DESCRIPT	TF factor AP-2-alpha (TFAP2A) is reported to repress the transcription of HSD17B1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 1. As a result, the interaction between TFAP2A and HSD17B1 can repress the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 1.
DME0422	DME___ID	DME0422
DME0422	DME_NAME	Estradiol 17-beta-dehydrogenase 2 (HSD17B2)
DME0422	SPESNAME	Homo sapiens
DME0422	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0422	UNIPROID	SP1_HUMAN	HPPI_DIS	Endometrial cancer [ICD-11: 2C76]
DME0422	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0422	UNIPROID	SP1_HUMAN	MOFDETAI	Repression
DME0422	UNIPROID	SP1_HUMAN	CELLLINE	Ishikawa and RL95-2 cell lines
DME0422	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-HSD17B2 interaction
DME0422	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to repress the transcription of HSD17B2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 2. As a result, the interaction between SP1 and HSD17B2 can repress the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 2.
DME0422	UNIPROID	SP1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0422	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0422	UNIPROID	SP1_HUMAN	CELLLINE	Human endometrial epithelial cell line
DME0422	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of HSD17B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 2. As a result, the interaction between SP1 and HSD17B2 can activate the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 2.
DME0422	UNIPROID	RARA_HUMAN	PROTNAME	Retinoic acid receptor alpha (RARA)
DME0422	UNIPROID	RARA_HUMAN	HPPI_DIS	Endometrial cancer [ICD-11: 2C76]
DME0422	UNIPROID	RARA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0422	UNIPROID	RARA_HUMAN	MOFDETAI	Activation
DME0422	UNIPROID	RARA_HUMAN	CELLLINE	Ishikawa and RL95-2 cell lines
DME0422	UNIPROID	RARA_HUMAN	PPI_SUMM	RARA-HSD17B2 interaction
DME0422	UNIPROID	RARA_HUMAN	DESCRIPT	Retinoic acid receptor alpha (RARA) is reported to activate the transcription of HSD17B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 2. As a result, the interaction between RARA and HSD17B2 can activate the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 2.
DME0422	UNIPROID	RXRA_HUMAN	PROTNAME	Retinoid X receptor alpha (RXRA)
DME0422	UNIPROID	RXRA_HUMAN	HPPI_DIS	Endometrial cancer [ICD-11: 2C76]
DME0422	UNIPROID	RXRA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0422	UNIPROID	RXRA_HUMAN	MOFDETAI	Activation
DME0422	UNIPROID	RXRA_HUMAN	CELLLINE	Ishikawa and RL95-2 cell lines
DME0422	UNIPROID	RXRA_HUMAN	PPI_SUMM	RXRA-HSD17B2 interaction
DME0422	UNIPROID	RXRA_HUMAN	DESCRIPT	Retinoid X receptor alpha (RXRA) is reported to activate the transcription of HSD17B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 2. As a result, the interaction between RXRA and HSD17B2 can activate the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 2.
DME0422	UNIPROID	SP2_HUMAN	PROTNAME	Transcription factor Sp2 (SP2)
DME0422	UNIPROID	SP2_HUMAN	HPPI_DIS	Endometrial cancer [ICD-11: 2C76]
DME0422	UNIPROID	SP2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0422	UNIPROID	SP2_HUMAN	MOFDETAI	Repression
DME0422	UNIPROID	SP2_HUMAN	CELLLINE	Ishikawa and RL95-2 cell lines
DME0422	UNIPROID	SP2_HUMAN	PPI_SUMM	SP2-HSD17B2 interaction
DME0422	UNIPROID	SP2_HUMAN	DESCRIPT	Transcription factor Sp2 (SP2) is reported to repress the transcription of HSD17B2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 2. As a result, the interaction between SP2 and HSD17B2 can repress the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 2.
DME0422	UNIPROID	SP3_HUMAN	PROTNAME	Transcription factor Sp3 (SP3)
DME0422	UNIPROID	SP3_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0422	UNIPROID	SP3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0422	UNIPROID	SP3_HUMAN	MOFDETAI	Activation
DME0422	UNIPROID	SP3_HUMAN	CELLLINE	Human endometrial epithelial cell line
DME0422	UNIPROID	SP3_HUMAN	PPI_SUMM	SP3-HSD17B2 interaction
DME0422	UNIPROID	SP3_HUMAN	DESCRIPT	Transcription factor Sp3 (SP3) is reported to activate the transcription of HSD17B2 gene, which leads to an increased expression of the drug-metabolizing enzyme Estradiol 17-beta-dehydrogenase 2. As a result, the interaction between SP3 and HSD17B2 can activate the drug-metabolizing process of Estradiol 17-beta-dehydrogenase 2.
DME0425	DME___ID	DME0425
DME0425	DME_NAME	Methylsterol monooxygenase 1 (MSMO1)
DME0425	SPESNAME	Homo sapiens
DME0425	MIRNA_ID	MIMAT0000073	PROTNAME	hsa-miR-19a-3p
DME0425	MIRNA_ID	MIMAT0000073	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0425	MIRNA_ID	MIMAT0000073	MOFCLASS	Non-coding RNA regulation
DME0425	MIRNA_ID	MIMAT0000073	MOFDETAI	microRNA regulation
DME0425	MIRNA_ID	MIMAT0000073	CELLLINE	LNCaP cell line
DME0425	MIRNA_ID	MIMAT0000073	PPI_SUMM	hsa-miR-19a-3p--MSMO1 regulation
DME0425	MIRNA_ID	MIMAT0000073	DESCRIPT	hsa-miR-19a-3p is reported to suppress MSMO1 mRNA translation by binding to the 3' untranslated region (3'UTR) of MSMO1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Methylsterol monooxygenase 1.
DME0429	DME___ID	DME0429
DME0429	DME_NAME	Prostaglandin reductase 1 (PTGR1)
DME0429	SPESNAME	Homo sapiens
DME0429	MIRNA_ID	MIMAT0002868	PROTNAME	hsa-miR-522-3p
DME0429	MIRNA_ID	MIMAT0002868	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0429	MIRNA_ID	MIMAT0002868	MOFCLASS	Non-coding RNA regulation
DME0429	MIRNA_ID	MIMAT0002868	MOFDETAI	microRNA regulation
DME0429	MIRNA_ID	MIMAT0002868	CELLLINE	MDA-MB-231 cell line
DME0429	MIRNA_ID	MIMAT0002868	PPI_SUMM	hsa-miR-522-3p--PTGR1 regulation
DME0429	MIRNA_ID	MIMAT0002868	DESCRIPT	hsa-miR-522-3p is reported to suppress PTGR1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGR1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin reductase 1.
DME0430	DME___ID	DME0430
DME0430	DME_NAME	Tyrosine-protein phosphatase STS1/TULA2 (UBASH3B)
DME0430	SPESNAME	Homo sapiens
DME0430	MIRNA_ID	MIMAT0000682	PROTNAME	hsa-miR-200a-3p
DME0430	MIRNA_ID	MIMAT0000682	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0430	MIRNA_ID	MIMAT0000682	MOFCLASS	Non-coding RNA regulation
DME0430	MIRNA_ID	MIMAT0000682	MOFDETAI	microRNA regulation
DME0430	MIRNA_ID	MIMAT0000682	CELLLINE	Triple-negative breast cancer cells
DME0430	MIRNA_ID	MIMAT0000682	PPI_SUMM	hsa-miR-200a-3p--UBASH3B regulation
DME0430	MIRNA_ID	MIMAT0000682	DESCRIPT	hsa-miR-200a-3p is reported to suppress UBASH3B mRNA translation by binding to the 3' untranslated region (3'UTR) of UBASH3B mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Tyrosine-protein phosphatase STS1/TULA2.
DME0437	DME___ID	DME0437
DME0437	DME_NAME	Purine nucleoside phosphorylase (PNP)
DME0437	SPESNAME	Homo sapiens
DME0437	MIRNA_ID	MIMAT0000427	PROTNAME	hsa-miR-133a-3p
DME0437	MIRNA_ID	MIMAT0000427	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0437	MIRNA_ID	MIMAT0000427	MOFCLASS	Non-coding RNA regulation
DME0437	MIRNA_ID	MIMAT0000427	MOFDETAI	microRNA regulation
DME0437	MIRNA_ID	MIMAT0000427	CELLLINE	PC3 and DU145 cell lines
DME0437	MIRNA_ID	MIMAT0000427	PPI_SUMM	hsa-miR-133a-3p--PNP regulation
DME0437	MIRNA_ID	MIMAT0000427	DESCRIPT	hsa-miR-133a-3p is reported to suppress PNP mRNA translation by binding to the 3' untranslated region (3'UTR) of PNP mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Purine nucleoside phosphorylase.
DME0437	MIRNA_ID	MIMAT0000416	PROTNAME	hsa-miR-1-3p
DME0437	MIRNA_ID	MIMAT0000416	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0437	MIRNA_ID	MIMAT0000416	MOFCLASS	Non-coding RNA regulation
DME0437	MIRNA_ID	MIMAT0000416	MOFDETAI	microRNA regulation
DME0437	MIRNA_ID	MIMAT0000416	CELLLINE	PC3 and DU145 cell lines
DME0437	MIRNA_ID	MIMAT0000416	PPI_SUMM	hsa-miR-1-3p--PNP regulation
DME0437	MIRNA_ID	MIMAT0000416	DESCRIPT	hsa-miR-1-3p is reported to suppress PNP mRNA translation by binding to the 3' untranslated region (3'UTR) of PNP mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Purine nucleoside phosphorylase.
DME0442	DME___ID	DME0442
DME0442	DME_NAME	Dihydropyrimidinase-related protein 1 (DRP1)
DME0442	SPESNAME	Homo sapiens
DME0442	MIRNA_ID	MIMAT0000262	PROTNAME	hsa-miR-187-3p
DME0442	MIRNA_ID	MIMAT0000262	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0442	MIRNA_ID	MIMAT0000262	MOFCLASS	Non-coding RNA regulation
DME0442	MIRNA_ID	MIMAT0000262	MOFDETAI	microRNA regulation
DME0442	MIRNA_ID	MIMAT0000262	CELLLINE	Hs-746T cell line
DME0442	MIRNA_ID	MIMAT0000262	PPI_SUMM	hsa-miR-187-3p--CRMP1 regulation
DME0442	MIRNA_ID	MIMAT0000262	DESCRIPT	hsa-miR-187-3p is reported to suppress CRMP1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CRMP1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dihydropyrimidinase-related protein 1.
DME0446	DME___ID	DME0446
DME0446	DME_NAME	Angiotensin-converting enzyme 2 (ACE2)
DME0446	SPESNAME	Homo sapiens
DME0446	UNIPROID	HIF1A_HUMAN	PROTNAME	ARNT-interacting protein (HIF1A)
DME0446	UNIPROID	HIF1A_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0446	UNIPROID	HIF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0446	UNIPROID	HIF1A_HUMAN	MOFDETAI	Repression
DME0446	UNIPROID	HIF1A_HUMAN	CELLLINE	Pulmonary artery smooth muscle cell line
DME0446	UNIPROID	HIF1A_HUMAN	PPI_SUMM	HIF1A-ACE2 interaction
DME0446	UNIPROID	HIF1A_HUMAN	DESCRIPT	ARNT-interacting protein (HIF1A) is reported to repress the transcription of ACE2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Angiotensin-converting enzyme 2. As a result, the interaction between HIF1A and ACE2 can repress the drug-metabolizing process of Angiotensin-converting enzyme 2.
DME0447	DME___ID	DME0447
DME0447	DME_NAME	Acid cholesteryl ester hydrolase (LIPA)
DME0447	SPESNAME	Homo sapiens
DME0447	MIRNA_ID	MIMAT0000423	PROTNAME	hsa-miR-125b-5p
DME0447	MIRNA_ID	MIMAT0000423	HPPI_DIS	Chronic lymphocytic leukaemia [ICD-11: 2A82]
DME0447	MIRNA_ID	MIMAT0000423	MOFCLASS	Non-coding RNA regulation
DME0447	MIRNA_ID	MIMAT0000423	MOFDETAI	microRNA regulation
DME0447	MIRNA_ID	MIMAT0000423	CELLLINE	MEC1 and MEC2 cell lines
DME0447	MIRNA_ID	MIMAT0000423	PPI_SUMM	hsa-miR-125b-5p--LIPA regulation
DME0447	MIRNA_ID	MIMAT0000423	DESCRIPT	hsa-miR-125b-5p is reported to suppress LIPA mRNA translation by binding to the 3' untranslated region (3'UTR) of LIPA mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Acid cholesteryl ester hydrolase.
DME0451	DME___ID	DME0451
DME0451	DME_NAME	Thyroid peroxidase (TPO)
DME0451	SPESNAME	Homo sapiens
DME0451	UNIPROID	FOXA2_HUMAN	PROTNAME	Hepatocyte NF 3-beta (FOXA2)
DME0451	UNIPROID	FOXA2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0451	UNIPROID	FOXA2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0451	UNIPROID	FOXA2_HUMAN	MOFDETAI	Activation
DME0451	UNIPROID	FOXA2_HUMAN	CELLLINE	Thyroid cell line
DME0451	UNIPROID	FOXA2_HUMAN	PPI_SUMM	FOXA2-TPO interaction
DME0451	UNIPROID	FOXA2_HUMAN	DESCRIPT	Hepatocyte NF 3-beta (FOXA2) is reported to activate the transcription of TPO gene, which leads to an increased expression of the drug-metabolizing enzyme Thyroid peroxidase. As a result, the interaction between FOXA2 and TPO can activate the drug-metabolizing process of Thyroid peroxidase.
DME0451	UNIPROID	TTF2_HUMAN	PROTNAME	Transcription release 2 (TTF2)
DME0451	UNIPROID	TTF2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0451	UNIPROID	TTF2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0451	UNIPROID	TTF2_HUMAN	MOFDETAI	Activation
DME0451	UNIPROID	TTF2_HUMAN	CELLLINE	Thyroid cell line
DME0451	UNIPROID	TTF2_HUMAN	PPI_SUMM	TTF2-TPO interaction
DME0451	UNIPROID	TTF2_HUMAN	DESCRIPT	Transcription release 2 (TTF2) is reported to activate the transcription of TPO gene, which leads to an increased expression of the drug-metabolizing enzyme Thyroid peroxidase. As a result, the interaction between TTF2 and TPO can activate the drug-metabolizing process of Thyroid peroxidase.
DME0456	DME___ID	DME0456
DME0456	DME_NAME	Uridine/cytidine monophosphate kinase (UMPK)
DME0456	SPESNAME	Homo sapiens
DME0456	MIRNA_ID	MIMAT0000691	PROTNAME	hsa-miR-130b-3p
DME0456	MIRNA_ID	MIMAT0000691	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0456	MIRNA_ID	MIMAT0000691	MOFCLASS	Non-coding RNA regulation
DME0456	MIRNA_ID	MIMAT0000691	MOFDETAI	microRNA regulation
DME0456	MIRNA_ID	MIMAT0000691	CELLLINE	OVCAR-3 and SK-OV-3 cell lines
DME0456	MIRNA_ID	MIMAT0000691	PPI_SUMM	hsa-miR-130b-3p--CMPK1 regulation
DME0456	MIRNA_ID	MIMAT0000691	DESCRIPT	hsa-miR-130b-3p is reported to suppress CMPK1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CMPK1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Uridine/cytidine monophosphate kinase.
DME0457	DME___ID	DME0457
DME0457	DME_NAME	Sucrase-isomaltase intestinal (SI)
DME0457	SPESNAME	Homo sapiens
DME0457	UNIPROID	PIAS1_HUMAN	PROTNAME	Gu-binding protein (PIAS1)
DME0457	UNIPROID	PIAS1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0457	UNIPROID	PIAS1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0457	UNIPROID	PIAS1_HUMAN	MOFDETAI	Activation
DME0457	UNIPROID	PIAS1_HUMAN	CELLLINE	HCT116 cell line
DME0457	UNIPROID	PIAS1_HUMAN	PPI_SUMM	PIAS1-SI interaction
DME0457	UNIPROID	PIAS1_HUMAN	DESCRIPT	Gu-binding protein (PIAS1) is reported to activate the transcription of SI gene, which leads to an increased expression of the drug-metabolizing enzyme Sucrase-isomaltase intestinal. As a result, the interaction between PIAS1 and SI can activate the drug-metabolizing process of Sucrase-isomaltase intestinal.
DME0457	UNIPROID	GATA4_HUMAN	PROTNAME	TF factor GATA-4 (GATA4)
DME0457	UNIPROID	GATA4_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0457	UNIPROID	GATA4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0457	UNIPROID	GATA4_HUMAN	MOFDETAI	Activation
DME0457	UNIPROID	GATA4_HUMAN	CELLLINE	HCT116 cell line
DME0457	UNIPROID	GATA4_HUMAN	PPI_SUMM	GATA4-SI interaction
DME0457	UNIPROID	GATA4_HUMAN	DESCRIPT	TF factor GATA-4 (GATA4) is reported to activate the transcription of SI gene, which leads to an increased expression of the drug-metabolizing enzyme Sucrase-isomaltase intestinal. As a result, the interaction between GATA4 and SI can activate the drug-metabolizing process of Sucrase-isomaltase intestinal.
DME0459	DME___ID	DME0459
DME0459	DME_NAME	Indoleamine 2,3-dioxygenase 2 (IDO2)
DME0459	SPESNAME	Homo sapiens
DME0459	UNIPROID	PTMA_HUMAN	PROTNAME	Prothymosin alpha (PTMA)
DME0459	UNIPROID	PTMA_HUMAN	HPPI_DIS	Aplastic anemia [ICD-11: 3A70]
DME0459	UNIPROID	PTMA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0459	UNIPROID	PTMA_HUMAN	MOFDETAI	Activation
DME0459	UNIPROID	PTMA_HUMAN	CELLLINE	Mesenchymal stem cell line
DME0459	UNIPROID	PTMA_HUMAN	PPI_SUMM	PTMA-IDO2 interaction
DME0459	UNIPROID	PTMA_HUMAN	DESCRIPT	Prothymosin alpha (PTMA) is reported to activate the transcription of IDO2 gene, which leads to an increased expression of the drug-metabolizing enzyme Indoleamine 2,3-dioxygenase 2. As a result, the interaction between PTMA and IDO2 can activate the drug-metabolizing process of Indoleamine 2,3-dioxygenase 2.
DME0461	DME___ID	DME0461
DME0461	DME_NAME	Prolyl 4-hydroxylase alpha-1 (P4HA1)
DME0461	SPESNAME	Homo sapiens
DME0461	MIRNA_ID	MIMAT0000421	PROTNAME	hsa-miR-122-5p
DME0461	MIRNA_ID	MIMAT0000421	HPPI_DIS	Health [ICD-11: N.A.]
DME0461	MIRNA_ID	MIMAT0000421	MOFCLASS	Non-coding RNA regulation
DME0461	MIRNA_ID	MIMAT0000421	MOFDETAI	microRNA regulation
DME0461	MIRNA_ID	MIMAT0000421	CELLLINE	Hepatic stellate cells
DME0461	MIRNA_ID	MIMAT0000421	PPI_SUMM	hsa-miR-122-5p--P4HA1 regulation
DME0461	MIRNA_ID	MIMAT0000421	DESCRIPT	hsa-miR-122-5p is reported to suppress P4HA1 mRNA translation by binding to the 3' untranslated region (3'UTR) of P4HA1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prolyl 4-hydroxylase alpha-1.
DME0461	MIRNA_ID	MIMAT0000692	PROTNAME	hsa-miR-30e-5p
DME0461	MIRNA_ID	MIMAT0000692	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0461	MIRNA_ID	MIMAT0000692	MOFCLASS	Non-coding RNA regulation
DME0461	MIRNA_ID	MIMAT0000692	MOFDETAI	microRNA regulation
DME0461	MIRNA_ID	MIMAT0000692	CELLLINE	HepG2 cell line
DME0461	MIRNA_ID	MIMAT0000692	PPI_SUMM	hsa-miR-30e-5p--P4HA1 regulation
DME0461	MIRNA_ID	MIMAT0000692	DESCRIPT	hsa-miR-30e-5p is reported to suppress P4HA1 mRNA translation by binding to the 3' untranslated region (3'UTR) of P4HA1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prolyl 4-hydroxylase alpha-1.
DME0461	UNIPROID	USF2_HUMAN	PROTNAME	Upstream stimulatory 2 (USF2)
DME0461	UNIPROID	USF2_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0461	UNIPROID	USF2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0461	UNIPROID	USF2_HUMAN	MOFDETAI	Activation
DME0461	UNIPROID	USF2_HUMAN	CELLLINE	HeLa and Human aortic vascular smooth muscle cell lines
DME0461	UNIPROID	USF2_HUMAN	PPI_SUMM	USF2-P4HA1 interaction
DME0461	UNIPROID	USF2_HUMAN	DESCRIPT	Upstream stimulatory 2 (USF2) is reported to activate the transcription of P4HA1 gene, which leads to an increased expression of the drug-metabolizing enzyme Prolyl 4-hydroxylase alpha-1. As a result, the interaction between USF2 and P4HA1 can activate the drug-metabolizing process of Prolyl 4-hydroxylase alpha-1.
DME0461	UNIPROID	USF1_HUMAN	PROTNAME	Upstream stimulatory 1 (USF1)
DME0461	UNIPROID	USF1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0461	UNIPROID	USF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0461	UNIPROID	USF1_HUMAN	MOFDETAI	Activation
DME0461	UNIPROID	USF1_HUMAN	CELLLINE	HeLa and Human aortic vascular smooth muscle cell lines
DME0461	UNIPROID	USF1_HUMAN	PPI_SUMM	USF1-P4HA1 interaction
DME0461	UNIPROID	USF1_HUMAN	DESCRIPT	Upstream stimulatory 1 (USF1) is reported to activate the transcription of P4HA1 gene, which leads to an increased expression of the drug-metabolizing enzyme Prolyl 4-hydroxylase alpha-1. As a result, the interaction between USF1 and P4HA1 can activate the drug-metabolizing process of Prolyl 4-hydroxylase alpha-1.
DME0461	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0461	UNIPROID	SP1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0461	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0461	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0461	UNIPROID	SP1_HUMAN	CELLLINE	Human aortic smooth muscle cell line
DME0461	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-P4HA1 interaction
DME0461	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of P4HA1 gene, which leads to an increased expression of the drug-metabolizing enzyme Prolyl 4-hydroxylase alpha-1. As a result, the interaction between SP1 and P4HA1 can activate the drug-metabolizing process of Prolyl 4-hydroxylase alpha-1.
DME0462	DME___ID	DME0462
DME0462	DME_NAME	HIF-prolyl hydroxylase 2 (EGLN1)
DME0462	SPESNAME	Homo sapiens
DME0462	MIRNA_ID	MIMAT0000076	PROTNAME	hsa-miR-21-5p
DME0462	MIRNA_ID	MIMAT0000076	HPPI_DIS	Health [ICD-11: N.A.]
DME0462	MIRNA_ID	MIMAT0000076	MOFCLASS	Non-coding RNA regulation
DME0462	MIRNA_ID	MIMAT0000076	MOFDETAI	microRNA regulation
DME0462	MIRNA_ID	MIMAT0000076	CELLLINE	HK-2 cell line
DME0462	MIRNA_ID	MIMAT0000076	PPI_SUMM	hsa-miR-21-5p--EGLN1 regulation
DME0462	MIRNA_ID	MIMAT0000076	DESCRIPT	hsa-miR-21-5p is reported to suppress EGLN1 mRNA translation by binding to the 3' untranslated region (3'UTR) of EGLN1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme HIF-prolyl hydroxylase 2.
DME0462	UNIPROID	SIR1_HUMAN	PROTNAME	SIR2-like protein 1 (SIRT1)
DME0462	UNIPROID	SIR1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0462	UNIPROID	SIR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0462	UNIPROID	SIR1_HUMAN	MOFDETAI	Repression
DME0462	UNIPROID	SIR1_HUMAN	CELLLINE	HepG2 cell line
DME0462	UNIPROID	SIR1_HUMAN	PPI_SUMM	SIRT1-EGLN1 interaction
DME0462	UNIPROID	SIR1_HUMAN	DESCRIPT	SIR2-like protein 1 (SIRT1) is reported to repress the transcription of EGLN1 gene, which leads to a decreased expression of the drug-metabolizing enzyme HIF-prolyl hydroxylase 2. As a result, the interaction between SIRT1 and EGLN1 can repress the drug-metabolizing process of HIF-prolyl hydroxylase 2.
DME0465	DME___ID	DME0465
DME0465	DME_NAME	UDP-glucose 6-dehydrogenase (UGDH)
DME0465	SPESNAME	Homo sapiens
DME0465	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0465	UNIPROID	SP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0465	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0465	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0465	UNIPROID	SP1_HUMAN	CELLLINE	HepG2 cell line
DME0465	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-UGDH interaction
DME0465	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of UGDH gene, which leads to an increased expression of the drug-metabolizing enzyme UDP-glucose 6-dehydrogenase. As a result, the interaction between SP1 and UGDH can activate the drug-metabolizing process of UDP-glucose 6-dehydrogenase.
DME0465	UNIPROID	SP1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0465	UNIPROID	SP1_HUMAN	CELLLINE	HeLa cell line
DME0484	DME___ID	DME0484
DME0484	DME_NAME	Sphingosine kinase 1 (SPHK1)
DME0484	SPESNAME	Homo sapiens
DME0484	MIRNA_ID	MIMAT0000423	PROTNAME	hsa-miR-125b-5p
DME0484	MIRNA_ID	MIMAT0000423	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0484	MIRNA_ID	MIMAT0000423	MOFCLASS	Non-coding RNA regulation
DME0484	MIRNA_ID	MIMAT0000423	MOFDETAI	microRNA regulation
DME0484	MIRNA_ID	MIMAT0000423	CELLLINE	T24 cell line
DME0484	MIRNA_ID	MIMAT0000423	PPI_SUMM	hsa-miR-125b-5p--SPHK1 regulation
DME0484	MIRNA_ID	MIMAT0000423	DESCRIPT	hsa-miR-125b-5p is reported to suppress SPHK1 mRNA translation by binding to the 3' untranslated region (3'UTR) of SPHK1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Sphingosine kinase 1.
DME0484	MIRNA_ID	MIMAT0002878	PROTNAME	hsa-miR-506-3p
DME0484	MIRNA_ID	MIMAT0002878	HPPI_DIS	Pancreatic adenocarcinoma [ICD-11: 2C10]
DME0484	MIRNA_ID	MIMAT0002878	MOFCLASS	Non-coding RNA regulation
DME0484	MIRNA_ID	MIMAT0002878	MOFDETAI	microRNA regulation
DME0484	MIRNA_ID	MIMAT0002878	CELLLINE	AsPC-1 and PANC-1 cell lines
DME0484	MIRNA_ID	MIMAT0002878	PPI_SUMM	hsa-miR-506-3p--SPHK1 regulation
DME0484	MIRNA_ID	MIMAT0002878	DESCRIPT	hsa-miR-506-3p is reported to suppress SPHK1 mRNA translation by binding to the 3' untranslated region (3'UTR) of SPHK1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Sphingosine kinase 1.
DME0484	MIRNA_ID	MIMAT0003337	PROTNAME	hsa-miR-659-3p
DME0484	MIRNA_ID	MIMAT0003337	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0484	MIRNA_ID	MIMAT0003337	MOFCLASS	Non-coding RNA regulation
DME0484	MIRNA_ID	MIMAT0003337	MOFDETAI	microRNA regulation
DME0484	MIRNA_ID	MIMAT0003337	CELLLINE	LOVO and HT29 cell lines
DME0484	MIRNA_ID	MIMAT0003337	PPI_SUMM	hsa-miR-659-3p--SPHK1 regulation
DME0484	MIRNA_ID	MIMAT0003337	DESCRIPT	hsa-miR-659-3p is reported to suppress SPHK1 mRNA translation by binding to the 3' untranslated region (3'UTR) of SPHK1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Sphingosine kinase 1.
DME0484	MIRNA_ID	MIMAT0000422	PROTNAME	hsa-miR-124-3p
DME0484	MIRNA_ID	MIMAT0000422	HPPI_DIS	Melanoma [ICD-11: 2C30]
DME0484	MIRNA_ID	MIMAT0000422	MOFCLASS	Non-coding RNA regulation
DME0484	MIRNA_ID	MIMAT0000422	MOFDETAI	microRNA regulation
DME0484	MIRNA_ID	MIMAT0000422	CELLLINE	A375 and SKMEL-1 cell lines
DME0484	MIRNA_ID	MIMAT0000422	PPI_SUMM	hsa-miR-124-3p--SPHK1 regulation
DME0484	MIRNA_ID	MIMAT0000422	DESCRIPT	hsa-miR-124-3p is reported to suppress SPHK1 mRNA translation by binding to the 3' untranslated region (3'UTR) of SPHK1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Sphingosine kinase 1.
DME0484	UNIPROID	BTG2_HUMAN	PROTNAME	Protein BTG2 (BTG2)
DME0484	UNIPROID	BTG2_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0484	UNIPROID	BTG2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0484	UNIPROID	BTG2_HUMAN	MOFDETAI	Activation
DME0484	UNIPROID	BTG2_HUMAN	CELLLINE	PC3, LNCaP and DU145 cell lines
DME0484	UNIPROID	BTG2_HUMAN	PPI_SUMM	BTG2-SPHK1 interaction
DME0484	UNIPROID	BTG2_HUMAN	DESCRIPT	Protein BTG2 (BTG2) is reported to activate the transcription of SPHK1 gene, which leads to an increased expression of the drug-metabolizing enzyme Sphingosine kinase 1. As a result, the interaction between BTG2 and SPHK1 can activate the drug-metabolizing process of Sphingosine kinase 1.
DME0485	DME___ID	DME0485
DME0485	DME_NAME	Glutamate-cysteine ligase catalytic (GCLC)
DME0485	SPESNAME	Homo sapiens
DME0485	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0485	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0485	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0485	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0485	UNIPROID	HDAC1_HUMAN	CELLLINE	Murine TAMH hepatocyte cell line
DME0485	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-GCLC interaction
DME0485	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the GCLC gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Glutamate-cysteine ligase catalytic. As a result, the interaction between HDACs and GCLC can inhibit the drug-metabolizing process of Glutamate-cysteine ligase catalytic.
DME0485	MIRNA_ID	MIMAT0026554	PROTNAME	hsa-miR-433-5p
DME0485	MIRNA_ID	MIMAT0026554	HPPI_DIS	Health [ICD-11: N.A.]
DME0485	MIRNA_ID	MIMAT0026554	MOFCLASS	Non-coding RNA regulation
DME0485	MIRNA_ID	MIMAT0026554	MOFDETAI	microRNA regulation
DME0485	MIRNA_ID	MIMAT0026554	CELLLINE	Human umbilical vein endothelial cell line
DME0485	MIRNA_ID	MIMAT0026554	PPI_SUMM	hsa-miR-433-5p--GCLC regulation
DME0485	MIRNA_ID	MIMAT0026554	DESCRIPT	hsa-miR-433-5p is reported to suppress GCLC mRNA translation by binding to the 3' untranslated region (3'UTR) of GCLC mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glutamate-cysteine ligase catalytic.
DME0485	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0485	UNIPROID	SP1_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0485	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0485	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0485	UNIPROID	SP1_HUMAN	CELLLINE	HL-60/ADR cell line
DME0485	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-GCLC interaction
DME0485	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of GCLC gene, which leads to an increased expression of the drug-metabolizing enzyme Glutamate-cysteine ligase catalytic. As a result, the interaction between SP1 and GCLC can activate the drug-metabolizing process of Glutamate-cysteine ligase catalytic.
DME0485	UNIPROID	MTF1_HUMAN	PROTNAME	Transcription factor MTF-1 (MTF1)
DME0485	UNIPROID	MTF1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0485	UNIPROID	MTF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0485	UNIPROID	MTF1_HUMAN	MOFDETAI	Activation
DME0485	UNIPROID	MTF1_HUMAN	CELLLINE	HepG2 cell line
DME0485	UNIPROID	MTF1_HUMAN	PPI_SUMM	MTF1-GCLC interaction
DME0485	UNIPROID	MTF1_HUMAN	DESCRIPT	Transcription factor MTF-1 (MTF1) is reported to activate the transcription of GCLC gene, which leads to an increased expression of the drug-metabolizing enzyme Glutamate-cysteine ligase catalytic. As a result, the interaction between MTF1 and GCLC can activate the drug-metabolizing process of Glutamate-cysteine ligase catalytic.
DME0485	UNIPROID	NF2L2_HUMAN	PROTNAME	NFE2-related factor 2 (NFE2L2)
DME0485	UNIPROID	NF2L2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0485	UNIPROID	NF2L2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0485	UNIPROID	NF2L2_HUMAN	MOFDETAI	Repression
DME0485	UNIPROID	NF2L2_HUMAN	CELLLINE	HepG2 cell line
DME0485	UNIPROID	NF2L2_HUMAN	PPI_SUMM	NFE2L2-GCLC interaction
DME0485	UNIPROID	NF2L2_HUMAN	DESCRIPT	NFE2-related factor 2 (NFE2L2) is reported to repress the transcription of GCLC gene, which leads to a decreased expression of the drug-metabolizing enzyme Glutamate-cysteine ligase catalytic. As a result, the interaction between NFE2L2 and GCLC can repress the drug-metabolizing process of Glutamate-cysteine ligase catalytic.
DME0486	DME___ID	DME0486
DME0486	DME_NAME	Glutamate-cysteine ligase regulatory (GCLM)
DME0486	SPESNAME	Homo sapiens
DME0486	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0486	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0486	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0486	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0486	UNIPROID	HDAC1_HUMAN	CELLLINE	Mouse Model
DME0486	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-GCLM interaction
DME0486	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the GCLM gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Glutamate-cysteine ligase regulatory. As a result, the interaction between HDACs and GCLM can inhibit the drug-metabolizing process of Glutamate-cysteine ligase regulatory.
DME0486	MIRNA_ID	MIMAT0026554	PROTNAME	hsa-miR-433-5p
DME0486	MIRNA_ID	MIMAT0026554	HPPI_DIS	Health [ICD-11: N.A.]
DME0486	MIRNA_ID	MIMAT0026554	MOFCLASS	Non-coding RNA regulation
DME0486	MIRNA_ID	MIMAT0026554	MOFDETAI	microRNA regulation
DME0486	MIRNA_ID	MIMAT0026554	CELLLINE	Human umbilical vein endothelial cell line
DME0486	MIRNA_ID	MIMAT0026554	PPI_SUMM	hsa-miR-433-5p--GCLM regulation
DME0486	MIRNA_ID	MIMAT0026554	DESCRIPT	hsa-miR-433-5p is reported to suppress GCLM mRNA translation by binding to the 3' untranslated region (3'UTR) of GCLM mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glutamate-cysteine ligase regulatory.
DME0487	DME___ID	DME0487
DME0487	DME_NAME	Delta-aminolevulinate synthase 2 (ALAS2)
DME0487	SPESNAME	Homo sapiens
DME0487	UNIPROID	HAT1_HUMAN	PROTNAME	Histone acetyltransferases (HATs)
DME0487	UNIPROID	HAT1_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0487	UNIPROID	HAT1_HUMAN	MOFCLASS	Histone modification
DME0487	UNIPROID	HAT1_HUMAN	MOFDETAI	Histone hyperacetylation
DME0487	UNIPROID	HAT1_HUMAN	CELLLINE	K562 cell line
DME0487	UNIPROID	HAT1_HUMAN	PPI_SUMM	HATs-ALAS2 interaction
DME0487	UNIPROID	HAT1_HUMAN	DESCRIPT	Histone acetyltransferases (HATs) are reported to acetylate the ALAS2 gene and thereby activate the transcriptional activity of the drug-metabolizing enzyme Delta-aminolevulinate synthase 2. As a result, the interaction between HATs and ALAS2 can enhance the drug-metabolizing process of Delta-aminolevulinate synthase 2.
DME0487	UNIPROID	HIF1A_HUMAN	PROTNAME	ARNT-interacting protein (HIF1A)
DME0487	UNIPROID	HIF1A_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0487	UNIPROID	HIF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0487	UNIPROID	HIF1A_HUMAN	MOFDETAI	Activation
DME0487	UNIPROID	HIF1A_HUMAN	CELLLINE	K562 cell line
DME0487	UNIPROID	HIF1A_HUMAN	PPI_SUMM	HIF1A-ALAS2 interaction
DME0487	UNIPROID	HIF1A_HUMAN	DESCRIPT	ARNT-interacting protein (HIF1A) is reported to activate the transcription of ALAS2 gene, which leads to an increased expression of the drug-metabolizing enzyme Delta-aminolevulinate synthase 2. As a result, the interaction between HIF1A and ALAS2 can activate the drug-metabolizing process of Delta-aminolevulinate synthase 2.
DME0487	UNIPROID	HIF1A_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0487	UNIPROID	HIF1A_HUMAN	CELLLINE	MCF-7 cell line
DME0489	DME___ID	DME0489
DME0489	DME_NAME	Liver-type arginase (ARG1)
DME0489	SPESNAME	Homo sapiens
DME0489	UNIPROID	ANDR_HUMAN	PROTNAME	Androgen receptor (AR)
DME0489	UNIPROID	ANDR_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0489	UNIPROID	ANDR_HUMAN	MOFCLASS	Transcription-factor regulation
DME0489	UNIPROID	ANDR_HUMAN	MOFDETAI	Activation
DME0489	UNIPROID	ANDR_HUMAN	CELLLINE	LNCaP, 22Rv1, DU145 and PC3 cell lines
DME0489	UNIPROID	ANDR_HUMAN	PPI_SUMM	AR-ARG1 interaction
DME0489	UNIPROID	ANDR_HUMAN	DESCRIPT	Androgen receptor (AR) is reported to activate the transcription of ARG1 gene, which leads to an increased expression of the drug-metabolizing enzyme Liver-type arginase. As a result, the interaction between AR and ARG1 can activate the drug-metabolizing process of Liver-type arginase.
DME0494	DME___ID	DME0494
DME0494	DME_NAME	Insulin-degrading enzyme (IDE)
DME0494	SPESNAME	Homo sapiens
DME0494	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0494	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0494	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0494	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0494	UNIPROID	HDAC1_HUMAN	CELLLINE	SH-SY5Y cell line
DME0494	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-IDE interaction
DME0494	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the IDE gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Insulin-degrading enzyme. As a result, the interaction between HDACs and IDE can inhibit the drug-metabolizing process of Insulin-degrading enzyme.
DME0494	UNIPROID	NF2L1_HUMAN	PROTNAME	NFE2-related factor 1 (NFE2L1)
DME0494	UNIPROID	NF2L1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0494	UNIPROID	NF2L1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0494	UNIPROID	NF2L1_HUMAN	MOFDETAI	Activation
DME0494	UNIPROID	NF2L1_HUMAN	CELLLINE	NIH-3T3 and HeLa cell lines
DME0494	UNIPROID	NF2L1_HUMAN	PPI_SUMM	NFE2L1-IDE interaction
DME0494	UNIPROID	NF2L1_HUMAN	DESCRIPT	NFE2-related factor 1 (NFE2L1) is reported to activate the transcription of IDE gene, which leads to an increased expression of the drug-metabolizing enzyme Insulin-degrading enzyme. As a result, the interaction between NFE2L1 and IDE can activate the drug-metabolizing process of Insulin-degrading enzyme.
DME0495	DME___ID	DME0495
DME0495	DME_NAME	Tyrosine-protein phosphatase non-receptor 1 (PTP1B)
DME0495	SPESNAME	Homo sapiens
DME0495	MIRNA_ID	MIMAT0000267	PROTNAME	hsa-miR-210-3p
DME0495	MIRNA_ID	MIMAT0000267	HPPI_DIS	Health [ICD-11: N.A.]
DME0495	MIRNA_ID	MIMAT0000267	MOFCLASS	Non-coding RNA regulation
DME0495	MIRNA_ID	MIMAT0000267	MOFDETAI	microRNA regulation
DME0495	MIRNA_ID	MIMAT0000267	CELLLINE	HEK293 cell line
DME0495	MIRNA_ID	MIMAT0000267	PPI_SUMM	hsa-miR-210-3p--PTPN1 regulation
DME0495	MIRNA_ID	MIMAT0000267	DESCRIPT	hsa-miR-210-3p is reported to suppress PTPN1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTPN1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Tyrosine-protein phosphatase non-receptor 1.
DME0495	MIRNA_ID	MIMAT0000421	PROTNAME	hsa-miR-122-5p
DME0495	MIRNA_ID	MIMAT0000421	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0495	MIRNA_ID	MIMAT0000421	MOFCLASS	Non-coding RNA regulation
DME0495	MIRNA_ID	MIMAT0000421	MOFDETAI	microRNA regulation
DME0495	MIRNA_ID	MIMAT0000421	CELLLINE	HepG2 cell line
DME0495	MIRNA_ID	MIMAT0000421	PPI_SUMM	hsa-miR-122-5p--PTPN1 regulation
DME0495	MIRNA_ID	MIMAT0000421	DESCRIPT	hsa-miR-122-5p is reported to suppress PTPN1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTPN1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Tyrosine-protein phosphatase non-receptor 1.
DME0495	MIRNA_ID	MIMAT0004683	PROTNAME	hsa-miR-362-3p
DME0495	MIRNA_ID	MIMAT0004683	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0495	MIRNA_ID	MIMAT0004683	MOFCLASS	Non-coding RNA regulation
DME0495	MIRNA_ID	MIMAT0004683	MOFDETAI	microRNA regulation
DME0495	MIRNA_ID	MIMAT0004683	CELLLINE	Colorectal cancer cells
DME0495	MIRNA_ID	MIMAT0004683	PPI_SUMM	hsa-miR-362-3p--PTPN1 regulation
DME0495	MIRNA_ID	MIMAT0004683	DESCRIPT	hsa-miR-362-3p is reported to suppress PTPN1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTPN1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Tyrosine-protein phosphatase non-receptor 1.
DME0496	DME___ID	DME0496
DME0496	DME_NAME	Phosphoenolpyruvate carboxykinase (PCK1)
DME0496	SPESNAME	Homo sapiens
DME0496	UNIPROID	HAT1_HUMAN	PROTNAME	Histone acetyltransferases (HATs)
DME0496	UNIPROID	HAT1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0496	UNIPROID	HAT1_HUMAN	MOFCLASS	Histone modification
DME0496	UNIPROID	HAT1_HUMAN	MOFDETAI	Histone hyperacetylation
DME0496	UNIPROID	HAT1_HUMAN	CELLLINE	HepG2 cell line
DME0496	UNIPROID	HAT1_HUMAN	PPI_SUMM	HATs-PCK1 interaction
DME0496	UNIPROID	HAT1_HUMAN	DESCRIPT	Histone acetyltransferases (HATs) are reported to acetylate the PCK1 gene and thereby activate the transcriptional activity of the drug-metabolizing enzyme Phosphoenolpyruvate carboxykinase. As a result, the interaction between HATs and PCK1 can enhance the drug-metabolizing process of Phosphoenolpyruvate carboxykinase.
DME0496	UNIPROID	HDAC4_HUMAN	PROTNAME	Histone deacetylase 4 (HDAC4)
DME0496	UNIPROID	HDAC4_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0496	UNIPROID	HDAC4_HUMAN	MOFCLASS	Histone modification
DME0496	UNIPROID	HDAC4_HUMAN	MOFDETAI	Histone hypoacetylation
DME0496	UNIPROID	HDAC4_HUMAN	CELLLINE	HepG2 cell line
DME0496	UNIPROID	HDAC4_HUMAN	PPI_SUMM	HDAC4-PCK1 interaction
DME0496	UNIPROID	HDAC4_HUMAN	DESCRIPT	Histone deacetylase 4 (HDAC4) is reported to deacetylate the PCK1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Phosphoenolpyruvate carboxykinase. As a result, the interaction between HDAC4 and PCK1 can inhibit the drug-metabolizing process of Phosphoenolpyruvate carboxykinase.
DME0496	MIRNA_ID	MIMAT0003301	PROTNAME	hsa-miR-33b-5p
DME0496	MIRNA_ID	MIMAT0003301	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0496	MIRNA_ID	MIMAT0003301	MOFCLASS	Non-coding RNA regulation
DME0496	MIRNA_ID	MIMAT0003301	MOFDETAI	microRNA regulation
DME0496	MIRNA_ID	MIMAT0003301	CELLLINE	HepG2 cell line
DME0496	MIRNA_ID	MIMAT0003301	PPI_SUMM	hsa-miR-33b-5p--PCK1 regulation
DME0496	MIRNA_ID	MIMAT0003301	DESCRIPT	hsa-miR-33b-5p is reported to suppress PCK1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PCK1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Phosphoenolpyruvate carboxykinase.
DME0496	MIRNA_ID	MIMAT0004499	PROTNAME	hsa-miR-26a-1-3p
DME0496	MIRNA_ID	MIMAT0004499	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0496	MIRNA_ID	MIMAT0004499	MOFCLASS	Non-coding RNA regulation
DME0496	MIRNA_ID	MIMAT0004499	MOFDETAI	microRNA regulation
DME0496	MIRNA_ID	MIMAT0004499	CELLLINE	Huh7 cell line
DME0496	MIRNA_ID	MIMAT0004499	PPI_SUMM	hsa-miR-26a-1-3p--PCK1 regulation
DME0496	MIRNA_ID	MIMAT0004499	DESCRIPT	hsa-miR-26a-1-3p is reported to suppress PCK1 mRNA translation by binding to the 3' untranslated region (3'UTR) of PCK1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Phosphoenolpyruvate carboxykinase.
DME0496	UNIPROID	ATF2_HUMAN	PROTNAME	Activating TF factor 2 (ATF2)
DME0496	UNIPROID	ATF2_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0496	UNIPROID	ATF2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0496	UNIPROID	ATF2_HUMAN	MOFDETAI	Activation
DME0496	UNIPROID	ATF2_HUMAN	CELLLINE	HepG2 cell line
DME0496	UNIPROID	ATF2_HUMAN	PPI_SUMM	ATF2-PCK1 interaction
DME0496	UNIPROID	ATF2_HUMAN	DESCRIPT	Activating TF factor 2 (ATF2) is reported to activate the transcription of PCK1 gene, which leads to an increased expression of the drug-metabolizing enzyme Phosphoenolpyruvate carboxykinase. As a result, the interaction between ATF2 and PCK1 can activate the drug-metabolizing process of Phosphoenolpyruvate carboxykinase.
DME0496	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0496	UNIPROID	SP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0496	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0496	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0496	UNIPROID	SP1_HUMAN	CELLLINE	HepG2 cell line
DME0496	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-PCK1 interaction
DME0496	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of PCK1 gene, which leads to an increased expression of the drug-metabolizing enzyme Phosphoenolpyruvate carboxykinase. As a result, the interaction between SP1 and PCK1 can activate the drug-metabolizing process of Phosphoenolpyruvate carboxykinase.
DME0496	UNIPROID	SRBP1_HUMAN	PROTNAME	Sterol element-binding 1 (SREBF1)
DME0496	UNIPROID	SRBP1_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0496	UNIPROID	SRBP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0496	UNIPROID	SRBP1_HUMAN	MOFDETAI	Repression
DME0496	UNIPROID	SRBP1_HUMAN	CELLLINE	HepG2 cell line
DME0496	UNIPROID	SRBP1_HUMAN	PPI_SUMM	SREBF1-PCK1 interaction
DME0496	UNIPROID	SRBP1_HUMAN	DESCRIPT	Sterol element-binding 1 (SREBF1) is reported to repress the transcription of PCK1 gene, which leads to a decreased expression of the drug-metabolizing enzyme Phosphoenolpyruvate carboxykinase. As a result, the interaction between SREBF1 and PCK1 can repress the drug-metabolizing process of Phosphoenolpyruvate carboxykinase.
DME0497	DME___ID	DME0497
DME0497	DME_NAME	Red cell/liver pyruvate kinase (PKLR)
DME0497	SPESNAME	Homo sapiens
DME0497	MIRNA_ID	MIMAT0000763	PROTNAME	hsa-miR-338-3p
DME0497	MIRNA_ID	MIMAT0000763	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0497	MIRNA_ID	MIMAT0000763	MOFCLASS	Non-coding RNA regulation
DME0497	MIRNA_ID	MIMAT0000763	MOFDETAI	microRNA regulation
DME0497	MIRNA_ID	MIMAT0000763	CELLLINE	SMMC-7721 cell line
DME0497	MIRNA_ID	MIMAT0000763	PPI_SUMM	hsa-miR-338-3p--PKLR regulation
DME0497	MIRNA_ID	MIMAT0000763	DESCRIPT	hsa-miR-338-3p is reported to suppress PKLR mRNA translation by binding to the 3' untranslated region (3'UTR) of PKLR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Red cell/liver pyruvate kinase.
DME0506	DME___ID	DME0506
DME0506	DME_NAME	Factor inhibiting HIF-1 (HIF1AN)
DME0506	SPESNAME	Homo sapiens
DME0506	MIRNA_ID	MIMAT0000089	PROTNAME	hsa-miR-31-5p
DME0506	MIRNA_ID	MIMAT0000089	HPPI_DIS	Health [ICD-11: N.A.]
DME0506	MIRNA_ID	MIMAT0000089	MOFCLASS	Non-coding RNA regulation
DME0506	MIRNA_ID	MIMAT0000089	MOFDETAI	microRNA regulation
DME0506	MIRNA_ID	MIMAT0000089	CELLLINE	Human corneal epithelial keratinocytes
DME0506	MIRNA_ID	MIMAT0000089	PPI_SUMM	hsa-miR-31-5p--HIF1AN regulation
DME0506	MIRNA_ID	MIMAT0000089	DESCRIPT	hsa-miR-31-5p is reported to suppress HIF1AN mRNA translation by binding to the 3' untranslated region (3'UTR) of HIF1AN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Factor inhibiting HIF-1.
DME0506	MIRNA_ID	MIMAT0000079	PROTNAME	hsa-miR-24-1-5p
DME0506	MIRNA_ID	MIMAT0000079	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0506	MIRNA_ID	MIMAT0000079	MOFCLASS	Non-coding RNA regulation
DME0506	MIRNA_ID	MIMAT0000079	MOFDETAI	microRNA regulation
DME0506	MIRNA_ID	MIMAT0000079	CELLLINE	MCF-7 and BT-549 cell lines
DME0506	MIRNA_ID	MIMAT0000079	PPI_SUMM	hsa-miR-24-1-5p--HIF1AN regulation
DME0506	MIRNA_ID	MIMAT0000079	DESCRIPT	hsa-miR-24-1-5p is reported to suppress HIF1AN mRNA translation by binding to the 3' untranslated region (3'UTR) of HIF1AN mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Factor inhibiting HIF-1.
DME0507	DME___ID	DME0507
DME0507	DME_NAME	HIF-prolyl hydroxylase 3 (EGLN3)
DME0507	SPESNAME	Homo sapiens
DME0507	MIRNA_ID	MIMAT0000421	PROTNAME	hsa-miR-122-5p
DME0507	MIRNA_ID	MIMAT0000421	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0507	MIRNA_ID	MIMAT0000421	MOFCLASS	Non-coding RNA regulation
DME0507	MIRNA_ID	MIMAT0000421	MOFDETAI	microRNA regulation
DME0507	MIRNA_ID	MIMAT0000421	CELLLINE	Mahlavu and SK-HEP-1 cell lines
DME0507	MIRNA_ID	MIMAT0000421	PPI_SUMM	hsa-miR-122-5p--EGLN3 regulation
DME0507	MIRNA_ID	MIMAT0000421	DESCRIPT	hsa-miR-122-5p is reported to suppress EGLN3 mRNA translation by binding to the 3' untranslated region (3'UTR) of EGLN3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme HIF-prolyl hydroxylase 3.
DME0507	MIRNA_ID	MIMAT0000075	PROTNAME	hsa-miR-20a-5p
DME0507	MIRNA_ID	MIMAT0000075	HPPI_DIS	Health [ICD-11: N.A.]
DME0507	MIRNA_ID	MIMAT0000075	MOFCLASS	Non-coding RNA regulation
DME0507	MIRNA_ID	MIMAT0000075	MOFDETAI	microRNA regulation
DME0507	MIRNA_ID	MIMAT0000075	CELLLINE	Cardiomyocytes
DME0507	MIRNA_ID	MIMAT0000075	PPI_SUMM	hsa-miR-20a-5p--EGLN3 regulation
DME0507	MIRNA_ID	MIMAT0000075	DESCRIPT	hsa-miR-20a-5p is reported to suppress EGLN3 mRNA translation by binding to the 3' untranslated region (3'UTR) of EGLN3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme HIF-prolyl hydroxylase 3.
DME0512	DME___ID	DME0512
DME0512	DME_NAME	Dinucleosidetriphosphatase (FHIT)
DME0512	SPESNAME	Homo sapiens
DME0512	MIRNA_ID	MIMAT0000435	PROTNAME	hsa-miR-143-3p
DME0512	MIRNA_ID	MIMAT0000435	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0512	MIRNA_ID	MIMAT0000435	MOFCLASS	Non-coding RNA regulation
DME0512	MIRNA_ID	MIMAT0000435	MOFDETAI	microRNA regulation
DME0512	MIRNA_ID	MIMAT0000435	CELLLINE	A549 cell line
DME0512	MIRNA_ID	MIMAT0000435	PPI_SUMM	hsa-miR-143-3p--FHIT regulation
DME0512	MIRNA_ID	MIMAT0000435	DESCRIPT	hsa-miR-143-3p is reported to suppress FHIT mRNA translation by binding to the 3' untranslated region (3'UTR) of FHIT mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dinucleosidetriphosphatase.
DME0512	MIRNA_ID	MI0000293	PROTNAME	hsa-miR-217
DME0512	MIRNA_ID	MI0000293	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0512	MIRNA_ID	MI0000293	MOFCLASS	Non-coding RNA regulation
DME0512	MIRNA_ID	MI0000293	MOFDETAI	microRNA regulation
DME0512	MIRNA_ID	MI0000293	CELLLINE	A549 cell line
DME0512	MIRNA_ID	MI0000293	PPI_SUMM	hsa-miR-217--FHIT regulation
DME0512	MIRNA_ID	MI0000293	DESCRIPT	hsa-miR-217 is reported to suppress FHIT mRNA translation by binding to the 3' untranslated region (3'UTR) of FHIT mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dinucleosidetriphosphatase.
DME0512	MIRNA_ID	MIMAT0000760	PROTNAME	hsa-miR-331-3p
DME0512	MIRNA_ID	MIMAT0000760	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0512	MIRNA_ID	MIMAT0000760	MOFCLASS	Non-coding RNA regulation
DME0512	MIRNA_ID	MIMAT0000760	MOFDETAI	microRNA regulation
DME0512	MIRNA_ID	MIMAT0000760	CELLLINE	A549 cell line
DME0512	MIRNA_ID	MIMAT0000760	PPI_SUMM	hsa-miR-331-3p--FHIT regulation
DME0512	MIRNA_ID	MIMAT0000760	DESCRIPT	hsa-miR-331-3p is reported to suppress FHIT mRNA translation by binding to the 3' untranslated region (3'UTR) of FHIT mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dinucleosidetriphosphatase.
DME0512	MIRNA_ID	MIMAT0003294	PROTNAME	hsa-miR-625-5p
DME0512	MIRNA_ID	MIMAT0003294	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0512	MIRNA_ID	MIMAT0003294	MOFCLASS	Non-coding RNA regulation
DME0512	MIRNA_ID	MIMAT0003294	MOFDETAI	microRNA regulation
DME0512	MIRNA_ID	MIMAT0003294	CELLLINE	A549 cell line
DME0512	MIRNA_ID	MIMAT0003294	PPI_SUMM	hsa-miR-625-5p--FHIT regulation
DME0512	MIRNA_ID	MIMAT0003294	DESCRIPT	hsa-miR-625-5p is reported to suppress FHIT mRNA translation by binding to the 3' untranslated region (3'UTR) of FHIT mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dinucleosidetriphosphatase.
DME0512	UNIPROID	E2F1_HUMAN	PROTNAME	TF factor E2F1 (E2F1)
DME0512	UNIPROID	E2F1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0512	UNIPROID	E2F1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0512	UNIPROID	E2F1_HUMAN	MOFDETAI	Repression
DME0512	UNIPROID	E2F1_HUMAN	CELLLINE	Fibroblasts
DME0512	UNIPROID	E2F1_HUMAN	PPI_SUMM	E2F1-FHIT interaction
DME0512	UNIPROID	E2F1_HUMAN	DESCRIPT	TF factor E2F1 (E2F1) is reported to repress the transcription of FHIT gene, which leads to a decreased expression of the drug-metabolizing enzyme Dinucleosidetriphosphatase. As a result, the interaction between E2F1 and FHIT can repress the drug-metabolizing process of Dinucleosidetriphosphatase.
DME0523	DME___ID	DME0523
DME0523	DME_NAME	Glucose-6-phosphatase beta (G6PC3)
DME0523	SPESNAME	Homo sapiens
DME0523	UNIPROID	HDAC4_HUMAN	PROTNAME	Histone deacetylase 4 (HDAC4)
DME0523	UNIPROID	HDAC4_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0523	UNIPROID	HDAC4_HUMAN	MOFCLASS	Histone modification
DME0523	UNIPROID	HDAC4_HUMAN	MOFDETAI	Histone hypoacetylation
DME0523	UNIPROID	HDAC4_HUMAN	CELLLINE	HepG2 cell line
DME0523	UNIPROID	HDAC4_HUMAN	PPI_SUMM	HDAC4-G6PC3 interaction
DME0523	UNIPROID	HDAC4_HUMAN	DESCRIPT	Histone deacetylase 4 (HDAC4) is reported to deacetylate the G6PC3 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Glucose-6-phosphatase beta. As a result, the interaction between HDAC4 and G6PC3 can inhibit the drug-metabolizing process of Glucose-6-phosphatase beta.
DME0523	MIRNA_ID	MIMAT0000421	PROTNAME	hsa-miR-122-5p
DME0523	MIRNA_ID	MIMAT0000421	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0523	MIRNA_ID	MIMAT0000421	MOFCLASS	Non-coding RNA regulation
DME0523	MIRNA_ID	MIMAT0000421	MOFDETAI	microRNA regulation
DME0523	MIRNA_ID	MIMAT0000421	CELLLINE	Mahlavu and SK-HEP-1 cell lines
DME0523	MIRNA_ID	MIMAT0000421	PPI_SUMM	hsa-miR-122-5p--G6PC3 regulation
DME0523	MIRNA_ID	MIMAT0000421	DESCRIPT	hsa-miR-122-5p is reported to suppress G6PC3 mRNA translation by binding to the 3' untranslated region (3'UTR) of G6PC3 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Glucose-6-phosphatase beta.
DME0525	DME___ID	DME0525
DME0525	DME_NAME	Inositol polyphosphate 4-phosphatase I (INPP4A)
DME0525	SPESNAME	Homo sapiens
DME0525	MIRNA_ID	MIMAT0014990	PROTNAME	hsa-miR-3127-5p
DME0525	MIRNA_ID	MIMAT0014990	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0525	MIRNA_ID	MIMAT0014990	MOFCLASS	Non-coding RNA regulation
DME0525	MIRNA_ID	MIMAT0014990	MOFDETAI	microRNA regulation
DME0525	MIRNA_ID	MIMAT0014990	CELLLINE	Hepatocellular carcinoma cells
DME0525	MIRNA_ID	MIMAT0014990	PPI_SUMM	hsa-miR-3127-5p--INPP4A regulation
DME0525	MIRNA_ID	MIMAT0014990	DESCRIPT	hsa-miR-3127-5p is reported to suppress INPP4A mRNA translation by binding to the 3' untranslated region (3'UTR) of INPP4A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Inositol polyphosphate 4-phosphatase I.
DME0538	DME___ID	DME0538
DME0538	DME_NAME	Cyclic ADP-ribose hydrolase 1 (CD38)
DME0538	SPESNAME	Homo sapiens
DME0538	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0538	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Multiple myeloma [ICD-11: 2A83]
DME0538	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0538	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0538	UNIPROID	HDAC1_HUMAN	CELLLINE	Multiple myeloma cell line
DME0538	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CD38 interaction
DME0538	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CD38 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cyclic ADP-ribose hydrolase 1. As a result, the interaction between HDACs and CD38 can inhibit the drug-metabolizing process of Cyclic ADP-ribose hydrolase 1.
DME0538	MIRNA_ID	MIMAT0004597	PROTNAME	hsa-miR-140-3p
DME0538	MIRNA_ID	MIMAT0004597	HPPI_DIS	Health [ICD-11: N.A.]
DME0538	MIRNA_ID	MIMAT0004597	MOFCLASS	Non-coding RNA regulation
DME0538	MIRNA_ID	MIMAT0004597	MOFDETAI	microRNA regulation
DME0538	MIRNA_ID	MIMAT0004597	CELLLINE	Airway smooth muscle cells
DME0538	MIRNA_ID	MIMAT0004597	PPI_SUMM	hsa-miR-140-3p--CD38 regulation
DME0538	MIRNA_ID	MIMAT0004597	DESCRIPT	hsa-miR-140-3p is reported to suppress CD38 mRNA translation by binding to the 3' untranslated region (3'UTR) of CD38 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cyclic ADP-ribose hydrolase 1.
DME0538	UNIPROID	MYC_HUMAN	PROTNAME	Proto-oncogene c-Myc (MYC)
DME0538	UNIPROID	MYC_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0538	UNIPROID	MYC_HUMAN	MOFCLASS	Transcription-factor regulation
DME0538	UNIPROID	MYC_HUMAN	MOFDETAI	Activation
DME0538	UNIPROID	MYC_HUMAN	CELLLINE	EREB2-5 cell line
DME0538	UNIPROID	MYC_HUMAN	PPI_SUMM	MYC-CD38 interaction
DME0538	UNIPROID	MYC_HUMAN	DESCRIPT	Proto-oncogene c-Myc (MYC) is reported to activate the transcription of CD38 gene, which leads to an increased expression of the drug-metabolizing enzyme Cyclic ADP-ribose hydrolase 1. As a result, the interaction between MYC and CD38 can activate the drug-metabolizing process of Cyclic ADP-ribose hydrolase 1.
DME0539	DME___ID	DME0539
DME0539	DME_NAME	Nicotinate-nucleotide adenylyltransferase 2 (NMNAT2)
DME0539	SPESNAME	Homo sapiens
DME0539	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0539	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Melanoma [ICD-11: 2C30]
DME0539	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0539	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0539	UNIPROID	HDAC1_HUMAN	CELLLINE	SK-MEL-3 cell line
DME0539	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-NMNAT2 interaction
DME0539	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the NMNAT2 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Nicotinate-nucleotide adenylyltransferase 2. As a result, the interaction between HDACs and NMNAT2 can inhibit the drug-metabolizing process of Nicotinate-nucleotide adenylyltransferase 2.
DME0548	DME___ID	DME0548
DME0548	DME_NAME	Dimethylarginine dimethylaminohydrolase 1 (DDAH1)
DME0548	SPESNAME	Homo sapiens
DME0548	MIRNA_ID	MIMAT0000267	PROTNAME	hsa-miR-210-3p
DME0548	MIRNA_ID	MIMAT0000267	HPPI_DIS	Health [ICD-11: N.A.]
DME0548	MIRNA_ID	MIMAT0000267	MOFCLASS	Non-coding RNA regulation
DME0548	MIRNA_ID	MIMAT0000267	MOFDETAI	microRNA regulation
DME0548	MIRNA_ID	MIMAT0000267	CELLLINE	HEK293 cell line
DME0548	MIRNA_ID	MIMAT0000267	PPI_SUMM	hsa-miR-210-3p--DDAH1 regulation
DME0548	MIRNA_ID	MIMAT0000267	DESCRIPT	hsa-miR-210-3p is reported to suppress DDAH1 mRNA translation by binding to the 3' untranslated region (3'UTR) of DDAH1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dimethylarginine dimethylaminohydrolase 1.
DME0548	MIRNA_ID	MIMAT0000076	PROTNAME	hsa-miR-21-5p
DME0548	MIRNA_ID	MIMAT0000076	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0548	MIRNA_ID	MIMAT0000076	MOFCLASS	Non-coding RNA regulation
DME0548	MIRNA_ID	MIMAT0000076	MOFDETAI	microRNA regulation
DME0548	MIRNA_ID	MIMAT0000076	CELLLINE	A549 cell line
DME0548	MIRNA_ID	MIMAT0000076	PPI_SUMM	hsa-miR-21-5p--DDAH1 regulation
DME0548	MIRNA_ID	MIMAT0000076	DESCRIPT	hsa-miR-21-5p is reported to suppress DDAH1 mRNA translation by binding to the 3' untranslated region (3'UTR) of DDAH1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Dimethylarginine dimethylaminohydrolase 1.
DME0561	DME___ID	DME0561
DME0561	DME_NAME	Matrix metalloproteinase-2 (MMP-2)
DME0561	SPESNAME	Homo sapiens
DME0561	UNIPROID	HDAC3_HUMAN	PROTNAME	Histone deacetylase 3 (HDAC3)
DME0561	UNIPROID	HDAC3_HUMAN	HPPI_DIS	Spinocerebellar ataxia type 3 [ICD-11: 8A03]
DME0561	UNIPROID	HDAC3_HUMAN	MOFCLASS	Histone modification
DME0561	UNIPROID	HDAC3_HUMAN	MOFDETAI	Histone hypoacetylation
DME0561	UNIPROID	HDAC3_HUMAN	CELLLINE	SCA3 cell model and human brain tissue
DME0561	UNIPROID	HDAC3_HUMAN	PPI_SUMM	HDAC3-MMP2 interaction
DME0561	UNIPROID	HDAC3_HUMAN	DESCRIPT	Histone deacetylase 3 (HDAC3) is reported to deacetylate the MMP2 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between HDAC3 and MMP2 can inhibit the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000070	PROTNAME	hsa-miR-17-5p
DME0561	MIRNA_ID	MIMAT0000070	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0561	MIRNA_ID	MIMAT0000070	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000070	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000070	CELLLINE	Hepatocellular carcinoma cells
DME0561	MIRNA_ID	MIMAT0000070	PPI_SUMM	hsa-miR-17-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000070	DESCRIPT	hsa-miR-17-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0002807	PROTNAME	hsa-miR-491-5p
DME0561	MIRNA_ID	MIMAT0002807	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0561	MIRNA_ID	MIMAT0002807	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0002807	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0002807	CELLLINE	HepG2, MHCC97H and MHCC97L cell lines
DME0561	MIRNA_ID	MIMAT0002807	PPI_SUMM	hsa-miR-491-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0002807	DESCRIPT	hsa-miR-491-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0004926	PROTNAME	hsa-miR-708-5p
DME0561	MIRNA_ID	MIMAT0004926	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0561	MIRNA_ID	MIMAT0004926	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0004926	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0004926	CELLLINE	A172 and T98G cell lines
DME0561	MIRNA_ID	MIMAT0004926	PPI_SUMM	hsa-miR-708-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0004926	DESCRIPT	hsa-miR-708-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000681	PROTNAME	hsa-miR-29c-3p
DME0561	MIRNA_ID	MIMAT0000681	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0561	MIRNA_ID	MIMAT0000681	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000681	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000681	CELLLINE	HGC-27, BGC-823, SGC-7901, MKN-25 and MGC-803 cell lines
DME0561	MIRNA_ID	MIMAT0000681	PPI_SUMM	hsa-miR-29c-3p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000681	DESCRIPT	hsa-miR-29c-3p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000278	PROTNAME	hsa-miR-221-3p
DME0561	MIRNA_ID	MIMAT0000278	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0561	MIRNA_ID	MIMAT0000278	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000278	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000278	CELLLINE	HuH28 and HuCCT1 cell lines
DME0561	MIRNA_ID	MIMAT0000278	PPI_SUMM	hsa-miR-221-3p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000278	DESCRIPT	hsa-miR-221-3p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000680	PROTNAME	hsa-miR-106b-5p
DME0561	MIRNA_ID	MIMAT0000680	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0561	MIRNA_ID	MIMAT0000680	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000680	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000680	CELLLINE	Breast cancer cells
DME0561	MIRNA_ID	MIMAT0000680	PPI_SUMM	hsa-miR-106b-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000680	DESCRIPT	hsa-miR-106b-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000691	PROTNAME	hsa-miR-130b-3p
DME0561	MIRNA_ID	MIMAT0000691	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0561	MIRNA_ID	MIMAT0000691	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000691	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000691	CELLLINE	M12 cell line
DME0561	MIRNA_ID	MIMAT0000691	PPI_SUMM	hsa-miR-130b-3p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000691	DESCRIPT	hsa-miR-130b-3p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0002853	PROTNAME	hsa-miR-519d-3p
DME0561	MIRNA_ID	MIMAT0002853	HPPI_DIS	Choriocarcinoma [ICD-11: 2C75]
DME0561	MIRNA_ID	MIMAT0002853	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0002853	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0002853	CELLLINE	Human choriocarcinoma JEG-3 cell line
DME0561	MIRNA_ID	MIMAT0002853	PPI_SUMM	hsa-miR-519d-3p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0002853	DESCRIPT	hsa-miR-519d-3p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000100	PROTNAME	hsa-miR-29b-3p
DME0561	MIRNA_ID	MIMAT0000100	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0561	MIRNA_ID	MIMAT0000100	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000100	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000100	CELLLINE	A549 cell line
DME0561	MIRNA_ID	MIMAT0000100	PPI_SUMM	hsa-miR-29b-3p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000100	DESCRIPT	hsa-miR-29b-3p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000275	PROTNAME	hsa-miR-218-5p
DME0561	MIRNA_ID	MIMAT0000275	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0561	MIRNA_ID	MIMAT0000275	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000275	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000275	CELLLINE	U373 cell line
DME0561	MIRNA_ID	MIMAT0000275	PPI_SUMM	hsa-miR-218-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000275	DESCRIPT	hsa-miR-218-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000683	PROTNAME	hsa-miR-302a-5p
DME0561	MIRNA_ID	MIMAT0000683	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0561	MIRNA_ID	MIMAT0000683	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000683	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000683	CELLLINE	SW480 cell line
DME0561	MIRNA_ID	MIMAT0000683	PPI_SUMM	hsa-miR-302a-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000683	DESCRIPT	hsa-miR-302a-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0031890	PROTNAME	hsa-miR-203a-5p
DME0561	MIRNA_ID	MIMAT0031890	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0561	MIRNA_ID	MIMAT0031890	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0031890	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0031890	CELLLINE	BT474 cell line
DME0561	MIRNA_ID	MIMAT0031890	PPI_SUMM	hsa-miR-203a-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0031890	DESCRIPT	hsa-miR-203a-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000086	PROTNAME	hsa-miR-29a-3p
DME0561	MIRNA_ID	MIMAT0000086	HPPI_DIS	Health [ICD-11: N.A.]
DME0561	MIRNA_ID	MIMAT0000086	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000086	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000086	CELLLINE	HEK293 cell line
DME0561	MIRNA_ID	MIMAT0000086	PPI_SUMM	hsa-miR-29a-3p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000086	DESCRIPT	hsa-miR-29a-3p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000435	PROTNAME	hsa-miR-143-3p
DME0561	MIRNA_ID	MIMAT0000435	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0561	MIRNA_ID	MIMAT0000435	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000435	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000435	CELLLINE	HepG2 cell line
DME0561	MIRNA_ID	MIMAT0000435	PPI_SUMM	hsa-miR-143-3p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000435	DESCRIPT	hsa-miR-143-3p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0002849	PROTNAME	hsa-miR-524-5p
DME0561	MIRNA_ID	MIMAT0002849	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0561	MIRNA_ID	MIMAT0002849	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0002849	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0002849	CELLLINE	SGC-7901 and MGC-803 cell lines
DME0561	MIRNA_ID	MIMAT0002849	PPI_SUMM	hsa-miR-524-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0002849	DESCRIPT	hsa-miR-524-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0000423	PROTNAME	hsa-miR-125b-5p
DME0561	MIRNA_ID	MIMAT0000423	HPPI_DIS	Health [ICD-11: N.A.]
DME0561	MIRNA_ID	MIMAT0000423	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0000423	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0000423	CELLLINE	HaCaT cell line
DME0561	MIRNA_ID	MIMAT0000423	PPI_SUMM	hsa-miR-125b-5p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0000423	DESCRIPT	hsa-miR-125b-5p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0001631	PROTNAME	hsa-miR-451a
DME0561	MIRNA_ID	MIMAT0001631	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0561	MIRNA_ID	MIMAT0001631	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0001631	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0001631	CELLLINE	SGC-7901 cell line
DME0561	MIRNA_ID	MIMAT0001631	PPI_SUMM	hsa-miR-451a--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0001631	DESCRIPT	hsa-miR-451a is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	MIRNA_ID	MIMAT0002858	PROTNAME	hsa-miR-520g-3p
DME0561	MIRNA_ID	MIMAT0002858	HPPI_DIS	Health [ICD-11: N.A.]
DME0561	MIRNA_ID	MIMAT0002858	MOFCLASS	Non-coding RNA regulation
DME0561	MIRNA_ID	MIMAT0002858	MOFDETAI	microRNA regulation
DME0561	MIRNA_ID	MIMAT0002858	CELLLINE	HTR-8/SVneo cell line
DME0561	MIRNA_ID	MIMAT0002858	PPI_SUMM	hsa-miR-520g-3p--MMP2 regulation
DME0561	MIRNA_ID	MIMAT0002858	DESCRIPT	hsa-miR-520g-3p is reported to suppress MMP2 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2.
DME0561	UNIPROID	STAT3_HUMAN	PROTNAME	STAT 3 (STAT3)
DME0561	UNIPROID	STAT3_HUMAN	HPPI_DIS	Pancreatic adenocarcinoma [ICD-11: 2C10]
DME0561	UNIPROID	STAT3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	STAT3_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	STAT3_HUMAN	CELLLINE	SW1990 cell line
DME0561	UNIPROID	STAT3_HUMAN	PPI_SUMM	STAT3-MMP2 interaction
DME0561	UNIPROID	STAT3_HUMAN	DESCRIPT	STAT 3 (STAT3) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between STAT3 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	HIF1A_HUMAN	PROTNAME	ARNT-interacting protein (HIF1A)
DME0561	UNIPROID	HIF1A_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0561	UNIPROID	HIF1A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	HIF1A_HUMAN	MOFDETAI	Repression
DME0561	UNIPROID	HIF1A_HUMAN	CELLLINE	U87MG, U251MG, U373MG and LN18 cell lines
DME0561	UNIPROID	HIF1A_HUMAN	PPI_SUMM	HIF1A-MMP2 interaction
DME0561	UNIPROID	HIF1A_HUMAN	DESCRIPT	ARNT-interacting protein (HIF1A) is reported to repress the transcription of MMP2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between HIF1A and MMP2 can repress the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	HIF1A_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0561	UNIPROID	HIF1A_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	HIF1A_HUMAN	CELLLINE	CL1-5 cell line
DME0561	UNIPROID	HIF1A_HUMAN	DESCRIPT	ARNT-interacting protein (HIF1A) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between HIF1A and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0561	UNIPROID	SP1_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0561	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	SP1_HUMAN	CELLLINE	LN-18, LN-382, U87MG, U251MG, LN-444, SNB19, U118MG and LN-428 cell lines
DME0561	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-MMP2 interaction
DME0561	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between SP1 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	TWST1_HUMAN	PROTNAME	Twist-related 1 (TWIST1)
DME0561	UNIPROID	TWST1_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0561	UNIPROID	TWST1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	TWST1_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	TWST1_HUMAN	CELLLINE	T98G, SNB19, SF767 and U87MG cell lines
DME0561	UNIPROID	TWST1_HUMAN	PPI_SUMM	TWIST1-MMP2 interaction
DME0561	UNIPROID	TWST1_HUMAN	DESCRIPT	Twist-related 1 (TWIST1) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between TWIST1 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	TWST2_HUMAN	PROTNAME	Twist-related 2 (TWIST2)
DME0561	UNIPROID	TWST2_HUMAN	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0561	UNIPROID	TWST2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	TWST2_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	TWST2_HUMAN	CELLLINE	T98G, SNB19, SF767 and U87MG cell lines
DME0561	UNIPROID	TWST2_HUMAN	PPI_SUMM	TWIST2-MMP2 interaction
DME0561	UNIPROID	TWST2_HUMAN	DESCRIPT	Twist-related 2 (TWIST2) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between TWIST2 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	HXB7_HUMAN	PROTNAME	Homeobox protein Hox-B7 (HOXB7)
DME0561	UNIPROID	HXB7_HUMAN	HPPI_DIS	Multiple myeloma [ICD-11: 2A83]
DME0561	UNIPROID	HXB7_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	HXB7_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	HXB7_HUMAN	CELLLINE	Multiple myeloma cell line
DME0561	UNIPROID	HXB7_HUMAN	PPI_SUMM	HOXB7-MMP2 interaction
DME0561	UNIPROID	HXB7_HUMAN	DESCRIPT	Homeobox protein Hox-B7 (HOXB7) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between HOXB7 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0561	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Fibrosarcoma [ICD-11: 2B5J]
DME0561	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	NFKB1_HUMAN	CELLLINE	HT1080 cell line
DME0561	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-MMP2 interaction
DME0561	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between NFKB1 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0561	UNIPROID	TF65_HUMAN	HPPI_DIS	Fibrosarcoma [ICD-11: 2B5J]
DME0561	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	TF65_HUMAN	CELLLINE	HT1080 cell line
DME0561	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-MMP2 interaction
DME0561	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between RELA and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	P53_HUMAN	PROTNAME	Tumor suppressor p53 (TP53)
DME0561	UNIPROID	P53_HUMAN	HPPI_DIS	Fibrosarcoma [ICD-11: 2B5J]
DME0561	UNIPROID	P53_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	P53_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	P53_HUMAN	CELLLINE	Human fibrosarcoma HT1080 cell line
DME0561	UNIPROID	P53_HUMAN	PPI_SUMM	TP53-MMP2 interaction
DME0561	UNIPROID	P53_HUMAN	DESCRIPT	Tumor suppressor p53 (TP53) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between TP53 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	ATF3_HUMAN	PROTNAME	Activating TF factor 3 (ATF3)
DME0561	UNIPROID	ATF3_HUMAN	HPPI_DIS	Fibrosarcoma [ICD-11: 2B5J]
DME0561	UNIPROID	ATF3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	ATF3_HUMAN	MOFDETAI	Repression
DME0561	UNIPROID	ATF3_HUMAN	CELLLINE	HT1080 cell line
DME0561	UNIPROID	ATF3_HUMAN	PPI_SUMM	ATF3-MMP2 interaction
DME0561	UNIPROID	ATF3_HUMAN	DESCRIPT	Activating TF factor 3 (ATF3) is reported to repress the transcription of MMP2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between ATF3 and MMP2 can repress the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	KLF4_HUMAN	PROTNAME	Krueppel-like factor 4 (KLF4)
DME0561	UNIPROID	KLF4_HUMAN	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0561	UNIPROID	KLF4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	KLF4_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	KLF4_HUMAN	CELLLINE	MKN-45 cell line
DME0561	UNIPROID	KLF4_HUMAN	PPI_SUMM	KLF4-MMP2 interaction
DME0561	UNIPROID	KLF4_HUMAN	DESCRIPT	Krueppel-like factor 4 (KLF4) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between KLF4 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	HTAI2_HUMAN	PROTNAME	Oxidoreductase HTATIP2 (HTATIP2)
DME0561	UNIPROID	HTAI2_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0561	UNIPROID	HTAI2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	HTAI2_HUMAN	MOFDETAI	Repression
DME0561	UNIPROID	HTAI2_HUMAN	CELLLINE	A549, NCI-H460, SK-MES-1, LTEP-a-2 and H1299 cell lines
DME0561	UNIPROID	HTAI2_HUMAN	PPI_SUMM	HTATIP2-MMP2 interaction
DME0561	UNIPROID	HTAI2_HUMAN	DESCRIPT	Oxidoreductase HTATIP2 (HTATIP2) is reported to repress the transcription of MMP2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between HTATIP2 and MMP2 can repress the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	JUN_HUMAN	PROTNAME	Transcription factor AP-1 (JUN)
DME0561	UNIPROID	JUN_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0561	UNIPROID	JUN_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	JUN_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	JUN_HUMAN	CELLLINE	MCF-7, MDA-MB-231, MDA-MB-468 and MDA-MB-435 cell lines
DME0561	UNIPROID	JUN_HUMAN	PPI_SUMM	JUN-MMP2 interaction
DME0561	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between JUN and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	MUSC_HUMAN	PROTNAME	Musculin (MSC)
DME0561	UNIPROID	MUSC_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0561	UNIPROID	MUSC_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	MUSC_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	MUSC_HUMAN	CELLLINE	MDA-MB-231 cell line
DME0561	UNIPROID	MUSC_HUMAN	PPI_SUMM	MSC-MMP2 interaction
DME0561	UNIPROID	MUSC_HUMAN	DESCRIPT	Musculin (MSC) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between MSC and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	EZH2_HUMAN	PROTNAME	Enhancer of zeste homolog 2 (EZH2)
DME0561	UNIPROID	EZH2_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0561	UNIPROID	EZH2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	EZH2_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	EZH2_HUMAN	CELLLINE	Cervical cancer cell line
DME0561	UNIPROID	EZH2_HUMAN	PPI_SUMM	EZH2-MMP2 interaction
DME0561	UNIPROID	EZH2_HUMAN	DESCRIPT	Enhancer of zeste homolog 2 (EZH2) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between EZH2 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	MZF1_HUMAN	PROTNAME	Myeloid zinc finger 1 (MZF1)
DME0561	UNIPROID	MZF1_HUMAN	HPPI_DIS	Cervical cancer [ICD-11: 2C77]
DME0561	UNIPROID	MZF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	MZF1_HUMAN	MOFDETAI	Repression
DME0561	UNIPROID	MZF1_HUMAN	CELLLINE	SiHa cell line
DME0561	UNIPROID	MZF1_HUMAN	PPI_SUMM	MZF1-MMP2 interaction
DME0561	UNIPROID	MZF1_HUMAN	DESCRIPT	Myeloid zinc finger 1 (MZF1) is reported to repress the transcription of MMP2 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between MZF1 and MMP2 can repress the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	RUNX2_HUMAN	PROTNAME	Runt transcription factor 2 (RUNX2)
DME0561	UNIPROID	RUNX2_HUMAN	HPPI_DIS	Thyroid cancer [ICD-11: 2D10]
DME0561	UNIPROID	RUNX2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	RUNX2_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	RUNX2_HUMAN	CELLLINE	WRO, TPC-1, KTC-1, 8505C, 8305C and TT cell lines
DME0561	UNIPROID	RUNX2_HUMAN	PPI_SUMM	RUNX2-MMP2 interaction
DME0561	UNIPROID	RUNX2_HUMAN	DESCRIPT	Runt transcription factor 2 (RUNX2) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between RUNX2 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	NR4A1_HUMAN	PROTNAME	Nuclear receptor family 4 A1 (NR4A1)
DME0561	UNIPROID	NR4A1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0561	UNIPROID	NR4A1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	NR4A1_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	NR4A1_HUMAN	CELLLINE	HTR-8/SVneo cell line
DME0561	UNIPROID	NR4A1_HUMAN	PPI_SUMM	NR4A1-MMP2 interaction
DME0561	UNIPROID	NR4A1_HUMAN	DESCRIPT	Nuclear receptor family 4 A1 (NR4A1) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between NR4A1 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	ATF2_HUMAN	PROTNAME	Activating TF factor 2 (ATF2)
DME0561	UNIPROID	ATF2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0561	UNIPROID	ATF2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	ATF2_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	ATF2_HUMAN	CELLLINE	MCF10A cell line
DME0561	UNIPROID	ATF2_HUMAN	PPI_SUMM	ATF2-MMP2 interaction
DME0561	UNIPROID	ATF2_HUMAN	DESCRIPT	Activating TF factor 2 (ATF2) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between ATF2 and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0561	UNIPROID	SRF_HUMAN	PROTNAME	Serum response factor (SRF)
DME0561	UNIPROID	SRF_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0561	UNIPROID	SRF_HUMAN	MOFCLASS	Transcription-factor regulation
DME0561	UNIPROID	SRF_HUMAN	MOFDETAI	Activation
DME0561	UNIPROID	SRF_HUMAN	CELLLINE	WI-38 and IMR-90 cell lines
DME0561	UNIPROID	SRF_HUMAN	PPI_SUMM	SRF-MMP2 interaction
DME0561	UNIPROID	SRF_HUMAN	DESCRIPT	Serum response factor (SRF) is reported to activate the transcription of MMP2 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-2. As a result, the interaction between SRF and MMP2 can activate the drug-metabolizing process of Matrix metalloproteinase-2.
DME0563	DME___ID	DME0563
DME0563	DME_NAME	Carboxypeptidase M (CPM)
DME0563	SPESNAME	Homo sapiens
DME0563	MIRNA_ID	MIMAT0000449	PROTNAME	hsa-miR-146a-5p
DME0563	MIRNA_ID	MIMAT0000449	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0563	MIRNA_ID	MIMAT0000449	MOFCLASS	Non-coding RNA regulation
DME0563	MIRNA_ID	MIMAT0000449	MOFDETAI	microRNA regulation
DME0563	MIRNA_ID	MIMAT0000449	CELLLINE	HT-29 cell line
DME0563	MIRNA_ID	MIMAT0000449	PPI_SUMM	hsa-miR-146a-5p--CPM regulation
DME0563	MIRNA_ID	MIMAT0000449	DESCRIPT	hsa-miR-146a-5p is reported to suppress CPM mRNA translation by binding to the 3' untranslated region (3'UTR) of CPM mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Carboxypeptidase M.
DME0564	DME___ID	DME0564
DME0564	DME_NAME	Matrix metalloproteinase-9 (MMP-9)
DME0564	SPESNAME	Homo sapiens
DME0564	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylase 1 (HDAC1)
DME0564	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Fibrosarcoma [ICD-11: 2B5J]
DME0564	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0564	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0564	UNIPROID	HDAC1_HUMAN	CELLLINE	HT1080 cell line
DME0564	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDAC1-MMP9 interaction
DME0564	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylase 1 (HDAC1) is reported to deacetylate the MMP9 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between HDAC1 and MMP9 can inhibit the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0001631	PROTNAME	hsa-miR-451a
DME0564	MIRNA_ID	MIMAT0001631	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0564	MIRNA_ID	MIMAT0001631	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0001631	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0001631	CELLLINE	A172, LN229 and U251 cell lines
DME0564	MIRNA_ID	MIMAT0001631	PPI_SUMM	hsa-miR-451a--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0001631	DESCRIPT	hsa-miR-451a is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000763	PROTNAME	hsa-miR-338-3p
DME0564	MIRNA_ID	MIMAT0000763	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0564	MIRNA_ID	MIMAT0000763	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000763	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000763	CELLLINE	SK-HEP-1 and SMMC-7721 cell lines
DME0564	MIRNA_ID	MIMAT0000763	PPI_SUMM	hsa-miR-338-3p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000763	DESCRIPT	hsa-miR-338-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000100	PROTNAME	hsa-miR-29b-3p
DME0564	MIRNA_ID	MIMAT0000100	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	MIRNA_ID	MIMAT0000100	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000100	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000100	CELLLINE	HEK293 cell line
DME0564	MIRNA_ID	MIMAT0000100	PPI_SUMM	hsa-miR-29b-3p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000100	DESCRIPT	hsa-miR-29b-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0026734	PROTNAME	hsa-miR-942-3p
DME0564	MIRNA_ID	MIMAT0026734	HPPI_DIS	Renal cell carcinoma [ICD-11: 2C90]
DME0564	MIRNA_ID	MIMAT0026734	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0026734	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0026734	CELLLINE	Metastatic renal cell carcinoma cells
DME0564	MIRNA_ID	MIMAT0026734	PPI_SUMM	hsa-miR-942-3p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0026734	DESCRIPT	hsa-miR-942-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000066	PROTNAME	hsa-let-7e-5p
DME0564	MIRNA_ID	MIMAT0000066	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	MIRNA_ID	MIMAT0000066	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000066	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000066	CELLLINE	Adipose-derived stem cells
DME0564	MIRNA_ID	MIMAT0000066	PPI_SUMM	hsa-let-7e-5p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000066	DESCRIPT	hsa-let-7e-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000770	PROTNAME	hsa-miR-133b
DME0564	MIRNA_ID	MIMAT0000770	HPPI_DIS	Renal cell carcinoma [ICD-11: 2C90]
DME0564	MIRNA_ID	MIMAT0000770	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000770	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000770	CELLLINE	786-O and A498 cell lines
DME0564	MIRNA_ID	MIMAT0000770	PPI_SUMM	hsa-miR-133b--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000770	DESCRIPT	hsa-miR-133b is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0026478	PROTNAME	hsa-miR-133a-5p
DME0564	MIRNA_ID	MIMAT0026478	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0564	MIRNA_ID	MIMAT0026478	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0026478	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0026478	CELLLINE	HepG2 and SMMC-7721 cell lines
DME0564	MIRNA_ID	MIMAT0026478	PPI_SUMM	hsa-miR-133a-5p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0026478	DESCRIPT	hsa-miR-133a-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000417	PROTNAME	hsa-miR-15b-5p
DME0564	MIRNA_ID	MIMAT0000417	HPPI_DIS	Glioblastoma [ICD-11: 2A00.00]
DME0564	MIRNA_ID	MIMAT0000417	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000417	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000417	CELLLINE	U87 cell line
DME0564	MIRNA_ID	MIMAT0000417	PPI_SUMM	hsa-miR-15b-5p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000417	DESCRIPT	hsa-miR-15b-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000683	PROTNAME	hsa-miR-302a-5p
DME0564	MIRNA_ID	MIMAT0000683	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0564	MIRNA_ID	MIMAT0000683	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000683	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000683	CELLLINE	SW480 cell line
DME0564	MIRNA_ID	MIMAT0000683	PPI_SUMM	hsa-miR-302a-5p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000683	DESCRIPT	hsa-miR-302a-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000426	PROTNAME	hsa-miR-132-3p
DME0564	MIRNA_ID	MIMAT0000426	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	MIRNA_ID	MIMAT0000426	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000426	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000426	CELLLINE	HEK293 cell line
DME0564	MIRNA_ID	MIMAT0000426	PPI_SUMM	hsa-miR-132-3p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000426	DESCRIPT	hsa-miR-132-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000435	PROTNAME	hsa-miR-143-3p
DME0564	MIRNA_ID	MIMAT0000435	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0564	MIRNA_ID	MIMAT0000435	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000435	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000435	CELLLINE	HepG2 cell line
DME0564	MIRNA_ID	MIMAT0000435	PPI_SUMM	hsa-miR-143-3p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000435	DESCRIPT	hsa-miR-143-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0002849	PROTNAME	hsa-miR-524-5p
DME0564	MIRNA_ID	MIMAT0002849	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0564	MIRNA_ID	MIMAT0002849	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0002849	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0002849	CELLLINE	SGC-7901 and MGC-803 cell lines
DME0564	MIRNA_ID	MIMAT0002849	PPI_SUMM	hsa-miR-524-5p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0002849	DESCRIPT	hsa-miR-524-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0002807	PROTNAME	hsa-miR-491-5p
DME0564	MIRNA_ID	MIMAT0002807	HPPI_DIS	Osteosarcoma [ICD-11: 2B51]
DME0564	MIRNA_ID	MIMAT0002807	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0002807	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0002807	CELLLINE	Osteosarcoma cells
DME0564	MIRNA_ID	MIMAT0002807	PPI_SUMM	hsa-miR-491-5p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0002807	DESCRIPT	hsa-miR-491-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000265	PROTNAME	hsa-miR-204-5p
DME0564	MIRNA_ID	MIMAT0000265	HPPI_DIS	Melanoma [ICD-11: 2C30]
DME0564	MIRNA_ID	MIMAT0000265	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000265	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000265	CELLLINE	A375 cell line
DME0564	MIRNA_ID	MIMAT0000265	PPI_SUMM	hsa-miR-204-5p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000265	DESCRIPT	hsa-miR-204-5p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	MIRNA_ID	MIMAT0000442	PROTNAME	hsa-miR-9-3p
DME0564	MIRNA_ID	MIMAT0000442	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0564	MIRNA_ID	MIMAT0000442	MOFCLASS	Non-coding RNA regulation
DME0564	MIRNA_ID	MIMAT0000442	MOFDETAI	microRNA regulation
DME0564	MIRNA_ID	MIMAT0000442	CELLLINE	OVCAR-3 cell line
DME0564	MIRNA_ID	MIMAT0000442	PPI_SUMM	hsa-miR-9-3p--MMP9 regulation
DME0564	MIRNA_ID	MIMAT0000442	DESCRIPT	hsa-miR-9-3p is reported to suppress MMP9 mRNA translation by binding to the 3' untranslated region (3'UTR) of MMP9 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9.
DME0564	UNIPROID	FOS_HUMAN	PROTNAME	Proto-oncogene c-Fos (FOS)
DME0564	UNIPROID	FOS_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	UNIPROID	FOS_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	FOS_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	FOS_HUMAN	CELLLINE	H9c2 cell line
DME0564	UNIPROID	FOS_HUMAN	PPI_SUMM	FOS-MMP9 interaction
DME0564	UNIPROID	FOS_HUMAN	DESCRIPT	Proto-oncogene c-Fos (FOS) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between FOS and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	JUN_HUMAN	PROTNAME	Transcription factor AP-1 (JUN)
DME0564	UNIPROID	JUN_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0564	UNIPROID	JUN_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	JUN_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	JUN_HUMAN	CELLLINE	MCF-7, MDA-MB-231, MDA-MB-468 and MDA-MB-435 cell lines
DME0564	UNIPROID	JUN_HUMAN	PPI_SUMM	JUN-MMP9 interaction
DME0564	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between JUN and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	JUN_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	UNIPROID	JUN_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	JUN_HUMAN	CELLLINE	Vascular smooth muscle cell line
DME0564	UNIPROID	JUN_HUMAN	DESCRIPT	Transcription factor AP-1 (JUN) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between JUN and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	AP2A_HUMAN	PROTNAME	TF factor AP-2-alpha (TFAP2A)
DME0564	UNIPROID	AP2A_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0564	UNIPROID	AP2A_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	AP2A_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	AP2A_HUMAN	CELLLINE	SW480 and KM12C cell lines
DME0564	UNIPROID	AP2A_HUMAN	PPI_SUMM	TFAP2A-MMP9 interaction
DME0564	UNIPROID	AP2A_HUMAN	DESCRIPT	TF factor AP-2-alpha (TFAP2A) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between TFAP2A and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0564	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	NFKB1_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	NFKB1_HUMAN	CELLLINE	Vascular smooth muscle cell line
DME0564	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-MMP9 interaction
DME0564	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between NFKB1 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	TF65_HUMAN	PROTNAME	Transcription factor p65 (RELA)
DME0564	UNIPROID	TF65_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0564	UNIPROID	TF65_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	TF65_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	TF65_HUMAN	CELLLINE	Mono-Mac-6 and RAW264.7 monocyte/macrophage cell lines
DME0564	UNIPROID	TF65_HUMAN	PPI_SUMM	RELA-MMP9 interaction
DME0564	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between RELA and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	TF65_HUMAN	HPPI_DIS	Fibrosarcoma [ICD-11: 2B5J]
DME0564	UNIPROID	TF65_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	TF65_HUMAN	CELLLINE	HT1080 cell line
DME0564	UNIPROID	TF65_HUMAN	DESCRIPT	Transcription factor p65 (RELA) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between RELA and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	KLF5_HUMAN	PROTNAME	Krueppel-like factor 5 (KLF5)
DME0564	UNIPROID	KLF5_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0564	UNIPROID	KLF5_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	KLF5_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	KLF5_HUMAN	CELLLINE	Caco-2 cell line
DME0564	UNIPROID	KLF5_HUMAN	PPI_SUMM	KLF5-MMP9 interaction
DME0564	UNIPROID	KLF5_HUMAN	DESCRIPT	Krueppel-like factor 5 (KLF5) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between KLF5 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	KLF5_HUMAN	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0564	UNIPROID	KLF5_HUMAN	CELLLINE	HepG2, HuH7 and HLE cell lines
DME0564	UNIPROID	STAT1_HUMAN	PROTNAME	STAT 1-alpha/beta (STAT1)
DME0564	UNIPROID	STAT1_HUMAN	HPPI_DIS	Chronic lymphocytic leukaemia [ICD-11: 2A82]
DME0564	UNIPROID	STAT1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	STAT1_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	STAT1_HUMAN	CELLLINE	B-cell chronic lymphocytic leukemia cell line
DME0564	UNIPROID	STAT1_HUMAN	PPI_SUMM	STAT1-MMP9 interaction
DME0564	UNIPROID	STAT1_HUMAN	DESCRIPT	STAT 1-alpha/beta (STAT1) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between STAT1 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	SMAD3_HUMAN	PROTNAME	MAD homolog 3 (SMAD3)
DME0564	UNIPROID	SMAD3_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0564	UNIPROID	SMAD3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	SMAD3_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	SMAD3_HUMAN	CELLLINE	Mono-Mac-6 and RAW264.7 monocyte/macrophage cell lines
DME0564	UNIPROID	SMAD3_HUMAN	PPI_SUMM	SMAD3-MMP9 interaction
DME0564	UNIPROID	SMAD3_HUMAN	DESCRIPT	MAD homolog 3 (SMAD3) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SMAD3 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	SIR1_HUMAN	PROTNAME	SIR2-like protein 1 (SIRT1)
DME0564	UNIPROID	SIR1_HUMAN	HPPI_DIS	Acute lymphoblastic leukemia [ICD-11: 2B33]
DME0564	UNIPROID	SIR1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	SIR1_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	SIR1_HUMAN	CELLLINE	U937 cell line
DME0564	UNIPROID	SIR1_HUMAN	PPI_SUMM	SIRT1-MMP9 interaction
DME0564	UNIPROID	SIR1_HUMAN	DESCRIPT	SIR2-like protein 1 (SIRT1) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SIRT1 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	ELF3_HUMAN	PROTNAME	E74-like factor 3 (ELF3)
DME0564	UNIPROID	ELF3_HUMAN	HPPI_DIS	Squamous cell carcinoma [ICD-11: 2B60]
DME0564	UNIPROID	ELF3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	ELF3_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	ELF3_HUMAN	CELLLINE	HSC-3 and KB cell lines
DME0564	UNIPROID	ELF3_HUMAN	PPI_SUMM	ELF3-MMP9 interaction
DME0564	UNIPROID	ELF3_HUMAN	DESCRIPT	E74-like factor 3 (ELF3) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between ELF3 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	RUNX3_HUMAN	PROTNAME	Runt transcription factor 3 (RUNX3)
DME0564	UNIPROID	RUNX3_HUMAN	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0564	UNIPROID	RUNX3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	RUNX3_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	RUNX3_HUMAN	CELLLINE	SGC7901 and MKN28 cell lines
DME0564	UNIPROID	RUNX3_HUMAN	PPI_SUMM	RUNX3-MMP9 interaction
DME0564	UNIPROID	RUNX3_HUMAN	DESCRIPT	Runt transcription factor 3 (RUNX3) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between RUNX3 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	SP1_HUMAN	PROTNAME	Transcription factor Sp1 (SP1)
DME0564	UNIPROID	SP1_HUMAN	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0564	UNIPROID	SP1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	SP1_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	SP1_HUMAN	CELLLINE	CT26 cell line
DME0564	UNIPROID	SP1_HUMAN	PPI_SUMM	SP1-MMP9 interaction
DME0564	UNIPROID	SP1_HUMAN	DESCRIPT	Transcription factor Sp1 (SP1) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SP1 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	ETS2_HUMAN	PROTNAME	Protein C-ets-2 (ETS2)
DME0564	UNIPROID	ETS2_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0564	UNIPROID	ETS2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	ETS2_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	ETS2_HUMAN	CELLLINE	A549 cell line
DME0564	UNIPROID	ETS2_HUMAN	PPI_SUMM	ETS2-MMP9 interaction
DME0564	UNIPROID	ETS2_HUMAN	DESCRIPT	Protein C-ets-2 (ETS2) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between ETS2 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	ELF4_HUMAN	PROTNAME	E74-like factor 4 (ELF4)
DME0564	UNIPROID	ELF4_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0564	UNIPROID	ELF4_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	ELF4_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	ELF4_HUMAN	CELLLINE	A549 cell line
DME0564	UNIPROID	ELF4_HUMAN	PPI_SUMM	ELF4-MMP9 interaction
DME0564	UNIPROID	ELF4_HUMAN	DESCRIPT	E74-like factor 4 (ELF4) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between ELF4 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	KLF8_HUMAN	PROTNAME	Krueppel-like factor 8 (KLF8)
DME0564	UNIPROID	KLF8_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0564	UNIPROID	KLF8_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	KLF8_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	KLF8_HUMAN	CELLLINE	MCF10A cell line
DME0564	UNIPROID	KLF8_HUMAN	PPI_SUMM	KLF8-MMP9 interaction
DME0564	UNIPROID	KLF8_HUMAN	DESCRIPT	Krueppel-like factor 8 (KLF8) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between KLF8 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	EP300_HUMAN	PROTNAME	His-acetyltransferase p300 (EP300)
DME0564	UNIPROID	EP300_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0564	UNIPROID	EP300_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	EP300_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	EP300_HUMAN	CELLLINE	MDA-MB-231 cell line
DME0564	UNIPROID	EP300_HUMAN	PPI_SUMM	EP300-MMP9 interaction
DME0564	UNIPROID	EP300_HUMAN	DESCRIPT	His-acetyltransferase p300 (EP300) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between EP300 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	STAT3_HUMAN	PROTNAME	STAT 3 (STAT3)
DME0564	UNIPROID	STAT3_HUMAN	HPPI_DIS	Breast cancer [ICD-11: 2C60-2C65]
DME0564	UNIPROID	STAT3_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	STAT3_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	STAT3_HUMAN	CELLLINE	MDA-MB-231 cell line
DME0564	UNIPROID	STAT3_HUMAN	PPI_SUMM	STAT3-MMP9 interaction
DME0564	UNIPROID	STAT3_HUMAN	DESCRIPT	STAT 3 (STAT3) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between STAT3 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	ETS1_HUMAN	PROTNAME	Protein C-ets-1 (ETS1)
DME0564	UNIPROID	ETS1_HUMAN	HPPI_DIS	Ovarian cancer [ICD-11: 2C73]
DME0564	UNIPROID	ETS1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	ETS1_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	ETS1_HUMAN	CELLLINE	SKOV3 cell line
DME0564	UNIPROID	ETS1_HUMAN	PPI_SUMM	ETS1-MMP9 interaction
DME0564	UNIPROID	ETS1_HUMAN	DESCRIPT	Protein C-ets-1 (ETS1) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between ETS1 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	SNAI2_HUMAN	PROTNAME	Zinc finger SNAI2 (SNAI2)
DME0564	UNIPROID	SNAI2_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0564	UNIPROID	SNAI2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	SNAI2_HUMAN	MOFDETAI	Activation
DME0564	UNIPROID	SNAI2_HUMAN	CELLLINE	PC3, DU145, 22RV1, and LNCaP cell lines
DME0564	UNIPROID	SNAI2_HUMAN	PPI_SUMM	SNAI2-MMP9 interaction
DME0564	UNIPROID	SNAI2_HUMAN	DESCRIPT	Zinc finger SNAI2 (SNAI2) is reported to activate the transcription of MMP9 gene, which leads to an increased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SNAI2 and MMP9 can activate the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	SPDEF_HUMAN	PROTNAME	Prostate-specific Ets (SPDEF)
DME0564	UNIPROID	SPDEF_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0564	UNIPROID	SPDEF_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	SPDEF_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	SPDEF_HUMAN	CELLLINE	PC3, LNCaP and C4-2B cell lines
DME0564	UNIPROID	SPDEF_HUMAN	PPI_SUMM	SPDEF-MMP9 interaction
DME0564	UNIPROID	SPDEF_HUMAN	DESCRIPT	Prostate-specific Ets (SPDEF) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SPDEF and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	PPARG_HUMAN	PROTNAME	PPA receptor gamma (PPARG)
DME0564	UNIPROID	PPARG_HUMAN	HPPI_DIS	Acute coronary syndrome [ICD-11: BA4Z]
DME0564	UNIPROID	PPARG_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	PPARG_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	PPARG_HUMAN	CELLLINE	Peripheral blood mononuclear cell line
DME0564	UNIPROID	PPARG_HUMAN	PPI_SUMM	PPARG-MMP9 interaction
DME0564	UNIPROID	PPARG_HUMAN	DESCRIPT	PPA receptor gamma (PPARG) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between PPARG and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	KLF6_HUMAN	PROTNAME	Krueppel-like factor 6 (KLF6)
DME0564	UNIPROID	KLF6_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	UNIPROID	KLF6_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	KLF6_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	KLF6_HUMAN	CELLLINE	Blood outgrowth endothelial cell line
DME0564	UNIPROID	KLF6_HUMAN	PPI_SUMM	KLF6-MMP9 interaction
DME0564	UNIPROID	KLF6_HUMAN	DESCRIPT	Krueppel-like factor 6 (KLF6) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between KLF6 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	SP2_HUMAN	PROTNAME	Transcription factor Sp2 (SP2)
DME0564	UNIPROID	SP2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	UNIPROID	SP2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	SP2_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	SP2_HUMAN	CELLLINE	Blood outgrowth endothelial cell line
DME0564	UNIPROID	SP2_HUMAN	PPI_SUMM	SP2-MMP9 interaction
DME0564	UNIPROID	SP2_HUMAN	DESCRIPT	Transcription factor Sp2 (SP2) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between SP2 and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	PPARA_HUMAN	PROTNAME	PPA receptor alpha (PPARA)
DME0564	UNIPROID	PPARA_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	UNIPROID	PPARA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	PPARA_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	PPARA_HUMAN	CELLLINE	hCMEC/D3 cell line
DME0564	UNIPROID	PPARA_HUMAN	PPI_SUMM	PPARA-MMP9 interaction
DME0564	UNIPROID	PPARA_HUMAN	DESCRIPT	PPA receptor alpha (PPARA) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between PPARA and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	IKKB_HUMAN	PROTNAME	I-kappa-B-kinase beta (IKBKB)
DME0564	UNIPROID	IKKB_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	UNIPROID	IKKB_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	IKKB_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	IKKB_HUMAN	CELLLINE	Human mesenchymal stem cell line
DME0564	UNIPROID	IKKB_HUMAN	PPI_SUMM	IKBKB-MMP9 interaction
DME0564	UNIPROID	IKKB_HUMAN	DESCRIPT	I-kappa-B-kinase beta (IKBKB) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between IKBKB and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0564	UNIPROID	C2TA_HUMAN	PROTNAME	MHC II transactivator (CIITA)
DME0564	UNIPROID	C2TA_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0564	UNIPROID	C2TA_HUMAN	MOFCLASS	Transcription-factor regulation
DME0564	UNIPROID	C2TA_HUMAN	MOFDETAI	Repression
DME0564	UNIPROID	C2TA_HUMAN	CELLLINE	STAT-1-deficient U3A cell line
DME0564	UNIPROID	C2TA_HUMAN	PPI_SUMM	CIITA-MMP9 interaction
DME0564	UNIPROID	C2TA_HUMAN	DESCRIPT	MHC II transactivator (CIITA) is reported to repress the transcription of MMP9 gene, which leads to a decreased expression of the drug-metabolizing enzyme Matrix metalloproteinase-9. As a result, the interaction between CIITA and MMP9 can repress the drug-metabolizing process of Matrix metalloproteinase-9.
DME0566	DME___ID	DME0566
DME0566	DME_NAME	Prostaglandin dehydrogenase 1 (HPGD)
DME0566	SPESNAME	Homo sapiens
DME0566	MIRNA_ID	MIMAT0000076	PROTNAME	hsa-miR-21-5p
DME0566	MIRNA_ID	MIMAT0000076	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0566	MIRNA_ID	MIMAT0000076	MOFCLASS	Non-coding RNA regulation
DME0566	MIRNA_ID	MIMAT0000076	MOFDETAI	microRNA regulation
DME0566	MIRNA_ID	MIMAT0000076	CELLLINE	CCLP1, SG231, HuCCT1 and TFK1 cell lines
DME0566	MIRNA_ID	MIMAT0000076	PPI_SUMM	hsa-miR-21-5p--HPGD regulation
DME0566	MIRNA_ID	MIMAT0000076	DESCRIPT	hsa-miR-21-5p is reported to suppress HPGD mRNA translation by binding to the 3' untranslated region (3'UTR) of HPGD mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin dehydrogenase 1.
DME0566	MIRNA_ID	MIMAT0004494	PROTNAME	hsa-miR-21-3p
DME0566	MIRNA_ID	MIMAT0004494	HPPI_DIS	Tongue squamous cell carcinoma [ICD-11: 2B62]
DME0566	MIRNA_ID	MIMAT0004494	MOFCLASS	Non-coding RNA regulation
DME0566	MIRNA_ID	MIMAT0004494	MOFDETAI	microRNA regulation
DME0566	MIRNA_ID	MIMAT0004494	CELLLINE	UM1, UM2, SCC9 and Tca8113 cell lines
DME0566	MIRNA_ID	MIMAT0004494	PPI_SUMM	hsa-miR-21-3p--HPGD regulation
DME0566	MIRNA_ID	MIMAT0004494	DESCRIPT	hsa-miR-21-3p is reported to suppress HPGD mRNA translation by binding to the 3' untranslated region (3'UTR) of HPGD mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin dehydrogenase 1.
DME0566	UNIPROID	SNAI2_HUMAN	PROTNAME	Zinc finger SNAI2 (SNAI2)
DME0566	UNIPROID	SNAI2_HUMAN	HPPI_DIS	Lung cancer [ICD-11: 2C25]
DME0566	UNIPROID	SNAI2_HUMAN	MOFCLASS	Transcription-factor regulation
DME0566	UNIPROID	SNAI2_HUMAN	MOFDETAI	Repression
DME0566	UNIPROID	SNAI2_HUMAN	CELLLINE	NSCLC cell line
DME0566	UNIPROID	SNAI2_HUMAN	PPI_SUMM	SNAI2-HPGD interaction
DME0566	UNIPROID	SNAI2_HUMAN	DESCRIPT	Zinc finger SNAI2 (SNAI2) is reported to repress the transcription of HPGD gene, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin dehydrogenase 1. As a result, the interaction between SNAI2 and HPGD can repress the drug-metabolizing process of Prostaglandin dehydrogenase 1.
DME0572	DME___ID	DME0572
DME0572	DME_NAME	Lipocalin-type prostaglandin-D synthase (PTGDS)
DME0572	SPESNAME	Homo sapiens
DME0572	UNIPROID	USF1_HUMAN	PROTNAME	Upstream stimulatory 1 (USF1)
DME0572	UNIPROID	USF1_HUMAN	HPPI_DIS	Medulloblastoma [ICD-11: 2A00.10]
DME0572	UNIPROID	USF1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0572	UNIPROID	USF1_HUMAN	MOFDETAI	Repression
DME0572	UNIPROID	USF1_HUMAN	CELLLINE	TE671 cell line
DME0572	UNIPROID	USF1_HUMAN	PPI_SUMM	USF1-PTGDS interaction
DME0572	UNIPROID	USF1_HUMAN	DESCRIPT	Upstream stimulatory 1 (USF1) is reported to repress the transcription of PTGDS gene, which leads to a decreased expression of the drug-metabolizing enzyme Lipocalin-type prostaglandin-D synthase. As a result, the interaction between USF1 and PTGDS can repress the drug-metabolizing process of Lipocalin-type prostaglandin-D synthase.
DME0572	UNIPROID	USF1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0572	UNIPROID	USF1_HUMAN	MOFDETAI	Activation
DME0572	UNIPROID	USF1_HUMAN	CELLLINE	Human brain-derived TE671 cell line
DME0572	UNIPROID	USF1_HUMAN	DESCRIPT	Upstream stimulatory 1 (USF1) is reported to activate the transcription of PTGDS gene, which leads to an increased expression of the drug-metabolizing enzyme Lipocalin-type prostaglandin-D synthase. As a result, the interaction between USF1 and PTGDS can activate the drug-metabolizing process of Lipocalin-type prostaglandin-D synthase.
DME0572	UNIPROID	AP2B_HUMAN	PROTNAME	TF factor AP-2-beta (TFAP2B)
DME0572	UNIPROID	AP2B_HUMAN	HPPI_DIS	Medulloblastoma [ICD-11: 2A00.10]
DME0572	UNIPROID	AP2B_HUMAN	MOFCLASS	Transcription-factor regulation
DME0572	UNIPROID	AP2B_HUMAN	MOFDETAI	Activation
DME0572	UNIPROID	AP2B_HUMAN	CELLLINE	TE671 cell line
DME0572	UNIPROID	AP2B_HUMAN	PPI_SUMM	TFAP2B-PTGDS interaction
DME0572	UNIPROID	AP2B_HUMAN	DESCRIPT	TF factor AP-2-beta (TFAP2B) is reported to activate the transcription of PTGDS gene, which leads to an increased expression of the drug-metabolizing enzyme Lipocalin-type prostaglandin-D synthase. As a result, the interaction between TFAP2B and PTGDS can activate the drug-metabolizing process of Lipocalin-type prostaglandin-D synthase.
DME0572	UNIPROID	HES1_HUMAN	PROTNAME	TF factor HES-1 (HES1)
DME0572	UNIPROID	HES1_HUMAN	HPPI_DIS	Medulloblastoma [ICD-11: 2A00.10]
DME0572	UNIPROID	HES1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0572	UNIPROID	HES1_HUMAN	MOFDETAI	Repression
DME0572	UNIPROID	HES1_HUMAN	CELLLINE	TE671 cell line
DME0572	UNIPROID	HES1_HUMAN	PPI_SUMM	HES1-PTGDS interaction
DME0572	UNIPROID	HES1_HUMAN	DESCRIPT	TF factor HES-1 (HES1) is reported to repress the transcription of PTGDS gene, which leads to a decreased expression of the drug-metabolizing enzyme Lipocalin-type prostaglandin-D synthase. As a result, the interaction between HES1 and PTGDS can repress the drug-metabolizing process of Lipocalin-type prostaglandin-D synthase.
DME0572	UNIPROID	NFKB1_HUMAN	PROTNAME	Nuclear factor kappa-B p105 (NFKB1)
DME0572	UNIPROID	NFKB1_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0572	UNIPROID	NFKB1_HUMAN	MOFCLASS	Transcription-factor regulation
DME0572	UNIPROID	NFKB1_HUMAN	MOFDETAI	Activation
DME0572	UNIPROID	NFKB1_HUMAN	CELLLINE	Human chondrocytes
DME0572	UNIPROID	NFKB1_HUMAN	PPI_SUMM	NFKB1-PTGDS interaction
DME0572	UNIPROID	NFKB1_HUMAN	DESCRIPT	Nuclear factor kappa-B p105 (NFKB1) is reported to activate the transcription of PTGDS gene, which leads to an increased expression of the drug-metabolizing enzyme Lipocalin-type prostaglandin-D synthase. As a result, the interaction between NFKB1 and PTGDS can activate the drug-metabolizing process of Lipocalin-type prostaglandin-D synthase.
DME0573	DME___ID	DME0573
DME0573	DME_NAME	Cathepsin K (CTSK)
DME0573	SPESNAME	Homo sapiens
DME0573	UNIPROID	MITF_HUMAN	PROTNAME	Microphthalmia-associated TF (MITF)
DME0573	UNIPROID	MITF_HUMAN	HPPI_DIS	Renal cell carcinoma [ICD-11: 2C90]
DME0573	UNIPROID	MITF_HUMAN	MOFCLASS	Transcription-factor regulation
DME0573	UNIPROID	MITF_HUMAN	MOFDETAI	Activation
DME0573	UNIPROID	MITF_HUMAN	CELLLINE	Renal cell carcinoma cell line
DME0573	UNIPROID	MITF_HUMAN	PPI_SUMM	MITF-CTSK interaction
DME0573	UNIPROID	MITF_HUMAN	DESCRIPT	Microphthalmia-associated TF (MITF) is reported to activate the transcription of CTSK gene, which leads to an increased expression of the drug-metabolizing enzyme Cathepsin K. As a result, the interaction between MITF and CTSK can activate the drug-metabolizing process of Cathepsin K.
DME0586	DME___ID	DME0586
DME0586	DME_NAME	Short-chain dehydrogenase/reductase retSDR8 (DHRS9)
DME0586	SPESNAME	Homo sapiens
DME0586	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0586	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Renal cell carcinoma [ICD-11: 2C90]
DME0586	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0586	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0586	UNIPROID	HDAC1_HUMAN	CELLLINE	Human renal cell carcinoma (RCC) lines
DME0586	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-DHRS9 interaction
DME0586	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the DHRS9 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Short-chain dehydrogenase/reductase retSDR8. As a result, the interaction between HDACs and DHRS9 can inhibit the drug-metabolizing process of Short-chain dehydrogenase/reductase retSDR8.
DME0588	DME___ID	DME0588
DME0588	DME_NAME	Serine racemase (SRR)
DME0588	SPESNAME	Homo sapiens
DME0588	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0588	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Neuroblastoma [ICD-11: 2A11]
DME0588	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0588	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0588	UNIPROID	HDAC1_HUMAN	CELLLINE	Neuro-2a cell line
DME0588	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-SRR interaction
DME0588	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the SRR gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Serine racemase. As a result, the interaction between HDACs and SRR can inhibit the drug-metabolizing process of Serine racemase.
DME0588	MIRNA_ID	MIMAT0004614	PROTNAME	hsa-miR-193a-5p
DME0588	MIRNA_ID	MIMAT0004614	HPPI_DIS	Osteosarcoma [ICD-11: 2B51]
DME0588	MIRNA_ID	MIMAT0004614	MOFCLASS	Non-coding RNA regulation
DME0588	MIRNA_ID	MIMAT0004614	MOFDETAI	microRNA regulation
DME0588	MIRNA_ID	MIMAT0004614	CELLLINE	MG63 cell line
DME0588	MIRNA_ID	MIMAT0004614	PPI_SUMM	hsa-miR-193a-5p--SRR regulation
DME0588	MIRNA_ID	MIMAT0004614	DESCRIPT	hsa-miR-193a-5p is reported to suppress SRR mRNA translation by binding to the 3' untranslated region (3'UTR) of SRR mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Serine racemase.
DME0588	UNIPROID	FOS_HUMAN	PROTNAME	Proto-oncogene c-Fos (FOS)
DME0588	UNIPROID	FOS_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0588	UNIPROID	FOS_HUMAN	MOFCLASS	Transcription-factor regulation
DME0588	UNIPROID	FOS_HUMAN	MOFDETAI	Activation
DME0588	UNIPROID	FOS_HUMAN	CELLLINE	HAPI, BV-2 and N9 cell lines
DME0588	UNIPROID	FOS_HUMAN	PPI_SUMM	FOS-SRR interaction
DME0588	UNIPROID	FOS_HUMAN	DESCRIPT	Proto-oncogene c-Fos (FOS) is reported to activate the transcription of SRR gene, which leads to an increased expression of the drug-metabolizing enzyme Serine racemase. As a result, the interaction between FOS and SRR can activate the drug-metabolizing process of Serine racemase.
DME0589	DME___ID	DME0589
DME0589	DME_NAME	Prostaglandin E synthase 2 (PTGES2)
DME0589	SPESNAME	Homo sapiens
DME0589	MIRNA_ID	MIMAT0000449	PROTNAME	hsa-miR-146a-5p
DME0589	MIRNA_ID	MIMAT0000449	HPPI_DIS	Health [ICD-11: N.A.]
DME0589	MIRNA_ID	MIMAT0000449	MOFCLASS	Non-coding RNA regulation
DME0589	MIRNA_ID	MIMAT0000449	MOFDETAI	microRNA regulation
DME0589	MIRNA_ID	MIMAT0000449	CELLLINE	Bone marrow-derived mesenchymal stem cells
DME0589	MIRNA_ID	MIMAT0000449	PPI_SUMM	hsa-miR-146a-5p--PTGES2 regulation
DME0589	MIRNA_ID	MIMAT0000449	DESCRIPT	hsa-miR-146a-5p is reported to suppress PTGES2 mRNA translation by binding to the 3' untranslated region (3'UTR) of PTGES2 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Prostaglandin E synthase 2.
DME0590	DME___ID	DME0590
DME0590	DME_NAME	Spermine oxidase (SMOX)
DME0590	SPESNAME	Homo sapiens
DME0590	MIRNA_ID	MIMAT0000422	PROTNAME	hsa-miR-124-3p
DME0590	MIRNA_ID	MIMAT0000422	HPPI_DIS	Gastric cancer [ICD-11: 2B71]
DME0590	MIRNA_ID	MIMAT0000422	MOFCLASS	Non-coding RNA regulation
DME0590	MIRNA_ID	MIMAT0000422	MOFDETAI	microRNA regulation
DME0590	MIRNA_ID	MIMAT0000422	CELLLINE	AGS cell line
DME0590	MIRNA_ID	MIMAT0000422	PPI_SUMM	hsa-miR-124-3p--SMOX regulation
DME0590	MIRNA_ID	MIMAT0000422	DESCRIPT	hsa-miR-124-3p is reported to suppress SMOX mRNA translation by binding to the 3' untranslated region (3'UTR) of SMOX mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Spermine oxidase.
DME0593	DME___ID	DME0593
DME0593	DME_NAME	Carboxypeptidase A4 (CPA4)
DME0593	SPESNAME	Homo sapiens
DME0593	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0593	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0593	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0593	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0593	UNIPROID	HDAC1_HUMAN	CELLLINE	prostate cancer cells
DME0593	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-CPA4 interaction
DME0593	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the CPA4 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Carboxypeptidase A4. As a result, the interaction between HDACs and CPA4 can inhibit the drug-metabolizing process of Carboxypeptidase A4.
DME0608	DME___ID	DME0608
DME0608	DME_NAME	Cytochrome P450 7B1 (CYP7B1)
DME0608	SPESNAME	Homo sapiens
DME0608	MIRNA_ID	MIMAT0000070	PROTNAME	hsa-miR-17-5p
DME0608	MIRNA_ID	MIMAT0000070	HPPI_DIS	Colorectal cancer [ICD-11: 2B90]
DME0608	MIRNA_ID	MIMAT0000070	MOFCLASS	Non-coding RNA regulation
DME0608	MIRNA_ID	MIMAT0000070	MOFDETAI	microRNA regulation
DME0608	MIRNA_ID	MIMAT0000070	CELLLINE	DLD1 cell line
DME0608	MIRNA_ID	MIMAT0000070	PPI_SUMM	hsa-miR-17-5p--CYP7B1 regulation
DME0608	MIRNA_ID	MIMAT0000070	DESCRIPT	hsa-miR-17-5p is reported to suppress CYP7B1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP7B1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 7B1.
DME0624	DME___ID	DME0624
DME0624	DME_NAME	Cytochrome P450 7A1 (CYP7A1)
DME0624	SPESNAME	Homo sapiens
DME0624	UNIPROID	EHMT1_HUMAN	PROTNAME	Histone methyltransferases (HMTs)
DME0624	UNIPROID	EHMT1_HUMAN	HPPI_DIS	Type II diabetic [ICD-11: 5A11]
DME0624	UNIPROID	EHMT1_HUMAN	MOFCLASS	Histone modification
DME0624	UNIPROID	EHMT1_HUMAN	MOFDETAI	Histone hypermethylation
DME0624	UNIPROID	EHMT1_HUMAN	CELLLINE	Humanized CYP7A1-transgenic mice
DME0624	UNIPROID	EHMT1_HUMAN	PPI_SUMM	HMTs-CYP7A1 interaction
DME0624	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 9 dimethylation of CYP7A1 gene is reported to repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 7A1. As a result, the interaction between Histone methyltransferases (HMTs) and CYP7A1 can inhibit the drug-metabolizing process of Cytochrome P450 7A1.
DME0624	UNIPROID	EHMT1_HUMAN	DESCRIPT	The Histone 3 lysine 9 trimethylation of CYP7A1 gene is reported to repress the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 7A1. As a result, the interaction between Histone methyltransferases (HMTs) and CYP7A1 can inhibit the drug-metabolizing process of Cytochrome P450 7A1.
DME0624	UNIPROID	HDAC2_HUMAN	PROTNAME	Histone deacetylase 2 (HDAC2)
DME0624	UNIPROID	HDAC2_HUMAN	HPPI_DIS	Health [ICD-11: N.A.]
DME0624	UNIPROID	HDAC2_HUMAN	MOFCLASS	Histone modification
DME0624	UNIPROID	HDAC2_HUMAN	MOFDETAI	Histone hypoacetylation
DME0624	UNIPROID	HDAC2_HUMAN	CELLLINE	Mouse Model
DME0624	UNIPROID	HDAC2_HUMAN	PPI_SUMM	HDAC2-CYP7A1 interaction
DME0624	UNIPROID	HDAC2_HUMAN	DESCRIPT	Histone deacetylase 2 (HDAC2) s-nitrosylation is reported to deacetylate the CYP7A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 7A1. As a result, the interaction between HDAC2 and CYP7A1 can inhibit the drug-metabolizing process of Cytochrome P450 7A1.
DME0624	UNIPROID	HDAC3_HUMAN	PROTNAME	Histone deacetylase 3 (HDAC3)
DME0624	UNIPROID	HDAC3_HUMAN	HPPI_DIS	Type II diabetic [ICD-11: 5A11]
DME0624	UNIPROID	HDAC3_HUMAN	MOFCLASS	Histone modification
DME0624	UNIPROID	HDAC3_HUMAN	MOFDETAI	Histone hypoacetylation
DME0624	UNIPROID	HDAC3_HUMAN	CELLLINE	Humanized CYP7A1-transgenic mice
DME0624	UNIPROID	HDAC3_HUMAN	PPI_SUMM	HDAC3-CYP7A1 interaction
DME0624	UNIPROID	HDAC3_HUMAN	DESCRIPT	Histone deacetylase 3 (HDAC3) is reported to deacetylate the CYP7A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 7A1. As a result, the interaction between HDAC3 and CYP7A1 can inhibit the drug-metabolizing process of Cytochrome P450 7A1.
DME0624	UNIPROID	HDAC4_HUMAN	PROTNAME	Histone deacetylase 4 (HDAC4)
DME0624	UNIPROID	HDAC4_HUMAN	HPPI_DIS	Type II diabetic [ICD-11: 5A11]
DME0624	UNIPROID	HDAC4_HUMAN	MOFCLASS	Histone modification
DME0624	UNIPROID	HDAC4_HUMAN	MOFDETAI	Histone hypoacetylation
DME0624	UNIPROID	HDAC4_HUMAN	CELLLINE	Humanized CYP7A1-transgenic mice
DME0624	UNIPROID	HDAC4_HUMAN	PPI_SUMM	HDAC4-CYP7A1 interaction
DME0624	UNIPROID	HDAC4_HUMAN	DESCRIPT	Histone deacetylase 4 (HDAC4) is reported to deacetylate the CYP7A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Cytochrome P450 7A1. As a result, the interaction between HDAC4 and CYP7A1 can inhibit the drug-metabolizing process of Cytochrome P450 7A1.
DME0624	MIRNA_ID	MIMAT0000421	PROTNAME	hsa-miR-122-5p
DME0624	MIRNA_ID	MIMAT0000421	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0624	MIRNA_ID	MIMAT0000421	MOFCLASS	Non-coding RNA regulation
DME0624	MIRNA_ID	MIMAT0000421	MOFDETAI	microRNA regulation
DME0624	MIRNA_ID	MIMAT0000421	CELLLINE	HepG2 cell line
DME0624	MIRNA_ID	MIMAT0000421	PPI_SUMM	hsa-miR-122-5p--CYP7A1 regulation
DME0624	MIRNA_ID	MIMAT0000421	DESCRIPT	hsa-miR-122-5p is reported to suppress CYP7A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP7A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 7A1.
DME0624	MIRNA_ID	MIMAT0001339	PROTNAME	hsa-miR-422a
DME0624	MIRNA_ID	MIMAT0001339	HPPI_DIS	Liver cancer [ICD-11: 2C12]
DME0624	MIRNA_ID	MIMAT0001339	MOFCLASS	Non-coding RNA regulation
DME0624	MIRNA_ID	MIMAT0001339	MOFDETAI	microRNA regulation
DME0624	MIRNA_ID	MIMAT0001339	CELLLINE	HepG2 cell line
DME0624	MIRNA_ID	MIMAT0001339	PPI_SUMM	hsa-miR-422a--CYP7A1 regulation
DME0624	MIRNA_ID	MIMAT0001339	DESCRIPT	hsa-miR-422a is reported to suppress CYP7A1 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP7A1 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 7A1.
DME0640	DME___ID	DME0640
DME0640	DME_NAME	UDP-glucuronosyltransferase 2B11 (UGT2B11)
DME0640	SPESNAME	Homo sapiens
DME0640	UNIPROID	HDAC1_HUMAN	PROTNAME	Histone deacetylases (HDACs)
DME0640	UNIPROID	HDAC1_HUMAN	HPPI_DIS	Prostate cancer [ICD-11: 2C82]
DME0640	UNIPROID	HDAC1_HUMAN	MOFCLASS	Histone modification
DME0640	UNIPROID	HDAC1_HUMAN	MOFDETAI	Histone hypoacetylation
DME0640	UNIPROID	HDAC1_HUMAN	CELLLINE	LNCaP cell line
DME0640	UNIPROID	HDAC1_HUMAN	PPI_SUMM	HDACs-UGT2B11 interaction
DME0640	UNIPROID	HDAC1_HUMAN	DESCRIPT	Histone deacetylases (HDACs) are reported to deacetylate the UGT2B11 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme UDP-glucuronosyltransferase 2B11. As a result, the interaction between HDACs and UGT2B11 can inhibit the drug-metabolizing process of UDP-glucuronosyltransferase 2B11.
DME1002	DME___ID	DME1002
DME1002	DME_NAME	Dipeptidase (pepV)
DME1002	SPESNAME	Lactococcus lactis
DME1002	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1002	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1002	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1002	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Enalapril
DME1002	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-pepV interaction
DME1002	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Dipeptidase from Lactococcus lactis which collectively metabolize the drug Enalapril, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1002	UNIPROID	EST1_HUMAN	PROTNAME	Carboxylesterase 1 (CES1)
DME1002	UNIPROID	EST1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1002	UNIPROID	EST1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1002	UNIPROID	EST1_HUMAN	SUBSTRAT	Enalapril
DME1002	UNIPROID	EST1_HUMAN	PPI_SUMM	CES1-pepV interaction
DME1002	UNIPROID	EST1_HUMAN	DESCRIPT	The interaction, between human Carboxylesterase 1 and Dipeptidase from Lactococcus lactis which collectively metabolize the drug Enalapril, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1004	DME___ID	DME1004
DME1004	DME_NAME	Beta-lactamase (blaB)
DME1004	SPESNAME	Enterobacter cloacae
DME1004	UNIPROID	DPEP1_HUMAN	PROTNAME	Dehydropeptidase-I (DPEP1)
DME1004	UNIPROID	DPEP1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1004	UNIPROID	DPEP1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1004	UNIPROID	DPEP1_HUMAN	SUBSTRAT	Doripenem
DME1004	UNIPROID	DPEP1_HUMAN	PPI_SUMM	DPEP1-blaB interaction
DME1004	UNIPROID	DPEP1_HUMAN	DESCRIPT	The interaction, between human Dehydropeptidase-I and Beta-lactamase from Enterobacter cloacae which collectively metabolize the drug Doripenem, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1009	DME___ID	DME1009
DME1009	DME_NAME	Biphenyl dioxygenase (bphC)
DME1009	SPESNAME	Pseudomonas furukawaii
DME1009	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1009	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1009	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1009	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Flavone
DME1009	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-bphC interaction
DME1009	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Biphenyl dioxygenase from Pseudomonas furukawaii which collectively metabolize the drug Flavone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1012	DME___ID	DME1012
DME1012	DME_NAME	Beta-lactamase (blaB)
DME1012	SPESNAME	Bacteroides eggerthii
DME1012	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1012	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1012	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1012	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1012	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1012	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides eggerthii which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1013	DME___ID	DME1013
DME1013	DME_NAME	Beta-lactamase (blaB)
DME1013	SPESNAME	Pseudoflavonifractor capillosus
DME1013	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1013	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1013	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1013	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1013	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1013	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Pseudoflavonifractor capillosus which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1014	DME___ID	DME1014
DME1014	DME_NAME	Beta-lactamase (blaB)
DME1014	SPESNAME	Acidaminococcus intestini
DME1014	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1014	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1014	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1014	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1014	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1014	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Acidaminococcus intestini which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1015	DME___ID	DME1015
DME1015	DME_NAME	Beta-lactamase (blaB)
DME1015	SPESNAME	Fusobacterium mortiferum
DME1015	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1015	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1015	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1015	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1015	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1015	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Fusobacterium mortiferum which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1016	DME___ID	DME1016
DME1016	DME_NAME	Beta-lactamase (blaB)
DME1016	SPESNAME	Prevotella melaninogenica
DME1016	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1016	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1016	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1016	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1016	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1016	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella melaninogenica which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1017	DME___ID	DME1017
DME1017	DME_NAME	Beta-lactamase (blaB)
DME1017	SPESNAME	Odoribacter splanchnicus
DME1017	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1017	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1017	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1017	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1017	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1017	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Odoribacter splanchnicus which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1018	DME___ID	DME1018
DME1018	DME_NAME	Beta-lactamase (blaB)
DME1018	SPESNAME	Prevotella oralis
DME1018	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1018	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1018	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1018	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1018	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1018	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella oralis which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1019	DME___ID	DME1019
DME1019	DME_NAME	Beta-lactamase (blaB)
DME1019	SPESNAME	Prevotella bivia
DME1019	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1019	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1019	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1019	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1019	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1019	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella bivia which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1020	DME___ID	DME1020
DME1020	DME_NAME	Beta-lactamase (blaB)
DME1020	SPESNAME	Acidaminococcus fermentans
DME1020	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1020	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1020	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1020	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1020	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1020	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Acidaminococcus fermentans which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1021	DME___ID	DME1021
DME1021	DME_NAME	N-acylhomoserine lactone acylase (lacA)
DME1021	SPESNAME	Acidovorax ebreus
DME1021	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1021	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1021	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1021	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1021	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-lacA interaction
DME1021	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and N-acylhomoserine lactone acylase from Acidovorax ebreus which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1021	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1021	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1021	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1021	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Cefalexin
DME1021	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-lacA interaction
DME1021	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and N-acylhomoserine lactone acylase from Acidovorax ebreus which collectively metabolize the drug Cefalexin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1021	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1021	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1021	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1021	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Cefalexin
DME1021	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-lacA interaction
DME1021	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and N-acylhomoserine lactone acylase from Acidovorax ebreus which collectively metabolize the drug Cefalexin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1022	DME___ID	DME1022
DME1022	DME_NAME	Tyramine oxidase (tynA)
DME1022	SPESNAME	Escherichia coli
DME1022	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1022	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1022	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1022	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Amphetamine
DME1022	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-tynA interaction
DME1022	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Tyramine oxidase from Escherichia coli which collectively metabolize the drug Amphetamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1023	DME___ID	DME1023
DME1023	DME_NAME	Beta-lactamase (blaB)
DME1023	SPESNAME	Klebsiella pneumoniae
DME1023	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1023	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1023	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1023	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Aztreonam
DME1023	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-blaB interaction
DME1023	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Beta-lactamase from Klebsiella pneumoniae which collectively metabolize the drug Aztreonam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1023	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1023	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1023	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1023	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Aztreonam
DME1023	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-blaB interaction
DME1023	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Beta-lactamase from Klebsiella pneumoniae which collectively metabolize the drug Aztreonam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1023	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1023	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1023	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1023	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Aztreonam
DME1023	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-blaB interaction
DME1023	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Beta-lactamase from Klebsiella pneumoniae which collectively metabolize the drug Aztreonam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1023	UNIPROID	TPMT_HUMAN	PROTNAME	Thiopurine methyltransferase (TPMT)
DME1023	UNIPROID	TPMT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1023	UNIPROID	TPMT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1023	UNIPROID	TPMT_HUMAN	SUBSTRAT	Cefazolin
DME1023	UNIPROID	TPMT_HUMAN	PPI_SUMM	TPMT-blaB interaction
DME1023	UNIPROID	TPMT_HUMAN	DESCRIPT	The interaction, between human Thiopurine methyltransferase and Beta-lactamase from Klebsiella pneumoniae which collectively metabolize the drug Cefazolin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1024	DME___ID	DME1024
DME1024	DME_NAME	Beta-lactamase (blaB)
DME1024	SPESNAME	Klebsiella variicola
DME1024	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1024	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1024	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1024	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Aztreonam
DME1024	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-blaB interaction
DME1024	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Beta-lactamase from Klebsiella variicola which collectively metabolize the drug Aztreonam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1024	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1024	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1024	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1024	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Aztreonam
DME1024	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-blaB interaction
DME1024	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Beta-lactamase from Klebsiella variicola which collectively metabolize the drug Aztreonam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1024	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1024	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1024	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1024	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Aztreonam
DME1024	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-blaB interaction
DME1024	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Beta-lactamase from Klebsiella variicola which collectively metabolize the drug Aztreonam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1025	DME___ID	DME1025
DME1025	DME_NAME	Beta-glucuronidase (uidA)
DME1025	SPESNAME	Lactobacillus gasseri
DME1025	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1025	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1025	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1025	UNIPROID	UD11_HUMAN	SUBSTRAT	Bazedoxifene
DME1025	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-uidA interaction
DME1025	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Beta-glucuronidase from Lactobacillus gasseri which collectively metabolize the drug Bazedoxifene, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1025	UNIPROID	UD110_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DME1025	UNIPROID	UD110_HUMAN	MOFCLASS	Host-microbiome interaction
DME1025	UNIPROID	UD110_HUMAN	MOFDETAI	Host-microbiome interaction
DME1025	UNIPROID	UD110_HUMAN	SUBSTRAT	Bazedoxifene
DME1025	UNIPROID	UD110_HUMAN	PPI_SUMM	UGT1A10-uidA interaction
DME1025	UNIPROID	UD110_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A10 and Beta-glucuronidase from Lactobacillus gasseri which collectively metabolize the drug Bazedoxifene, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1026	DME___ID	DME1026
DME1026	DME_NAME	Beta-lactamase (blaB)
DME1026	SPESNAME	Bacteroides uniformis
DME1026	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1026	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1026	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1026	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1026	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1026	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides uniformis which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1026	UNIPROID	CP2C8_HUMAN	PROTNAME	Cytochrome P450 2C8 (CYP2C8)
DME1026	UNIPROID	CP2C8_HUMAN	MOFCLASS	Host-microbiome interaction
DME1026	UNIPROID	CP2C8_HUMAN	MOFDETAI	Host-microbiome interaction
DME1026	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Cefaloridine
DME1026	UNIPROID	CP2C8_HUMAN	PPI_SUMM	CYP2C8-blaB interaction
DME1026	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Beta-lactamase from Bacteroides uniformis which collectively metabolize the drug Cefaloridine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1028	DME___ID	DME1028
DME1028	DME_NAME	Chloramphenicolase (chlR)
DME1028	SPESNAME	Escherichia coli
DME1028	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1028	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1028	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1028	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Chloramphenicol
DME1028	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-chlR interaction
DME1028	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Chloramphenicolase from Escherichia coli which collectively metabolize the drug Chloramphenicol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1029	DME___ID	DME1029
DME1029	DME_NAME	Glycerol-3-phosphate dehydrogenase (gpsA)
DME1029	SPESNAME	Erysipelothrix rhusiopathiae
DME1029	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1029	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1029	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1029	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Chloramphenicol
DME1029	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-gpsA interaction
DME1029	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Glycerol-3-phosphate dehydrogenase from Erysipelothrix rhusiopathiae which collectively metabolize the drug Chloramphenicol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1030	DME___ID	DME1030
DME1030	DME_NAME	Chloramphenicolase (chlR)
DME1030	SPESNAME	Bacillus pumilus
DME1030	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1030	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1030	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1030	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Chloramphenicol
DME1030	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-chlR interaction
DME1030	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Chloramphenicolase from Bacillus pumilus which collectively metabolize the drug Chloramphenicol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1031	DME___ID	DME1031
DME1031	DME_NAME	Chloramphenicolase (chlR)
DME1031	SPESNAME	Proteus penneri
DME1031	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1031	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1031	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1031	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Chloramphenicol
DME1031	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-chlR interaction
DME1031	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Chloramphenicolase from Proteus penneri which collectively metabolize the drug Chloramphenicol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1033	DME___ID	DME1033
DME1033	DME_NAME	Beta-lactamase (blaB)
DME1033	SPESNAME	Edwardsiella tarda
DME1033	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1033	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1033	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1033	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Clindamycin
DME1033	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-blaB interaction
DME1033	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Beta-lactamase from Edwardsiella tarda which collectively metabolize the drug Clindamycin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1035	DME___ID	DME1035
DME1035	DME_NAME	Cardiac glycoside reductase 1 (cgr1)
DME1035	SPESNAME	Eggerthella lenta
DME1035	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1035	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1035	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1035	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Digoxin
DME1035	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cgr1 interaction
DME1035	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cardiac glycoside reductase 1 from Eggerthella lenta which collectively metabolize the drug Digoxin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1036	DME___ID	DME1036
DME1036	DME_NAME	Cardiac glycoside reductase 2 (cgr2)
DME1036	SPESNAME	Eggerthella lenta
DME1036	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1036	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1036	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1036	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Digoxin
DME1036	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cgr2 interaction
DME1036	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cardiac glycoside reductase 2 from Eggerthella lenta which collectively metabolize the drug Digoxin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1037	DME___ID	DME1037
DME1037	DME_NAME	Dopamine dehydroxylase (dadH)
DME1037	SPESNAME	Eggerthella lenta
DME1037	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1037	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1037	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1037	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Dopamine hydrochloride
DME1037	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-dadH interaction
DME1037	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Dopamine dehydroxylase from Eggerthella lenta which collectively metabolize the drug Dopamine hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1037	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1037	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1037	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1037	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Dopamine hydrochloride
DME1037	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-dadH interaction
DME1037	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Dopamine dehydroxylase from Eggerthella lenta which collectively metabolize the drug Dopamine hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1037	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1037	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1037	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1037	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Dopamine hydrochloride
DME1037	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-dadH interaction
DME1037	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Dopamine dehydroxylase from Eggerthella lenta which collectively metabolize the drug Dopamine hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1037	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1037	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1037	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1037	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Dopamine hydrochloride
DME1037	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-dadH interaction
DME1037	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Dopamine dehydroxylase from Eggerthella lenta which collectively metabolize the drug Dopamine hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1037	UNIPROID	COMT_HUMAN	PROTNAME	Catechol O-methyltransferase (COMT)
DME1037	UNIPROID	COMT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1037	UNIPROID	COMT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1037	UNIPROID	COMT_HUMAN	SUBSTRAT	Dopamine hydrochloride
DME1037	UNIPROID	COMT_HUMAN	PPI_SUMM	COMT-dadH interaction
DME1037	UNIPROID	COMT_HUMAN	DESCRIPT	The interaction, between human Catechol O-methyltransferase and Dopamine dehydroxylase from Eggerthella lenta which collectively metabolize the drug Dopamine hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1037	UNIPROID	AOFB_HUMAN	PROTNAME	Monoamine oxidase type B (MAO-B)
DME1037	UNIPROID	AOFB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1037	UNIPROID	AOFB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1037	UNIPROID	AOFB_HUMAN	SUBSTRAT	Dopamine hydrochloride
DME1037	UNIPROID	AOFB_HUMAN	PPI_SUMM	MAO-B-dadH interaction
DME1037	UNIPROID	AOFB_HUMAN	DESCRIPT	The interaction, between human Monoamine oxidase type B and Dopamine dehydroxylase from Eggerthella lenta which collectively metabolize the drug Dopamine hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1037	UNIPROID	ST1B1_HUMAN	PROTNAME	Sulfotransferase 1B1 (SULT1B1)
DME1037	UNIPROID	ST1B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1037	UNIPROID	ST1B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1037	UNIPROID	ST1B1_HUMAN	SUBSTRAT	Dopamine hydrochloride
DME1037	UNIPROID	ST1B1_HUMAN	PPI_SUMM	SULT1B1-dadH interaction
DME1037	UNIPROID	ST1B1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1B1 and Dopamine dehydroxylase from Eggerthella lenta which collectively metabolize the drug Dopamine hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	DME___ID	DME1039
DME1039	DME_NAME	Molybdopterin-dependent enzyme (molD)
DME1039	SPESNAME	Klebsiella pneumoniae
DME1039	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1039	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-molD interaction
DME1039	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1039	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-molD interaction
DME1039	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1039	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-molD interaction
DME1039	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	XDH_HUMAN	PROTNAME	Xanthine dehydrogenase/oxidase (XDH)
DME1039	UNIPROID	XDH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	XDH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	XDH_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	XDH_HUMAN	PPI_SUMM	XDH-molD interaction
DME1039	UNIPROID	XDH_HUMAN	DESCRIPT	The interaction, between human Xanthine dehydrogenase/oxidase and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1039	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	NCPR_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-molD interaction
DME1039	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1039	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	NQO1_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-molD interaction
DME1039	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	AK1A1_HUMAN	PROTNAME	Aldo-keto reductase 1A1 (AKR1A1)
DME1039	UNIPROID	AK1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	AK1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	AK1A1_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	AK1A1_HUMAN	PPI_SUMM	AKR1A1-molD interaction
DME1039	UNIPROID	AK1A1_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1A1 and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	AK1C3_HUMAN	PROTNAME	Aldo-keto reductase 1C3 (AKR1C3)
DME1039	UNIPROID	AK1C3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	AK1C3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	AK1C3_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	AK1C3_HUMAN	PPI_SUMM	AKR1C3-molD interaction
DME1039	UNIPROID	AK1C3_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1C3 and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	NDUS2_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2)
DME1039	UNIPROID	NDUS2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	NDUS2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	NDUS2_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	NDUS2_HUMAN	PPI_SUMM	NDUFS2-molD interaction
DME1039	UNIPROID	NDUS2_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 49 kDa and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	NDUS3_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3)
DME1039	UNIPROID	NDUS3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	NDUS3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	NDUS3_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	NDUS3_HUMAN	PPI_SUMM	NDUFS3-molD interaction
DME1039	UNIPROID	NDUS3_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 30 kDa and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	NDUS7_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7)
DME1039	UNIPROID	NDUS7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	NDUS7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	NDUS7_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	NDUS7_HUMAN	PPI_SUMM	NDUFS7-molD interaction
DME1039	UNIPROID	NDUS7_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 20 kDa and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	NOS1_HUMAN	PROTNAME	Nitric oxide synthase brain (NOS1)
DME1039	UNIPROID	NOS1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	NOS1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	NOS1_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	NOS1_HUMAN	PPI_SUMM	NOS1-molD interaction
DME1039	UNIPROID	NOS1_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase brain and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	NOS3_HUMAN	PROTNAME	Nitric oxide synthase endothelial (NOS3)
DME1039	UNIPROID	NOS3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	NOS3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	NOS3_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	NOS3_HUMAN	PPI_SUMM	NOS3-molD interaction
DME1039	UNIPROID	NOS3_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase endothelial and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	NOS2_HUMAN	PROTNAME	Nitric oxide synthase inducible (NOS2)
DME1039	UNIPROID	NOS2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	NOS2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	NOS2_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	NOS2_HUMAN	PPI_SUMM	NOS2-molD interaction
DME1039	UNIPROID	NOS2_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase inducible and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	ARK72_HUMAN	PROTNAME	Succinic semialdehyde reductase (AKR7A2)
DME1039	UNIPROID	ARK72_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	ARK72_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	ARK72_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	ARK72_HUMAN	PPI_SUMM	AKR7A2-molD interaction
DME1039	UNIPROID	ARK72_HUMAN	DESCRIPT	The interaction, between human Succinic semialdehyde reductase and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1039	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1039	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1039	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1039	UNIPROID	MTRR_HUMAN	SUBSTRAT	Doxorubicin
DME1039	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-molD interaction
DME1039	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and Molybdopterin-dependent enzyme from Klebsiella pneumoniae which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	DME___ID	DME1040
DME1040	DME_NAME	Molybdopterin-dependent enzyme (molD)
DME1040	SPESNAME	Raoultella planticola
DME1040	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1040	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-molD interaction
DME1040	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1040	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-molD interaction
DME1040	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1040	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-molD interaction
DME1040	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	XDH_HUMAN	PROTNAME	Xanthine dehydrogenase/oxidase (XDH)
DME1040	UNIPROID	XDH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	XDH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	XDH_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	XDH_HUMAN	PPI_SUMM	XDH-molD interaction
DME1040	UNIPROID	XDH_HUMAN	DESCRIPT	The interaction, between human Xanthine dehydrogenase/oxidase and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1040	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	NCPR_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-molD interaction
DME1040	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1040	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	NQO1_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-molD interaction
DME1040	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	AK1A1_HUMAN	PROTNAME	Aldo-keto reductase 1A1 (AKR1A1)
DME1040	UNIPROID	AK1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	AK1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	AK1A1_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	AK1A1_HUMAN	PPI_SUMM	AKR1A1-molD interaction
DME1040	UNIPROID	AK1A1_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1A1 and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	AK1C3_HUMAN	PROTNAME	Aldo-keto reductase 1C3 (AKR1C3)
DME1040	UNIPROID	AK1C3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	AK1C3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	AK1C3_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	AK1C3_HUMAN	PPI_SUMM	AKR1C3-molD interaction
DME1040	UNIPROID	AK1C3_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1C3 and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	NDUS2_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2)
DME1040	UNIPROID	NDUS2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	NDUS2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	NDUS2_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	NDUS2_HUMAN	PPI_SUMM	NDUFS2-molD interaction
DME1040	UNIPROID	NDUS2_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 49 kDa and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	NDUS3_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3)
DME1040	UNIPROID	NDUS3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	NDUS3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	NDUS3_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	NDUS3_HUMAN	PPI_SUMM	NDUFS3-molD interaction
DME1040	UNIPROID	NDUS3_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 30 kDa and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	NDUS7_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7)
DME1040	UNIPROID	NDUS7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	NDUS7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	NDUS7_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	NDUS7_HUMAN	PPI_SUMM	NDUFS7-molD interaction
DME1040	UNIPROID	NDUS7_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 20 kDa and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	NOS1_HUMAN	PROTNAME	Nitric oxide synthase brain (NOS1)
DME1040	UNIPROID	NOS1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	NOS1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	NOS1_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	NOS1_HUMAN	PPI_SUMM	NOS1-molD interaction
DME1040	UNIPROID	NOS1_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase brain and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	NOS3_HUMAN	PROTNAME	Nitric oxide synthase endothelial (NOS3)
DME1040	UNIPROID	NOS3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	NOS3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	NOS3_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	NOS3_HUMAN	PPI_SUMM	NOS3-molD interaction
DME1040	UNIPROID	NOS3_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase endothelial and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	NOS2_HUMAN	PROTNAME	Nitric oxide synthase inducible (NOS2)
DME1040	UNIPROID	NOS2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	NOS2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	NOS2_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	NOS2_HUMAN	PPI_SUMM	NOS2-molD interaction
DME1040	UNIPROID	NOS2_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase inducible and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	ARK72_HUMAN	PROTNAME	Succinic semialdehyde reductase (AKR7A2)
DME1040	UNIPROID	ARK72_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	ARK72_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	ARK72_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	ARK72_HUMAN	PPI_SUMM	AKR7A2-molD interaction
DME1040	UNIPROID	ARK72_HUMAN	DESCRIPT	The interaction, between human Succinic semialdehyde reductase and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1040	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1040	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1040	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1040	UNIPROID	MTRR_HUMAN	SUBSTRAT	Doxorubicin
DME1040	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-molD interaction
DME1040	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and Molybdopterin-dependent enzyme from Raoultella planticola which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	DME___ID	DME1041
DME1041	DME_NAME	NADH dehydrogenase (nuoE)
DME1041	SPESNAME	Streptomyces griseus
DME1041	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1041	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-nuoE interaction
DME1041	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1041	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-nuoE interaction
DME1041	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1041	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-nuoE interaction
DME1041	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	XDH_HUMAN	PROTNAME	Xanthine dehydrogenase/oxidase (XDH)
DME1041	UNIPROID	XDH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	XDH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	XDH_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	XDH_HUMAN	PPI_SUMM	XDH-nuoE interaction
DME1041	UNIPROID	XDH_HUMAN	DESCRIPT	The interaction, between human Xanthine dehydrogenase/oxidase and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1041	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	NCPR_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-nuoE interaction
DME1041	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1041	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	NQO1_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-nuoE interaction
DME1041	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	AK1A1_HUMAN	PROTNAME	Aldo-keto reductase 1A1 (AKR1A1)
DME1041	UNIPROID	AK1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	AK1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	AK1A1_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	AK1A1_HUMAN	PPI_SUMM	AKR1A1-nuoE interaction
DME1041	UNIPROID	AK1A1_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1A1 and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	AK1C3_HUMAN	PROTNAME	Aldo-keto reductase 1C3 (AKR1C3)
DME1041	UNIPROID	AK1C3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	AK1C3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	AK1C3_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	AK1C3_HUMAN	PPI_SUMM	AKR1C3-nuoE interaction
DME1041	UNIPROID	AK1C3_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1C3 and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	NDUS2_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2)
DME1041	UNIPROID	NDUS2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	NDUS2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	NDUS2_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	NDUS2_HUMAN	PPI_SUMM	NDUFS2-nuoE interaction
DME1041	UNIPROID	NDUS2_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 49 kDa and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	NDUS3_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3)
DME1041	UNIPROID	NDUS3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	NDUS3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	NDUS3_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	NDUS3_HUMAN	PPI_SUMM	NDUFS3-nuoE interaction
DME1041	UNIPROID	NDUS3_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 30 kDa and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	NDUS7_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7)
DME1041	UNIPROID	NDUS7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	NDUS7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	NDUS7_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	NDUS7_HUMAN	PPI_SUMM	NDUFS7-nuoE interaction
DME1041	UNIPROID	NDUS7_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 20 kDa and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	NOS1_HUMAN	PROTNAME	Nitric oxide synthase brain (NOS1)
DME1041	UNIPROID	NOS1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	NOS1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	NOS1_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	NOS1_HUMAN	PPI_SUMM	NOS1-nuoE interaction
DME1041	UNIPROID	NOS1_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase brain and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	NOS3_HUMAN	PROTNAME	Nitric oxide synthase endothelial (NOS3)
DME1041	UNIPROID	NOS3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	NOS3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	NOS3_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	NOS3_HUMAN	PPI_SUMM	NOS3-nuoE interaction
DME1041	UNIPROID	NOS3_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase endothelial and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	NOS2_HUMAN	PROTNAME	Nitric oxide synthase inducible (NOS2)
DME1041	UNIPROID	NOS2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	NOS2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	NOS2_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	NOS2_HUMAN	PPI_SUMM	NOS2-nuoE interaction
DME1041	UNIPROID	NOS2_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase inducible and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	ARK72_HUMAN	PROTNAME	Succinic semialdehyde reductase (AKR7A2)
DME1041	UNIPROID	ARK72_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	ARK72_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	ARK72_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	ARK72_HUMAN	PPI_SUMM	AKR7A2-nuoE interaction
DME1041	UNIPROID	ARK72_HUMAN	DESCRIPT	The interaction, between human Succinic semialdehyde reductase and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1041	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1041	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1041	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1041	UNIPROID	MTRR_HUMAN	SUBSTRAT	Doxorubicin
DME1041	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-nuoE interaction
DME1041	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and NADH dehydrogenase from Streptomyces griseus which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1042	DME___ID	DME1042
DME1042	DME_NAME	Beta-glucuronidase (uidA)
DME1042	SPESNAME	Lactobacillus sakei
DME1042	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1042	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1042	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1042	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Erythromycin stearate
DME1042	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-uidA interaction
DME1042	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1042	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1042	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1042	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1042	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Erythromycin stearate
DME1042	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-uidA interaction
DME1042	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1042	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1042	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1042	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1042	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Erythromycin stearate
DME1042	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-uidA interaction
DME1042	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1042	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1042	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1042	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1042	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Erythromycin stearate
DME1042	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-uidA interaction
DME1042	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1042	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1042	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1042	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1042	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Erythromycin stearate
DME1042	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-uidA interaction
DME1042	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1042	UNIPROID	CP1B1_HUMAN	PROTNAME	Cytochrome P450 1B1 (CYP1B1)
DME1042	UNIPROID	CP1B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1042	UNIPROID	CP1B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1042	UNIPROID	CP1B1_HUMAN	SUBSTRAT	Erythromycin stearate
DME1042	UNIPROID	CP1B1_HUMAN	PPI_SUMM	CYP1B1-uidA interaction
DME1042	UNIPROID	CP1B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1B1 and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1042	UNIPROID	CP4FB_HUMAN	PROTNAME	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DME1042	UNIPROID	CP4FB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1042	UNIPROID	CP4FB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1042	UNIPROID	CP4FB_HUMAN	SUBSTRAT	Erythromycin stearate
DME1042	UNIPROID	CP4FB_HUMAN	PPI_SUMM	CYP4F11-uidA interaction
DME1042	UNIPROID	CP4FB_HUMAN	DESCRIPT	The interaction, between human Docosahexaenoic acid omega-hydroxylase and Beta-glucuronidase from Lactobacillus sakei which collectively metabolize the drug Erythromycin stearate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1043	DME___ID	DME1043
DME1043	DME_NAME	Beta-glucosidase (bglA)
DME1043	SPESNAME	Malassezia furfur
DME1043	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1043	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1043	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1043	UNIPROID	GLSK_HUMAN	SUBSTRAT	Esculin
DME1043	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-bglA interaction
DME1043	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Beta-glucosidase from Malassezia furfur which collectively metabolize the drug Esculin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1044	DME___ID	DME1044
DME1044	DME_NAME	Beta-glucosidase (bglA)
DME1044	SPESNAME	Malassezia sympodialis
DME1044	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1044	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1044	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1044	UNIPROID	GLSK_HUMAN	SUBSTRAT	Esculin
DME1044	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-bglA interaction
DME1044	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Beta-glucosidase from Malassezia sympodialis which collectively metabolize the drug Esculin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1045	DME___ID	DME1045
DME1045	DME_NAME	Beta-glucosidase (bglA)
DME1045	SPESNAME	Trichophyton interdigitale
DME1045	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1045	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1045	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1045	UNIPROID	GLSK_HUMAN	SUBSTRAT	Esculin
DME1045	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-bglA interaction
DME1045	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Beta-glucosidase from Trichophyton interdigitale which collectively metabolize the drug Esculin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1047	DME___ID	DME1047
DME1047	DME_NAME	Beta-glucosidase (bglA)
DME1047	SPESNAME	Trichophyton rubrum
DME1047	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1047	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1047	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1047	UNIPROID	GLSK_HUMAN	SUBSTRAT	Esculin
DME1047	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-bglA interaction
DME1047	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Beta-glucosidase from Trichophyton rubrum which collectively metabolize the drug Esculin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	DME___ID	DME1048
DME1048	DME_NAME	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DME1048	SPESNAME	Escherichia coli
DME1048	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1048	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Clonazepam
DME1048	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-nfsB interaction
DME1048	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Clonazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1048	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	NAT10_HUMAN	SUBSTRAT	Clonazepam
DME1048	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-nfsB interaction
DME1048	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Clonazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Flunitrazepam
DME1048	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Flunitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1048	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Flunitrazepam
DME1048	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-nfsB interaction
DME1048	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Flunitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1048	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Flunitrazepam
DME1048	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-nfsB interaction
DME1048	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Flunitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1048	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Flunitrazepam
DME1048	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-nfsB interaction
DME1048	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Flunitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1048	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Flunitrazepam
DME1048	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-nfsB interaction
DME1048	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Flunitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1048	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Flunitrazepam
DME1048	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-nfsB interaction
DME1048	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Flunitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1048	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrobenzodiazepine
DME1048	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-nfsB interaction
DME1048	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Nitrobenzodiazepine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Nitrazepam
DME1048	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Nitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1048	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	NQO1_HUMAN	SUBSTRAT	CBL-954
DME1048	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-nfsB interaction
DME1048	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug CBL-954, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1048	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1048	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1048	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1048	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Nitrofural
DME1048	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-nfsB interaction
DME1048	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Oxygen-insensitive NADPH nitroreductase B from Escherichia coli which collectively metabolize the drug Nitrofural, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1049	DME___ID	DME1049
DME1049	DME_NAME	Dihydrofolate reductase (folA)
DME1049	SPESNAME	Escherichia coli
DME1049	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1049	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1049	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1049	UNIPROID	NAT10_HUMAN	SUBSTRAT	Folic acid
DME1049	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-folA interaction
DME1049	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Dihydrofolate reductase from Escherichia coli which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1049	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1049	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1049	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1049	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Folic acid
DME1049	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-folA interaction
DME1049	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Dihydrofolate reductase from Escherichia coli which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1049	UNIPROID	MTHR_HUMAN	PROTNAME	Methylenetetrahydrofolate reductase (MTHFR)
DME1049	UNIPROID	MTHR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1049	UNIPROID	MTHR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1049	UNIPROID	MTHR_HUMAN	SUBSTRAT	Folic acid
DME1049	UNIPROID	MTHR_HUMAN	PPI_SUMM	MTHFR-folA interaction
DME1049	UNIPROID	MTHR_HUMAN	DESCRIPT	The interaction, between human Methylenetetrahydrofolate reductase and Dihydrofolate reductase from Escherichia coli which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1049	UNIPROID	DYR_HUMAN	PROTNAME	Dihydrofolate reductase (DHFR)
DME1049	UNIPROID	DYR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1049	UNIPROID	DYR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1049	UNIPROID	DYR_HUMAN	SUBSTRAT	Folic acid
DME1049	UNIPROID	DYR_HUMAN	PPI_SUMM	DHFR-folA interaction
DME1049	UNIPROID	DYR_HUMAN	DESCRIPT	The interaction, between human Dihydrofolate reductase and Dihydrofolate reductase from Escherichia coli which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1049	UNIPROID	GGH_HUMAN	PROTNAME	Gamma-Glu-X carboxypeptidase (GGH)
DME1049	UNIPROID	GGH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1049	UNIPROID	GGH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1049	UNIPROID	GGH_HUMAN	SUBSTRAT	Folic acid
DME1049	UNIPROID	GGH_HUMAN	PPI_SUMM	GGH-folA interaction
DME1049	UNIPROID	GGH_HUMAN	DESCRIPT	The interaction, between human Gamma-Glu-X carboxypeptidase and Dihydrofolate reductase from Escherichia coli which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1049	UNIPROID	METH_HUMAN	PROTNAME	Vitamin B12 methionine synthase (MTR)
DME1049	UNIPROID	METH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1049	UNIPROID	METH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1049	UNIPROID	METH_HUMAN	SUBSTRAT	Folic acid
DME1049	UNIPROID	METH_HUMAN	PPI_SUMM	MTR-folA interaction
DME1049	UNIPROID	METH_HUMAN	DESCRIPT	The interaction, between human Vitamin B12 methionine synthase and Dihydrofolate reductase from Escherichia coli which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1049	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1049	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1049	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1049	UNIPROID	MTRR_HUMAN	SUBSTRAT	Folic acid
DME1049	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-folA interaction
DME1049	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and Dihydrofolate reductase from Escherichia coli which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1050	DME___ID	DME1050
DME1050	DME_NAME	Dihydrofolate reductase (folA)
DME1050	SPESNAME	Lactobacillus casei
DME1050	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1050	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1050	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1050	UNIPROID	NAT10_HUMAN	SUBSTRAT	Folic acid
DME1050	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-folA interaction
DME1050	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Dihydrofolate reductase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1050	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1050	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1050	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1050	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Folic acid
DME1050	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-folA interaction
DME1050	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Dihydrofolate reductase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1050	UNIPROID	MTHR_HUMAN	PROTNAME	Methylenetetrahydrofolate reductase (MTHFR)
DME1050	UNIPROID	MTHR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1050	UNIPROID	MTHR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1050	UNIPROID	MTHR_HUMAN	SUBSTRAT	Folic acid
DME1050	UNIPROID	MTHR_HUMAN	PPI_SUMM	MTHFR-folA interaction
DME1050	UNIPROID	MTHR_HUMAN	DESCRIPT	The interaction, between human Methylenetetrahydrofolate reductase and Dihydrofolate reductase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1050	UNIPROID	DYR_HUMAN	PROTNAME	Dihydrofolate reductase (DHFR)
DME1050	UNIPROID	DYR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1050	UNIPROID	DYR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1050	UNIPROID	DYR_HUMAN	SUBSTRAT	Folic acid
DME1050	UNIPROID	DYR_HUMAN	PPI_SUMM	DHFR-folA interaction
DME1050	UNIPROID	DYR_HUMAN	DESCRIPT	The interaction, between human Dihydrofolate reductase and Dihydrofolate reductase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1050	UNIPROID	GGH_HUMAN	PROTNAME	Gamma-Glu-X carboxypeptidase (GGH)
DME1050	UNIPROID	GGH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1050	UNIPROID	GGH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1050	UNIPROID	GGH_HUMAN	SUBSTRAT	Folic acid
DME1050	UNIPROID	GGH_HUMAN	PPI_SUMM	GGH-folA interaction
DME1050	UNIPROID	GGH_HUMAN	DESCRIPT	The interaction, between human Gamma-Glu-X carboxypeptidase and Dihydrofolate reductase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1050	UNIPROID	METH_HUMAN	PROTNAME	Vitamin B12 methionine synthase (MTR)
DME1050	UNIPROID	METH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1050	UNIPROID	METH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1050	UNIPROID	METH_HUMAN	SUBSTRAT	Folic acid
DME1050	UNIPROID	METH_HUMAN	PPI_SUMM	MTR-folA interaction
DME1050	UNIPROID	METH_HUMAN	DESCRIPT	The interaction, between human Vitamin B12 methionine synthase and Dihydrofolate reductase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1050	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1050	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1050	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1050	UNIPROID	MTRR_HUMAN	SUBSTRAT	Folic acid
DME1050	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-folA interaction
DME1050	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and Dihydrofolate reductase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1051	DME___ID	DME1051
DME1051	DME_NAME	Dihydrofolate reductase (folA)
DME1051	SPESNAME	Chlamydia muridarum
DME1051	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1051	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1051	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1051	UNIPROID	NAT10_HUMAN	SUBSTRAT	Folic acid
DME1051	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-folA interaction
DME1051	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Dihydrofolate reductase from Chlamydia muridarum which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1051	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1051	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1051	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1051	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Folic acid
DME1051	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-folA interaction
DME1051	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Dihydrofolate reductase from Chlamydia muridarum which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1051	UNIPROID	MTHR_HUMAN	PROTNAME	Methylenetetrahydrofolate reductase (MTHFR)
DME1051	UNIPROID	MTHR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1051	UNIPROID	MTHR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1051	UNIPROID	MTHR_HUMAN	SUBSTRAT	Folic acid
DME1051	UNIPROID	MTHR_HUMAN	PPI_SUMM	MTHFR-folA interaction
DME1051	UNIPROID	MTHR_HUMAN	DESCRIPT	The interaction, between human Methylenetetrahydrofolate reductase and Dihydrofolate reductase from Chlamydia muridarum which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1051	UNIPROID	DYR_HUMAN	PROTNAME	Dihydrofolate reductase (DHFR)
DME1051	UNIPROID	DYR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1051	UNIPROID	DYR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1051	UNIPROID	DYR_HUMAN	SUBSTRAT	Folic acid
DME1051	UNIPROID	DYR_HUMAN	PPI_SUMM	DHFR-folA interaction
DME1051	UNIPROID	DYR_HUMAN	DESCRIPT	The interaction, between human Dihydrofolate reductase and Dihydrofolate reductase from Chlamydia muridarum which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1051	UNIPROID	GGH_HUMAN	PROTNAME	Gamma-Glu-X carboxypeptidase (GGH)
DME1051	UNIPROID	GGH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1051	UNIPROID	GGH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1051	UNIPROID	GGH_HUMAN	SUBSTRAT	Folic acid
DME1051	UNIPROID	GGH_HUMAN	PPI_SUMM	GGH-folA interaction
DME1051	UNIPROID	GGH_HUMAN	DESCRIPT	The interaction, between human Gamma-Glu-X carboxypeptidase and Dihydrofolate reductase from Chlamydia muridarum which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1051	UNIPROID	METH_HUMAN	PROTNAME	Vitamin B12 methionine synthase (MTR)
DME1051	UNIPROID	METH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1051	UNIPROID	METH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1051	UNIPROID	METH_HUMAN	SUBSTRAT	Folic acid
DME1051	UNIPROID	METH_HUMAN	PPI_SUMM	MTR-folA interaction
DME1051	UNIPROID	METH_HUMAN	DESCRIPT	The interaction, between human Vitamin B12 methionine synthase and Dihydrofolate reductase from Chlamydia muridarum which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1051	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1051	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1051	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1051	UNIPROID	MTRR_HUMAN	SUBSTRAT	Folic acid
DME1051	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-folA interaction
DME1051	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and Dihydrofolate reductase from Chlamydia muridarum which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1052	DME___ID	DME1052
DME1052	DME_NAME	Glyceraldehyde-3-phosphate dehydrogenase (gap)
DME1052	SPESNAME	Lactobacillus acidophilus
DME1052	UNIPROID	AGM1_HUMAN	PROTNAME	Phosphoglucomutase 3 (PGM3)
DME1052	UNIPROID	AGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1052	UNIPROID	AGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1052	UNIPROID	AGM1_HUMAN	SUBSTRAT	NA-alpha-D-glucosamine
DME1052	UNIPROID	AGM1_HUMAN	PPI_SUMM	PGM3-gap interaction
DME1052	UNIPROID	AGM1_HUMAN	DESCRIPT	The interaction, between human Phosphoglucomutase 3 and Glyceraldehyde-3-phosphate dehydrogenase from Lactobacillus acidophilus which collectively metabolize the drug NA-alpha-D-glucosamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1052	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1052	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1052	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1052	UNIPROID	ST1A1_HUMAN	SUBSTRAT	CERC-801
DME1052	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-gap interaction
DME1052	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and Glyceraldehyde-3-phosphate dehydrogenase from Lactobacillus acidophilus which collectively metabolize the drug CERC-801, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1052	UNIPROID	GALK1_HUMAN	PROTNAME	Galactose kinase (GALK1)
DME1052	UNIPROID	GALK1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1052	UNIPROID	GALK1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1052	UNIPROID	GALK1_HUMAN	SUBSTRAT	CERC-801
DME1052	UNIPROID	GALK1_HUMAN	PPI_SUMM	GALK1-gap interaction
DME1052	UNIPROID	GALK1_HUMAN	DESCRIPT	The interaction, between human Galactose kinase and Glyceraldehyde-3-phosphate dehydrogenase from Lactobacillus acidophilus which collectively metabolize the drug CERC-801, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1053	DME___ID	DME1053
DME1053	DME_NAME	L-arabinose isomerase (araA)
DME1053	SPESNAME	Lactobacillus sakei
DME1053	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1053	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1053	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1053	UNIPROID	ST1A1_HUMAN	SUBSTRAT	CERC-801
DME1053	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-araA interaction
DME1053	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and L-arabinose isomerase from Lactobacillus sakei which collectively metabolize the drug CERC-801, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1053	UNIPROID	GALK1_HUMAN	PROTNAME	Galactose kinase (GALK1)
DME1053	UNIPROID	GALK1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1053	UNIPROID	GALK1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1053	UNIPROID	GALK1_HUMAN	SUBSTRAT	CERC-801
DME1053	UNIPROID	GALK1_HUMAN	PPI_SUMM	GALK1-araA interaction
DME1053	UNIPROID	GALK1_HUMAN	DESCRIPT	The interaction, between human Galactose kinase and L-arabinose isomerase from Lactobacillus sakei which collectively metabolize the drug CERC-801, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1054	DME___ID	DME1054
DME1054	DME_NAME	L-arabinose isomerase (araA)
DME1054	SPESNAME	Clostridium hylemonae
DME1054	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1054	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1054	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1054	UNIPROID	ST1A1_HUMAN	SUBSTRAT	CERC-801
DME1054	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-araA interaction
DME1054	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and L-arabinose isomerase from Clostridium hylemonae which collectively metabolize the drug CERC-801, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1054	UNIPROID	GALK1_HUMAN	PROTNAME	Galactose kinase (GALK1)
DME1054	UNIPROID	GALK1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1054	UNIPROID	GALK1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1054	UNIPROID	GALK1_HUMAN	SUBSTRAT	CERC-801
DME1054	UNIPROID	GALK1_HUMAN	PPI_SUMM	GALK1-araA interaction
DME1054	UNIPROID	GALK1_HUMAN	DESCRIPT	The interaction, between human Galactose kinase and L-arabinose isomerase from Clostridium hylemonae which collectively metabolize the drug CERC-801, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1055	DME___ID	DME1055
DME1055	DME_NAME	Cytidine deaminase (cdd)
DME1055	SPESNAME	Escherichia coli
DME1055	UNIPROID	CDD_HUMAN	PROTNAME	Cytidine aminohydrolase (CDA)
DME1055	UNIPROID	CDD_HUMAN	MOFCLASS	Host-microbiome interaction
DME1055	UNIPROID	CDD_HUMAN	MOFDETAI	Host-microbiome interaction
DME1055	UNIPROID	CDD_HUMAN	SUBSTRAT	Gemcitabine
DME1055	UNIPROID	CDD_HUMAN	PPI_SUMM	CDA-cdd interaction
DME1055	UNIPROID	CDD_HUMAN	DESCRIPT	The interaction, between human Cytidine aminohydrolase and Cytidine deaminase from Escherichia coli which collectively metabolize the drug Gemcitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1055	UNIPROID	KCY_HUMAN	PROTNAME	Uridine/cytidine monophosphate kinase (UMPK)
DME1055	UNIPROID	KCY_HUMAN	MOFCLASS	Host-microbiome interaction
DME1055	UNIPROID	KCY_HUMAN	MOFDETAI	Host-microbiome interaction
DME1055	UNIPROID	KCY_HUMAN	SUBSTRAT	Gemcitabine
DME1055	UNIPROID	KCY_HUMAN	PPI_SUMM	UMPK-cdd interaction
DME1055	UNIPROID	KCY_HUMAN	DESCRIPT	The interaction, between human Uridine/cytidine monophosphate kinase and Cytidine deaminase from Escherichia coli which collectively metabolize the drug Gemcitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1056	DME___ID	DME1056
DME1056	DME_NAME	Cytidine deaminase (cdd)
DME1056	SPESNAME	Klebsiella pneumoniae
DME1056	UNIPROID	CDD_HUMAN	PROTNAME	Cytidine aminohydrolase (CDA)
DME1056	UNIPROID	CDD_HUMAN	MOFCLASS	Host-microbiome interaction
DME1056	UNIPROID	CDD_HUMAN	MOFDETAI	Host-microbiome interaction
DME1056	UNIPROID	CDD_HUMAN	SUBSTRAT	Gemcitabine
DME1056	UNIPROID	CDD_HUMAN	PPI_SUMM	CDA-cdd interaction
DME1056	UNIPROID	CDD_HUMAN	DESCRIPT	The interaction, between human Cytidine aminohydrolase and Cytidine deaminase from Klebsiella pneumoniae which collectively metabolize the drug Gemcitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1056	UNIPROID	KCY_HUMAN	PROTNAME	Uridine/cytidine monophosphate kinase (UMPK)
DME1056	UNIPROID	KCY_HUMAN	MOFCLASS	Host-microbiome interaction
DME1056	UNIPROID	KCY_HUMAN	MOFDETAI	Host-microbiome interaction
DME1056	UNIPROID	KCY_HUMAN	SUBSTRAT	Gemcitabine
DME1056	UNIPROID	KCY_HUMAN	PPI_SUMM	UMPK-cdd interaction
DME1056	UNIPROID	KCY_HUMAN	DESCRIPT	The interaction, between human Uridine/cytidine monophosphate kinase and Cytidine deaminase from Klebsiella pneumoniae which collectively metabolize the drug Gemcitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1057	DME___ID	DME1057
DME1057	DME_NAME	Catechol-2,3-dioxygenase (caD)
DME1057	SPESNAME	Bacillus pumilus
DME1057	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1057	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1057	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1057	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Gemfibrozil
DME1057	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-caD interaction
DME1057	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Catechol-2,3-dioxygenase from Bacillus pumilus which collectively metabolize the drug Gemfibrozil, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1057	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1057	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1057	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1057	UNIPROID	UD11_HUMAN	SUBSTRAT	Gemfibrozil
DME1057	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-caD interaction
DME1057	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Catechol-2,3-dioxygenase from Bacillus pumilus which collectively metabolize the drug Gemfibrozil, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1057	UNIPROID	UD2B7_HUMAN	PROTNAME	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DME1057	UNIPROID	UD2B7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1057	UNIPROID	UD2B7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1057	UNIPROID	UD2B7_HUMAN	SUBSTRAT	Gemfibrozil
DME1057	UNIPROID	UD2B7_HUMAN	PPI_SUMM	UGT2B7-caD interaction
DME1057	UNIPROID	UD2B7_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 2B7 and Catechol-2,3-dioxygenase from Bacillus pumilus which collectively metabolize the drug Gemfibrozil, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1057	UNIPROID	UD13_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DME1057	UNIPROID	UD13_HUMAN	MOFCLASS	Host-microbiome interaction
DME1057	UNIPROID	UD13_HUMAN	MOFDETAI	Host-microbiome interaction
DME1057	UNIPROID	UD13_HUMAN	SUBSTRAT	Gemfibrozil
DME1057	UNIPROID	UD13_HUMAN	PPI_SUMM	UGT1A3-caD interaction
DME1057	UNIPROID	UD13_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A3 and Catechol-2,3-dioxygenase from Bacillus pumilus which collectively metabolize the drug Gemfibrozil, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1057	UNIPROID	UD19_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DME1057	UNIPROID	UD19_HUMAN	MOFCLASS	Host-microbiome interaction
DME1057	UNIPROID	UD19_HUMAN	MOFDETAI	Host-microbiome interaction
DME1057	UNIPROID	UD19_HUMAN	SUBSTRAT	Gemfibrozil
DME1057	UNIPROID	UD19_HUMAN	PPI_SUMM	UGT1A9-caD interaction
DME1057	UNIPROID	UD19_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A9 and Catechol-2,3-dioxygenase from Bacillus pumilus which collectively metabolize the drug Gemfibrozil, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1058	DME___ID	DME1058
DME1058	DME_NAME	Propanediol dehydrogenase (dhaT)
DME1058	SPESNAME	Lactobacillus brevis
DME1058	UNIPROID	AQP7_HUMAN	PROTNAME	Aquaporin adipose (AQP7)
DME1058	UNIPROID	AQP7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1058	UNIPROID	AQP7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1058	UNIPROID	AQP7_HUMAN	SUBSTRAT	Glycerol
DME1058	UNIPROID	AQP7_HUMAN	PPI_SUMM	AQP7-dhaT interaction
DME1058	UNIPROID	AQP7_HUMAN	DESCRIPT	The interaction, between human Aquaporin adipose and Propanediol dehydrogenase from Lactobacillus brevis which collectively metabolize the drug Glycerol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1059	DME___ID	DME1059
DME1059	DME_NAME	Fumarate reductase flavoprotein (frdA)
DME1059	SPESNAME	Wolinella succinogenes
DME1059	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1059	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1059	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1059	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Hydroquinone
DME1059	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-frdA interaction
DME1059	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Fumarate reductase flavoprotein from Wolinella succinogenes which collectively metabolize the drug Hydroquinone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1061	DME___ID	DME1061
DME1061	DME_NAME	Tyrosine decarboxylase (tdc)
DME1061	SPESNAME	Enterococcus faecalis
DME1061	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1061	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1061	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1061	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Levodopa
DME1061	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-tdc interaction
DME1061	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Tyrosine decarboxylase from Enterococcus faecalis which collectively metabolize the drug Levodopa, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1061	UNIPROID	TPMT_HUMAN	PROTNAME	Thiopurine methyltransferase (TPMT)
DME1061	UNIPROID	TPMT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1061	UNIPROID	TPMT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1061	UNIPROID	TPMT_HUMAN	SUBSTRAT	Levodopa
DME1061	UNIPROID	TPMT_HUMAN	PPI_SUMM	TPMT-tdc interaction
DME1061	UNIPROID	TPMT_HUMAN	DESCRIPT	The interaction, between human Thiopurine methyltransferase and Tyrosine decarboxylase from Enterococcus faecalis which collectively metabolize the drug Levodopa, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1061	UNIPROID	DDC_HUMAN	PROTNAME	DOPA decarboxylase (DDC)
DME1061	UNIPROID	DDC_HUMAN	MOFCLASS	Host-microbiome interaction
DME1061	UNIPROID	DDC_HUMAN	MOFDETAI	Host-microbiome interaction
DME1061	UNIPROID	DDC_HUMAN	SUBSTRAT	Levodopa
DME1061	UNIPROID	DDC_HUMAN	PPI_SUMM	DDC-tdc interaction
DME1061	UNIPROID	DDC_HUMAN	DESCRIPT	The interaction, between human DOPA decarboxylase and Tyrosine decarboxylase from Enterococcus faecalis which collectively metabolize the drug Levodopa, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	DME___ID	DME1063
DME1063	DME_NAME	Nitroreductase (NTR)
DME1063	SPESNAME	Salmonella enterica
DME1063	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1063	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-NTR interaction
DME1063	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1063	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-NTR interaction
DME1063	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1063	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-NTR interaction
DME1063	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	UNIPROID	CBR1_HUMAN	PROTNAME	NADPH-dependent carbonyl reductase 1 (CBR1)
DME1063	UNIPROID	CBR1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	CBR1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	CBR1_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	CBR1_HUMAN	PPI_SUMM	CBR1-NTR interaction
DME1063	UNIPROID	CBR1_HUMAN	DESCRIPT	The interaction, between human NADPH-dependent carbonyl reductase 1 and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	UNIPROID	CBR3_HUMAN	PROTNAME	NADPH-dependent carbonyl reductase 3 (CBR3)
DME1063	UNIPROID	CBR3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	CBR3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	CBR3_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	CBR3_HUMAN	PPI_SUMM	CBR3-NTR interaction
DME1063	UNIPROID	CBR3_HUMAN	DESCRIPT	The interaction, between human NADPH-dependent carbonyl reductase 3 and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	UNIPROID	MTHR_HUMAN	PROTNAME	Methylenetetrahydrofolate reductase (MTHFR)
DME1063	UNIPROID	MTHR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	MTHR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	MTHR_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	MTHR_HUMAN	PPI_SUMM	MTHFR-NTR interaction
DME1063	UNIPROID	MTHR_HUMAN	DESCRIPT	The interaction, between human Methylenetetrahydrofolate reductase and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1063	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	MTRR_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-NTR interaction
DME1063	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	UNIPROID	QOR_HUMAN	PROTNAME	NADPH:quinone reductase (CRYZ)
DME1063	UNIPROID	QOR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	QOR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	QOR_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	QOR_HUMAN	PPI_SUMM	CRYZ-NTR interaction
DME1063	UNIPROID	QOR_HUMAN	DESCRIPT	The interaction, between human NADPH:quinone reductase and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1063	UNIPROID	SPRE_HUMAN	PROTNAME	Sepiapterin reductase (SPR)
DME1063	UNIPROID	SPRE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1063	UNIPROID	SPRE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1063	UNIPROID	SPRE_HUMAN	SUBSTRAT	Menadione
DME1063	UNIPROID	SPRE_HUMAN	PPI_SUMM	SPR-NTR interaction
DME1063	UNIPROID	SPRE_HUMAN	DESCRIPT	The interaction, between human Sepiapterin reductase and Nitroreductase from Salmonella enterica which collectively metabolize the drug Menadione, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1064	DME___ID	DME1064
DME1064	DME_NAME	Nitroreductase (NTR)
DME1064	SPESNAME	Giardia intestinalis
DME1064	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1064	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1064	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1064	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Metronidazole
DME1064	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1064	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Giardia intestinalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1064	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1064	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1064	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1064	UNIPROID	UD11_HUMAN	SUBSTRAT	Metronidazole
DME1064	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-NTR interaction
DME1064	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nitroreductase from Giardia intestinalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1064	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1064	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1064	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1064	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Metronidazole
DME1064	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-NTR interaction
DME1064	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nitroreductase from Giardia intestinalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1064	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1064	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1064	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1064	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Metronidazole
DME1064	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-NTR interaction
DME1064	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Nitroreductase from Giardia intestinalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1064	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1064	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1064	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1064	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Metronidazole
DME1064	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-NTR interaction
DME1064	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Nitroreductase from Giardia intestinalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1064	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1064	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1064	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1064	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Metronidazole
DME1064	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1064	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Giardia intestinalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1065	DME___ID	DME1065
DME1065	DME_NAME	Nitroreductase (NTR)
DME1065	SPESNAME	Trichomonas vaginalis
DME1065	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1065	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1065	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1065	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Metronidazole
DME1065	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1065	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Trichomonas vaginalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1065	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1065	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1065	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1065	UNIPROID	UD11_HUMAN	SUBSTRAT	Metronidazole
DME1065	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-NTR interaction
DME1065	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nitroreductase from Trichomonas vaginalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1065	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1065	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1065	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1065	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Metronidazole
DME1065	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-NTR interaction
DME1065	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nitroreductase from Trichomonas vaginalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1065	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1065	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1065	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1065	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Metronidazole
DME1065	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-NTR interaction
DME1065	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Nitroreductase from Trichomonas vaginalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1065	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1065	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1065	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1065	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Metronidazole
DME1065	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-NTR interaction
DME1065	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Nitroreductase from Trichomonas vaginalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1065	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1065	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1065	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1065	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Metronidazole
DME1065	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1065	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Trichomonas vaginalis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1066	DME___ID	DME1066
DME1066	DME_NAME	Nitroreductase (NTR)
DME1066	SPESNAME	Entamoeba histolytica
DME1066	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1066	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1066	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1066	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Metronidazole
DME1066	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1066	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Entamoeba histolytica which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1066	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1066	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1066	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1066	UNIPROID	UD11_HUMAN	SUBSTRAT	Metronidazole
DME1066	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-NTR interaction
DME1066	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nitroreductase from Entamoeba histolytica which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1066	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1066	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1066	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1066	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Metronidazole
DME1066	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-NTR interaction
DME1066	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nitroreductase from Entamoeba histolytica which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1066	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1066	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1066	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1066	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Metronidazole
DME1066	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-NTR interaction
DME1066	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Nitroreductase from Entamoeba histolytica which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1066	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1066	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1066	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1066	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Metronidazole
DME1066	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-NTR interaction
DME1066	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Nitroreductase from Entamoeba histolytica which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1066	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1066	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1066	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1066	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Metronidazole
DME1066	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1066	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Entamoeba histolytica which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1068	DME___ID	DME1068
DME1068	DME_NAME	Aminoglycoside O-phosphotransferase (aphA6)
DME1068	SPESNAME	Acinetobacter baumannii
DME1068	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1068	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1068	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1068	UNIPROID	NAT10_HUMAN	SUBSTRAT	Tobramycin
DME1068	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-aphA6 interaction
DME1068	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Aminoglycoside O-phosphotransferase from Acinetobacter baumannii which collectively metabolize the drug Tobramycin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1068	UNIPROID	NAT10_HUMAN	SUBSTRAT	Netilmicin
DME1068	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Aminoglycoside O-phosphotransferase from Acinetobacter baumannii which collectively metabolize the drug Netilmicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	DME___ID	DME1069
DME1069	DME_NAME	Nicotinate dehydrogenase (nicA)
DME1069	SPESNAME	Pseudomonas putida
DME1069	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1069	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-nicA interaction
DME1069	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1069	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-nicA interaction
DME1069	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1069	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	UD11_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-nicA interaction
DME1069	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1069	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-nicA interaction
DME1069	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1069	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-nicA interaction
DME1069	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1069	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-nicA interaction
DME1069	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1069	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-nicA interaction
DME1069	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP2C8_HUMAN	PROTNAME	Cytochrome P450 2C8 (CYP2C8)
DME1069	UNIPROID	CP2C8_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP2C8_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP2C8_HUMAN	PPI_SUMM	CYP2C8-nicA interaction
DME1069	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1069	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-nicA interaction
DME1069	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1069	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-nicA interaction
DME1069	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1069	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-nicA interaction
DME1069	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1069	UNIPROID	CP2AD_HUMAN	PROTNAME	Cytochrome P450 2A13 (CYP2A13)
DME1069	UNIPROID	CP2AD_HUMAN	MOFCLASS	Host-microbiome interaction
DME1069	UNIPROID	CP2AD_HUMAN	MOFDETAI	Host-microbiome interaction
DME1069	UNIPROID	CP2AD_HUMAN	SUBSTRAT	Nicotine
DME1069	UNIPROID	CP2AD_HUMAN	PPI_SUMM	CYP2A13-nicA interaction
DME1069	UNIPROID	CP2AD_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A13 and Nicotinate dehydrogenase from Pseudomonas putida which collectively metabolize the drug Nicotine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1070	DME___ID	DME1070
DME1070	DME_NAME	Nitroreductase (NTR)
DME1070	SPESNAME	Clostridium leptum
DME1070	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1070	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1070	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1070	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Nitrazepam
DME1070	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1070	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Clostridium leptum which collectively metabolize the drug Nitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1070	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1070	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1070	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1070	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1070	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-NTR interaction
DME1070	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Nitroreductase from Clostridium leptum which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	DME___ID	DME1072
DME1072	DME_NAME	Cytochrome P450 MEG (cyp106)
DME1072	SPESNAME	Bacillus megaterium
DME1072	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1072	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cyp106 interaction
DME1072	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP19A_HUMAN	PROTNAME	Aromatase (CYP19A1)
DME1072	UNIPROID	CP19A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP19A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP19A_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP19A_HUMAN	PPI_SUMM	CYP19A1-cyp106 interaction
DME1072	UNIPROID	CP19A_HUMAN	DESCRIPT	The interaction, between human Aromatase and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1072	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-cyp106 interaction
DME1072	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP4B1_HUMAN	PROTNAME	Cytochrome P450 4B1 (CYP4B1)
DME1072	UNIPROID	CP4B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP4B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP4B1_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP4B1_HUMAN	PPI_SUMM	CYP4B1-cyp106 interaction
DME1072	UNIPROID	CP4B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 4B1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1072	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-cyp106 interaction
DME1072	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1072	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-cyp106 interaction
DME1072	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2C8_HUMAN	PROTNAME	Cytochrome P450 2C8 (CYP2C8)
DME1072	UNIPROID	CP2C8_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP2C8_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP2C8_HUMAN	PPI_SUMM	CYP2C8-cyp106 interaction
DME1072	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1072	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-cyp106 interaction
DME1072	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1072	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-cyp106 interaction
DME1072	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1072	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-cyp106 interaction
DME1072	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP343_HUMAN	PROTNAME	Cytochrome P450 3A43 (CYP3A43)
DME1072	UNIPROID	CP343_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP343_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP343_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP343_HUMAN	PPI_SUMM	CYP3A43-cyp106 interaction
DME1072	UNIPROID	CP343_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A43 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP1B1_HUMAN	PROTNAME	Cytochrome P450 1B1 (CYP1B1)
DME1072	UNIPROID	CP1B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP1B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP1B1_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP1B1_HUMAN	PPI_SUMM	CYP1B1-cyp106 interaction
DME1072	UNIPROID	CP1B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1B1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1072	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP46A_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp106 interaction
DME1072	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2AD_HUMAN	PROTNAME	Cytochrome P450 2A13 (CYP2A13)
DME1072	UNIPROID	CP2AD_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP2AD_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP2AD_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	CP2AD_HUMAN	PPI_SUMM	CYP2A13-cyp106 interaction
DME1072	UNIPROID	CP2AD_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A13 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	S5A1_HUMAN	PROTNAME	Steroid 5-alpha-reductase 1 (SRD5A1)
DME1072	UNIPROID	S5A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	S5A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	S5A1_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	S5A1_HUMAN	PPI_SUMM	SRD5A1-cyp106 interaction
DME1072	UNIPROID	S5A1_HUMAN	DESCRIPT	The interaction, between human Steroid 5-alpha-reductase 1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	S5A2_HUMAN	PROTNAME	Steroid 5-alpha-reductase 2 (SRD5A2)
DME1072	UNIPROID	S5A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	S5A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	S5A2_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	S5A2_HUMAN	PPI_SUMM	SRD5A2-cyp106 interaction
DME1072	UNIPROID	S5A2_HUMAN	DESCRIPT	The interaction, between human Steroid 5-alpha-reductase 2 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	PORED_HUMAN	PROTNAME	Steroid 5-alpha-reductase 3 (SRD5A3)
DME1072	UNIPROID	PORED_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	PORED_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	PORED_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	PORED_HUMAN	PPI_SUMM	SRD5A3-cyp106 interaction
DME1072	UNIPROID	PORED_HUMAN	DESCRIPT	The interaction, between human Steroid 5-alpha-reductase 3 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	AK1BF_HUMAN	PROTNAME	Farnesol dehydrogenase (AKR1B15)
DME1072	UNIPROID	AK1BF_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	AK1BF_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	AK1BF_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	AK1BF_HUMAN	PPI_SUMM	AKR1B15-cyp106 interaction
DME1072	UNIPROID	AK1BF_HUMAN	DESCRIPT	The interaction, between human Farnesol dehydrogenase and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	DHB14_HUMAN	PROTNAME	Dehydrogenase/reductase retSDR3 (HSD17B14)
DME1072	UNIPROID	DHB14_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	DHB14_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	DHB14_HUMAN	SUBSTRAT	Testosterone cypionate
DME1072	UNIPROID	DHB14_HUMAN	PPI_SUMM	HSD17B14-cyp106 interaction
DME1072	UNIPROID	DHB14_HUMAN	DESCRIPT	The interaction, between human Dehydrogenase/reductase retSDR3 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1072	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-cyp106 interaction
DME1072	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1072	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-cyp106 interaction
DME1072	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1072	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-cyp106 interaction
DME1072	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP4B1_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP4B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 4B1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	GSTA1_HUMAN	PROTNAME	Glutathione S-transferase alpha-1 (GSTA1)
DME1072	UNIPROID	GSTA1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	GSTA1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	GSTA1_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	GSTA1_HUMAN	PPI_SUMM	GSTA1-cyp106 interaction
DME1072	UNIPROID	GSTA1_HUMAN	DESCRIPT	The interaction, between human Glutathione S-transferase alpha-1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP1B1_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP1B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1B1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP46A_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	CP21A_HUMAN	PROTNAME	Steroid 21-hydroxylase (CYP21A2)
DME1072	UNIPROID	CP21A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	CP21A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	CP21A_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	CP21A_HUMAN	PPI_SUMM	CYP21A2-cyp106 interaction
DME1072	UNIPROID	CP21A_HUMAN	DESCRIPT	The interaction, between human Steroid 21-hydroxylase and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1072	UNIPROID	AK1C1_HUMAN	PROTNAME	Aldo-keto reductase 1C1 (AKR1C1)
DME1072	UNIPROID	AK1C1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1072	UNIPROID	AK1C1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1072	UNIPROID	AK1C1_HUMAN	SUBSTRAT	Progesterone
DME1072	UNIPROID	AK1C1_HUMAN	PPI_SUMM	AKR1C1-cyp106 interaction
DME1072	UNIPROID	AK1C1_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1C1 and Cytochrome P450 MEG from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	DME___ID	DME1075
DME1075	DME_NAME	Cytochrome P450 102A1 (cyp102)
DME1075	SPESNAME	Bacillus megaterium
DME1075	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1075	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Amodiaquine
DME1075	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-cyp102 interaction
DME1075	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Amodiaquine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2C8_HUMAN	PROTNAME	Cytochrome P450 2C8 (CYP2C8)
DME1075	UNIPROID	CP2C8_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP2C8_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Amodiaquine
DME1075	UNIPROID	CP2C8_HUMAN	PPI_SUMM	CYP2C8-cyp102 interaction
DME1075	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Amodiaquine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP1B1_HUMAN	PROTNAME	Cytochrome P450 1B1 (CYP1B1)
DME1075	UNIPROID	CP1B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP1B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP1B1_HUMAN	SUBSTRAT	Amodiaquine
DME1075	UNIPROID	CP1B1_HUMAN	PPI_SUMM	CYP1B1-cyp102 interaction
DME1075	UNIPROID	CP1B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1B1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Amodiaquine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	GSTM4_HUMAN	PROTNAME	Glutathione S-transferase mu-4 (GSTM4)
DME1075	UNIPROID	GSTM4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	GSTM4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	GSTM4_HUMAN	SUBSTRAT	Amodiaquine
DME1075	UNIPROID	GSTM4_HUMAN	PPI_SUMM	GSTM4-cyp102 interaction
DME1075	UNIPROID	GSTM4_HUMAN	DESCRIPT	The interaction, between human Glutathione S-transferase mu-4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Amodiaquine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1075	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Buspirone
DME1075	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cyp102 interaction
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Buspirone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1075	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Buspirone
DME1075	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-cyp102 interaction
DME1075	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Buspirone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1075	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Buspirone
DME1075	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-cyp102 interaction
DME1075	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Buspirone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1075	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Buspirone
DME1075	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-cyp102 interaction
DME1075	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Buspirone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Chlorzoxazone
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Chlorzoxazone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1075	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Chlorzoxazone
DME1075	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-cyp102 interaction
DME1075	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Chlorzoxazone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1075	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Chlorzoxazone
DME1075	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-cyp102 interaction
DME1075	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Chlorzoxazone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Chlorzoxazone
DME1075	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Chlorzoxazone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1075	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Chlorzoxazone
DME1075	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-cyp102 interaction
DME1075	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Chlorzoxazone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Mefenamic acid
DME1075	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Mefenamic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1075	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Mefenamic acid
DME1075	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-cyp102 interaction
DME1075	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Mefenamic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2D6_HUMAN	SUBSTRAT	CCRIS-9277
DME1075	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug CCRIS-9277, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	COMT_HUMAN	PROTNAME	Catechol O-methyltransferase (COMT)
DME1075	UNIPROID	COMT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	COMT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	COMT_HUMAN	SUBSTRAT	CCRIS-9277
DME1075	UNIPROID	COMT_HUMAN	PPI_SUMM	COMT-cyp102 interaction
DME1075	UNIPROID	COMT_HUMAN	DESCRIPT	The interaction, between human Catechol O-methyltransferase and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug CCRIS-9277, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Nifedipine
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Nifedipine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Nifedipine
DME1075	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Nifedipine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Nifedipine
DME1075	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Nifedipine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Nifedipine
DME1075	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Nifedipine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Propranolol hydrochloride
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Propranolol hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Propranolol hydrochloride
DME1075	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Propranolol hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Propranolol hydrochloride
DME1075	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Propranolol hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Propranolol hydrochloride
DME1075	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Propranolol hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Propranolol hydrochloride
DME1075	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Propranolol hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1075	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Propranolol hydrochloride
DME1075	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-cyp102 interaction
DME1075	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Propranolol hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	FMO2_HUMAN	PROTNAME	Dimethylaniline oxidase 2 (FMO2)
DME1075	UNIPROID	FMO2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	FMO2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	FMO2_HUMAN	SUBSTRAT	Propranolol hydrochloride
DME1075	UNIPROID	FMO2_HUMAN	PPI_SUMM	FMO2-cyp102 interaction
DME1075	UNIPROID	FMO2_HUMAN	DESCRIPT	The interaction, between human Dimethylaniline oxidase 2 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Propranolol hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	GEA-6414
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug GEA-6414, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Benzyloxyresorufin
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Benzyloxyresorufin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2CI_HUMAN	PROTNAME	Cytochrome P450 2C18 (CYP2C18)
DME1075	UNIPROID	CP2CI_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP2CI_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP2CI_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP2CI_HUMAN	PPI_SUMM	CYP2C18-cyp102 interaction
DME1075	UNIPROID	CP2CI_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C18 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1075	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-cyp102 interaction
DME1075	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1075	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	CP46A_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp102 interaction
DME1075	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	UD2B7_HUMAN	PROTNAME	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DME1075	UNIPROID	UD2B7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	UD2B7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	UD2B7_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	UD2B7_HUMAN	PPI_SUMM	UGT2B7-cyp102 interaction
DME1075	UNIPROID	UD2B7_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 2B7 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	UD13_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DME1075	UNIPROID	UD13_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	UD13_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	UD13_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	UD13_HUMAN	PPI_SUMM	UGT1A3-cyp102 interaction
DME1075	UNIPROID	UD13_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A3 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	UD19_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DME1075	UNIPROID	UD19_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	UD19_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	UD19_HUMAN	SUBSTRAT	Diclofenac sodium
DME1075	UNIPROID	UD19_HUMAN	PPI_SUMM	UGT1A9-cyp102 interaction
DME1075	UNIPROID	UD19_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A9 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1075	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	UD11_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-cyp102 interaction
DME1075	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1075	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-cyp102 interaction
DME1075	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	GSTA1_HUMAN	PROTNAME	Glutathione S-transferase alpha-1 (GSTA1)
DME1075	UNIPROID	GSTA1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	GSTA1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	GSTA1_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	GSTA1_HUMAN	PPI_SUMM	GSTA1-cyp102 interaction
DME1075	UNIPROID	GSTA1_HUMAN	DESCRIPT	The interaction, between human Glutathione S-transferase alpha-1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	UD19_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	UD19_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A9 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	UDB15_HUMAN	PROTNAME	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DME1075	UNIPROID	UDB15_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	UDB15_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	UDB15_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	UDB15_HUMAN	PPI_SUMM	UGT2B15-cyp102 interaction
DME1075	UNIPROID	UDB15_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 2B15 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	UD16_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DME1075	UNIPROID	UD16_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	UD16_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	UD16_HUMAN	SUBSTRAT	Acetaminophen
DME1075	UNIPROID	UD16_HUMAN	PPI_SUMM	UGT1A6-cyp102 interaction
DME1075	UNIPROID	UD16_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Acetaminophen, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1075	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1075	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1075	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1075	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1075	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1075	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1075	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	CP46A_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1075	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	ST1A2_HUMAN	PROTNAME	Sulfotransferase 1A2 (SULT1A2)
DME1075	UNIPROID	ST1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	ST1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	ST1A2_HUMAN	SUBSTRAT	Mononitrophenol
DME1075	UNIPROID	ST1A2_HUMAN	PPI_SUMM	SULT1A2-cyp102 interaction
DME1075	UNIPROID	ST1A2_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A2 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Mononitrophenol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1075	UNIPROID	ST1B1_HUMAN	PROTNAME	Sulfotransferase 1B1 (SULT1B1)
DME1075	UNIPROID	ST1B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1075	UNIPROID	ST1B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1075	UNIPROID	ST1B1_HUMAN	SUBSTRAT	Mononitrophenol
DME1075	UNIPROID	ST1B1_HUMAN	PPI_SUMM	SULT1B1-cyp102 interaction
DME1075	UNIPROID	ST1B1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1B1 and Cytochrome P450 102A1 from Bacillus megaterium which collectively metabolize the drug Mononitrophenol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1076	DME___ID	DME1076
DME1076	DME_NAME	Nicotinamidase (pncA)
DME1076	SPESNAME	Acinetobacter baumannii
DME1076	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1076	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1076	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1076	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Pyrazinamide
DME1076	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-pncA interaction
DME1076	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nicotinamidase from Acinetobacter baumannii which collectively metabolize the drug Pyrazinamide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1076	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1076	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1076	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1076	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Pyrazinamide
DME1076	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-pncA interaction
DME1076	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Nicotinamidase from Acinetobacter baumannii which collectively metabolize the drug Pyrazinamide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1077	DME___ID	DME1077
DME1077	DME_NAME	NADPH-dependent curcumin reductase (curA)
DME1077	SPESNAME	Escherichia coli
DME1077	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1077	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1077	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1077	UNIPROID	CP1A2_HUMAN	SUBSTRAT	SRT-501
DME1077	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-curA interaction
DME1077	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and NADPH-dependent curcumin reductase from Escherichia coli which collectively metabolize the drug SRT-501, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1077	UNIPROID	ST1C2_HUMAN	PROTNAME	Sulfotransferase 1C2 (SULT1C2)
DME1077	UNIPROID	ST1C2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1077	UNIPROID	ST1C2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1077	UNIPROID	ST1C2_HUMAN	SUBSTRAT	SRT-501
DME1077	UNIPROID	ST1C2_HUMAN	PPI_SUMM	SULT1C2-curA interaction
DME1077	UNIPROID	ST1C2_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1C2 and NADPH-dependent curcumin reductase from Escherichia coli which collectively metabolize the drug SRT-501, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1077	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1077	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1077	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1077	UNIPROID	UD11_HUMAN	SUBSTRAT	Curcumin
DME1077	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-curA interaction
DME1077	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and NADPH-dependent curcumin reductase from Escherichia coli which collectively metabolize the drug Curcumin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1077	UNIPROID	UD19_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DME1077	UNIPROID	UD19_HUMAN	MOFCLASS	Host-microbiome interaction
DME1077	UNIPROID	UD19_HUMAN	MOFDETAI	Host-microbiome interaction
DME1077	UNIPROID	UD19_HUMAN	SUBSTRAT	Curcumin
DME1077	UNIPROID	UD19_HUMAN	PPI_SUMM	UGT1A9-curA interaction
DME1077	UNIPROID	UD19_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A9 and NADPH-dependent curcumin reductase from Escherichia coli which collectively metabolize the drug Curcumin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1077	UNIPROID	UD18_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DME1077	UNIPROID	UD18_HUMAN	MOFCLASS	Host-microbiome interaction
DME1077	UNIPROID	UD18_HUMAN	MOFDETAI	Host-microbiome interaction
DME1077	UNIPROID	UD18_HUMAN	SUBSTRAT	Curcumin
DME1077	UNIPROID	UD18_HUMAN	PPI_SUMM	UGT1A8-curA interaction
DME1077	UNIPROID	UD18_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A8 and NADPH-dependent curcumin reductase from Escherichia coli which collectively metabolize the drug Curcumin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1077	UNIPROID	UD17_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DME1077	UNIPROID	UD17_HUMAN	MOFCLASS	Host-microbiome interaction
DME1077	UNIPROID	UD17_HUMAN	MOFDETAI	Host-microbiome interaction
DME1077	UNIPROID	UD17_HUMAN	SUBSTRAT	Curcumin
DME1077	UNIPROID	UD17_HUMAN	PPI_SUMM	UGT1A7-curA interaction
DME1077	UNIPROID	UD17_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A7 and NADPH-dependent curcumin reductase from Escherichia coli which collectively metabolize the drug Curcumin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1080	DME___ID	DME1080
DME1080	DME_NAME	Azoreductase (azoR)
DME1080	SPESNAME	Streptococcus salivarius
DME1080	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1080	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1080	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1080	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1080	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1080	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Streptococcus salivarius which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1081	DME___ID	DME1081
DME1081	DME_NAME	Azoreductase (azoR)
DME1081	SPESNAME	Enterococcus casseliflavus
DME1081	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1081	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1081	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1081	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1081	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1081	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Enterococcus casseliflavus which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1082	DME___ID	DME1082
DME1082	DME_NAME	Azoreductase (azoR)
DME1082	SPESNAME	Bacteroides thetaiotaomicron
DME1082	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1082	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1082	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1082	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1082	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1082	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Bacteroides thetaiotaomicron which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1083	DME___ID	DME1083
DME1083	DME_NAME	Azoreductase (azoR)
DME1083	SPESNAME	Bifidobacterium dentium
DME1083	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1083	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1083	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1083	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1083	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1083	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Bifidobacterium dentium which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1085	DME___ID	DME1085
DME1085	DME_NAME	VanA ligase (vanA)
DME1085	SPESNAME	Enterococcus faecalis
DME1085	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1085	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1085	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1085	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Teicoplanin
DME1085	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-vanA interaction
DME1085	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and VanA ligase from Enterococcus faecalis which collectively metabolize the drug Teicoplanin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1086	DME___ID	DME1086
DME1086	DME_NAME	VanA ligase (vanA)
DME1086	SPESNAME	Enterococcus faecium
DME1086	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1086	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1086	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1086	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Teicoplanin
DME1086	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-vanA interaction
DME1086	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and VanA ligase from Enterococcus faecium which collectively metabolize the drug Teicoplanin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1087	DME___ID	DME1087
DME1087	DME_NAME	Hydroxybenzoate 3-monooxygenase (pobA)
DME1087	SPESNAME	Pseudomonas aeruginosa
DME1087	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1087	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1087	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1087	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Tetracycline
DME1087	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-pobA interaction
DME1087	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Hydroxybenzoate 3-monooxygenase from Pseudomonas aeruginosa which collectively metabolize the drug Tetracycline, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1088	DME___ID	DME1088
DME1088	DME_NAME	Hydroxybenzoate 3-monooxygenase (pobA)
DME1088	SPESNAME	Pseudomonas fluorescens
DME1088	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1088	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1088	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1088	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Tetracycline
DME1088	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-pobA interaction
DME1088	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Hydroxybenzoate 3-monooxygenase from Pseudomonas fluorescens which collectively metabolize the drug Tetracycline, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1089	DME___ID	DME1089
DME1089	DME_NAME	Hydroxybenzoate 3-monooxygenase (pobA)
DME1089	SPESNAME	Pseudomonas putida
DME1089	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1089	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1089	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1089	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Tetracycline
DME1089	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-pobA interaction
DME1089	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Hydroxybenzoate 3-monooxygenase from Pseudomonas putida which collectively metabolize the drug Tetracycline, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1090	DME___ID	DME1090
DME1090	DME_NAME	Aminoglycoside phosphotransferase (aph-Ib)
DME1090	SPESNAME	Campylobacter jejuni
DME1090	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1090	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1090	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1090	UNIPROID	NAT10_HUMAN	SUBSTRAT	Tobramycin
DME1090	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-aph-Ib interaction
DME1090	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Aminoglycoside phosphotransferase from Campylobacter jejuni which collectively metabolize the drug Tobramycin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1091	DME___ID	DME1091
DME1091	DME_NAME	Kanamycin/gentamycin-resistance enzyme (aacA)
DME1091	SPESNAME	Campylobacter coli
DME1091	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1091	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1091	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1091	UNIPROID	NAT10_HUMAN	SUBSTRAT	Tobramycin
DME1091	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-aacA interaction
DME1091	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Kanamycin/gentamycin-resistance enzyme from Campylobacter coli which collectively metabolize the drug Tobramycin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1092	DME___ID	DME1092
DME1092	DME_NAME	Aldehyde oxidase (AOX)
DME1092	SPESNAME	Clostridium sporogenes
DME1092	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1092	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1092	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1092	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Zonisamide
DME1092	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-AOX interaction
DME1092	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Aldehyde oxidase from Clostridium sporogenes which collectively metabolize the drug Zonisamide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1092	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1092	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1092	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1092	UNIPROID	UD11_HUMAN	SUBSTRAT	Zonisamide
DME1092	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-AOX interaction
DME1092	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Aldehyde oxidase from Clostridium sporogenes which collectively metabolize the drug Zonisamide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1092	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1092	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1092	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1092	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Zonisamide
DME1092	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-AOX interaction
DME1092	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Aldehyde oxidase from Clostridium sporogenes which collectively metabolize the drug Zonisamide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1092	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1092	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1092	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1092	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Zonisamide
DME1092	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-AOX interaction
DME1092	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Aldehyde oxidase from Clostridium sporogenes which collectively metabolize the drug Zonisamide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1092	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1092	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1092	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1092	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Zonisamide
DME1092	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-AOX interaction
DME1092	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Aldehyde oxidase from Clostridium sporogenes which collectively metabolize the drug Zonisamide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1094	DME___ID	DME1094
DME1094	DME_NAME	Beta-lactamase (blaB)
DME1094	SPESNAME	Citrobacter freundii
DME1094	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1094	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1094	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1094	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1094	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1094	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Citrobacter freundii which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1094	UNIPROID	TPMT_HUMAN	PROTNAME	Thiopurine methyltransferase (TPMT)
DME1094	UNIPROID	TPMT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1094	UNIPROID	TPMT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1094	UNIPROID	TPMT_HUMAN	SUBSTRAT	Cefazolin
DME1094	UNIPROID	TPMT_HUMAN	PPI_SUMM	TPMT-blaB interaction
DME1094	UNIPROID	TPMT_HUMAN	DESCRIPT	The interaction, between human Thiopurine methyltransferase and Beta-lactamase from Citrobacter freundii which collectively metabolize the drug Cefazolin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1095	DME___ID	DME1095
DME1095	DME_NAME	Beta-lactamase (blaB)
DME1095	SPESNAME	Bacteroides fragilis
DME1095	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1095	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1095	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1095	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1095	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1095	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides fragilis which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1095	UNIPROID	TPMT_HUMAN	PROTNAME	Thiopurine methyltransferase (TPMT)
DME1095	UNIPROID	TPMT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1095	UNIPROID	TPMT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1095	UNIPROID	TPMT_HUMAN	SUBSTRAT	Cefazolin
DME1095	UNIPROID	TPMT_HUMAN	PPI_SUMM	TPMT-blaB interaction
DME1095	UNIPROID	TPMT_HUMAN	DESCRIPT	The interaction, between human Thiopurine methyltransferase and Beta-lactamase from Bacteroides fragilis which collectively metabolize the drug Cefazolin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1096	DME___ID	DME1096
DME1096	DME_NAME	Azoreductase (azoR)
DME1096	SPESNAME	Escherichia coli
DME1096	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1096	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1096	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1096	UNIPROID	NQO1_HUMAN	SUBSTRAT	CBL-954
DME1096	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-azoR interaction
DME1096	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and Azoreductase from Escherichia coli which collectively metabolize the drug CBL-954, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1097	DME___ID	DME1097
DME1097	DME_NAME	N-ethylmaleimide reductase (nemA)
DME1097	SPESNAME	Escherichia coli
DME1097	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1097	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1097	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1097	UNIPROID	NQO1_HUMAN	SUBSTRAT	CBL-954
DME1097	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-nemA interaction
DME1097	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and N-ethylmaleimide reductase from Escherichia coli which collectively metabolize the drug CBL-954, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1098	DME___ID	DME1098
DME1098	DME_NAME	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DME1098	SPESNAME	Escherichia coli
DME1098	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1098	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1098	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1098	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Nitrazepam
DME1098	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-nfsA interaction
DME1098	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Oxygen-insensitive NADPH nitroreductase A from Escherichia coli which collectively metabolize the drug Nitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1098	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1098	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1098	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1098	UNIPROID	NQO1_HUMAN	SUBSTRAT	CBL-954
DME1098	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-nfsA interaction
DME1098	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and Oxygen-insensitive NADPH nitroreductase A from Escherichia coli which collectively metabolize the drug CBL-954, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1098	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1098	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1098	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1098	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Nitrofural
DME1098	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-nfsA interaction
DME1098	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Oxygen-insensitive NADPH nitroreductase A from Escherichia coli which collectively metabolize the drug Nitrofural, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1098	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Loperamide hydrochloride
DME1098	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Oxygen-insensitive NADPH nitroreductase A from Escherichia coli which collectively metabolize the drug Loperamide hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1098	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Loperamide hydrochloride
DME1098	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Oxygen-insensitive NADPH nitroreductase A from Escherichia coli which collectively metabolize the drug Loperamide hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1098	UNIPROID	CP2C8_HUMAN	PROTNAME	Cytochrome P450 2C8 (CYP2C8)
DME1098	UNIPROID	CP2C8_HUMAN	MOFCLASS	Host-microbiome interaction
DME1098	UNIPROID	CP2C8_HUMAN	MOFDETAI	Host-microbiome interaction
DME1098	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Loperamide hydrochloride
DME1098	UNIPROID	CP2C8_HUMAN	PPI_SUMM	CYP2C8-nfsA interaction
DME1098	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Oxygen-insensitive NADPH nitroreductase A from Escherichia coli which collectively metabolize the drug Loperamide hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1098	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1098	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1098	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1098	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Loperamide hydrochloride
DME1098	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-nfsA interaction
DME1098	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Oxygen-insensitive NADPH nitroreductase A from Escherichia coli which collectively metabolize the drug Loperamide hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1099	DME___ID	DME1099
DME1099	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1099	SPESNAME	Vibrio cholerae
DME1099	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1099	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1099	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1099	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1099	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1099	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Vibrio cholerae which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1099	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1099	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1099	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1099	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1099	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1099	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Vibrio cholerae which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1100	DME___ID	DME1100
DME1100	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1100	SPESNAME	Shigella flexneri
DME1100	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1100	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1100	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1100	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1100	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1100	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Shigella flexneri which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1100	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1100	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1100	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1100	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1100	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1100	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Shigella flexneri which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1101	DME___ID	DME1101
DME1101	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1101	SPESNAME	Plesiomonas shigelloides
DME1101	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1101	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1101	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1101	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1101	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1101	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Plesiomonas shigelloides which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1101	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1101	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1101	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1101	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1101	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1101	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Plesiomonas shigelloides which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1102	DME___ID	DME1102
DME1102	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1102	SPESNAME	Morganella morganii
DME1102	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1102	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1102	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1102	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1102	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1102	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Morganella morganii which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1102	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1102	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1102	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1102	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1102	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1102	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Morganella morganii which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1103	DME___ID	DME1103
DME1103	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1103	SPESNAME	Citrobacter freundii
DME1103	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1103	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1103	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1103	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1103	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1103	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Citrobacter freundii which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1103	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1103	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1103	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1103	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1103	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1103	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Citrobacter freundii which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1104	DME___ID	DME1104
DME1104	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1104	SPESNAME	Serratia marcescens
DME1104	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1104	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1104	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1104	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1104	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1104	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Serratia marcescens which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1104	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1104	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1104	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1104	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1104	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1104	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Serratia marcescens which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1106	DME___ID	DME1106
DME1106	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1106	SPESNAME	Klebsiella pneumoniae
DME1106	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1106	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1106	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1106	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1106	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1106	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Klebsiella pneumoniae which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1106	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1106	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1106	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1106	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1106	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1106	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Klebsiella pneumoniae which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1107	DME___ID	DME1107
DME1107	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1107	SPESNAME	Citrobacter farmeri
DME1107	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1107	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1107	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1107	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1107	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1107	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Citrobacter farmeri which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1107	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1107	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1107	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1107	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1107	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1107	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Citrobacter farmeri which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1108	DME___ID	DME1108
DME1108	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1108	SPESNAME	Klebsiella oxytoca
DME1108	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1108	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1108	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1108	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1108	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1108	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Klebsiella oxytoca which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1108	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1108	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1108	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1108	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1108	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1108	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Klebsiella oxytoca which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1109	DME___ID	DME1109
DME1109	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1109	SPESNAME	Citrobacter amalonaticus
DME1109	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1109	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1109	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1109	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1109	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1109	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Citrobacter amalonaticus which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1109	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1109	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1109	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1109	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1109	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1109	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Citrobacter amalonaticus which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1110	DME___ID	DME1110
DME1110	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1110	SPESNAME	Pseudomonas aeruginosa
DME1110	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1110	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1110	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1110	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1110	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1110	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Pseudomonas aeruginosa which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1110	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1110	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1110	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1110	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1110	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1110	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Pseudomonas aeruginosa which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1111	DME___ID	DME1111
DME1111	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1111	SPESNAME	Salmonella enterica
DME1111	UNIPROID	ARY1_HUMAN	PROTNAME	N-acetyltransferase 1 (NAT1)
DME1111	UNIPROID	ARY1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1111	UNIPROID	ARY1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1111	UNIPROID	ARY1_HUMAN	SUBSTRAT	Asacolitin
DME1111	UNIPROID	ARY1_HUMAN	PPI_SUMM	NAT1-NAT interaction
DME1111	UNIPROID	ARY1_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 1 and Arylamine N-acetyltransferase from Salmonella enterica which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1111	UNIPROID	ARY2_HUMAN	PROTNAME	N-acetyltransferase 2 (NAT2)
DME1111	UNIPROID	ARY2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1111	UNIPROID	ARY2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1111	UNIPROID	ARY2_HUMAN	SUBSTRAT	Asacolitin
DME1111	UNIPROID	ARY2_HUMAN	PPI_SUMM	NAT2-NAT interaction
DME1111	UNIPROID	ARY2_HUMAN	DESCRIPT	The interaction, between human N-acetyltransferase 2 and Arylamine N-acetyltransferase from Salmonella enterica which collectively metabolize the drug Asacolitin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1112	DME___ID	DME1112
DME1112	DME_NAME	Carboxylic ester hydrolase (CEH)
DME1112	SPESNAME	Butyrivibrio fibrisolvens
DME1112	UNIPROID	PGH1_HUMAN	PROTNAME	Prostaglandin G/H synthase 1 (COX-1)
DME1112	UNIPROID	PGH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1112	UNIPROID	PGH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1112	UNIPROID	PGH1_HUMAN	SUBSTRAT	Alpha-linolenic acid
DME1112	UNIPROID	PGH1_HUMAN	PPI_SUMM	COX-1-CEH interaction
DME1112	UNIPROID	PGH1_HUMAN	DESCRIPT	The interaction, between human Prostaglandin G/H synthase 1 and Carboxylic ester hydrolase from Butyrivibrio fibrisolvens which collectively metabolize the drug Alpha-linolenic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1112	UNIPROID	PGH2_HUMAN	PROTNAME	Prostaglandin G/H synthase 2 (COX-2)
DME1112	UNIPROID	PGH2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1112	UNIPROID	PGH2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1112	UNIPROID	PGH2_HUMAN	SUBSTRAT	Alpha-linolenic acid
DME1112	UNIPROID	PGH2_HUMAN	PPI_SUMM	COX-2-CEH interaction
DME1112	UNIPROID	PGH2_HUMAN	DESCRIPT	The interaction, between human Prostaglandin G/H synthase 2 and Carboxylic ester hydrolase from Butyrivibrio fibrisolvens which collectively metabolize the drug Alpha-linolenic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1113	DME___ID	DME1113
DME1113	DME_NAME	Thymidylate synthase (thyA)
DME1113	SPESNAME	Lactobacillus casei
DME1113	UNIPROID	TYSY_HUMAN	PROTNAME	Thymidylate synthase (TYMS)
DME1113	UNIPROID	TYSY_HUMAN	MOFCLASS	Host-microbiome interaction
DME1113	UNIPROID	TYSY_HUMAN	MOFDETAI	Host-microbiome interaction
DME1113	UNIPROID	TYSY_HUMAN	SUBSTRAT	Deoxy-UMP
DME1113	UNIPROID	TYSY_HUMAN	PPI_SUMM	TYMS-thyA interaction
DME1113	UNIPROID	TYSY_HUMAN	DESCRIPT	The interaction, between human Thymidylate synthase and Thymidylate synthase from Lactobacillus casei which collectively metabolize the drug Deoxy-UMP, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1115	DME___ID	DME1115
DME1115	DME_NAME	S-adenosylhomocysteine nucleosidase (mtnN)
DME1115	SPESNAME	Klebsiella pneumoniae
DME1115	UNIPROID	MTAP_HUMAN	PROTNAME	S-methyl-5'-thioadenosine phosphorylase (MTAP)
DME1115	UNIPROID	MTAP_HUMAN	MOFCLASS	Host-microbiome interaction
DME1115	UNIPROID	MTAP_HUMAN	MOFDETAI	Host-microbiome interaction
DME1115	UNIPROID	MTAP_HUMAN	SUBSTRAT	Methylthioadenosine
DME1115	UNIPROID	MTAP_HUMAN	PPI_SUMM	MTAP-mtnN interaction
DME1115	UNIPROID	MTAP_HUMAN	DESCRIPT	The interaction, between human S-methyl-5'-thioadenosine phosphorylase and S-adenosylhomocysteine nucleosidase from Klebsiella pneumoniae which collectively metabolize the drug Methylthioadenosine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1116	DME___ID	DME1116
DME1116	DME_NAME	D-Lactate dehydrogenase (ldhA)
DME1116	SPESNAME	Megasphaera elsdenii
DME1116	UNIPROID	ADPGK_HUMAN	PROTNAME	ADP-dependent glucokinase (ADPGK)
DME1116	UNIPROID	ADPGK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1116	UNIPROID	ADPGK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1116	UNIPROID	ADPGK_HUMAN	SUBSTRAT	D-glucose
DME1116	UNIPROID	ADPGK_HUMAN	PPI_SUMM	ADPGK-ldhA interaction
DME1116	UNIPROID	ADPGK_HUMAN	DESCRIPT	The interaction, between human ADP-dependent glucokinase and D-Lactate dehydrogenase from Megasphaera elsdenii which collectively metabolize the drug D-glucose, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1116	UNIPROID	HXK1_HUMAN	PROTNAME	Brain form hexokinase (HK1)
DME1116	UNIPROID	HXK1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1116	UNIPROID	HXK1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1116	UNIPROID	HXK1_HUMAN	SUBSTRAT	D-glucose
DME1116	UNIPROID	HXK1_HUMAN	PPI_SUMM	HK1-ldhA interaction
DME1116	UNIPROID	HXK1_HUMAN	DESCRIPT	The interaction, between human Brain form hexokinase and D-Lactate dehydrogenase from Megasphaera elsdenii which collectively metabolize the drug D-glucose, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	DME___ID	DME1118
DME1118	DME_NAME	Glutamate decarboxylase (gadB)
DME1118	SPESNAME	Lactobacillus johnsonii
DME1118	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1118	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1118	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1118	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1118	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1118	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1118	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1118	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1118	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1118	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1118	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1118	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1118	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1118	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1118	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1118	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1118	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1118	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1118	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1118	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1118	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1118	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1118	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1118	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1118	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1118	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1118	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1118	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1118	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1118	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1118	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1118	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1118	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1118	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1118	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1118	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1118	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1118	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1118	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1118	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1118	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Lactobacillus johnsonii which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	DME___ID	DME1120
DME1120	DME_NAME	Glutamate racemase (MurI)
DME1120	SPESNAME	Aquifex pyrophilus
DME1120	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1120	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-MurI interaction
DME1120	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1120	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-MurI interaction
DME1120	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1120	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-MurI interaction
DME1120	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1120	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-MurI interaction
DME1120	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1120	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-MurI interaction
DME1120	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1120	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-MurI interaction
DME1120	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1120	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-MurI interaction
DME1120	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1120	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-MurI interaction
DME1120	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1120	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-MurI interaction
DME1120	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1120	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-MurI interaction
DME1120	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1120	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-MurI interaction
DME1120	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1120	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-MurI interaction
DME1120	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1120	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-MurI interaction
DME1120	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1120	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-MurI interaction
DME1120	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1120	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-MurI interaction
DME1120	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1120	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-MurI interaction
DME1120	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1120	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-MurI interaction
DME1120	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1120	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1120	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1120	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1120	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1120	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-MurI interaction
DME1120	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate racemase from Aquifex pyrophilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	DME___ID	DME1121
DME1121	DME_NAME	Glutamate racemase (MurI)
DME1121	SPESNAME	Escherichia coli
DME1121	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1121	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-MurI interaction
DME1121	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1121	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-MurI interaction
DME1121	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1121	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-MurI interaction
DME1121	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1121	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-MurI interaction
DME1121	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1121	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-MurI interaction
DME1121	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1121	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-MurI interaction
DME1121	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1121	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-MurI interaction
DME1121	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1121	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-MurI interaction
DME1121	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1121	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-MurI interaction
DME1121	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1121	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-MurI interaction
DME1121	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1121	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-MurI interaction
DME1121	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1121	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-MurI interaction
DME1121	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1121	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-MurI interaction
DME1121	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1121	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-MurI interaction
DME1121	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1121	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-MurI interaction
DME1121	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1121	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-MurI interaction
DME1121	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1121	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-MurI interaction
DME1121	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1121	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1121	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1121	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1121	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1121	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-MurI interaction
DME1121	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate racemase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	DME___ID	DME1123
DME1123	DME_NAME	Glutamate racemase (MurI)
DME1123	SPESNAME	Lactobacillus fermentum
DME1123	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1123	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-MurI interaction
DME1123	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1123	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-MurI interaction
DME1123	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1123	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-MurI interaction
DME1123	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1123	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-MurI interaction
DME1123	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1123	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-MurI interaction
DME1123	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1123	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-MurI interaction
DME1123	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1123	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-MurI interaction
DME1123	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1123	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-MurI interaction
DME1123	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1123	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-MurI interaction
DME1123	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1123	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-MurI interaction
DME1123	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1123	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-MurI interaction
DME1123	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1123	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-MurI interaction
DME1123	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1123	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-MurI interaction
DME1123	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1123	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-MurI interaction
DME1123	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1123	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-MurI interaction
DME1123	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1123	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-MurI interaction
DME1123	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1123	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-MurI interaction
DME1123	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1123	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1123	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1123	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1123	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1123	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-MurI interaction
DME1123	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate racemase from Lactobacillus fermentum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	DME___ID	DME1124
DME1124	DME_NAME	Glutamate racemase (MurI)
DME1124	SPESNAME	Bacillus subtilis
DME1124	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1124	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-MurI interaction
DME1124	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1124	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-MurI interaction
DME1124	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1124	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-MurI interaction
DME1124	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1124	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-MurI interaction
DME1124	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1124	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-MurI interaction
DME1124	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1124	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-MurI interaction
DME1124	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1124	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-MurI interaction
DME1124	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1124	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-MurI interaction
DME1124	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1124	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-MurI interaction
DME1124	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1124	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-MurI interaction
DME1124	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1124	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-MurI interaction
DME1124	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1124	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-MurI interaction
DME1124	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1124	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-MurI interaction
DME1124	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1124	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-MurI interaction
DME1124	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1124	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-MurI interaction
DME1124	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1124	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-MurI interaction
DME1124	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1124	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-MurI interaction
DME1124	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1124	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1124	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1124	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1124	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1124	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-MurI interaction
DME1124	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate racemase from Bacillus subtilis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	DME___ID	DME1125
DME1125	DME_NAME	Glutamate racemase (MurI)
DME1125	SPESNAME	Bacillus pumilus
DME1125	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1125	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-MurI interaction
DME1125	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1125	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-MurI interaction
DME1125	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1125	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-MurI interaction
DME1125	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1125	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-MurI interaction
DME1125	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1125	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-MurI interaction
DME1125	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1125	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-MurI interaction
DME1125	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1125	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-MurI interaction
DME1125	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1125	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-MurI interaction
DME1125	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1125	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-MurI interaction
DME1125	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1125	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-MurI interaction
DME1125	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1125	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-MurI interaction
DME1125	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1125	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-MurI interaction
DME1125	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1125	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-MurI interaction
DME1125	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1125	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-MurI interaction
DME1125	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1125	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-MurI interaction
DME1125	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1125	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-MurI interaction
DME1125	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1125	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-MurI interaction
DME1125	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1125	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1125	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1125	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1125	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1125	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-MurI interaction
DME1125	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate racemase from Bacillus pumilus which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	DME___ID	DME1126
DME1126	DME_NAME	Glutamate racemase (MurI)
DME1126	SPESNAME	Bacillus anthracis
DME1126	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1126	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-MurI interaction
DME1126	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1126	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-MurI interaction
DME1126	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1126	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-MurI interaction
DME1126	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1126	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-MurI interaction
DME1126	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1126	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-MurI interaction
DME1126	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1126	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-MurI interaction
DME1126	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1126	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-MurI interaction
DME1126	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1126	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-MurI interaction
DME1126	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1126	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-MurI interaction
DME1126	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1126	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-MurI interaction
DME1126	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1126	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-MurI interaction
DME1126	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1126	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-MurI interaction
DME1126	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1126	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-MurI interaction
DME1126	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1126	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-MurI interaction
DME1126	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1126	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-MurI interaction
DME1126	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1126	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-MurI interaction
DME1126	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1126	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-MurI interaction
DME1126	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1126	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1126	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1126	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1126	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1126	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-MurI interaction
DME1126	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate racemase from Bacillus anthracis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1128	DME___ID	DME1128
DME1128	DME_NAME	Cellobiose 2-epimerase (CE)
DME1128	SPESNAME	Faecalibacterium prausnitzii
DME1128	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1128	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1128	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1128	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1128	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-CE interaction
DME1128	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Cellobiose 2-epimerase from Faecalibacterium prausnitzii which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1129	DME___ID	DME1129
DME1129	DME_NAME	Cellobiose 2-epimerase (CE)
DME1129	SPESNAME	Coprococcus eutactus
DME1129	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1129	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1129	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1129	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1129	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-CE interaction
DME1129	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Cellobiose 2-epimerase from Coprococcus eutactus which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1130	DME___ID	DME1130
DME1130	DME_NAME	Cellobiose 2-epimerase (CE)
DME1130	SPESNAME	Eubacterium siraeum
DME1130	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1130	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1130	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1130	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1130	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-CE interaction
DME1130	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Cellobiose 2-epimerase from Eubacterium siraeum which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1132	DME___ID	DME1132
DME1132	DME_NAME	Cellobiose 2-epimerase (CE)
DME1132	SPESNAME	Lachnoclostridium phytofermentans
DME1132	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1132	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1132	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1132	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1132	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-CE interaction
DME1132	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Cellobiose 2-epimerase from Lachnoclostridium phytofermentans which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1133	DME___ID	DME1133
DME1133	DME_NAME	Cellobiose 2-epimerase (CE)
DME1133	SPESNAME	Eubacterium cellulosolvens
DME1133	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1133	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1133	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1133	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1133	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-CE interaction
DME1133	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Cellobiose 2-epimerase from Eubacterium cellulosolvens which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1134	DME___ID	DME1134
DME1134	DME_NAME	Cellobiose 2-epimerase (CE)
DME1134	SPESNAME	Ruminococcus albus
DME1134	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1134	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1134	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1134	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1134	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-CE interaction
DME1134	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Cellobiose 2-epimerase from Ruminococcus albus which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1136	DME___ID	DME1136
DME1136	DME_NAME	Fructokinase (scrK)
DME1136	SPESNAME	Fusobacterium mortiferum
DME1136	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1136	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1136	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1136	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1136	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-scrK interaction
DME1136	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Fructokinase from Fusobacterium mortiferum which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1137	DME___ID	DME1137
DME1137	DME_NAME	Maltose phosphorylase (malP)
DME1137	SPESNAME	Lactobacillus acidophilus
DME1137	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1137	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1137	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1137	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1137	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-malP interaction
DME1137	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Maltose phosphorylase from Lactobacillus acidophilus which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1138	DME___ID	DME1138
DME1138	DME_NAME	Alpha-glucosidase (aglA)
DME1138	SPESNAME	Blautia obeum
DME1138	UNIPROID	SUIS_HUMAN	PROTNAME	Sucrase-isomaltase intestinal (SI)
DME1138	UNIPROID	SUIS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1138	UNIPROID	SUIS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1138	UNIPROID	SUIS_HUMAN	SUBSTRAT	M-7403
DME1138	UNIPROID	SUIS_HUMAN	PPI_SUMM	SI-aglA interaction
DME1138	UNIPROID	SUIS_HUMAN	DESCRIPT	The interaction, between human Sucrase-isomaltase intestinal and Alpha-glucosidase from Blautia obeum which collectively metabolize the drug M-7403, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1139	DME___ID	DME1139
DME1139	DME_NAME	Beta-galactosidase (bgaB)
DME1139	SPESNAME	Victivallis vadensis
DME1139	UNIPROID	GLU2B_HUMAN	PROTNAME	Glucosidase II beta (PRKCSH)
DME1139	UNIPROID	GLU2B_HUMAN	MOFCLASS	Host-microbiome interaction
DME1139	UNIPROID	GLU2B_HUMAN	MOFDETAI	Host-microbiome interaction
DME1139	UNIPROID	GLU2B_HUMAN	SUBSTRAT	PNA-D-glucopyranoside
DME1139	UNIPROID	GLU2B_HUMAN	PPI_SUMM	PRKCSH-bgaB interaction
DME1139	UNIPROID	GLU2B_HUMAN	DESCRIPT	The interaction, between human Glucosidase II beta and Beta-galactosidase from Victivallis vadensis which collectively metabolize the drug PNA-D-glucopyranoside, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1139	UNIPROID	GANAB_HUMAN	PROTNAME	Neutral alpha-glucosidase AB (GANAB)
DME1139	UNIPROID	GANAB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1139	UNIPROID	GANAB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1139	UNIPROID	GANAB_HUMAN	SUBSTRAT	PNA-D-glucopyranoside
DME1139	UNIPROID	GANAB_HUMAN	PPI_SUMM	GANAB-bgaB interaction
DME1139	UNIPROID	GANAB_HUMAN	DESCRIPT	The interaction, between human Neutral alpha-glucosidase AB and Beta-galactosidase from Victivallis vadensis which collectively metabolize the drug PNA-D-glucopyranoside, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1140	DME___ID	DME1140
DME1140	DME_NAME	Beta-galactosidase (bgaB)
DME1140	SPESNAME	Bifidobacterium adolescentis
DME1140	UNIPROID	GLU2B_HUMAN	PROTNAME	Glucosidase II beta (PRKCSH)
DME1140	UNIPROID	GLU2B_HUMAN	MOFCLASS	Host-microbiome interaction
DME1140	UNIPROID	GLU2B_HUMAN	MOFDETAI	Host-microbiome interaction
DME1140	UNIPROID	GLU2B_HUMAN	SUBSTRAT	PNA-D-glucopyranoside
DME1140	UNIPROID	GLU2B_HUMAN	PPI_SUMM	PRKCSH-bgaB interaction
DME1140	UNIPROID	GLU2B_HUMAN	DESCRIPT	The interaction, between human Glucosidase II beta and Beta-galactosidase from Bifidobacterium adolescentis which collectively metabolize the drug PNA-D-glucopyranoside, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1140	UNIPROID	GANAB_HUMAN	PROTNAME	Neutral alpha-glucosidase AB (GANAB)
DME1140	UNIPROID	GANAB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1140	UNIPROID	GANAB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1140	UNIPROID	GANAB_HUMAN	SUBSTRAT	PNA-D-glucopyranoside
DME1140	UNIPROID	GANAB_HUMAN	PPI_SUMM	GANAB-bgaB interaction
DME1140	UNIPROID	GANAB_HUMAN	DESCRIPT	The interaction, between human Neutral alpha-glucosidase AB and Beta-galactosidase from Bifidobacterium adolescentis which collectively metabolize the drug PNA-D-glucopyranoside, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1156	DME___ID	DME1156
DME1156	DME_NAME	Ribosomal 23S RNA methyltransferase Erm (erm)
DME1156	SPESNAME	Corynebacterium amycolatum
DME1156	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1156	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1156	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1156	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Tacrolimus
DME1156	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-erm interaction
DME1156	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Ribosomal 23S RNA methyltransferase Erm from Corynebacterium amycolatum which collectively metabolize the drug Tacrolimus, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1156	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1156	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1156	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1156	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Tacrolimus
DME1156	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-erm interaction
DME1156	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Ribosomal 23S RNA methyltransferase Erm from Corynebacterium amycolatum which collectively metabolize the drug Tacrolimus, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1156	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1156	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1156	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1156	UNIPROID	NCPR_HUMAN	SUBSTRAT	Tacrolimus
DME1156	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-erm interaction
DME1156	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Ribosomal 23S RNA methyltransferase Erm from Corynebacterium amycolatum which collectively metabolize the drug Tacrolimus, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1172	DME___ID	DME1172
DME1172	DME_NAME	Aminoglycoside N-acetyltransferase (aacC2)
DME1172	SPESNAME	Acinetobacter baumannii
DME1172	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1172	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1172	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1172	UNIPROID	NAT10_HUMAN	SUBSTRAT	Tobramycin
DME1172	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-aacC2 interaction
DME1172	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Aminoglycoside N-acetyltransferase from Acinetobacter baumannii which collectively metabolize the drug Tobramycin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1172	UNIPROID	NAT10_HUMAN	SUBSTRAT	Netilmicin
DME1172	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Aminoglycoside N-acetyltransferase from Acinetobacter baumannii which collectively metabolize the drug Netilmicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1196	DME___ID	DME1196
DME1196	DME_NAME	Cytidine deaminase (cdd)
DME1196	SPESNAME	Mycoplasma hyorhinis
DME1196	UNIPROID	CDD_HUMAN	PROTNAME	Cytidine aminohydrolase (CDA)
DME1196	UNIPROID	CDD_HUMAN	MOFCLASS	Host-microbiome interaction
DME1196	UNIPROID	CDD_HUMAN	MOFDETAI	Host-microbiome interaction
DME1196	UNIPROID	CDD_HUMAN	SUBSTRAT	Gemcitabine
DME1196	UNIPROID	CDD_HUMAN	PPI_SUMM	CDA-cdd interaction
DME1196	UNIPROID	CDD_HUMAN	DESCRIPT	The interaction, between human Cytidine aminohydrolase and Cytidine deaminase from Mycoplasma hyorhinis which collectively metabolize the drug Gemcitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1196	UNIPROID	KCY_HUMAN	PROTNAME	Uridine/cytidine monophosphate kinase (UMPK)
DME1196	UNIPROID	KCY_HUMAN	MOFCLASS	Host-microbiome interaction
DME1196	UNIPROID	KCY_HUMAN	MOFDETAI	Host-microbiome interaction
DME1196	UNIPROID	KCY_HUMAN	SUBSTRAT	Gemcitabine
DME1196	UNIPROID	KCY_HUMAN	PPI_SUMM	UMPK-cdd interaction
DME1196	UNIPROID	KCY_HUMAN	DESCRIPT	The interaction, between human Uridine/cytidine monophosphate kinase and Cytidine deaminase from Mycoplasma hyorhinis which collectively metabolize the drug Gemcitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1196	UNIPROID	CDD_HUMAN	SUBSTRAT	Azacitidine
DME1196	UNIPROID	CDD_HUMAN	DESCRIPT	The interaction, between human Cytidine aminohydrolase and Cytidine deaminase from Mycoplasma hyorhinis which collectively metabolize the drug Azacitidine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1196	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1196	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1196	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1196	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Cytarabine
DME1196	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cdd interaction
DME1196	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytidine deaminase from Mycoplasma hyorhinis which collectively metabolize the drug Cytarabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1196	UNIPROID	CDD_HUMAN	SUBSTRAT	Cytarabine
DME1196	UNIPROID	CDD_HUMAN	DESCRIPT	The interaction, between human Cytidine aminohydrolase and Cytidine deaminase from Mycoplasma hyorhinis which collectively metabolize the drug Cytarabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1196	UNIPROID	5NTD_HUMAN	PROTNAME	Ecto-5'-nucleotidase (NT5E)
DME1196	UNIPROID	5NTD_HUMAN	MOFCLASS	Host-microbiome interaction
DME1196	UNIPROID	5NTD_HUMAN	MOFDETAI	Host-microbiome interaction
DME1196	UNIPROID	5NTD_HUMAN	SUBSTRAT	Cytarabine
DME1196	UNIPROID	5NTD_HUMAN	PPI_SUMM	NT5E-cdd interaction
DME1196	UNIPROID	5NTD_HUMAN	DESCRIPT	The interaction, between human Ecto-5'-nucleotidase and Cytidine deaminase from Mycoplasma hyorhinis which collectively metabolize the drug Cytarabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1196	UNIPROID	DCTD_HUMAN	PROTNAME	Deoxycytidylate deaminase (DCTD)
DME1196	UNIPROID	DCTD_HUMAN	MOFCLASS	Host-microbiome interaction
DME1196	UNIPROID	DCTD_HUMAN	MOFDETAI	Host-microbiome interaction
DME1196	UNIPROID	DCTD_HUMAN	SUBSTRAT	Cytarabine
DME1196	UNIPROID	DCTD_HUMAN	PPI_SUMM	DCTD-cdd interaction
DME1196	UNIPROID	DCTD_HUMAN	DESCRIPT	The interaction, between human Deoxycytidylate deaminase and Cytidine deaminase from Mycoplasma hyorhinis which collectively metabolize the drug Cytarabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1196	UNIPROID	CDD_HUMAN	SUBSTRAT	Decitabine
DME1196	UNIPROID	CDD_HUMAN	DESCRIPT	The interaction, between human Cytidine aminohydrolase and Cytidine deaminase from Mycoplasma hyorhinis which collectively metabolize the drug Decitabine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1215	DME___ID	DME1215
DME1215	DME_NAME	Beta-lactamase (blaB)
DME1215	SPESNAME	Bacteroides caccae
DME1215	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1215	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1215	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1215	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1215	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1215	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides caccae which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1216	DME___ID	DME1216
DME1216	DME_NAME	Beta-lactamase (blaB)
DME1216	SPESNAME	Parabacteroides distasonis
DME1216	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1216	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1216	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1216	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1216	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1216	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Parabacteroides distasonis which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1218	DME___ID	DME1218
DME1218	DME_NAME	Beta-lactamase (blaB)
DME1218	SPESNAME	Bacteroides ovatus
DME1218	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1218	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1218	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1218	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1218	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1218	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides ovatus which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1219	DME___ID	DME1219
DME1219	DME_NAME	Beta-lactamase (blaB)
DME1219	SPESNAME	Bacteroides thetaiotaomicron
DME1219	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1219	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1219	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1219	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1219	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1219	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides thetaiotaomicron which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1220	DME___ID	DME1220
DME1220	DME_NAME	Beta-lactamase (blaB)
DME1220	SPESNAME	Bacteroides vulgatus
DME1220	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1220	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1220	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1220	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1220	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1220	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides vulgatus which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1221	DME___ID	DME1221
DME1221	DME_NAME	Beta-lactamase (blaB)
DME1221	SPESNAME	Capnocytophaga haemolytica
DME1221	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1221	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1221	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1221	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1221	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1221	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Capnocytophaga haemolytica which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1225	DME___ID	DME1225
DME1225	DME_NAME	Beta-lactamase (blaB)
DME1225	SPESNAME	Fusobacterium varium
DME1225	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1225	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1225	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1225	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1225	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1225	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Fusobacterium varium which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1227	DME___ID	DME1227
DME1227	DME_NAME	Beta-lactamase (blaB)
DME1227	SPESNAME	Neisseria sicca
DME1227	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1227	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1227	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1227	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1227	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1227	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Neisseria sicca which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1229	DME___ID	DME1229
DME1229	DME_NAME	Beta-lactamase (blaB)
DME1229	SPESNAME	Prevotella intermedia
DME1229	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1229	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1229	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1229	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1229	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1229	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella intermedia which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1230	DME___ID	DME1230
DME1230	DME_NAME	Beta-lactamase (blaB)
DME1230	SPESNAME	Prevotella nigrescens
DME1230	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1230	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1230	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1230	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1230	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1230	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella nigrescens which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	DME___ID	DME1233
DME1233	DME_NAME	Cytochrome P450 105D7 (cyp105)
DME1233	SPESNAME	Streptomyces avermitilis
DME1233	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1233	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cyp105 interaction
DME1233	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1233	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-cyp105 interaction
DME1233	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1233	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-cyp105 interaction
DME1233	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	CP2CI_HUMAN	PROTNAME	Cytochrome P450 2C18 (CYP2C18)
DME1233	UNIPROID	CP2CI_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP2CI_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP2CI_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP2CI_HUMAN	PPI_SUMM	CYP2C18-cyp105 interaction
DME1233	UNIPROID	CP2CI_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C18 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	CP2C8_HUMAN	PROTNAME	Cytochrome P450 2C8 (CYP2C8)
DME1233	UNIPROID	CP2C8_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP2C8_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP2C8_HUMAN	PPI_SUMM	CYP2C8-cyp105 interaction
DME1233	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1233	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-cyp105 interaction
DME1233	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1233	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-cyp105 interaction
DME1233	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1233	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-cyp105 interaction
DME1233	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1233	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	CP46A_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp105 interaction
DME1233	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	UD2B7_HUMAN	PROTNAME	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DME1233	UNIPROID	UD2B7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	UD2B7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	UD2B7_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	UD2B7_HUMAN	PPI_SUMM	UGT2B7-cyp105 interaction
DME1233	UNIPROID	UD2B7_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 2B7 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	UD13_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DME1233	UNIPROID	UD13_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	UD13_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	UD13_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	UD13_HUMAN	PPI_SUMM	UGT1A3-cyp105 interaction
DME1233	UNIPROID	UD13_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A3 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1233	UNIPROID	UD19_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DME1233	UNIPROID	UD19_HUMAN	MOFCLASS	Host-microbiome interaction
DME1233	UNIPROID	UD19_HUMAN	MOFDETAI	Host-microbiome interaction
DME1233	UNIPROID	UD19_HUMAN	SUBSTRAT	Diclofenac sodium
DME1233	UNIPROID	UD19_HUMAN	PPI_SUMM	UGT1A9-cyp105 interaction
DME1233	UNIPROID	UD19_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A9 and Cytochrome P450 105D7 from Streptomyces avermitilis which collectively metabolize the drug Diclofenac sodium, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1234	DME___ID	DME1234
DME1234	DME_NAME	Cytochrome P450 124 (cyp124)
DME1234	SPESNAME	Mycobacterium tuberculosis
DME1234	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1234	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1234	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1234	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Vitamin D
DME1234	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cyp124 interaction
DME1234	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 124 from Mycobacterium tuberculosis which collectively metabolize the drug Vitamin D, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1234	UNIPROID	CP27A_HUMAN	PROTNAME	Vitamin D(3) 25-hydroxylase (CYP27A1)
DME1234	UNIPROID	CP27A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1234	UNIPROID	CP27A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1234	UNIPROID	CP27A_HUMAN	SUBSTRAT	Vitamin D
DME1234	UNIPROID	CP27A_HUMAN	PPI_SUMM	CYP27A1-cyp124 interaction
DME1234	UNIPROID	CP27A_HUMAN	DESCRIPT	The interaction, between human Vitamin D(3 25-hydroxylase and Cytochrome P450 124 from Mycobacterium tuberculosis which collectively metabolize the drug Vitamin D, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1234	UNIPROID	CP2J2_HUMAN	PROTNAME	Cytochrome P450 2J2 (CYP2J2)
DME1234	UNIPROID	CP2J2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1234	UNIPROID	CP2J2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1234	UNIPROID	CP2J2_HUMAN	SUBSTRAT	Vitamin D
DME1234	UNIPROID	CP2J2_HUMAN	PPI_SUMM	CYP2J2-cyp124 interaction
DME1234	UNIPROID	CP2J2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2J2 and Cytochrome P450 124 from Mycobacterium tuberculosis which collectively metabolize the drug Vitamin D, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1234	UNIPROID	CP11A_HUMAN	PROTNAME	Cholesterol desmolase (CYP11A1)
DME1234	UNIPROID	CP11A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1234	UNIPROID	CP11A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1234	UNIPROID	CP11A_HUMAN	SUBSTRAT	Vitamin D
DME1234	UNIPROID	CP11A_HUMAN	PPI_SUMM	CYP11A1-cyp124 interaction
DME1234	UNIPROID	CP11A_HUMAN	DESCRIPT	The interaction, between human Cholesterol desmolase and Cytochrome P450 124 from Mycobacterium tuberculosis which collectively metabolize the drug Vitamin D, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1234	UNIPROID	CP2R1_HUMAN	PROTNAME	Vitamin D 25-hydroxylase (CYP2R1)
DME1234	UNIPROID	CP2R1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1234	UNIPROID	CP2R1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1234	UNIPROID	CP2R1_HUMAN	SUBSTRAT	Vitamin D
DME1234	UNIPROID	CP2R1_HUMAN	PPI_SUMM	CYP2R1-cyp124 interaction
DME1234	UNIPROID	CP2R1_HUMAN	DESCRIPT	The interaction, between human Vitamin D 25-hydroxylase and Cytochrome P450 124 from Mycobacterium tuberculosis which collectively metabolize the drug Vitamin D, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1238	DME___ID	DME1238
DME1238	DME_NAME	Ribosomal 23S RNA methyltransferase Erm (erm)
DME1238	SPESNAME	Corynebacterium jeikeium
DME1238	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1238	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1238	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1238	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Tacrolimus
DME1238	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-erm interaction
DME1238	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Ribosomal 23S RNA methyltransferase Erm from Corynebacterium jeikeium which collectively metabolize the drug Tacrolimus, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1238	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1238	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1238	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1238	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Tacrolimus
DME1238	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-erm interaction
DME1238	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Ribosomal 23S RNA methyltransferase Erm from Corynebacterium jeikeium which collectively metabolize the drug Tacrolimus, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1238	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1238	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1238	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1238	UNIPROID	NCPR_HUMAN	SUBSTRAT	Tacrolimus
DME1238	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-erm interaction
DME1238	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Ribosomal 23S RNA methyltransferase Erm from Corynebacterium jeikeium which collectively metabolize the drug Tacrolimus, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	DME___ID	DME1239
DME1239	DME_NAME	Folylpolyglutamate synthetase (fpgS)
DME1239	SPESNAME	Lactobacillus casei
DME1239	UNIPROID	NAT10_HUMAN	PROTNAME	RNA cytidine acetyltransferase (hALP)
DME1239	UNIPROID	NAT10_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	NAT10_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	NAT10_HUMAN	SUBSTRAT	Folic acid
DME1239	UNIPROID	NAT10_HUMAN	PPI_SUMM	hALP-fpgS interaction
DME1239	UNIPROID	NAT10_HUMAN	DESCRIPT	The interaction, between human RNA cytidine acetyltransferase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1239	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Folic acid
DME1239	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-fpgS interaction
DME1239	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	MTHR_HUMAN	PROTNAME	Methylenetetrahydrofolate reductase (MTHFR)
DME1239	UNIPROID	MTHR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	MTHR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	MTHR_HUMAN	SUBSTRAT	Folic acid
DME1239	UNIPROID	MTHR_HUMAN	PPI_SUMM	MTHFR-fpgS interaction
DME1239	UNIPROID	MTHR_HUMAN	DESCRIPT	The interaction, between human Methylenetetrahydrofolate reductase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	DYR_HUMAN	PROTNAME	Dihydrofolate reductase (DHFR)
DME1239	UNIPROID	DYR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	DYR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	DYR_HUMAN	SUBSTRAT	Folic acid
DME1239	UNIPROID	DYR_HUMAN	PPI_SUMM	DHFR-fpgS interaction
DME1239	UNIPROID	DYR_HUMAN	DESCRIPT	The interaction, between human Dihydrofolate reductase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	GGH_HUMAN	PROTNAME	Gamma-Glu-X carboxypeptidase (GGH)
DME1239	UNIPROID	GGH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	GGH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	GGH_HUMAN	SUBSTRAT	Folic acid
DME1239	UNIPROID	GGH_HUMAN	PPI_SUMM	GGH-fpgS interaction
DME1239	UNIPROID	GGH_HUMAN	DESCRIPT	The interaction, between human Gamma-Glu-X carboxypeptidase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	METH_HUMAN	PROTNAME	Vitamin B12 methionine synthase (MTR)
DME1239	UNIPROID	METH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	METH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	METH_HUMAN	SUBSTRAT	Folic acid
DME1239	UNIPROID	METH_HUMAN	PPI_SUMM	MTR-fpgS interaction
DME1239	UNIPROID	METH_HUMAN	DESCRIPT	The interaction, between human Vitamin B12 methionine synthase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1239	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	MTRR_HUMAN	SUBSTRAT	Folic acid
DME1239	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-fpgS interaction
DME1239	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug Folic acid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1239	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-fpgS interaction
DME1239	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1239	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-fpgS interaction
DME1239	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1239	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-fpgS interaction
DME1239	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1239	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-fpgS interaction
DME1239	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1239	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-fpgS interaction
DME1239	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1239	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-fpgS interaction
DME1239	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1239	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-fpgS interaction
DME1239	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1239	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-fpgS interaction
DME1239	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1239	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-fpgS interaction
DME1239	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1239	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-fpgS interaction
DME1239	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1239	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-fpgS interaction
DME1239	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1239	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-fpgS interaction
DME1239	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1239	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-fpgS interaction
DME1239	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1239	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-fpgS interaction
DME1239	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1239	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-fpgS interaction
DME1239	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1239	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-fpgS interaction
DME1239	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1239	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-fpgS interaction
DME1239	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1239	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1239	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1239	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1239	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1239	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-fpgS interaction
DME1239	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Folylpolyglutamate synthetase from Lactobacillus casei which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1240	DME___ID	DME1240
DME1240	DME_NAME	Hyaluronate lyase (hyaL)
DME1240	SPESNAME	Streptobacillus moniliformis
DME1240	UNIPROID	IDUA_HUMAN	PROTNAME	Alpha-L-iduronidase (IDUA)
DME1240	UNIPROID	IDUA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1240	UNIPROID	IDUA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1240	UNIPROID	IDUA_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1240	UNIPROID	IDUA_HUMAN	PPI_SUMM	IDUA-hyaL interaction
DME1240	UNIPROID	IDUA_HUMAN	DESCRIPT	The interaction, between human Alpha-L-iduronidase and Hyaluronate lyase from Streptobacillus moniliformis which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1240	UNIPROID	ARSB_HUMAN	PROTNAME	Arylsulfatase B (ARSB)
DME1240	UNIPROID	ARSB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1240	UNIPROID	ARSB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1240	UNIPROID	ARSB_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1240	UNIPROID	ARSB_HUMAN	PPI_SUMM	ARSB-hyaL interaction
DME1240	UNIPROID	ARSB_HUMAN	DESCRIPT	The interaction, between human Arylsulfatase B and Hyaluronate lyase from Streptobacillus moniliformis which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1240	UNIPROID	BGLR_HUMAN	PROTNAME	Beta-glucuronidase (GUSB)
DME1240	UNIPROID	BGLR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1240	UNIPROID	BGLR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1240	UNIPROID	BGLR_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1240	UNIPROID	BGLR_HUMAN	PPI_SUMM	GUSB-hyaL interaction
DME1240	UNIPROID	BGLR_HUMAN	DESCRIPT	The interaction, between human Beta-glucuronidase and Hyaluronate lyase from Streptobacillus moniliformis which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1240	UNIPROID	HEXB_HUMAN	PROTNAME	N-acetyl-beta-glucosaminidase beta (HEXB)
DME1240	UNIPROID	HEXB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1240	UNIPROID	HEXB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1240	UNIPROID	HEXB_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1240	UNIPROID	HEXB_HUMAN	PPI_SUMM	HEXB-hyaL interaction
DME1240	UNIPROID	HEXB_HUMAN	DESCRIPT	The interaction, between human N-acetyl-beta-glucosaminidase beta and Hyaluronate lyase from Streptobacillus moniliformis which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1240	UNIPROID	IDS_HUMAN	PROTNAME	Iduronate 2-sulfatase (IDS)
DME1240	UNIPROID	IDS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1240	UNIPROID	IDS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1240	UNIPROID	IDS_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1240	UNIPROID	IDS_HUMAN	PPI_SUMM	IDS-hyaL interaction
DME1240	UNIPROID	IDS_HUMAN	DESCRIPT	The interaction, between human Iduronate 2-sulfatase and Hyaluronate lyase from Streptobacillus moniliformis which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1240	UNIPROID	CHST3_HUMAN	PROTNAME	Chondroitin 6-sulfotransferase (CHST3)
DME1240	UNIPROID	CHST3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1240	UNIPROID	CHST3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1240	UNIPROID	CHST3_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1240	UNIPROID	CHST3_HUMAN	PPI_SUMM	CHST3-hyaL interaction
DME1240	UNIPROID	CHST3_HUMAN	DESCRIPT	The interaction, between human Chondroitin 6-sulfotransferase and Hyaluronate lyase from Streptobacillus moniliformis which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1241	DME___ID	DME1241
DME1241	DME_NAME	Hyaluronoglucosaminidase (nagH)
DME1241	SPESNAME	Treponema vincentii
DME1241	UNIPROID	IDUA_HUMAN	PROTNAME	Alpha-L-iduronidase (IDUA)
DME1241	UNIPROID	IDUA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1241	UNIPROID	IDUA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1241	UNIPROID	IDUA_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1241	UNIPROID	IDUA_HUMAN	PPI_SUMM	IDUA-nagH interaction
DME1241	UNIPROID	IDUA_HUMAN	DESCRIPT	The interaction, between human Alpha-L-iduronidase and Hyaluronoglucosaminidase from Treponema vincentii which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1241	UNIPROID	ARSB_HUMAN	PROTNAME	Arylsulfatase B (ARSB)
DME1241	UNIPROID	ARSB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1241	UNIPROID	ARSB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1241	UNIPROID	ARSB_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1241	UNIPROID	ARSB_HUMAN	PPI_SUMM	ARSB-nagH interaction
DME1241	UNIPROID	ARSB_HUMAN	DESCRIPT	The interaction, between human Arylsulfatase B and Hyaluronoglucosaminidase from Treponema vincentii which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1241	UNIPROID	BGLR_HUMAN	PROTNAME	Beta-glucuronidase (GUSB)
DME1241	UNIPROID	BGLR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1241	UNIPROID	BGLR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1241	UNIPROID	BGLR_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1241	UNIPROID	BGLR_HUMAN	PPI_SUMM	GUSB-nagH interaction
DME1241	UNIPROID	BGLR_HUMAN	DESCRIPT	The interaction, between human Beta-glucuronidase and Hyaluronoglucosaminidase from Treponema vincentii which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1241	UNIPROID	HEXB_HUMAN	PROTNAME	N-acetyl-beta-glucosaminidase beta (HEXB)
DME1241	UNIPROID	HEXB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1241	UNIPROID	HEXB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1241	UNIPROID	HEXB_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1241	UNIPROID	HEXB_HUMAN	PPI_SUMM	HEXB-nagH interaction
DME1241	UNIPROID	HEXB_HUMAN	DESCRIPT	The interaction, between human N-acetyl-beta-glucosaminidase beta and Hyaluronoglucosaminidase from Treponema vincentii which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1241	UNIPROID	IDS_HUMAN	PROTNAME	Iduronate 2-sulfatase (IDS)
DME1241	UNIPROID	IDS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1241	UNIPROID	IDS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1241	UNIPROID	IDS_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1241	UNIPROID	IDS_HUMAN	PPI_SUMM	IDS-nagH interaction
DME1241	UNIPROID	IDS_HUMAN	DESCRIPT	The interaction, between human Iduronate 2-sulfatase and Hyaluronoglucosaminidase from Treponema vincentii which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1241	UNIPROID	CHST3_HUMAN	PROTNAME	Chondroitin 6-sulfotransferase (CHST3)
DME1241	UNIPROID	CHST3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1241	UNIPROID	CHST3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1241	UNIPROID	CHST3_HUMAN	SUBSTRAT	Chondroitin sulfate
DME1241	UNIPROID	CHST3_HUMAN	PPI_SUMM	CHST3-nagH interaction
DME1241	UNIPROID	CHST3_HUMAN	DESCRIPT	The interaction, between human Chondroitin 6-sulfotransferase and Hyaluronoglucosaminidase from Treponema vincentii which collectively metabolize the drug Chondroitin sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	DME___ID	DME1242
DME1242	DME_NAME	NADPH-dependent oxidoreductase (nfrA)
DME1242	SPESNAME	Staphylococcus aureus
DME1242	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1242	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Nitrofural
DME1242	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-nfrA interaction
DME1242	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Nitrofural, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1242	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1242	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-nfrA interaction
DME1242	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1242	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Riboflavin
DME1242	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-nfrA interaction
DME1242	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	UNIPROID	PPAT_HUMAN	PROTNAME	Testicular acid phosphatase (ACP4)
DME1242	UNIPROID	PPAT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	PPAT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	PPAT_HUMAN	SUBSTRAT	Riboflavin
DME1242	UNIPROID	PPAT_HUMAN	PPI_SUMM	ACP4-nfrA interaction
DME1242	UNIPROID	PPAT_HUMAN	DESCRIPT	The interaction, between human Testicular acid phosphatase and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	UNIPROID	PPA5_HUMAN	PROTNAME	Tartrate-resistant acid ATPase (ACP5)
DME1242	UNIPROID	PPA5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	PPA5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	PPA5_HUMAN	SUBSTRAT	Riboflavin
DME1242	UNIPROID	PPA5_HUMAN	PPI_SUMM	ACP5-nfrA interaction
DME1242	UNIPROID	PPA5_HUMAN	DESCRIPT	The interaction, between human Tartrate-resistant acid ATPase and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	UNIPROID	PPA6_HUMAN	PROTNAME	Acid phosphatase-like protein 1 (ACP6)
DME1242	UNIPROID	PPA6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	PPA6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	PPA6_HUMAN	SUBSTRAT	Riboflavin
DME1242	UNIPROID	PPA6_HUMAN	PPI_SUMM	ACP6-nfrA interaction
DME1242	UNIPROID	PPA6_HUMAN	DESCRIPT	The interaction, between human Acid phosphatase-like protein 1 and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	UNIPROID	PPAP_HUMAN	PROTNAME	Prostatic acid phosphatase (ACP3)
DME1242	UNIPROID	PPAP_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	PPAP_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	PPAP_HUMAN	SUBSTRAT	Riboflavin
DME1242	UNIPROID	PPAP_HUMAN	PPI_SUMM	ACP3-nfrA interaction
DME1242	UNIPROID	PPAP_HUMAN	DESCRIPT	The interaction, between human Prostatic acid phosphatase and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	UNIPROID	PERE_HUMAN	PROTNAME	Eosinophil peroxidase (EPX)
DME1242	UNIPROID	PERE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	PERE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	PERE_HUMAN	SUBSTRAT	Riboflavin
DME1242	UNIPROID	PERE_HUMAN	PPI_SUMM	EPX-nfrA interaction
DME1242	UNIPROID	PERE_HUMAN	DESCRIPT	The interaction, between human Eosinophil peroxidase and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1242	UNIPROID	PXYP1_HUMAN	PROTNAME	Xylosyl phosphatase (PXYLP1)
DME1242	UNIPROID	PXYP1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1242	UNIPROID	PXYP1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1242	UNIPROID	PXYP1_HUMAN	SUBSTRAT	Riboflavin
DME1242	UNIPROID	PXYP1_HUMAN	PPI_SUMM	PXYLP1-nfrA interaction
DME1242	UNIPROID	PXYP1_HUMAN	DESCRIPT	The interaction, between human Xylosyl phosphatase and NADPH-dependent oxidoreductase from Staphylococcus aureus which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	DME___ID	DME1243
DME1243	DME_NAME	NADPH-dependent nitroreductase (nfrA1)
DME1243	SPESNAME	Bacillus subtilis
DME1243	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1243	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Nitrofural
DME1243	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-nfrA1 interaction
DME1243	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Nitrofural, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1243	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1243	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-nfrA1 interaction
DME1243	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1243	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Riboflavin
DME1243	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-nfrA1 interaction
DME1243	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	UNIPROID	PPAT_HUMAN	PROTNAME	Testicular acid phosphatase (ACP4)
DME1243	UNIPROID	PPAT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	PPAT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	PPAT_HUMAN	SUBSTRAT	Riboflavin
DME1243	UNIPROID	PPAT_HUMAN	PPI_SUMM	ACP4-nfrA1 interaction
DME1243	UNIPROID	PPAT_HUMAN	DESCRIPT	The interaction, between human Testicular acid phosphatase and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	UNIPROID	PPA5_HUMAN	PROTNAME	Tartrate-resistant acid ATPase (ACP5)
DME1243	UNIPROID	PPA5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	PPA5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	PPA5_HUMAN	SUBSTRAT	Riboflavin
DME1243	UNIPROID	PPA5_HUMAN	PPI_SUMM	ACP5-nfrA1 interaction
DME1243	UNIPROID	PPA5_HUMAN	DESCRIPT	The interaction, between human Tartrate-resistant acid ATPase and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	UNIPROID	PPA6_HUMAN	PROTNAME	Acid phosphatase-like protein 1 (ACP6)
DME1243	UNIPROID	PPA6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	PPA6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	PPA6_HUMAN	SUBSTRAT	Riboflavin
DME1243	UNIPROID	PPA6_HUMAN	PPI_SUMM	ACP6-nfrA1 interaction
DME1243	UNIPROID	PPA6_HUMAN	DESCRIPT	The interaction, between human Acid phosphatase-like protein 1 and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	UNIPROID	PPAP_HUMAN	PROTNAME	Prostatic acid phosphatase (ACP3)
DME1243	UNIPROID	PPAP_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	PPAP_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	PPAP_HUMAN	SUBSTRAT	Riboflavin
DME1243	UNIPROID	PPAP_HUMAN	PPI_SUMM	ACP3-nfrA1 interaction
DME1243	UNIPROID	PPAP_HUMAN	DESCRIPT	The interaction, between human Prostatic acid phosphatase and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	UNIPROID	PERE_HUMAN	PROTNAME	Eosinophil peroxidase (EPX)
DME1243	UNIPROID	PERE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	PERE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	PERE_HUMAN	SUBSTRAT	Riboflavin
DME1243	UNIPROID	PERE_HUMAN	PPI_SUMM	EPX-nfrA1 interaction
DME1243	UNIPROID	PERE_HUMAN	DESCRIPT	The interaction, between human Eosinophil peroxidase and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1243	UNIPROID	PXYP1_HUMAN	PROTNAME	Xylosyl phosphatase (PXYLP1)
DME1243	UNIPROID	PXYP1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1243	UNIPROID	PXYP1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1243	UNIPROID	PXYP1_HUMAN	SUBSTRAT	Riboflavin
DME1243	UNIPROID	PXYP1_HUMAN	PPI_SUMM	PXYLP1-nfrA1 interaction
DME1243	UNIPROID	PXYP1_HUMAN	DESCRIPT	The interaction, between human Xylosyl phosphatase and NADPH-dependent nitroreductase from Bacillus subtilis which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1244	DME___ID	DME1244
DME1244	DME_NAME	Nitroreductase (NTR)
DME1244	SPESNAME	Clostridium paraputrificum
DME1244	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1244	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1244	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1244	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1244	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-NTR interaction
DME1244	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Nitroreductase from Clostridium paraputrificum which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1245	DME___ID	DME1245
DME1245	DME_NAME	Nitroreductase (NTR)
DME1245	SPESNAME	Clostridium perfringens
DME1245	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1245	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1245	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1245	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Metronidazole
DME1245	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1245	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Clostridium perfringens which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1245	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1245	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1245	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1245	UNIPROID	UD11_HUMAN	SUBSTRAT	Metronidazole
DME1245	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-NTR interaction
DME1245	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nitroreductase from Clostridium perfringens which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1245	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1245	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1245	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1245	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Metronidazole
DME1245	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-NTR interaction
DME1245	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nitroreductase from Clostridium perfringens which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1245	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1245	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1245	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1245	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Metronidazole
DME1245	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-NTR interaction
DME1245	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Nitroreductase from Clostridium perfringens which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1245	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1245	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1245	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1245	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Metronidazole
DME1245	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-NTR interaction
DME1245	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Nitroreductase from Clostridium perfringens which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1245	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1245	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1245	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1245	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Metronidazole
DME1245	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1245	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Clostridium perfringens which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1245	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1245	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1245	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1245	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1245	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-NTR interaction
DME1245	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Nitroreductase from Clostridium perfringens which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1246	DME___ID	DME1246
DME1246	DME_NAME	Nitroreductase (NTR)
DME1246	SPESNAME	Clostridium hiranonis
DME1246	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1246	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1246	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1246	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1246	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-NTR interaction
DME1246	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Nitroreductase from Clostridium hiranonis which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1247	DME___ID	DME1247
DME1247	DME_NAME	Nitroreductase (NTR)
DME1247	SPESNAME	Enterobacter cloacae
DME1247	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1247	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1247	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1247	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Metronidazole
DME1247	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1247	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Enterobacter cloacae which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1247	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1247	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1247	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1247	UNIPROID	UD11_HUMAN	SUBSTRAT	Metronidazole
DME1247	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-NTR interaction
DME1247	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nitroreductase from Enterobacter cloacae which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1247	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1247	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1247	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1247	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Metronidazole
DME1247	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-NTR interaction
DME1247	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nitroreductase from Enterobacter cloacae which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1247	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1247	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1247	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1247	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Metronidazole
DME1247	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-NTR interaction
DME1247	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Nitroreductase from Enterobacter cloacae which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1247	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1247	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1247	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1247	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Metronidazole
DME1247	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-NTR interaction
DME1247	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Nitroreductase from Enterobacter cloacae which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1247	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1247	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1247	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1247	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Metronidazole
DME1247	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1247	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Enterobacter cloacae which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1247	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Tinidazole
DME1247	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Enterobacter cloacae which collectively metabolize the drug Tinidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1291	DME___ID	DME1291
DME1291	DME_NAME	VanA ligase (vanA)
DME1291	SPESNAME	Enterococcus avium
DME1291	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1291	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1291	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1291	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Teicoplanin
DME1291	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-vanA interaction
DME1291	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and VanA ligase from Enterococcus avium which collectively metabolize the drug Teicoplanin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1294	DME___ID	DME1294
DME1294	DME_NAME	Rifampicin monooxygenase (rox)
DME1294	SPESNAME	Nocardia farcinica
DME1294	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1294	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1294	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1294	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Rifampicin
DME1294	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-rox interaction
DME1294	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1294	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1294	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1294	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1294	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Rifampicin
DME1294	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-rox interaction
DME1294	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1294	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1294	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1294	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1294	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Rifampicin
DME1294	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-rox interaction
DME1294	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1294	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1294	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1294	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1294	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Rifampicin
DME1294	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-rox interaction
DME1294	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1294	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1294	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1294	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1294	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Rifampicin
DME1294	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-rox interaction
DME1294	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1294	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1294	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1294	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1294	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Rifampicin
DME1294	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-rox interaction
DME1294	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1294	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1294	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1294	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1294	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Rifampicin
DME1294	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-rox interaction
DME1294	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Rifampicin monooxygenase from Nocardia farcinica which collectively metabolize the drug Rifampicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1295	DME___ID	DME1295
DME1295	DME_NAME	Beta-lactamase (blaB)
DME1295	SPESNAME	Prevotella buccae
DME1295	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1295	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1295	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1295	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1295	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1295	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella buccae which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1296	DME___ID	DME1296
DME1296	DME_NAME	Metallo-beta-lactamase (blaM)
DME1296	SPESNAME	Achromobacter xylosoxidans
DME1296	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1296	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1296	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1296	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1296	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaM interaction
DME1296	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Metallo-beta-lactamase from Achromobacter xylosoxidans which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1298	DME___ID	DME1298
DME1298	DME_NAME	Beta-lactamase (blaB)
DME1298	SPESNAME	Shigella sonnei
DME1298	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1298	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1298	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1298	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1298	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1298	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Shigella sonnei which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1299	DME___ID	DME1299
DME1299	DME_NAME	Alpha-glucosidase (aglA)
DME1299	SPESNAME	Lactobacillus paracasei
DME1299	UNIPROID	ADPGK_HUMAN	PROTNAME	ADP-dependent glucokinase (ADPGK)
DME1299	UNIPROID	ADPGK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1299	UNIPROID	ADPGK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1299	UNIPROID	ADPGK_HUMAN	SUBSTRAT	D-glucose
DME1299	UNIPROID	ADPGK_HUMAN	PPI_SUMM	ADPGK-aglA interaction
DME1299	UNIPROID	ADPGK_HUMAN	DESCRIPT	The interaction, between human ADP-dependent glucokinase and Alpha-glucosidase from Lactobacillus paracasei which collectively metabolize the drug D-glucose, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1299	UNIPROID	HXK1_HUMAN	PROTNAME	Brain form hexokinase (HK1)
DME1299	UNIPROID	HXK1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1299	UNIPROID	HXK1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1299	UNIPROID	HXK1_HUMAN	SUBSTRAT	D-glucose
DME1299	UNIPROID	HXK1_HUMAN	PPI_SUMM	HK1-aglA interaction
DME1299	UNIPROID	HXK1_HUMAN	DESCRIPT	The interaction, between human Brain form hexokinase and Alpha-glucosidase from Lactobacillus paracasei which collectively metabolize the drug D-glucose, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1300	DME___ID	DME1300
DME1300	DME_NAME	Beta-lactamase (blaB)
DME1300	SPESNAME	Capnocytophaga ochracea
DME1300	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1300	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1300	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1300	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1300	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1300	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Capnocytophaga ochracea which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1301	DME___ID	DME1301
DME1301	DME_NAME	Catalase-peroxidase (katG)
DME1301	SPESNAME	Synechococcus elongatus
DME1301	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1301	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1301	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1301	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Isoniazid
DME1301	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-katG interaction
DME1301	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Catalase-peroxidase from Synechococcus elongatus which collectively metabolize the drug Isoniazid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1302	DME___ID	DME1302
DME1302	DME_NAME	General stress protein 14 (ywrO)
DME1302	SPESNAME	Bacillus subtilis
DME1302	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1302	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1302	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1302	UNIPROID	NQO1_HUMAN	SUBSTRAT	CBL-954
DME1302	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-ywrO interaction
DME1302	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and General stress protein 14 from Bacillus subtilis which collectively metabolize the drug CBL-954, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	DME___ID	DME1303
DME1303	DME_NAME	Glutamate decarboxylase (gadB)
DME1303	SPESNAME	Listeria monocytogenes
DME1303	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1303	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1303	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1303	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1303	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1303	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1303	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1303	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1303	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1303	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1303	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1303	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1303	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1303	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1303	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1303	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1303	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1303	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1303	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1303	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1303	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1303	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1303	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1303	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1303	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1303	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1303	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1303	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1303	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1303	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1303	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1303	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1303	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1303	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1303	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1303	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1303	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1303	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1303	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1303	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1303	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Listeria monocytogenes which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	DME___ID	DME1304
DME1304	DME_NAME	Glutamate decarboxylase (gadB)
DME1304	SPESNAME	Escherichia coli
DME1304	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1304	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1304	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1304	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1304	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1304	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1304	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1304	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1304	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1304	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1304	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1304	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1304	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1304	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1304	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1304	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1304	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1304	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1304	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1304	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1304	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1304	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1304	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1304	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1304	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1304	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1304	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1304	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1304	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1304	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1304	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1304	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1304	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1304	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1304	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1304	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1304	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1304	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1304	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1304	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1304	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Escherichia coli which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	DME___ID	DME1305
DME1305	DME_NAME	Glutamate decarboxylase (gadB)
DME1305	SPESNAME	Shigella flexneri
DME1305	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1305	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1305	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1305	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1305	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1305	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1305	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1305	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1305	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1305	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1305	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1305	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1305	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1305	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1305	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1305	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1305	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1305	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1305	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1305	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1305	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1305	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1305	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1305	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1305	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1305	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1305	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1305	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1305	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1305	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1305	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1305	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1305	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1305	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1305	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1305	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1305	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1305	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1305	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1305	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1305	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Shigella flexneri which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	DME___ID	DME1306
DME1306	DME_NAME	Glutamate decarboxylase (gadB)
DME1306	SPESNAME	Lactococcus lactis
DME1306	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1306	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1306	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1306	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1306	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1306	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1306	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1306	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1306	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1306	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1306	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1306	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1306	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1306	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1306	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1306	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1306	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1306	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1306	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1306	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1306	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1306	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1306	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1306	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1306	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1306	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1306	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1306	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1306	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1306	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1306	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1306	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1306	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1306	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1306	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1306	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1306	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1306	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1306	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1306	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1306	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Lactococcus lactis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	DME___ID	DME1307
DME1307	DME_NAME	Glutamate decarboxylase (gadB)
DME1307	SPESNAME	Bifidobacterium dentium
DME1307	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1307	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1307	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1307	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1307	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1307	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1307	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1307	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1307	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1307	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1307	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1307	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1307	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1307	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1307	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1307	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1307	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1307	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1307	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1307	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1307	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1307	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1307	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1307	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1307	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1307	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1307	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1307	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1307	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1307	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1307	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1307	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1307	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1307	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1307	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1307	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1307	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1307	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1307	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1307	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1307	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Bifidobacterium dentium which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1308	DME___ID	DME1308
DME1308	DME_NAME	Beta-lactamase (blaB)
DME1308	SPESNAME	Prevotella veroralis
DME1308	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1308	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1308	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1308	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1308	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1308	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella veroralis which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1309	DME___ID	DME1309
DME1309	DME_NAME	Beta-lactamase (blaB)
DME1309	SPESNAME	Alloprevotella tannerae
DME1309	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1309	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1309	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1309	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1309	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1309	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Alloprevotella tannerae which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1310	DME___ID	DME1310
DME1310	DME_NAME	Beta-lactamase (blaB)
DME1310	SPESNAME	Capnocytophaga gingivalis
DME1310	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1310	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1310	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1310	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1310	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1310	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Capnocytophaga gingivalis which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1314	DME___ID	DME1314
DME1314	DME_NAME	Beta-lactamase (blaB)
DME1314	SPESNAME	Photorhabdus asymbiotica
DME1314	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1314	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1314	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1314	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1314	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1314	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Photorhabdus asymbiotica which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1315	DME___ID	DME1315
DME1315	DME_NAME	Azoreductase (azoR)
DME1315	SPESNAME	Enterococcus faecalis
DME1315	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1315	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1315	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1315	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1315	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1315	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Enterococcus faecalis which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1316	DME___ID	DME1316
DME1316	DME_NAME	Azoreductase (azoR)
DME1316	SPESNAME	Clostridium perfringens
DME1316	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1316	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1316	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1316	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1316	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1316	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Clostridium perfringens which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1317	DME___ID	DME1317
DME1317	DME_NAME	Alcohol dehydrogenase (ADH)
DME1317	SPESNAME	Lactobacillus reuteri
DME1317	UNIPROID	ADPGK_HUMAN	PROTNAME	ADP-dependent glucokinase (ADPGK)
DME1317	UNIPROID	ADPGK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1317	UNIPROID	ADPGK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1317	UNIPROID	ADPGK_HUMAN	SUBSTRAT	D-glucose
DME1317	UNIPROID	ADPGK_HUMAN	PPI_SUMM	ADPGK-ADH interaction
DME1317	UNIPROID	ADPGK_HUMAN	DESCRIPT	The interaction, between human ADP-dependent glucokinase and Alcohol dehydrogenase from Lactobacillus reuteri which collectively metabolize the drug D-glucose, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1317	UNIPROID	HXK1_HUMAN	PROTNAME	Brain form hexokinase (HK1)
DME1317	UNIPROID	HXK1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1317	UNIPROID	HXK1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1317	UNIPROID	HXK1_HUMAN	SUBSTRAT	D-glucose
DME1317	UNIPROID	HXK1_HUMAN	PPI_SUMM	HK1-ADH interaction
DME1317	UNIPROID	HXK1_HUMAN	DESCRIPT	The interaction, between human Brain form hexokinase and Alcohol dehydrogenase from Lactobacillus reuteri which collectively metabolize the drug D-glucose, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1318	DME___ID	DME1318
DME1318	DME_NAME	Beta-lactamase (blaB)
DME1318	SPESNAME	Bacteroides dorei
DME1318	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1318	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1318	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1318	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1318	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1318	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides dorei which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1319	DME___ID	DME1319
DME1319	DME_NAME	Beta-lactamase (blaB)
DME1319	SPESNAME	Bacteroides intestinalis
DME1319	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1319	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1319	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1319	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1319	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1319	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides intestinalis which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1321	DME___ID	DME1321
DME1321	DME_NAME	Arylamine N-acetyltransferase (NAT)
DME1321	SPESNAME	Tsukamurella paurometabola
DME1321	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1321	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1321	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1321	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Isoniazid
DME1321	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-NAT interaction
DME1321	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Arylamine N-acetyltransferase from Tsukamurella paurometabola which collectively metabolize the drug Isoniazid, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1322	DME___ID	DME1322
DME1322	DME_NAME	Azoreductase (azoR)
DME1322	SPESNAME	Lactobacillus buchneri
DME1322	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1322	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1322	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1322	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1322	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1322	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Lactobacillus buchneri which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1326	DME___ID	DME1326
DME1326	DME_NAME	Beta-lactamase (blaB)
DME1326	SPESNAME	Capnocytophaga granulosa
DME1326	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1326	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1326	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1326	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1326	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1326	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Capnocytophaga granulosa which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1327	DME___ID	DME1327
DME1327	DME_NAME	Nitroreductase (NTR)
DME1327	SPESNAME	Enterococcus casseliflavus
DME1327	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1327	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1327	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1327	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Nitrofural
DME1327	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-NTR interaction
DME1327	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Nitroreductase from Enterococcus casseliflavus which collectively metabolize the drug Nitrofural, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1327	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1327	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1327	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1327	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Metronidazole
DME1327	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1327	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Enterococcus casseliflavus which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1327	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1327	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1327	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1327	UNIPROID	UD11_HUMAN	SUBSTRAT	Metronidazole
DME1327	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-NTR interaction
DME1327	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nitroreductase from Enterococcus casseliflavus which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1327	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1327	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1327	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1327	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Metronidazole
DME1327	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-NTR interaction
DME1327	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nitroreductase from Enterococcus casseliflavus which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1327	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1327	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1327	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1327	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Metronidazole
DME1327	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-NTR interaction
DME1327	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Nitroreductase from Enterococcus casseliflavus which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1327	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1327	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1327	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1327	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Metronidazole
DME1327	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-NTR interaction
DME1327	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Nitroreductase from Enterococcus casseliflavus which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1327	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1327	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1327	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1327	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Metronidazole
DME1327	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1327	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Enterococcus casseliflavus which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1327	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1327	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1327	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1327	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1327	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-NTR interaction
DME1327	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Nitroreductase from Enterococcus casseliflavus which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1328	DME___ID	DME1328
DME1328	DME_NAME	Nitroreductase (NTR)
DME1328	SPESNAME	Enterococcus gallinarum
DME1328	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1328	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1328	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1328	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Nitrofural
DME1328	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-NTR interaction
DME1328	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Nitroreductase from Enterococcus gallinarum which collectively metabolize the drug Nitrofural, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1328	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1328	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1328	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1328	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Metronidazole
DME1328	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1328	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Enterococcus gallinarum which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1328	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1328	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1328	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1328	UNIPROID	UD11_HUMAN	SUBSTRAT	Metronidazole
DME1328	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-NTR interaction
DME1328	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nitroreductase from Enterococcus gallinarum which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1328	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1328	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1328	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1328	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Metronidazole
DME1328	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-NTR interaction
DME1328	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nitroreductase from Enterococcus gallinarum which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1328	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1328	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1328	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1328	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Metronidazole
DME1328	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-NTR interaction
DME1328	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Nitroreductase from Enterococcus gallinarum which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1328	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1328	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1328	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1328	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Metronidazole
DME1328	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-NTR interaction
DME1328	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Nitroreductase from Enterococcus gallinarum which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1328	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1328	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1328	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1328	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Metronidazole
DME1328	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1328	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Enterococcus gallinarum which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1328	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1328	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1328	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1328	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1328	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-NTR interaction
DME1328	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Nitroreductase from Enterococcus gallinarum which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1329	DME___ID	DME1329
DME1329	DME_NAME	Beta-lactamase (blaB)
DME1329	SPESNAME	Prevotella denticola
DME1329	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1329	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1329	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1329	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1329	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1329	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella denticola which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1331	DME___ID	DME1331
DME1331	DME_NAME	Nitroreductase (NTR)
DME1331	SPESNAME	Clostridium sporogenes
DME1331	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1331	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1331	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1331	UNIPROID	NCPR_HUMAN	SUBSTRAT	Nitrofurantoin
DME1331	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-NTR interaction
DME1331	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Nitroreductase from Clostridium sporogenes which collectively metabolize the drug Nitrofurantoin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1333	DME___ID	DME1333
DME1333	DME_NAME	Methylenetetrahydrofolate dehydrogenase (folD)
DME1333	SPESNAME	Blautia producta
DME1333	UNIPROID	MTHR_HUMAN	PROTNAME	Methylenetetrahydrofolate reductase (MTHFR)
DME1333	UNIPROID	MTHR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1333	UNIPROID	MTHR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1333	UNIPROID	MTHR_HUMAN	SUBSTRAT	ISO-901
DME1333	UNIPROID	MTHR_HUMAN	PPI_SUMM	MTHFR-folD interaction
DME1333	UNIPROID	MTHR_HUMAN	DESCRIPT	The interaction, between human Methylenetetrahydrofolate reductase and Methylenetetrahydrofolate dehydrogenase from Blautia producta which collectively metabolize the drug ISO-901, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1334	DME___ID	DME1334
DME1334	DME_NAME	Beta-lactamase (blaB)
DME1334	SPESNAME	Capnocytophaga sputigena
DME1334	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1334	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1334	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1334	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1334	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1334	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Capnocytophaga sputigena which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1335	DME___ID	DME1335
DME1335	DME_NAME	Beta-lactamase (blaB)
DME1335	SPESNAME	Capnocytophaga leadbetteri
DME1335	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1335	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1335	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1335	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1335	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1335	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Capnocytophaga leadbetteri which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	DME___ID	DME1339
DME1339	DME_NAME	Glutamate decarboxylase (gadB)
DME1339	SPESNAME	Lactobacillus plantarum
DME1339	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1339	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1339	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1339	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1339	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1339	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1339	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1339	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1339	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1339	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1339	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1339	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1339	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1339	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1339	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1339	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1339	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1339	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1339	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1339	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1339	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1339	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1339	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1339	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1339	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1339	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1339	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1339	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1339	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1339	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1339	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1339	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1339	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1339	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1339	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1339	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1339	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1339	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1339	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1339	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1339	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Lactobacillus plantarum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1340	DME___ID	DME1340
DME1340	DME_NAME	Nitroreductase (NTR)
DME1340	SPESNAME	Bacteroides fragilis
DME1340	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1340	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1340	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1340	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Metronidazole
DME1340	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1340	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Bacteroides fragilis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1340	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1340	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1340	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1340	UNIPROID	UD11_HUMAN	SUBSTRAT	Metronidazole
DME1340	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-NTR interaction
DME1340	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Nitroreductase from Bacteroides fragilis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1340	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1340	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1340	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1340	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Metronidazole
DME1340	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-NTR interaction
DME1340	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Nitroreductase from Bacteroides fragilis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1340	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1340	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1340	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1340	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Metronidazole
DME1340	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-NTR interaction
DME1340	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Nitroreductase from Bacteroides fragilis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1340	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1340	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1340	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1340	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Metronidazole
DME1340	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-NTR interaction
DME1340	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Nitroreductase from Bacteroides fragilis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1340	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1340	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1340	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1340	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Metronidazole
DME1340	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1340	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Bacteroides fragilis which collectively metabolize the drug Metronidazole, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	DME___ID	DME1344
DME1344	DME_NAME	Glutamate decarboxylase (gadB)
DME1344	SPESNAME	Bifidobacterium adolescentis
DME1344	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1344	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1344	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1344	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1344	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1344	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1344	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1344	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1344	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1344	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1344	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1344	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1344	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1344	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1344	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1344	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1344	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1344	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1344	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1344	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1344	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1344	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1344	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1344	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1344	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1344	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1344	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1344	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1344	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1344	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1344	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1344	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1344	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1344	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1344	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1344	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1344	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1344	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1344	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1344	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1344	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Bifidobacterium adolescentis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1345	DME___ID	DME1345
DME1345	DME_NAME	Azoreductase (azoR)
DME1345	SPESNAME	Enterococcus faecium
DME1345	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1345	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1345	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1345	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1345	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1345	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Enterococcus faecium which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	DME___ID	DME1346
DME1346	DME_NAME	Glutamate decarboxylase (gadB)
DME1346	SPESNAME	Bifidobacterium angulatum
DME1346	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1346	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME1346	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1346	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME1346	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1346	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME1346	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1346	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME1346	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1346	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME1346	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1346	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME1346	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1346	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME1346	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1346	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME1346	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1346	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME1346	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1346	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME1346	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1346	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME1346	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1346	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME1346	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1346	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME1346	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1346	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME1346	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1346	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME1346	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1346	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME1346	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1346	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-gadB interaction
DME1346	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1346	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1346	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1346	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1346	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1346	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-gadB interaction
DME1346	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate decarboxylase from Bifidobacterium angulatum which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1347	DME___ID	DME1347
DME1347	DME_NAME	Beta-lactamase (blaB)
DME1347	SPESNAME	Bacteroides stercoris
DME1347	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1347	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1347	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1347	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1347	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1347	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides stercoris which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1348	DME___ID	DME1348
DME1348	DME_NAME	Beta-lactamase (blaB)
DME1348	SPESNAME	Bacteroides cellulosilyticus
DME1348	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1348	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1348	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1348	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1348	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1348	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides cellulosilyticus which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1353	DME___ID	DME1353
DME1353	DME_NAME	Gamma-glutamylcyclotransferase (GGCT)
DME1353	SPESNAME	Ralstonia solanacearum
DME1353	UNIPROID	GSTO1_HUMAN	PROTNAME	Glutathione S-transferase omega-1 (GSTO1)
DME1353	UNIPROID	GSTO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1353	UNIPROID	GSTO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1353	UNIPROID	GSTO1_HUMAN	SUBSTRAT	ANW-43980
DME1353	UNIPROID	GSTO1_HUMAN	PPI_SUMM	GSTO1-GGCT interaction
DME1353	UNIPROID	GSTO1_HUMAN	DESCRIPT	The interaction, between human Glutathione S-transferase omega-1 and Gamma-glutamylcyclotransferase from Ralstonia solanacearum which collectively metabolize the drug ANW-43980, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1353	UNIPROID	GSTO2_HUMAN	PROTNAME	Glutathione S-transferase omega-2 (GSTO2)
DME1353	UNIPROID	GSTO2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1353	UNIPROID	GSTO2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1353	UNIPROID	GSTO2_HUMAN	SUBSTRAT	ANW-43980
DME1353	UNIPROID	GSTO2_HUMAN	PPI_SUMM	GSTO2-GGCT interaction
DME1353	UNIPROID	GSTO2_HUMAN	DESCRIPT	The interaction, between human Glutathione S-transferase omega-2 and Gamma-glutamylcyclotransferase from Ralstonia solanacearum which collectively metabolize the drug ANW-43980, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1353	UNIPROID	GGT5_HUMAN	PROTNAME	Gamma-glutamyltranspeptidase 5 (GGT5)
DME1353	UNIPROID	GGT5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1353	UNIPROID	GGT5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1353	UNIPROID	GGT5_HUMAN	SUBSTRAT	ANW-43980
DME1353	UNIPROID	GGT5_HUMAN	PPI_SUMM	GGT5-GGCT interaction
DME1353	UNIPROID	GGT5_HUMAN	DESCRIPT	The interaction, between human Gamma-glutamyltranspeptidase 5 and Gamma-glutamylcyclotransferase from Ralstonia solanacearum which collectively metabolize the drug ANW-43980, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1353	UNIPROID	CHAC2_HUMAN	PROTNAME	Gamma-glutamylcyclotransferase 2 (CHAC2)
DME1353	UNIPROID	CHAC2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1353	UNIPROID	CHAC2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1353	UNIPROID	CHAC2_HUMAN	SUBSTRAT	ANW-43980
DME1353	UNIPROID	CHAC2_HUMAN	PPI_SUMM	CHAC2-GGCT interaction
DME1353	UNIPROID	CHAC2_HUMAN	DESCRIPT	The interaction, between human Gamma-glutamylcyclotransferase 2 and Gamma-glutamylcyclotransferase from Ralstonia solanacearum which collectively metabolize the drug ANW-43980, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1353	UNIPROID	GPX6_HUMAN	PROTNAME	Glutathione peroxidase 6 (GPX6)
DME1353	UNIPROID	GPX6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1353	UNIPROID	GPX6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1353	UNIPROID	GPX6_HUMAN	SUBSTRAT	ANW-43980
DME1353	UNIPROID	GPX6_HUMAN	PPI_SUMM	GPX6-GGCT interaction
DME1353	UNIPROID	GPX6_HUMAN	DESCRIPT	The interaction, between human Glutathione peroxidase 6 and Gamma-glutamylcyclotransferase from Ralstonia solanacearum which collectively metabolize the drug ANW-43980, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1354	DME___ID	DME1354
DME1354	DME_NAME	Beta-lactamase (blaB)
DME1354	SPESNAME	Prevotella loescheii
DME1354	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1354	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1354	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1354	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1354	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1354	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella loescheii which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	DME___ID	DME1422
DME1422	DME_NAME	Molybdopterin-dependent enzyme (molD)
DME1422	SPESNAME	Escherichia coli
DME1422	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1422	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-molD interaction
DME1422	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1422	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-molD interaction
DME1422	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1422	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-molD interaction
DME1422	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	XDH_HUMAN	PROTNAME	Xanthine dehydrogenase/oxidase (XDH)
DME1422	UNIPROID	XDH_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	XDH_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	XDH_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	XDH_HUMAN	PPI_SUMM	XDH-molD interaction
DME1422	UNIPROID	XDH_HUMAN	DESCRIPT	The interaction, between human Xanthine dehydrogenase/oxidase and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	NCPR_HUMAN	PROTNAME	NADPH-cytochrome P450 reductase (CPR)
DME1422	UNIPROID	NCPR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	NCPR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	NCPR_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	NCPR_HUMAN	PPI_SUMM	CPR-molD interaction
DME1422	UNIPROID	NCPR_HUMAN	DESCRIPT	The interaction, between human NADPH-cytochrome P450 reductase and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	NQO1_HUMAN	PROTNAME	Quinone reductase 1 (NQO1)
DME1422	UNIPROID	NQO1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	NQO1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	NQO1_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	NQO1_HUMAN	PPI_SUMM	NQO1-molD interaction
DME1422	UNIPROID	NQO1_HUMAN	DESCRIPT	The interaction, between human Quinone reductase 1 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	AK1A1_HUMAN	PROTNAME	Aldo-keto reductase 1A1 (AKR1A1)
DME1422	UNIPROID	AK1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	AK1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	AK1A1_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	AK1A1_HUMAN	PPI_SUMM	AKR1A1-molD interaction
DME1422	UNIPROID	AK1A1_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1A1 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	AK1C3_HUMAN	PROTNAME	Aldo-keto reductase 1C3 (AKR1C3)
DME1422	UNIPROID	AK1C3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	AK1C3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	AK1C3_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	AK1C3_HUMAN	PPI_SUMM	AKR1C3-molD interaction
DME1422	UNIPROID	AK1C3_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1C3 and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	NDUS2_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2)
DME1422	UNIPROID	NDUS2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	NDUS2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	NDUS2_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	NDUS2_HUMAN	PPI_SUMM	NDUFS2-molD interaction
DME1422	UNIPROID	NDUS2_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 49 kDa and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	NDUS3_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3)
DME1422	UNIPROID	NDUS3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	NDUS3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	NDUS3_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	NDUS3_HUMAN	PPI_SUMM	NDUFS3-molD interaction
DME1422	UNIPROID	NDUS3_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 30 kDa and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	NDUS7_HUMAN	PROTNAME	NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7)
DME1422	UNIPROID	NDUS7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	NDUS7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	NDUS7_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	NDUS7_HUMAN	PPI_SUMM	NDUFS7-molD interaction
DME1422	UNIPROID	NDUS7_HUMAN	DESCRIPT	The interaction, between human NADH-ubiquinone oxidoreductase 20 kDa and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	NOS1_HUMAN	PROTNAME	Nitric oxide synthase brain (NOS1)
DME1422	UNIPROID	NOS1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	NOS1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	NOS1_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	NOS1_HUMAN	PPI_SUMM	NOS1-molD interaction
DME1422	UNIPROID	NOS1_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase brain and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	NOS3_HUMAN	PROTNAME	Nitric oxide synthase endothelial (NOS3)
DME1422	UNIPROID	NOS3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	NOS3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	NOS3_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	NOS3_HUMAN	PPI_SUMM	NOS3-molD interaction
DME1422	UNIPROID	NOS3_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase endothelial and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	NOS2_HUMAN	PROTNAME	Nitric oxide synthase inducible (NOS2)
DME1422	UNIPROID	NOS2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	NOS2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	NOS2_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	NOS2_HUMAN	PPI_SUMM	NOS2-molD interaction
DME1422	UNIPROID	NOS2_HUMAN	DESCRIPT	The interaction, between human Nitric oxide synthase inducible and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	ARK72_HUMAN	PROTNAME	Succinic semialdehyde reductase (AKR7A2)
DME1422	UNIPROID	ARK72_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	ARK72_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	ARK72_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	ARK72_HUMAN	PPI_SUMM	AKR7A2-molD interaction
DME1422	UNIPROID	ARK72_HUMAN	DESCRIPT	The interaction, between human Succinic semialdehyde reductase and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1422	UNIPROID	MTRR_HUMAN	PROTNAME	Methionine synthase reductase (MTRR)
DME1422	UNIPROID	MTRR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1422	UNIPROID	MTRR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1422	UNIPROID	MTRR_HUMAN	SUBSTRAT	Doxorubicin
DME1422	UNIPROID	MTRR_HUMAN	PPI_SUMM	MTRR-molD interaction
DME1422	UNIPROID	MTRR_HUMAN	DESCRIPT	The interaction, between human Methionine synthase reductase and Molybdopterin-dependent enzyme from Escherichia coli which collectively metabolize the drug Doxorubicin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1442	DME___ID	DME1442
DME1442	DME_NAME	Cytochrome P450 130A1 (cyp130)
DME1442	SPESNAME	Mycobacterium tuberculosis
DME1442	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1442	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1442	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1442	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1442	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cyp130 interaction
DME1442	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 130A1 from Mycobacterium tuberculosis which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1442	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1442	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1442	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1442	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1442	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-cyp130 interaction
DME1442	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 130A1 from Mycobacterium tuberculosis which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1442	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1442	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1442	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1442	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1442	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-cyp130 interaction
DME1442	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 130A1 from Mycobacterium tuberculosis which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1442	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1442	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1442	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1442	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1442	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-cyp130 interaction
DME1442	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Cytochrome P450 130A1 from Mycobacterium tuberculosis which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1442	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1442	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1442	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1442	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1442	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-cyp130 interaction
DME1442	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 130A1 from Mycobacterium tuberculosis which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1442	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1442	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1442	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1442	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1442	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-cyp130 interaction
DME1442	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Cytochrome P450 130A1 from Mycobacterium tuberculosis which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1442	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1442	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1442	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1442	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1442	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-cyp130 interaction
DME1442	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 130A1 from Mycobacterium tuberculosis which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1442	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1442	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1442	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1442	UNIPROID	CP46A_HUMAN	SUBSTRAT	Dextromethorphan hydrobromide
DME1442	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp130 interaction
DME1442	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 130A1 from Mycobacterium tuberculosis which collectively metabolize the drug Dextromethorphan hydrobromide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1461	DME___ID	DME1461
DME1461	DME_NAME	Homoserine-O-transsuccinylase (metAA)
DME1461	SPESNAME	Salmonella enterica
DME1461	UNIPROID	MAT2B_HUMAN	PROTNAME	Methionine adenosyltransferase II beta (MAT2B)
DME1461	UNIPROID	MAT2B_HUMAN	MOFCLASS	Host-microbiome interaction
DME1461	UNIPROID	MAT2B_HUMAN	MOFDETAI	Host-microbiome interaction
DME1461	UNIPROID	MAT2B_HUMAN	SUBSTRAT	Methionine
DME1461	UNIPROID	MAT2B_HUMAN	PPI_SUMM	MAT2B-metAA interaction
DME1461	UNIPROID	MAT2B_HUMAN	DESCRIPT	The interaction, between human Methionine adenosyltransferase II beta and Homoserine-O-transsuccinylase from Salmonella enterica which collectively metabolize the drug Methionine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1461	UNIPROID	MSRB1_HUMAN	PROTNAME	Methionine-R-sulfoxide reductase B1 (MSRB1)
DME1461	UNIPROID	MSRB1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1461	UNIPROID	MSRB1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1461	UNIPROID	MSRB1_HUMAN	SUBSTRAT	Methionine
DME1461	UNIPROID	MSRB1_HUMAN	PPI_SUMM	MSRB1-metAA interaction
DME1461	UNIPROID	MSRB1_HUMAN	DESCRIPT	The interaction, between human Methionine-R-sulfoxide reductase B1 and Homoserine-O-transsuccinylase from Salmonella enterica which collectively metabolize the drug Methionine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1461	UNIPROID	MSRB2_HUMAN	PROTNAME	Methionine-R-sulfoxide reductase B2 (MSRB2)
DME1461	UNIPROID	MSRB2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1461	UNIPROID	MSRB2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1461	UNIPROID	MSRB2_HUMAN	SUBSTRAT	Methionine
DME1461	UNIPROID	MSRB2_HUMAN	PPI_SUMM	MSRB2-metAA interaction
DME1461	UNIPROID	MSRB2_HUMAN	DESCRIPT	The interaction, between human Methionine-R-sulfoxide reductase B2 and Homoserine-O-transsuccinylase from Salmonella enterica which collectively metabolize the drug Methionine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1461	UNIPROID	SYMC_HUMAN	PROTNAME	Methionine-tRNA ligase cytoplasmic (MARS)
DME1461	UNIPROID	SYMC_HUMAN	MOFCLASS	Host-microbiome interaction
DME1461	UNIPROID	SYMC_HUMAN	MOFDETAI	Host-microbiome interaction
DME1461	UNIPROID	SYMC_HUMAN	SUBSTRAT	Methionine
DME1461	UNIPROID	SYMC_HUMAN	PPI_SUMM	MARS-metAA interaction
DME1461	UNIPROID	SYMC_HUMAN	DESCRIPT	The interaction, between human Methionine-tRNA ligase cytoplasmic and Homoserine-O-transsuccinylase from Salmonella enterica which collectively metabolize the drug Methionine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1461	UNIPROID	SYMM_HUMAN	PROTNAME	Methionine-tRNA ligase mitochondrial (MARS2)
DME1461	UNIPROID	SYMM_HUMAN	MOFCLASS	Host-microbiome interaction
DME1461	UNIPROID	SYMM_HUMAN	MOFDETAI	Host-microbiome interaction
DME1461	UNIPROID	SYMM_HUMAN	SUBSTRAT	Methionine
DME1461	UNIPROID	SYMM_HUMAN	PPI_SUMM	MARS2-metAA interaction
DME1461	UNIPROID	SYMM_HUMAN	DESCRIPT	The interaction, between human Methionine-tRNA ligase mitochondrial and Homoserine-O-transsuccinylase from Salmonella enterica which collectively metabolize the drug Methionine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1461	UNIPROID	MSRA_HUMAN	PROTNAME	Peptide methionine sulfoxide reductase (MSRA)
DME1461	UNIPROID	MSRA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1461	UNIPROID	MSRA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1461	UNIPROID	MSRA_HUMAN	SUBSTRAT	Methionine
DME1461	UNIPROID	MSRA_HUMAN	PPI_SUMM	MSRA-metAA interaction
DME1461	UNIPROID	MSRA_HUMAN	DESCRIPT	The interaction, between human Peptide methionine sulfoxide reductase and Homoserine-O-transsuccinylase from Salmonella enterica which collectively metabolize the drug Methionine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1461	UNIPROID	METK1_HUMAN	PROTNAME	S-adenosylmethionine synthase 1 (MAT1A)
DME1461	UNIPROID	METK1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1461	UNIPROID	METK1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1461	UNIPROID	METK1_HUMAN	SUBSTRAT	Methionine
DME1461	UNIPROID	METK1_HUMAN	PPI_SUMM	MAT1A-metAA interaction
DME1461	UNIPROID	METK1_HUMAN	DESCRIPT	The interaction, between human S-adenosylmethionine synthase 1 and Homoserine-O-transsuccinylase from Salmonella enterica which collectively metabolize the drug Methionine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1461	UNIPROID	METK2_HUMAN	PROTNAME	S-adenosylmethionine synthase 2 (MAT2A)
DME1461	UNIPROID	METK2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1461	UNIPROID	METK2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1461	UNIPROID	METK2_HUMAN	SUBSTRAT	Methionine
DME1461	UNIPROID	METK2_HUMAN	PPI_SUMM	MAT2A-metAA interaction
DME1461	UNIPROID	METK2_HUMAN	DESCRIPT	The interaction, between human S-adenosylmethionine synthase 2 and Homoserine-O-transsuccinylase from Salmonella enterica which collectively metabolize the drug Methionine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1465	DME___ID	DME1465
DME1465	DME_NAME	Cytochrome P450 102D1 (cyp102)
DME1465	SPESNAME	Streptomyces avermitilis
DME1465	UNIPROID	ST2A1_HUMAN	PROTNAME	Sulfotransferase 2A1 (SULT2A1)
DME1465	UNIPROID	ST2A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1465	UNIPROID	ST2A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1465	UNIPROID	ST2A1_HUMAN	SUBSTRAT	Daidzein
DME1465	UNIPROID	ST2A1_HUMAN	PPI_SUMM	SULT2A1-cyp102 interaction
DME1465	UNIPROID	ST2A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 2A1 and Cytochrome P450 102D1 from Streptomyces avermitilis which collectively metabolize the drug Daidzein, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1465	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1465	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1465	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1465	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Coumarin
DME1465	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-cyp102 interaction
DME1465	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 102D1 from Streptomyces avermitilis which collectively metabolize the drug Coumarin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	DME___ID	DME1466
DME1466	DME_NAME	Cytochrome P450 154C2 (cyp154)
DME1466	SPESNAME	Streptomyces avermitilis
DME1466	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1466	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cyp154 interaction
DME1466	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP19A_HUMAN	PROTNAME	Aromatase (CYP19A1)
DME1466	UNIPROID	CP19A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP19A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP19A_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP19A_HUMAN	PPI_SUMM	CYP19A1-cyp154 interaction
DME1466	UNIPROID	CP19A_HUMAN	DESCRIPT	The interaction, between human Aromatase and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1466	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-cyp154 interaction
DME1466	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP4B1_HUMAN	PROTNAME	Cytochrome P450 4B1 (CYP4B1)
DME1466	UNIPROID	CP4B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP4B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP4B1_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP4B1_HUMAN	PPI_SUMM	CYP4B1-cyp154 interaction
DME1466	UNIPROID	CP4B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 4B1 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1466	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-cyp154 interaction
DME1466	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1466	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-cyp154 interaction
DME1466	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP2C8_HUMAN	PROTNAME	Cytochrome P450 2C8 (CYP2C8)
DME1466	UNIPROID	CP2C8_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP2C8_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP2C8_HUMAN	PPI_SUMM	CYP2C8-cyp154 interaction
DME1466	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1466	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-cyp154 interaction
DME1466	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1466	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-cyp154 interaction
DME1466	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1466	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-cyp154 interaction
DME1466	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP343_HUMAN	PROTNAME	Cytochrome P450 3A43 (CYP3A43)
DME1466	UNIPROID	CP343_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP343_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP343_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP343_HUMAN	PPI_SUMM	CYP3A43-cyp154 interaction
DME1466	UNIPROID	CP343_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A43 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP1B1_HUMAN	PROTNAME	Cytochrome P450 1B1 (CYP1B1)
DME1466	UNIPROID	CP1B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP1B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP1B1_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP1B1_HUMAN	PPI_SUMM	CYP1B1-cyp154 interaction
DME1466	UNIPROID	CP1B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1B1 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1466	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP46A_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp154 interaction
DME1466	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	CP2AD_HUMAN	PROTNAME	Cytochrome P450 2A13 (CYP2A13)
DME1466	UNIPROID	CP2AD_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	CP2AD_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	CP2AD_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	CP2AD_HUMAN	PPI_SUMM	CYP2A13-cyp154 interaction
DME1466	UNIPROID	CP2AD_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A13 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	S5A1_HUMAN	PROTNAME	Steroid 5-alpha-reductase 1 (SRD5A1)
DME1466	UNIPROID	S5A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	S5A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	S5A1_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	S5A1_HUMAN	PPI_SUMM	SRD5A1-cyp154 interaction
DME1466	UNIPROID	S5A1_HUMAN	DESCRIPT	The interaction, between human Steroid 5-alpha-reductase 1 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	S5A2_HUMAN	PROTNAME	Steroid 5-alpha-reductase 2 (SRD5A2)
DME1466	UNIPROID	S5A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	S5A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	S5A2_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	S5A2_HUMAN	PPI_SUMM	SRD5A2-cyp154 interaction
DME1466	UNIPROID	S5A2_HUMAN	DESCRIPT	The interaction, between human Steroid 5-alpha-reductase 2 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	PORED_HUMAN	PROTNAME	Steroid 5-alpha-reductase 3 (SRD5A3)
DME1466	UNIPROID	PORED_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	PORED_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	PORED_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	PORED_HUMAN	PPI_SUMM	SRD5A3-cyp154 interaction
DME1466	UNIPROID	PORED_HUMAN	DESCRIPT	The interaction, between human Steroid 5-alpha-reductase 3 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	AK1BF_HUMAN	PROTNAME	Farnesol dehydrogenase (AKR1B15)
DME1466	UNIPROID	AK1BF_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	AK1BF_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	AK1BF_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	AK1BF_HUMAN	PPI_SUMM	AKR1B15-cyp154 interaction
DME1466	UNIPROID	AK1BF_HUMAN	DESCRIPT	The interaction, between human Farnesol dehydrogenase and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1466	UNIPROID	DHB14_HUMAN	PROTNAME	Dehydrogenase/reductase retSDR3 (HSD17B14)
DME1466	UNIPROID	DHB14_HUMAN	MOFCLASS	Host-microbiome interaction
DME1466	UNIPROID	DHB14_HUMAN	MOFDETAI	Host-microbiome interaction
DME1466	UNIPROID	DHB14_HUMAN	SUBSTRAT	Testosterone cypionate
DME1466	UNIPROID	DHB14_HUMAN	PPI_SUMM	HSD17B14-cyp154 interaction
DME1466	UNIPROID	DHB14_HUMAN	DESCRIPT	The interaction, between human Dehydrogenase/reductase retSDR3 and Cytochrome P450 154C2 from Streptomyces avermitilis which collectively metabolize the drug Testosterone cypionate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1471	DME___ID	DME1471
DME1471	DME_NAME	L-malate:NADP(+) oxidoreductase (maeB)
DME1471	SPESNAME	Hungateiclostridium thermocellum
DME1471	UNIPROID	MAOX_HUMAN	PROTNAME	NADP-dependent malic enzyme (ME1)
DME1471	UNIPROID	MAOX_HUMAN	MOFCLASS	Host-microbiome interaction
DME1471	UNIPROID	MAOX_HUMAN	MOFDETAI	Host-microbiome interaction
DME1471	UNIPROID	MAOX_HUMAN	SUBSTRAT	Malate
DME1471	UNIPROID	MAOX_HUMAN	PPI_SUMM	ME1-maeB interaction
DME1471	UNIPROID	MAOX_HUMAN	DESCRIPT	The interaction, between human NADP-dependent malic enzyme and L-malate:NADP(+ oxidoreductase from Hungateiclostridium thermocellum which collectively metabolize the drug Malate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	DME___ID	DME1472
DME1472	DME_NAME	Cytochrome P450 21A2 (cyp21)
DME1472	SPESNAME	Bacillus megaterium
DME1472	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1472	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-cyp21 interaction
DME1472	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1472	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-cyp21 interaction
DME1472	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1472	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-cyp21 interaction
DME1472	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1472	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-cyp21 interaction
DME1472	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1472	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-cyp21 interaction
DME1472	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP4B1_HUMAN	PROTNAME	Cytochrome P450 4B1 (CYP4B1)
DME1472	UNIPROID	CP4B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP4B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP4B1_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP4B1_HUMAN	PPI_SUMM	CYP4B1-cyp21 interaction
DME1472	UNIPROID	CP4B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 4B1 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	GSTA1_HUMAN	PROTNAME	Glutathione S-transferase alpha-1 (GSTA1)
DME1472	UNIPROID	GSTA1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	GSTA1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	GSTA1_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	GSTA1_HUMAN	PPI_SUMM	GSTA1-cyp21 interaction
DME1472	UNIPROID	GSTA1_HUMAN	DESCRIPT	The interaction, between human Glutathione S-transferase alpha-1 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1472	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-cyp21 interaction
DME1472	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1472	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-cyp21 interaction
DME1472	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1472	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-cyp21 interaction
DME1472	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1472	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-cyp21 interaction
DME1472	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP1B1_HUMAN	PROTNAME	Cytochrome P450 1B1 (CYP1B1)
DME1472	UNIPROID	CP1B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP1B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP1B1_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP1B1_HUMAN	PPI_SUMM	CYP1B1-cyp21 interaction
DME1472	UNIPROID	CP1B1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1B1 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1472	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP46A_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp21 interaction
DME1472	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	CP21A_HUMAN	PROTNAME	Steroid 21-hydroxylase (CYP21A2)
DME1472	UNIPROID	CP21A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	CP21A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	CP21A_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	CP21A_HUMAN	PPI_SUMM	CYP21A2-cyp21 interaction
DME1472	UNIPROID	CP21A_HUMAN	DESCRIPT	The interaction, between human Steroid 21-hydroxylase and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1472	UNIPROID	AK1C1_HUMAN	PROTNAME	Aldo-keto reductase 1C1 (AKR1C1)
DME1472	UNIPROID	AK1C1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1472	UNIPROID	AK1C1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1472	UNIPROID	AK1C1_HUMAN	SUBSTRAT	Progesterone
DME1472	UNIPROID	AK1C1_HUMAN	PPI_SUMM	AKR1C1-cyp21 interaction
DME1472	UNIPROID	AK1C1_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1C1 and Cytochrome P450 21A2 from Bacillus megaterium which collectively metabolize the drug Progesterone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1473	DME___ID	DME1473
DME1473	DME_NAME	Azoreductase (azoR)
DME1473	SPESNAME	Bacteroides fragilis
DME1473	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1473	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1473	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1473	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1473	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1473	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Bacteroides fragilis which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1474	DME___ID	DME1474
DME1474	DME_NAME	Azoreductase (azoR)
DME1474	SPESNAME	Bifidobacterium animalis
DME1474	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1474	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1474	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1474	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1474	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1474	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Bifidobacterium animalis which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1475	DME___ID	DME1475
DME1475	DME_NAME	Azoreductase (azoR)
DME1475	SPESNAME	Lactobacillus acidophilus
DME1475	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1475	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1475	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1475	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Sulfasalazine
DME1475	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-azoR interaction
DME1475	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Azoreductase from Lactobacillus acidophilus which collectively metabolize the drug Sulfasalazine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1485	DME___ID	DME1485
DME1485	DME_NAME	Beta-lactamase (blaB)
DME1485	SPESNAME	Peptostreptococcus anaerobius
DME1485	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1485	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1485	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1485	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1485	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1485	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Peptostreptococcus anaerobius which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1488	DME___ID	DME1488
DME1488	DME_NAME	Heparin lyase (hepB)
DME1488	SPESNAME	Streptobacillus moniliformis
DME1488	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1488	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1488	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1488	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Heparin
DME1488	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-hepB interaction
DME1488	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and Heparin lyase from Streptobacillus moniliformis which collectively metabolize the drug Heparin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1488	UNIPROID	HPSE_HUMAN	PROTNAME	Heparanase (HPSE)
DME1488	UNIPROID	HPSE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1488	UNIPROID	HPSE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1488	UNIPROID	HPSE_HUMAN	SUBSTRAT	Heparin
DME1488	UNIPROID	HPSE_HUMAN	PPI_SUMM	HPSE-hepB interaction
DME1488	UNIPROID	HPSE_HUMAN	DESCRIPT	The interaction, between human Heparanase and Heparin lyase from Streptobacillus moniliformis which collectively metabolize the drug Heparin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1524	DME___ID	DME1524
DME1524	DME_NAME	Cytochrome P450 101D1 (cyp101)
DME1524	SPESNAME	Novosphingobium aromaticivorans
DME1524	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1524	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1524	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1524	UNIPROID	CP2A6_HUMAN	SUBSTRAT	BRN-1907611
DME1524	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-cyp101 interaction
DME1524	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Cytochrome P450 101D1 from Novosphingobium aromaticivorans which collectively metabolize the drug BRN-1907611, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1525	DME___ID	DME1525
DME1525	DME_NAME	Cytochrome P450 101D2 (cyp101)
DME1525	SPESNAME	Novosphingobium aromaticivorans
DME1525	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1525	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1525	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1525	UNIPROID	CP2A6_HUMAN	SUBSTRAT	BRN-1907611
DME1525	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-cyp101 interaction
DME1525	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Cytochrome P450 101D2 from Novosphingobium aromaticivorans which collectively metabolize the drug BRN-1907611, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1549	DME___ID	DME1549
DME1549	DME_NAME	Cytochrome P450 125A3 (cyp125)
DME1549	SPESNAME	Mycolicibacterium smegmatis
DME1549	UNIPROID	CP27A_HUMAN	PROTNAME	Vitamin D(3) 25-hydroxylase (CYP27A1)
DME1549	UNIPROID	CP27A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1549	UNIPROID	CP27A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1549	UNIPROID	CP27A_HUMAN	SUBSTRAT	ANW-32821
DME1549	UNIPROID	CP27A_HUMAN	PPI_SUMM	CYP27A1-cyp125 interaction
DME1549	UNIPROID	CP27A_HUMAN	DESCRIPT	The interaction, between human Vitamin D(3 25-hydroxylase and Cytochrome P450 125A3 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1549	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1549	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1549	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1549	UNIPROID	CP46A_HUMAN	SUBSTRAT	ANW-32821
DME1549	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp125 interaction
DME1549	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 125A3 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1549	UNIPROID	CP11A_HUMAN	PROTNAME	Cholesterol desmolase (CYP11A1)
DME1549	UNIPROID	CP11A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1549	UNIPROID	CP11A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1549	UNIPROID	CP11A_HUMAN	SUBSTRAT	ANW-32821
DME1549	UNIPROID	CP11A_HUMAN	PPI_SUMM	CYP11A1-cyp125 interaction
DME1549	UNIPROID	CP11A_HUMAN	DESCRIPT	The interaction, between human Cholesterol desmolase and Cytochrome P450 125A3 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1549	UNIPROID	CP7A1_HUMAN	PROTNAME	Cytochrome P450 7A1 (CYP7A1)
DME1549	UNIPROID	CP7A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1549	UNIPROID	CP7A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1549	UNIPROID	CP7A1_HUMAN	SUBSTRAT	ANW-32821
DME1549	UNIPROID	CP7A1_HUMAN	PPI_SUMM	CYP7A1-cyp125 interaction
DME1549	UNIPROID	CP7A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 7A1 and Cytochrome P450 125A3 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1550	DME___ID	DME1550
DME1550	DME_NAME	Cytochrome P450 142A2 (cyp142)
DME1550	SPESNAME	Mycolicibacterium smegmatis
DME1550	UNIPROID	CP27A_HUMAN	PROTNAME	Vitamin D(3) 25-hydroxylase (CYP27A1)
DME1550	UNIPROID	CP27A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1550	UNIPROID	CP27A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1550	UNIPROID	CP27A_HUMAN	SUBSTRAT	ANW-32821
DME1550	UNIPROID	CP27A_HUMAN	PPI_SUMM	CYP27A1-cyp142 interaction
DME1550	UNIPROID	CP27A_HUMAN	DESCRIPT	The interaction, between human Vitamin D(3 25-hydroxylase and Cytochrome P450 142A2 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1550	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1550	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1550	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1550	UNIPROID	CP46A_HUMAN	SUBSTRAT	ANW-32821
DME1550	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp142 interaction
DME1550	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 142A2 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1550	UNIPROID	CP11A_HUMAN	PROTNAME	Cholesterol desmolase (CYP11A1)
DME1550	UNIPROID	CP11A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1550	UNIPROID	CP11A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1550	UNIPROID	CP11A_HUMAN	SUBSTRAT	ANW-32821
DME1550	UNIPROID	CP11A_HUMAN	PPI_SUMM	CYP11A1-cyp142 interaction
DME1550	UNIPROID	CP11A_HUMAN	DESCRIPT	The interaction, between human Cholesterol desmolase and Cytochrome P450 142A2 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1550	UNIPROID	CP7A1_HUMAN	PROTNAME	Cytochrome P450 7A1 (CYP7A1)
DME1550	UNIPROID	CP7A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1550	UNIPROID	CP7A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1550	UNIPROID	CP7A1_HUMAN	SUBSTRAT	ANW-32821
DME1550	UNIPROID	CP7A1_HUMAN	PPI_SUMM	CYP7A1-cyp142 interaction
DME1550	UNIPROID	CP7A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 7A1 and Cytochrome P450 142A2 from Mycolicibacterium smegmatis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1551	DME___ID	DME1551
DME1551	DME_NAME	Cytochrome P450 125A1 (cyp125)
DME1551	SPESNAME	Mycobacterium tuberculosis
DME1551	UNIPROID	CP27A_HUMAN	PROTNAME	Vitamin D(3) 25-hydroxylase (CYP27A1)
DME1551	UNIPROID	CP27A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1551	UNIPROID	CP27A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1551	UNIPROID	CP27A_HUMAN	SUBSTRAT	ANW-32821
DME1551	UNIPROID	CP27A_HUMAN	PPI_SUMM	CYP27A1-cyp125 interaction
DME1551	UNIPROID	CP27A_HUMAN	DESCRIPT	The interaction, between human Vitamin D(3 25-hydroxylase and Cytochrome P450 125A1 from Mycobacterium tuberculosis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1551	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1551	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1551	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1551	UNIPROID	CP46A_HUMAN	SUBSTRAT	ANW-32821
DME1551	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp125 interaction
DME1551	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 125A1 from Mycobacterium tuberculosis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1551	UNIPROID	CP11A_HUMAN	PROTNAME	Cholesterol desmolase (CYP11A1)
DME1551	UNIPROID	CP11A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1551	UNIPROID	CP11A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1551	UNIPROID	CP11A_HUMAN	SUBSTRAT	ANW-32821
DME1551	UNIPROID	CP11A_HUMAN	PPI_SUMM	CYP11A1-cyp125 interaction
DME1551	UNIPROID	CP11A_HUMAN	DESCRIPT	The interaction, between human Cholesterol desmolase and Cytochrome P450 125A1 from Mycobacterium tuberculosis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1551	UNIPROID	CP7A1_HUMAN	PROTNAME	Cytochrome P450 7A1 (CYP7A1)
DME1551	UNIPROID	CP7A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1551	UNIPROID	CP7A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1551	UNIPROID	CP7A1_HUMAN	SUBSTRAT	ANW-32821
DME1551	UNIPROID	CP7A1_HUMAN	PPI_SUMM	CYP7A1-cyp125 interaction
DME1551	UNIPROID	CP7A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 7A1 and Cytochrome P450 125A1 from Mycobacterium tuberculosis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1552	DME___ID	DME1552
DME1552	DME_NAME	Cytochrome P450 142A1 (cyp142)
DME1552	SPESNAME	Mycobacterium tuberculosis
DME1552	UNIPROID	CP27A_HUMAN	PROTNAME	Vitamin D(3) 25-hydroxylase (CYP27A1)
DME1552	UNIPROID	CP27A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1552	UNIPROID	CP27A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1552	UNIPROID	CP27A_HUMAN	SUBSTRAT	ANW-32821
DME1552	UNIPROID	CP27A_HUMAN	PPI_SUMM	CYP27A1-cyp142 interaction
DME1552	UNIPROID	CP27A_HUMAN	DESCRIPT	The interaction, between human Vitamin D(3 25-hydroxylase and Cytochrome P450 142A1 from Mycobacterium tuberculosis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1552	UNIPROID	CP46A_HUMAN	PROTNAME	Cholesterol 24-hydroxylase (CYP46A1)
DME1552	UNIPROID	CP46A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1552	UNIPROID	CP46A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1552	UNIPROID	CP46A_HUMAN	SUBSTRAT	ANW-32821
DME1552	UNIPROID	CP46A_HUMAN	PPI_SUMM	CYP46A1-cyp142 interaction
DME1552	UNIPROID	CP46A_HUMAN	DESCRIPT	The interaction, between human Cholesterol 24-hydroxylase and Cytochrome P450 142A1 from Mycobacterium tuberculosis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1552	UNIPROID	CP11A_HUMAN	PROTNAME	Cholesterol desmolase (CYP11A1)
DME1552	UNIPROID	CP11A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1552	UNIPROID	CP11A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1552	UNIPROID	CP11A_HUMAN	SUBSTRAT	ANW-32821
DME1552	UNIPROID	CP11A_HUMAN	PPI_SUMM	CYP11A1-cyp142 interaction
DME1552	UNIPROID	CP11A_HUMAN	DESCRIPT	The interaction, between human Cholesterol desmolase and Cytochrome P450 142A1 from Mycobacterium tuberculosis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1552	UNIPROID	CP7A1_HUMAN	PROTNAME	Cytochrome P450 7A1 (CYP7A1)
DME1552	UNIPROID	CP7A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1552	UNIPROID	CP7A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1552	UNIPROID	CP7A1_HUMAN	SUBSTRAT	ANW-32821
DME1552	UNIPROID	CP7A1_HUMAN	PPI_SUMM	CYP7A1-cyp142 interaction
DME1552	UNIPROID	CP7A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 7A1 and Cytochrome P450 142A1 from Mycobacterium tuberculosis which collectively metabolize the drug ANW-32821, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1553	DME___ID	DME1553
DME1553	DME_NAME	Tyrosine decarboxylase (tdc)
DME1553	SPESNAME	Lactobacillus brevis
DME1553	UNIPROID	CP2D6_HUMAN	PROTNAME	Cytochrome P450 2D6 (CYP2D6)
DME1553	UNIPROID	CP2D6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1553	UNIPROID	CP2D6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1553	UNIPROID	CP2D6_HUMAN	SUBSTRAT	Levodopa
DME1553	UNIPROID	CP2D6_HUMAN	PPI_SUMM	CYP2D6-tdc interaction
DME1553	UNIPROID	CP2D6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2D6 and Tyrosine decarboxylase from Lactobacillus brevis which collectively metabolize the drug Levodopa, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1553	UNIPROID	TPMT_HUMAN	PROTNAME	Thiopurine methyltransferase (TPMT)
DME1553	UNIPROID	TPMT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1553	UNIPROID	TPMT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1553	UNIPROID	TPMT_HUMAN	SUBSTRAT	Levodopa
DME1553	UNIPROID	TPMT_HUMAN	PPI_SUMM	TPMT-tdc interaction
DME1553	UNIPROID	TPMT_HUMAN	DESCRIPT	The interaction, between human Thiopurine methyltransferase and Tyrosine decarboxylase from Lactobacillus brevis which collectively metabolize the drug Levodopa, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1553	UNIPROID	DDC_HUMAN	PROTNAME	DOPA decarboxylase (DDC)
DME1553	UNIPROID	DDC_HUMAN	MOFCLASS	Host-microbiome interaction
DME1553	UNIPROID	DDC_HUMAN	MOFDETAI	Host-microbiome interaction
DME1553	UNIPROID	DDC_HUMAN	SUBSTRAT	Levodopa
DME1553	UNIPROID	DDC_HUMAN	PPI_SUMM	DDC-tdc interaction
DME1553	UNIPROID	DDC_HUMAN	DESCRIPT	The interaction, between human DOPA decarboxylase and Tyrosine decarboxylase from Lactobacillus brevis which collectively metabolize the drug Levodopa, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1615	DME___ID	DME1615
DME1615	DME_NAME	Naphthalene dioxygenase (doxB)
DME1615	SPESNAME	Pseudomonas furukawaii
DME1615	UNIPROID	CP2A6_HUMAN	PROTNAME	Cytochrome P450 2A6 (CYP2A6)
DME1615	UNIPROID	CP2A6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1615	UNIPROID	CP2A6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1615	UNIPROID	CP2A6_HUMAN	SUBSTRAT	Flavone
DME1615	UNIPROID	CP2A6_HUMAN	PPI_SUMM	CYP2A6-doxB interaction
DME1615	UNIPROID	CP2A6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2A6 and Naphthalene dioxygenase from Pseudomonas furukawaii which collectively metabolize the drug Flavone, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1630	DME___ID	DME1630
DME1630	DME_NAME	VanA ligase (vanA)
DME1630	SPESNAME	Enterococcus gallinarum
DME1630	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1630	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1630	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1630	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Teicoplanin
DME1630	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-vanA interaction
DME1630	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and VanA ligase from Enterococcus gallinarum which collectively metabolize the drug Teicoplanin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1631	DME___ID	DME1631
DME1631	DME_NAME	VanA ligase (vanA)
DME1631	SPESNAME	Enterococcus casseliflavus
DME1631	UNIPROID	ST1A1_HUMAN	PROTNAME	Sulfotransferase 1A1 (SULT1A1)
DME1631	UNIPROID	ST1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1631	UNIPROID	ST1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1631	UNIPROID	ST1A1_HUMAN	SUBSTRAT	Teicoplanin
DME1631	UNIPROID	ST1A1_HUMAN	PPI_SUMM	SULT1A1-vanA interaction
DME1631	UNIPROID	ST1A1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A1 and VanA ligase from Enterococcus casseliflavus which collectively metabolize the drug Teicoplanin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1732	DME___ID	DME1732
DME1732	DME_NAME	New delhi metallo-beta-lactamase NDM-1 (blaNDM)
DME1732	SPESNAME	Salmonella enterica
DME1732	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1732	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1732	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1732	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1732	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaNDM interaction
DME1732	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and New delhi metallo-beta-lactamase NDM-1 from Salmonella enterica which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	DME___ID	DME1788
DME1788	DME_NAME	Beta-glucuronidase (uidA)
DME1788	SPESNAME	Escherichia coli
DME1788	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1788	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Irinotecan hydrochloride
DME1788	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-uidA interaction
DME1788	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1788	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	CP3A5_HUMAN	SUBSTRAT	Irinotecan hydrochloride
DME1788	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-uidA interaction
DME1788	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1788	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	CP3A7_HUMAN	SUBSTRAT	Irinotecan hydrochloride
DME1788	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-uidA interaction
DME1788	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	CP2B6_HUMAN	PROTNAME	Cytochrome P450 2B6 (CYP2B6)
DME1788	UNIPROID	CP2B6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	CP2B6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	CP2B6_HUMAN	SUBSTRAT	Irinotecan hydrochloride
DME1788	UNIPROID	CP2B6_HUMAN	PPI_SUMM	CYP2B6-uidA interaction
DME1788	UNIPROID	CP2B6_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2B6 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	EST1_HUMAN	PROTNAME	Carboxylesterase 1 (CES1)
DME1788	UNIPROID	EST1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	EST1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	EST1_HUMAN	SUBSTRAT	Irinotecan hydrochloride
DME1788	UNIPROID	EST1_HUMAN	PPI_SUMM	CES1-uidA interaction
DME1788	UNIPROID	EST1_HUMAN	DESCRIPT	The interaction, between human Carboxylesterase 1 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	EST3_HUMAN	PROTNAME	Carboxylesterase 3 (CES3)
DME1788	UNIPROID	EST3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	EST3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	EST3_HUMAN	SUBSTRAT	Irinotecan hydrochloride
DME1788	UNIPROID	EST3_HUMAN	PPI_SUMM	CES3-uidA interaction
DME1788	UNIPROID	EST3_HUMAN	DESCRIPT	The interaction, between human Carboxylesterase 3 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	EST2_HUMAN	PROTNAME	Carboxylesterase 2 (CES2)
DME1788	UNIPROID	EST2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	EST2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	EST2_HUMAN	SUBSTRAT	Irinotecan hydrochloride
DME1788	UNIPROID	EST2_HUMAN	PPI_SUMM	CES2-uidA interaction
DME1788	UNIPROID	EST2_HUMAN	DESCRIPT	The interaction, between human Carboxylesterase 2 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Irinotecan hydrochloride, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Conjugated estrogens
DME1788	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Conjugated estrogens, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1788	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Conjugated estrogens
DME1788	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-uidA interaction
DME1788	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug Conjugated estrogens, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1788	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1788	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1788	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1788	UNIPROID	UD11_HUMAN	SUBSTRAT	SN-38
DME1788	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-uidA interaction
DME1788	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Beta-glucuronidase from Escherichia coli which collectively metabolize the drug SN-38, is reported to cause an adverse drug reaction.
DME1864	DME___ID	DME1864
DME1864	DME_NAME	Flavin adenine dinucleotide dehydrogenase (fadd)
DME1864	SPESNAME	Clostridium leptum
DME1864	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1864	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1864	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1864	UNIPROID	CP3A4_HUMAN	SUBSTRAT	RO-7-0207
DME1864	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-fadd interaction
DME1864	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Flavin adenine dinucleotide dehydrogenase from Clostridium leptum which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1864	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1864	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1864	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1864	UNIPROID	CP3A5_HUMAN	SUBSTRAT	RO-7-0207
DME1864	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-fadd interaction
DME1864	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Flavin adenine dinucleotide dehydrogenase from Clostridium leptum which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1864	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1864	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1864	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1864	UNIPROID	CP3A7_HUMAN	SUBSTRAT	RO-7-0207
DME1864	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-fadd interaction
DME1864	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Flavin adenine dinucleotide dehydrogenase from Clostridium leptum which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1865	DME___ID	DME1865
DME1865	DME_NAME	Flavin adenine dinucleotide dehydrogenase (fadd)
DME1865	SPESNAME	Clostridium perfringens
DME1865	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1865	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1865	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1865	UNIPROID	CP3A4_HUMAN	SUBSTRAT	RO-7-0207
DME1865	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-fadd interaction
DME1865	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Flavin adenine dinucleotide dehydrogenase from Clostridium perfringens which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1865	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1865	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1865	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1865	UNIPROID	CP3A5_HUMAN	SUBSTRAT	RO-7-0207
DME1865	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-fadd interaction
DME1865	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Flavin adenine dinucleotide dehydrogenase from Clostridium perfringens which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1865	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1865	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1865	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1865	UNIPROID	CP3A7_HUMAN	SUBSTRAT	RO-7-0207
DME1865	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-fadd interaction
DME1865	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Flavin adenine dinucleotide dehydrogenase from Clostridium perfringens which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1866	DME___ID	DME1866
DME1866	DME_NAME	Flavin adenine dinucleotide dehydrogenase (fadd)
DME1866	SPESNAME	Clostridium sporogenes
DME1866	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1866	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1866	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1866	UNIPROID	CP3A4_HUMAN	SUBSTRAT	RO-7-0207
DME1866	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-fadd interaction
DME1866	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Flavin adenine dinucleotide dehydrogenase from Clostridium sporogenes which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1866	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1866	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1866	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1866	UNIPROID	CP3A5_HUMAN	SUBSTRAT	RO-7-0207
DME1866	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-fadd interaction
DME1866	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Flavin adenine dinucleotide dehydrogenase from Clostridium sporogenes which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1866	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1866	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1866	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1866	UNIPROID	CP3A7_HUMAN	SUBSTRAT	RO-7-0207
DME1866	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-fadd interaction
DME1866	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Flavin adenine dinucleotide dehydrogenase from Clostridium sporogenes which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1868	DME___ID	DME1868
DME1868	DME_NAME	Flavin adenine dinucleotide dehydrogenase (fadd)
DME1868	SPESNAME	Eubacterium oxidoreducens
DME1868	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1868	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1868	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1868	UNIPROID	CP3A4_HUMAN	SUBSTRAT	RO-7-0207
DME1868	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-fadd interaction
DME1868	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Flavin adenine dinucleotide dehydrogenase from Eubacterium oxidoreducens which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1868	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1868	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1868	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1868	UNIPROID	CP3A5_HUMAN	SUBSTRAT	RO-7-0207
DME1868	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-fadd interaction
DME1868	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Flavin adenine dinucleotide dehydrogenase from Eubacterium oxidoreducens which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1868	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1868	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1868	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1868	UNIPROID	CP3A7_HUMAN	SUBSTRAT	RO-7-0207
DME1868	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-fadd interaction
DME1868	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Flavin adenine dinucleotide dehydrogenase from Eubacterium oxidoreducens which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1880	DME___ID	DME1880
DME1880	DME_NAME	Beta-lactamase (blaB)
DME1880	SPESNAME	Klebsiella aerogenes
DME1880	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1880	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1880	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1880	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1880	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1880	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Klebsiella aerogenes which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1881	DME___ID	DME1881
DME1881	DME_NAME	Metallo-beta-lactamase (blaM)
DME1881	SPESNAME	Klebsiella pneumoniae
DME1881	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1881	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1881	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1881	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1881	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaM interaction
DME1881	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Metallo-beta-lactamase from Klebsiella pneumoniae which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1905	DME___ID	DME1905
DME1905	DME_NAME	Cytochrome P450 147G1 (cyp147)
DME1905	SPESNAME	Mycobacterium marinum
DME1905	UNIPROID	PGH2_HUMAN	PROTNAME	Prostaglandin G/H synthase 2 (COX-2)
DME1905	UNIPROID	PGH2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1905	UNIPROID	PGH2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1905	UNIPROID	PGH2_HUMAN	SUBSTRAT	Omega-3 Fatty acids
DME1905	UNIPROID	PGH2_HUMAN	PPI_SUMM	COX-2-cyp147 interaction
DME1905	UNIPROID	PGH2_HUMAN	DESCRIPT	The interaction, between human Prostaglandin G/H synthase 2 and Cytochrome P450 147G1 from Mycobacterium marinum which collectively metabolize the drug Omega-3 Fatty acids, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1905	UNIPROID	LOX5_HUMAN	PROTNAME	Arachidonate 5-lipoxygenase (ALOX5)
DME1905	UNIPROID	LOX5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1905	UNIPROID	LOX5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1905	UNIPROID	LOX5_HUMAN	SUBSTRAT	Omega-3 Fatty acids
DME1905	UNIPROID	LOX5_HUMAN	PPI_SUMM	ALOX5-cyp147 interaction
DME1905	UNIPROID	LOX5_HUMAN	DESCRIPT	The interaction, between human Arachidonate 5-lipoxygenase and Cytochrome P450 147G1 from Mycobacterium marinum which collectively metabolize the drug Omega-3 Fatty acids, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	DME___ID	DME1906
DME1906	DME_NAME	Alcohol dehydrogenase (ADH)
DME1906	SPESNAME	Neisseria sicca
DME1906	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1906	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-ADH interaction
DME1906	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1906	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-ADH interaction
DME1906	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	UD11_HUMAN	PROTNAME	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DME1906	UNIPROID	UD11_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	UD11_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	UD11_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	UD11_HUMAN	PPI_SUMM	UGT1A1-ADH interaction
DME1906	UNIPROID	UD11_HUMAN	DESCRIPT	The interaction, between human UDP-glucuronosyltransferase 1A1 and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	CP2E1_HUMAN	PROTNAME	Cytochrome P450 2E1 (CYP2E1)
DME1906	UNIPROID	CP2E1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	CP2E1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	CP2E1_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	CP2E1_HUMAN	PPI_SUMM	CYP2E1-ADH interaction
DME1906	UNIPROID	CP2E1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2E1 and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	ADH6_HUMAN	PROTNAME	Alcohol dehydrogenase class-V (ADH6)
DME1906	UNIPROID	ADH6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	ADH6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	ADH6_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	ADH6_HUMAN	PPI_SUMM	ADH6-ADH interaction
DME1906	UNIPROID	ADH6_HUMAN	DESCRIPT	The interaction, between human Alcohol dehydrogenase class-V and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	AK1A1_HUMAN	PROTNAME	Aldo-keto reductase 1A1 (AKR1A1)
DME1906	UNIPROID	AK1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	AK1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	AK1A1_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	AK1A1_HUMAN	PPI_SUMM	AKR1A1-ADH interaction
DME1906	UNIPROID	AK1A1_HUMAN	DESCRIPT	The interaction, between human Aldo-keto reductase 1A1 and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	ADH1A_HUMAN	PROTNAME	Alcohol dehydrogenase class-I alpha (ADH1A)
DME1906	UNIPROID	ADH1A_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	ADH1A_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	ADH1A_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	ADH1A_HUMAN	PPI_SUMM	ADH1A-ADH interaction
DME1906	UNIPROID	ADH1A_HUMAN	DESCRIPT	The interaction, between human Alcohol dehydrogenase class-I alpha and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	ADH1B_HUMAN	PROTNAME	Alcohol dehydrogenase class-I beta (ADH1B)
DME1906	UNIPROID	ADH1B_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	ADH1B_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	ADH1B_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	ADH1B_HUMAN	PPI_SUMM	ADH1B-ADH interaction
DME1906	UNIPROID	ADH1B_HUMAN	DESCRIPT	The interaction, between human Alcohol dehydrogenase class-I beta and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	ADH1G_HUMAN	PROTNAME	Alcohol dehydrogenase class-I gamma (ADH1C)
DME1906	UNIPROID	ADH1G_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	ADH1G_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	ADH1G_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	ADH1G_HUMAN	PPI_SUMM	ADH1C-ADH interaction
DME1906	UNIPROID	ADH1G_HUMAN	DESCRIPT	The interaction, between human Alcohol dehydrogenase class-I gamma and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	ADH4_HUMAN	PROTNAME	Alcohol dehydrogenase class-II (ADH4)
DME1906	UNIPROID	ADH4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	ADH4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	ADH4_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	ADH4_HUMAN	PPI_SUMM	ADH4-ADH interaction
DME1906	UNIPROID	ADH4_HUMAN	DESCRIPT	The interaction, between human Alcohol dehydrogenase class-II and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	ADH7_HUMAN	PROTNAME	Gastric alcohol dehydrogenase (ADH7)
DME1906	UNIPROID	ADH7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	ADH7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	ADH7_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	ADH7_HUMAN	PPI_SUMM	ADH7-ADH interaction
DME1906	UNIPROID	ADH7_HUMAN	DESCRIPT	The interaction, between human Gastric alcohol dehydrogenase and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1906	UNIPROID	ADHX_HUMAN	PROTNAME	Alcohol dehydrogenase class-III (ADH5)
DME1906	UNIPROID	ADHX_HUMAN	MOFCLASS	Host-microbiome interaction
DME1906	UNIPROID	ADHX_HUMAN	MOFDETAI	Host-microbiome interaction
DME1906	UNIPROID	ADHX_HUMAN	SUBSTRAT	Ethanol
DME1906	UNIPROID	ADHX_HUMAN	PPI_SUMM	ADH5-ADH interaction
DME1906	UNIPROID	ADHX_HUMAN	DESCRIPT	The interaction, between human Alcohol dehydrogenase class-III and Alcohol dehydrogenase from Neisseria sicca which collectively metabolize the drug Ethanol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1911	DME___ID	DME1911
DME1911	DME_NAME	Sulfatase (sulF)
DME1911	SPESNAME	Parabacteroides johnsonii
DME1911	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1911	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1911	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1911	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Estrone sulfate
DME1911	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-sulF interaction
DME1911	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Sulfatase from Parabacteroides johnsonii which collectively metabolize the drug Estrone sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1911	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1911	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1911	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1911	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Estrone sulfate
DME1911	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-sulF interaction
DME1911	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Sulfatase from Parabacteroides johnsonii which collectively metabolize the drug Estrone sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1911	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1911	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1911	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1911	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Estrone sulfate
DME1911	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-sulF interaction
DME1911	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Sulfatase from Parabacteroides johnsonii which collectively metabolize the drug Estrone sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1911	UNIPROID	UBS3B_HUMAN	PROTNAME	Tyrosine-protein phosphatase STS1/TULA2 (UBASH3B)
DME1911	UNIPROID	UBS3B_HUMAN	MOFCLASS	Host-microbiome interaction
DME1911	UNIPROID	UBS3B_HUMAN	MOFDETAI	Host-microbiome interaction
DME1911	UNIPROID	UBS3B_HUMAN	SUBSTRAT	Estrone sulfate
DME1911	UNIPROID	UBS3B_HUMAN	PPI_SUMM	UBASH3B-sulF interaction
DME1911	UNIPROID	UBS3B_HUMAN	DESCRIPT	The interaction, between human Tyrosine-protein phosphatase STS1/TULA2 and Sulfatase from Parabacteroides johnsonii which collectively metabolize the drug Estrone sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1919	DME___ID	DME1919
DME1919	DME_NAME	Sulfatase (sulF)
DME1919	SPESNAME	Prevotella buccae
DME1919	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1919	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1919	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1919	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Estrone sulfate
DME1919	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-sulF interaction
DME1919	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Sulfatase from Prevotella buccae which collectively metabolize the drug Estrone sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1919	UNIPROID	CP1A2_HUMAN	PROTNAME	Cytochrome P450 1A2 (CYP1A2)
DME1919	UNIPROID	CP1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1919	UNIPROID	CP1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1919	UNIPROID	CP1A2_HUMAN	SUBSTRAT	Estrone sulfate
DME1919	UNIPROID	CP1A2_HUMAN	PPI_SUMM	CYP1A2-sulF interaction
DME1919	UNIPROID	CP1A2_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A2 and Sulfatase from Prevotella buccae which collectively metabolize the drug Estrone sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1919	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1919	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1919	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1919	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Estrone sulfate
DME1919	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-sulF interaction
DME1919	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Sulfatase from Prevotella buccae which collectively metabolize the drug Estrone sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1919	UNIPROID	UBS3B_HUMAN	PROTNAME	Tyrosine-protein phosphatase STS1/TULA2 (UBASH3B)
DME1919	UNIPROID	UBS3B_HUMAN	MOFCLASS	Host-microbiome interaction
DME1919	UNIPROID	UBS3B_HUMAN	MOFDETAI	Host-microbiome interaction
DME1919	UNIPROID	UBS3B_HUMAN	SUBSTRAT	Estrone sulfate
DME1919	UNIPROID	UBS3B_HUMAN	PPI_SUMM	UBASH3B-sulF interaction
DME1919	UNIPROID	UBS3B_HUMAN	DESCRIPT	The interaction, between human Tyrosine-protein phosphatase STS1/TULA2 and Sulfatase from Prevotella buccae which collectively metabolize the drug Estrone sulfate, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1921	DME___ID	DME1921
DME1921	DME_NAME	Beta-lactamase (blaB)
DME1921	SPESNAME	Prevotella copri
DME1921	UNIPROID	CP2CJ_HUMAN	PROTNAME	Mephenytoin 4-hydroxylase (CYP2C19)
DME1921	UNIPROID	CP2CJ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1921	UNIPROID	CP2CJ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1921	UNIPROID	CP2CJ_HUMAN	SUBSTRAT	Amoxicillin
DME1921	UNIPROID	CP2CJ_HUMAN	PPI_SUMM	CYP2C19-blaB interaction
DME1921	UNIPROID	CP2CJ_HUMAN	DESCRIPT	The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Prevotella copri which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1949	DME___ID	DME1949
DME1949	DME_NAME	Arginine dihydrolase (arcA)
DME1949	SPESNAME	Staphylococcus petrasii
DME1949	UNIPROID	ARGI1_HUMAN	PROTNAME	Liver-type arginase (ARG1)
DME1949	UNIPROID	ARGI1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1949	UNIPROID	ARGI1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1949	UNIPROID	ARGI1_HUMAN	SUBSTRAT	L-arginine
DME1949	UNIPROID	ARGI1_HUMAN	PPI_SUMM	ARG1-arcA interaction
DME1949	UNIPROID	ARGI1_HUMAN	DESCRIPT	The interaction, between human Liver-type arginase and Arginine dihydrolase from Staphylococcus petrasii which collectively metabolize the drug L-arginine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	DME___ID	DME1953
DME1953	DME_NAME	Glutamate racemase (MurI)
DME1953	SPESNAME	Streptococcus mutans
DME1953	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME1953	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-MurI interaction
DME1953	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME1953	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-MurI interaction
DME1953	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME1953	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-MurI interaction
DME1953	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME1953	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-MurI interaction
DME1953	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME1953	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-MurI interaction
DME1953	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME1953	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-MurI interaction
DME1953	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME1953	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-MurI interaction
DME1953	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME1953	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-MurI interaction
DME1953	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME1953	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-MurI interaction
DME1953	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME1953	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-MurI interaction
DME1953	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME1953	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-MurI interaction
DME1953	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME1953	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-MurI interaction
DME1953	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME1953	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-MurI interaction
DME1953	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME1953	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-MurI interaction
DME1953	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME1953	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-MurI interaction
DME1953	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME1953	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-MurI interaction
DME1953	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	GSH0_HUMAN	PROTNAME	Glutamate-cysteine ligase regulatory (GCLM)
DME1953	UNIPROID	GSH0_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	GSH0_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	GSH0_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	GSH0_HUMAN	PPI_SUMM	GCLM-MurI interaction
DME1953	UNIPROID	GSH0_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase regulatory and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1953	UNIPROID	NAGS_HUMAN	PROTNAME	N-acetylglutamate synthase (NAGS)
DME1953	UNIPROID	NAGS_HUMAN	MOFCLASS	Host-microbiome interaction
DME1953	UNIPROID	NAGS_HUMAN	MOFDETAI	Host-microbiome interaction
DME1953	UNIPROID	NAGS_HUMAN	SUBSTRAT	L-glutamine
DME1953	UNIPROID	NAGS_HUMAN	PPI_SUMM	NAGS-MurI interaction
DME1953	UNIPROID	NAGS_HUMAN	DESCRIPT	The interaction, between human N-acetylglutamate synthase and Glutamate racemase from Streptococcus mutans which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1957	DME___ID	DME1957
DME1957	DME_NAME	Methylenetetrahydrofolate reductase (metF)
DME1957	SPESNAME	Streptococcus sanguinis
DME1957	UNIPROID	MTHR_HUMAN	PROTNAME	Methylenetetrahydrofolate reductase (MTHFR)
DME1957	UNIPROID	MTHR_HUMAN	MOFCLASS	Host-microbiome interaction
DME1957	UNIPROID	MTHR_HUMAN	MOFDETAI	Host-microbiome interaction
DME1957	UNIPROID	MTHR_HUMAN	SUBSTRAT	ISO-901
DME1957	UNIPROID	MTHR_HUMAN	PPI_SUMM	MTHFR-metF interaction
DME1957	UNIPROID	MTHR_HUMAN	DESCRIPT	The interaction, between human Methylenetetrahydrofolate reductase and Methylenetetrahydrofolate reductase from Streptococcus sanguinis which collectively metabolize the drug ISO-901, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1958	DME___ID	DME1958
DME1958	DME_NAME	Nitroreductase (NTR)
DME1958	SPESNAME	Prevotella copri
DME1958	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1958	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1958	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1958	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Nitrazepam
DME1958	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1958	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Prevotella copri which collectively metabolize the drug Nitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	DME___ID	DME1968
DME1968	DME_NAME	Nitroreductase (NTR)
DME1968	SPESNAME	Salmonella typhimurium
DME1968	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1968	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Nitrazepam
DME1968	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-NTR interaction
DME1968	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Nitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	ST1A2_HUMAN	PROTNAME	Sulfotransferase 1A2 (SULT1A2)
DME1968	UNIPROID	ST1A2_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	ST1A2_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	ST1A2_HUMAN	SUBSTRAT	Mononitrophenol
DME1968	UNIPROID	ST1A2_HUMAN	PPI_SUMM	SULT1A2-NTR interaction
DME1968	UNIPROID	ST1A2_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1A2 and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Mononitrophenol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	ST1B1_HUMAN	PROTNAME	Sulfotransferase 1B1 (SULT1B1)
DME1968	UNIPROID	ST1B1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	ST1B1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	ST1B1_HUMAN	SUBSTRAT	Mononitrophenol
DME1968	UNIPROID	ST1B1_HUMAN	PPI_SUMM	SULT1B1-NTR interaction
DME1968	UNIPROID	ST1B1_HUMAN	DESCRIPT	The interaction, between human Sulfotransferase 1B1 and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Mononitrophenol, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	CP1A1_HUMAN	PROTNAME	Cytochrome P450 1A1 (CYP1A1)
DME1968	UNIPROID	CP1A1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	CP1A1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	CP1A1_HUMAN	SUBSTRAT	Riboflavin
DME1968	UNIPROID	CP1A1_HUMAN	PPI_SUMM	CYP1A1-NTR interaction
DME1968	UNIPROID	CP1A1_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 1A1 and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	PPAT_HUMAN	PROTNAME	Testicular acid phosphatase (ACP4)
DME1968	UNIPROID	PPAT_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	PPAT_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	PPAT_HUMAN	SUBSTRAT	Riboflavin
DME1968	UNIPROID	PPAT_HUMAN	PPI_SUMM	ACP4-NTR interaction
DME1968	UNIPROID	PPAT_HUMAN	DESCRIPT	The interaction, between human Testicular acid phosphatase and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	PPA5_HUMAN	PROTNAME	Tartrate-resistant acid ATPase (ACP5)
DME1968	UNIPROID	PPA5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	PPA5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	PPA5_HUMAN	SUBSTRAT	Riboflavin
DME1968	UNIPROID	PPA5_HUMAN	PPI_SUMM	ACP5-NTR interaction
DME1968	UNIPROID	PPA5_HUMAN	DESCRIPT	The interaction, between human Tartrate-resistant acid ATPase and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	PPA6_HUMAN	PROTNAME	Acid phosphatase-like protein 1 (ACP6)
DME1968	UNIPROID	PPA6_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	PPA6_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	PPA6_HUMAN	SUBSTRAT	Riboflavin
DME1968	UNIPROID	PPA6_HUMAN	PPI_SUMM	ACP6-NTR interaction
DME1968	UNIPROID	PPA6_HUMAN	DESCRIPT	The interaction, between human Acid phosphatase-like protein 1 and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	PPAP_HUMAN	PROTNAME	Prostatic acid phosphatase (ACP3)
DME1968	UNIPROID	PPAP_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	PPAP_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	PPAP_HUMAN	SUBSTRAT	Riboflavin
DME1968	UNIPROID	PPAP_HUMAN	PPI_SUMM	ACP3-NTR interaction
DME1968	UNIPROID	PPAP_HUMAN	DESCRIPT	The interaction, between human Prostatic acid phosphatase and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	PERE_HUMAN	PROTNAME	Eosinophil peroxidase (EPX)
DME1968	UNIPROID	PERE_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	PERE_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	PERE_HUMAN	SUBSTRAT	Riboflavin
DME1968	UNIPROID	PERE_HUMAN	PPI_SUMM	EPX-NTR interaction
DME1968	UNIPROID	PERE_HUMAN	DESCRIPT	The interaction, between human Eosinophil peroxidase and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	PXYP1_HUMAN	PROTNAME	Xylosyl phosphatase (PXYLP1)
DME1968	UNIPROID	PXYP1_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	PXYP1_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	PXYP1_HUMAN	SUBSTRAT	Riboflavin
DME1968	UNIPROID	PXYP1_HUMAN	PPI_SUMM	PXYLP1-NTR interaction
DME1968	UNIPROID	PXYP1_HUMAN	DESCRIPT	The interaction, between human Xylosyl phosphatase and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Riboflavin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1968	UNIPROID	CP2C9_HUMAN	PROTNAME	Cytochrome P450 2C9 (CYP2C9)
DME1968	UNIPROID	CP2C9_HUMAN	MOFCLASS	Host-microbiome interaction
DME1968	UNIPROID	CP2C9_HUMAN	MOFDETAI	Host-microbiome interaction
DME1968	UNIPROID	CP2C9_HUMAN	SUBSTRAT	Niclosamide
DME1968	UNIPROID	CP2C9_HUMAN	PPI_SUMM	CYP2C9-NTR interaction
DME1968	UNIPROID	CP2C9_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C9 and Nitroreductase from Salmonella typhimurium which collectively metabolize the drug Niclosamide, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1971	DME___ID	DME1971
DME1971	DME_NAME	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DME1971	SPESNAME	Salmonella enterica
DME1971	UNIPROID	CP3A4_HUMAN	PROTNAME	Cytochrome P450 3A4 (CYP3A4)
DME1971	UNIPROID	CP3A4_HUMAN	MOFCLASS	Host-microbiome interaction
DME1971	UNIPROID	CP3A4_HUMAN	MOFDETAI	Host-microbiome interaction
DME1971	UNIPROID	CP3A4_HUMAN	SUBSTRAT	Nitrazepam
DME1971	UNIPROID	CP3A4_HUMAN	PPI_SUMM	CYP3A4-nfsA interaction
DME1971	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Oxygen-insensitive NADPH nitroreductase A from Salmonella enterica which collectively metabolize the drug Nitrazepam, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1971	UNIPROID	CP3A4_HUMAN	SUBSTRAT	RO-7-0207
DME1971	UNIPROID	CP3A4_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A4 and Oxygen-insensitive NADPH nitroreductase A from Salmonella enterica which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1971	UNIPROID	CP3A5_HUMAN	PROTNAME	Cytochrome P450 3A5 (CYP3A5)
DME1971	UNIPROID	CP3A5_HUMAN	MOFCLASS	Host-microbiome interaction
DME1971	UNIPROID	CP3A5_HUMAN	MOFDETAI	Host-microbiome interaction
DME1971	UNIPROID	CP3A5_HUMAN	SUBSTRAT	RO-7-0207
DME1971	UNIPROID	CP3A5_HUMAN	PPI_SUMM	CYP3A5-nfsA interaction
DME1971	UNIPROID	CP3A5_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A5 and Oxygen-insensitive NADPH nitroreductase A from Salmonella enterica which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME1971	UNIPROID	CP3A7_HUMAN	PROTNAME	Cytochrome P450 3A7 (CYP3A7)
DME1971	UNIPROID	CP3A7_HUMAN	MOFCLASS	Host-microbiome interaction
DME1971	UNIPROID	CP3A7_HUMAN	MOFDETAI	Host-microbiome interaction
DME1971	UNIPROID	CP3A7_HUMAN	SUBSTRAT	RO-7-0207
DME1971	UNIPROID	CP3A7_HUMAN	PPI_SUMM	CYP3A7-nfsA interaction
DME1971	UNIPROID	CP3A7_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 3A7 and Oxygen-insensitive NADPH nitroreductase A from Salmonella enterica which collectively metabolize the drug RO-7-0207, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2014	DME___ID	DME2014
DME2014	DME_NAME	Insulin-degrading enzyme (ide)
DME2014	SPESNAME	Vibrio vulnificus
DME2014	UNIPROID	IDE_HUMAN	PROTNAME	Insulin-degrading enzyme (IDE)
DME2014	UNIPROID	IDE_HUMAN	MOFCLASS	Host-microbiome interaction
DME2014	UNIPROID	IDE_HUMAN	MOFDETAI	Host-microbiome interaction
DME2014	UNIPROID	IDE_HUMAN	SUBSTRAT	Insulin
DME2014	UNIPROID	IDE_HUMAN	PPI_SUMM	IDE-ide interaction
DME2014	UNIPROID	IDE_HUMAN	DESCRIPT	The interaction, between human Insulin-degrading enzyme and Insulin-degrading enzyme from Vibrio vulnificus which collectively metabolize the drug Insulin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2100	DME___ID	DME2100
DME2100	DME_NAME	Beta-lactamase (blaB)
DME2100	SPESNAME	Burkholderia multivorans
DME2100	UNIPROID	CP2C8_HUMAN	PROTNAME	Cytochrome P450 2C8 (CYP2C8)
DME2100	UNIPROID	CP2C8_HUMAN	MOFCLASS	Host-microbiome interaction
DME2100	UNIPROID	CP2C8_HUMAN	MOFDETAI	Host-microbiome interaction
DME2100	UNIPROID	CP2C8_HUMAN	SUBSTRAT	Cefaloridine
DME2100	UNIPROID	CP2C8_HUMAN	PPI_SUMM	CYP2C8-blaB interaction
DME2100	UNIPROID	CP2C8_HUMAN	DESCRIPT	The interaction, between human Cytochrome P450 2C8 and Beta-lactamase from Burkholderia multivorans which collectively metabolize the drug Cefaloridine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	DME___ID	DME2101
DME2101	DME_NAME	Glutamate decarboxylase (gadB)
DME2101	SPESNAME	Lactobacillus brevis
DME2101	UNIPROID	GLSK_HUMAN	PROTNAME	L-glutamine amidohydrolase (GLS)
DME2101	UNIPROID	GLSK_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	GLSK_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	GLSK_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	GLSK_HUMAN	PPI_SUMM	GLS-gadB interaction
DME2101	UNIPROID	GLSK_HUMAN	DESCRIPT	The interaction, between human L-glutamine amidohydrolase and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	ASNS_HUMAN	PROTNAME	Asparagine synthetase (ASNS)
DME2101	UNIPROID	ASNS_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	ASNS_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	ASNS_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	ASNS_HUMAN	PPI_SUMM	ASNS-gadB interaction
DME2101	UNIPROID	ASNS_HUMAN	DESCRIPT	The interaction, between human Asparagine synthetase and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	NADE_HUMAN	PROTNAME	Glutamine-dependent NAD(+) synthetase (NADSYN1)
DME2101	UNIPROID	NADE_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	NADE_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	NADE_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	NADE_HUMAN	PPI_SUMM	NADSYN1-gadB interaction
DME2101	UNIPROID	NADE_HUMAN	DESCRIPT	The interaction, between human Glutamine-dependent NAD(+ synthetase and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	GFPT2_HUMAN	PROTNAME	Hexosephosphate aminotransferase 2 (GFPT2)
DME2101	UNIPROID	GFPT2_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	GFPT2_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	GFPT2_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	GFPT2_HUMAN	PPI_SUMM	GFPT2-gadB interaction
DME2101	UNIPROID	GFPT2_HUMAN	DESCRIPT	The interaction, between human Hexosephosphate aminotransferase 2 and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	SYQ_HUMAN	PROTNAME	Glutaminyl-tRNA synthetase (GLNRS)
DME2101	UNIPROID	SYQ_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	SYQ_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	SYQ_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	SYQ_HUMAN	PPI_SUMM	GLNRS-gadB interaction
DME2101	UNIPROID	SYQ_HUMAN	DESCRIPT	The interaction, between human Glutaminyl-tRNA synthetase and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	GATB_HUMAN	PROTNAME	Glutamyl-tRNA(Gln) amidotransferase B (GATB)
DME2101	UNIPROID	GATB_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	GATB_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	GATB_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	GATB_HUMAN	PPI_SUMM	GATB-gadB interaction
DME2101	UNIPROID	GATB_HUMAN	DESCRIPT	The interaction, between human Glutamyl-tRNA(Gln amidotransferase B and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	GUAA_HUMAN	PROTNAME	Glutamine amidotransferase (GMPS)
DME2101	UNIPROID	GUAA_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	GUAA_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	GUAA_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	GUAA_HUMAN	PPI_SUMM	GMPS-gadB interaction
DME2101	UNIPROID	GUAA_HUMAN	DESCRIPT	The interaction, between human Glutamine amidotransferase and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	KAT1_HUMAN	PROTNAME	Kynurenine aminotransferase I (KYAT1)
DME2101	UNIPROID	KAT1_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	KAT1_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	KAT1_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	KAT1_HUMAN	PPI_SUMM	KYAT1-gadB interaction
DME2101	UNIPROID	KAT1_HUMAN	DESCRIPT	The interaction, between human Kynurenine aminotransferase I and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	PUR4_HUMAN	PROTNAME	Phosphoribosylformylglycinamidine synthase (PFAS)
DME2101	UNIPROID	PUR4_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	PUR4_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	PUR4_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	PUR4_HUMAN	PPI_SUMM	PFAS-gadB interaction
DME2101	UNIPROID	PUR4_HUMAN	DESCRIPT	The interaction, between human Phosphoribosylformylglycinamidine synthase and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	TGM2_HUMAN	PROTNAME	Transglutaminase H (TGM2)
DME2101	UNIPROID	TGM2_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	TGM2_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	TGM2_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	TGM2_HUMAN	PPI_SUMM	TGM2-gadB interaction
DME2101	UNIPROID	TGM2_HUMAN	DESCRIPT	The interaction, between human Transglutaminase H and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	TGM5_HUMAN	PROTNAME	Transglutaminase X (TGM5)
DME2101	UNIPROID	TGM5_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	TGM5_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	TGM5_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	TGM5_HUMAN	PPI_SUMM	TGM5-gadB interaction
DME2101	UNIPROID	TGM5_HUMAN	DESCRIPT	The interaction, between human Transglutaminase X and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	TGM3L_HUMAN	PROTNAME	Transglutaminase Y (TGM6)
DME2101	UNIPROID	TGM3L_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	TGM3L_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	TGM3L_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	TGM3L_HUMAN	PPI_SUMM	TGM6-gadB interaction
DME2101	UNIPROID	TGM3L_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Y and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	TGM3_HUMAN	PROTNAME	Transglutaminase E (TGM3)
DME2101	UNIPROID	TGM3_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	TGM3_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	TGM3_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	TGM3_HUMAN	PPI_SUMM	TGM3-gadB interaction
DME2101	UNIPROID	TGM3_HUMAN	DESCRIPT	The interaction, between human Transglutaminase E and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	TGM1_HUMAN	PROTNAME	Transglutaminase K (TGM1)
DME2101	UNIPROID	TGM1_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	TGM1_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	TGM1_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	TGM1_HUMAN	PPI_SUMM	TGM1-gadB interaction
DME2101	UNIPROID	TGM1_HUMAN	DESCRIPT	The interaction, between human Transglutaminase K and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	TGM7_HUMAN	PROTNAME	Transglutaminase Z (TGM7)
DME2101	UNIPROID	TGM7_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	TGM7_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	TGM7_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	TGM7_HUMAN	PPI_SUMM	TGM7-gadB interaction
DME2101	UNIPROID	TGM7_HUMAN	DESCRIPT	The interaction, between human Transglutaminase Z and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.
DME2101	UNIPROID	GSH1_HUMAN	PROTNAME	Glutamate-cysteine ligase catalytic (GCLC)
DME2101	UNIPROID	GSH1_HUMAN	MOFCLASS	Host-microbiome interaction
DME2101	UNIPROID	GSH1_HUMAN	MOFDETAI	Host-microbiome interaction
DME2101	UNIPROID	GSH1_HUMAN	SUBSTRAT	L-glutamine
DME2101	UNIPROID	GSH1_HUMAN	PPI_SUMM	GCLC-gadB interaction
DME2101	UNIPROID	GSH1_HUMAN	DESCRIPT	The interaction, between human Glutamate-cysteine ligase catalytic and Glutamate decarboxylase from Lactobacillus brevis which collectively metabolize the drug L-glutamine, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism.